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Biology and Microenvironment
T004
ANALYSIS OF THE MUTATIONAL LANDSCAPE AND DYNAMICS IN HODGKIN LYMPHOMA
USING NGS
E. Mata1, A. Díaz-López1, C. Montalban1, R. Fernandez2, C. Bellas3,
F. Burgos4, M.J. Mestre5, J. Menárguez6, M. Provencio7, C. Santonja7,
M.A. Piris8, J.F. Garcia1
1MD Anderson Cancer Center, Madrid, Spain; 2Hospital de Cabueñes, Gijon,
Spain; 3Hospital Puerta de Hierro, Madrid, Spain; 4Hospital Severo Ochoa,
Leganés, Madrid, Spain; 5Hospital Universitario de Móstoles, Madrid, Spain;
6Hospital General Universitario Gregorio Marañón, Madrid, Spain; 7Fundación
Jiménez Díaz, Madrid, Spain; 8Hospital Universitario Marqués de Valdecilla,
Santander, Spain
Few studies have been aimed to the identification of driver mutations
in classical Hodgkin Lymphoma (cHL), and only occasional gene muta-
tions in members of the NF-kappaB and JAK/STAT pathways, and, more
recently B2M, have been previously described. We analyzed 57 cHL
tumor samples (FFPE) using massive parallel sequencing (Ion Torrent™
semiconductor technology). To increase coverage a previous tumor cell
enrichment process by punch tissue cores from selected tumor-rich areas
was implemented. In addition, we have also analyzed an independent
group of 12 patients with primary refractory cHL (patients that did not
achieve complete response after first line ABVD, or who presented with
primary progressive disease), using the same methodology for NGS, but
with an enrichment procedure based on laser microdissection of HRS
cells (CD30+). Overall, the results show very high genomic heterogeneity
with a range of 10-400 SNVs per sample, most of them (~60%) missense
type. We found a relatively large number of genes recurrently mutated at
low frequency and only a few genes mutated in up to 15-20% of the
patients, reflecting a high level of genomic instability in the neoplasm.
Specific mutations in genes previously described in cHL (NFKBIA,
TNFRSF14) and in diffuse large B-cell lymphomas (CARD11, STAT6,
CREBBP, CMYB) were consistently found, as well as new SNVs in genes
not previously described (STAT6, BTK, NFKB2). Of note, we found high
prevalence of mutations affecting BTK and the BCR pathway, suggesting
some dependencies of active BCR signaling albeit the absence of BCR
expression by HRS cells. Consistent with this interpretation, incubation
of a panel of cHL cellular models with either Ibrutinib or AVL-292, selec-
tive-BTK inhibitors, in vitro constrains cell proliferation and causes cell
death. Indeed, gene expression and GSEA analysis of the cHL HDML-2
cell line showed a similar basal BCR pathway activation levels than the
HBL1 DLBCL cell followed by an intense inhibition after ibrutinib incu-
bation. In conclusion, cHL is characterized by high genomic instability,
including numerous mutations in genes related with B-cell function and
specific signaling pathways. Pathogenic predictions of the different SNVs
identify potential driver mutations that can be associated with the patho-
genesis of the disease and might represent new therapeutic targets.
T005
HIGH EXPRESSION OF PROGRAMMED CELL DEATH RECEPTOR 1 IN THE TUMOR
MICROENVIRONMENT IS ASSOCIATED WITH INFERIOR EVENT FREE SURVIVAL IN
CLASSICAL HODGKIN LYMPHOMA
P. Hollander1,2, P. Kamper3, K.E. Smedby4,5, G. Enblad1, J. Mortensen3,
R.-M. Amini2, F. d’Amore3, D. Molin1,*, I. Glimelius1,4,*
1Experimental and Clinical Oncology, Department of Immunology, Genetics and
Pathology; Uppsala University, Uppsala, Sweden; 2Clinical and Experimental
Pathology, Department of Immunology, Genetics and Pathology; Uppsala
University, Uppsala, Sweden; 3Department of Hematology, Aarhus University
Hospital, Aarhus, Denmark; 4Clinical Epidemiology Unit, Department of Medicine
Solna, Karolinska Institutet, Stockholm, Sweden; 5Hematology Center, Karolinska
University Hospital, Stockholm, Sweden
*Shared last authorship
Immune checkpoint inhibition targeting the programmed cell death
receptor 1 (PD-1) pathway is a novel treatment approach in relapsed and
refractory classical Hodgkin lymphoma (cHL). Use of PD1-inhibitors may
be justified early on in selected patients if patients with high risk of treat-
ment failure could be identified at the time of diagnosis. Our aim was to
investigate the prognostic impact of PD-1 expression in tumor infiltrating
lymphocytes in diagnostic cHL biopsies. Patients from Aarhus, Denmark
(n=283) diagnosed 1990-2006 aged 15-86, and Sweden (n=132) diagnosed
1999-2002 aged 18-74 were included. The patients were mostly treated
with chemotherapy (mainly ABVD) ± radiotherapy. Tissue microarray
samples were available from 387 patients. Immunohistochemistry was
used to detect PD-1 and the percentage of positive cells was estimated
using a digital image analysis program. Fifty-seven patients (15%) pre-
sented with a high expression of PD-1, defined as ≥10% positive lym-
phocytes in the tumor microenvironment. Overall survival (OS) and event
free survival (EFS) (treatment failure or death from any cause) were ana-
lyzed using log rank test and Cox proportional hazards regression. The
median follow-up time was 10.8 years. Among patients with a high
expression of PD-1 there were 29 (51%) events, and among those with
a low expression 104 (32%) (Figure 1).
Figure 1.
A high PD-1 expression was associated with an inferior EFS (age-adjust-
ed hazard ratio (HR)=1.69; 95% confidence interval (95%CI) 1.12-2.54),
an observation which persisted also in a fully adjusted analysis (adjusted
for age, albumin <40g/L, B-symptoms, bulky tumor, country, extranodal
tumor involvement, sex, stage IIB-IV, and white blood cell count
>15x109/L) (HR=1.80; 95%CI 1.19-2.90). High PD-1 was not significantly
associated with worse OS. There was a weak correlation between high
expression of PD-1 and intratumoral Epstein-Barr virus negativity (Spear-
man correlation coefficient 0.12, p=0.015), and nodular sclerosis histologic
subtype (correlation coefficient 0.10, p=0.04). This is the first study to
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show that high expression of PD-1 in the tumor microenvironment of
cHL is associated with inferior EFS (fully adjusted multivariate analyses).
Patients with high expression of PD-1 have a tumor permissive exhausted
immune system and may therefore be more likely to experience treat-
ment failure after conventional treatment regimens.
T006
THE AP-1 TRANSCRIPTION FACTOR BATF3 REGULATES MYC EXPRESSION AND IS
REQUIRED FOR TUMOR CELL SURVIVAL IN CLASSICAL HODGKIN LYMPHOMA AND
ANAPLASTIC LARGE CELL LYMPHOMA
A. Lollies1, S. Hartmann2, M. Schneider1, T. Bracht3, J. Arnolds4,
L. Klein-Hitpass1, B. Sitek3, M.-L. Hansmann2, R. Küppers1,*,
M.A. Weniger1,*
1Institute of Cell Biology (Cancer Research), Faculty of Medicine, University of
Duisburg-Essen, Essen, Germany; 2Dr. Senckenberg Institute of Pathology,
Goethe-University of Frankfurt, Medical School, Frankf urt am Main, Germany;
3Medical Proteom Center, Ruhr-University Bochum, Bochum, Germany;
4Department of Otorhinolaryngology, Faculty of Medicine, University of
Duisburg-Essen, Essen, Germany
*Co senior authors
The malignant cells in classical Hodgkin lymphoma (cHL) and
anaplastic large cell lymphoma (ALCL) are characterized by deregulated
transcription factor activity of several signaling pathways including
constitutive active JAK/STAT and AP-1. Our group and others have
performed gene expression profiling (GEP) of cHL and ALCL and iden-
tified BATF3, a member of the AP-1 transcription factor family, as one
of the most up-regulated genes in cHL and ALCL cells. In the present
study, up-regulated expression of BATF3 was confirmed at mRNA and
protein level in cHL and ALCL cells. To assess BATF3 function, small
hairpin (sh)RNA vectors against BATF3 were generated to downregu-
late BATF3 in lymphoma cell lines. Transduction experiments demon-
strate that downregulation of BATF3 leads to reduced cell proliferation
and induced apoptosis in cHL and ALCL cell lines. To identify BATF3-
regulated targets in BATF3-knockdown cells, GEP was performed. GEP
after BATF3 knockdown demonstrated a significant downregulation of
known MYC target genes and immunoblot analysis confirmed down-
regulation of MYC in shBATF3-transduced cells. Chromatin-immuno-
precipitation (ChIP) experiments demonstrated that BATF3 regulates
MYC expression by binding to an AP-1 element present in the MYC
promoter. To examine whether BATF3 activity was connected to the
constitutive JAK/STAT activation in cHL and ALCL, we treated cHL
and ALCL cell lines with the JAK2 inhibitor TG101348 and found
decreased levels of BATF3 protein, suggesting that BATF3 is regulated
by STAT factors. Additionally, activation of JAK/STAT signaling by
interleukin stimulation induced BATF3 expression in cHL and ALCL
cell lines. ChIP experiments validated STAT binding to the BATF3 pro-
moter, indicating that STATs directly regulate BATF3 expression. In
conclusion, we recognized a new oncogenic axis in cHL and ALCL and
revealed a complex transcription factor network in which BATF3 links
STAT signaling to MYC expression.
P024
INACTIVATION OF THE PUTATIVE UBIQUITIN-E3 LIGASE PDLIM2 IN CLASSICAL HODGKIN
AND ANAPLASTIC LARGE CELL LYMPHOMA
K.D. Wurster1,2, F. Hummel1,2, J. Richter3, M. Giefing3,4, S. Hartmann5,
M.-L. Hansmann5, S. Kreher2, K. Köchert1,2, D. Krappmann6, W. Klapper7,
M. Hummel8, S.-S. Wenzel2, G. Lenz9, M. Janz1,2, B. Dörken1,2,10,
R. Siebert3, S. Mathas1,2,10
1Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; 2Hematology,
Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin,
Germany; 3Institute of Human Genetics, Christian-Albrechts University Kiel,
Kiel, Germany; 4Institute of Human Genetics, Polish Academy of Sciences,
Department of Cancer Genetics, Poznan, Poland; 5Dr. Senckenberg Institute of
Pathology, University of Frankfurt, Medical School, Frankfurt, Germany;
6Research Unit Cellular Signal Integration, Helmholtz Zentrum München für
Gesundheit und Umwelt, Neuherberg, Germany; 7Department of Pathology,
Haematopathology Section and Lymph Node Registry, Christian-Albrechts
University Kiel, Kiel, Germany; 8Institute of Pathology, Charité-
Universitätsmedzin Berlin, Berlin Germany; 9Division of Translational Oncology,
Department of Medicine A, University Hospital Münster, and Cluster of Excellence
EXC 1003, Cells in Motion, Münster, Germany; 10German Cancer Consortium
(DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany 
Apart from its unique histopathological appearance with rare tumor
cells embedded in an inflammatory background of bystander cells, clas-
sical Hodgkin lymphoma (cHL) is characterized by an unusual activa-
tion of a broad range of signaling pathways involved in cellular activa-
tion. This includes constitutive high-level activity of NF- B, JAK/STAT,
AP-1 and IRF transcription factors (TFs), which are physiologically only
transiently activated. Here, we demonstrate that inactivation of the
putative ubiquitin E3-ligase PDLIM2 contributes to this TF activation.
PDLIM2 expression is lost at the mRNA and protein level in the major-
ity of cHL cell lines and HRS cells of nearly all cHL primary samples.
This loss is associated with PDLIM2 promoter methylation, altered
splicing and, in rare cases, genomic alterations. Reconstitution of
PDLIM2 in HRS cell lines inhibits proliferation, blocks NF- B transcrip-
tional activity and contributes to cHL-specific gene expression. In non-
Hodgkin B cell lines, siRNA-mediated PDLIM2 knockdown results in
super-activation of TFs NF- B and AP-1 following PMA stimulation.
Furthermore, expression of PDLIM2 is lost in anaplastic large cell lym-
phoma (ALCL), which shares key biological aspects with cHL. We con-
clude that inactivation of PDLIM2 is a recurrent finding in cHL and
ALCL, promotes activation of inflammatory signaling pathways and
thereby contributes to their pathogenesis. 
P025
DETERMINATION OF THE MUTATIONAL LANDSCAPE OF PRIMARY HODGKIN AND
REED/STERNBERG CELLS OF CLASSICAL HODGKIN LYMPHOMA
M. Schneider1,2, C. Döring1, J.C. Czeschik3, A. Lollies3, S. Hartmann1,
S. Rahmann3, M.-L. Hansmann1, R. Küppers2
1Dr. Senckenberg Institute of Pathology, Goethe-University of Frankfurt, Medical
School, Frankfurt, Germany; 2Institute of Cell Biology (Cancer Research), Faculty
of Medicine, University of Duisburg-Essen, Essen, Germany; 3Genome
Informatics, Institute of Human Genetics, Faculty of Medicine, University of
Duisburg-Essen, Essen, Germany
Despite recent advances in our understanding of classical HL (cHL)
the pathogenesis of this disease is still largely unknown. For instance,
only a few genetic aberrations in the tumor cells of cHL, the Hodgkin
and Reed/Sternberg (HRS) cells, have been identified. In general, the
analysis of HRS cells is hampered by the rarity of the HRS cells which
usually comprises only about 1% of the tumor tissue. To better under-
stand the pathogenesis of cHL and to identify new genes critically
involved in this process, we developed a method to perform whole
exome sequencing of microdissected HRS cells. So far 11 primary cHL
cases were successfully sequenced. The successful validation of 16 of
21 selected mutations in HRS cells of three cHL cases by direct PCR
with microdissected cells and Sanger sequencing showed the reliability
of the analysis. In a preliminary analysis of the data, NFKBIE mutations
were identified in three cases. Thus, NFKBIE mutations are a recurrent
event in cHL.
P026
HODGKIN CELL-DERIVED EXTRACELLULAR VESICLES SHAPE FIBROBLAST ACTIVITY
T. Bösl, H.P. Hansen, A. Engert, E. Pogge von Strandmann
University Hospital of Cologne, Department of Internal Medicine I, Innate
Immunity Group and German Hodgkin Study Group, Cologne, Germany
In Hodgkin lymphoma (HL) the malignant cells are greatly outnum-
2 | haematologica | 2016; 101(s5)
10th International Symposium on Hodgkin Lymphoma
ISHL_2016_S5_Abstract book_indice nomi ok.qxp  19/09/16  12:05  Pagina 2
bered by non-malignant immune cells supporting tumor growth and
progression. Hodgkin Reed Sternberg (HRS) cells grow highly depend-
ent on the microenvironment, which is actively shaped by a very com-
plex cross-talk between the tumor cells and the reactive infiltrate. HRS
cells secrete cytokines and angiogenic factors capable of recruiting and
inducing the proliferation of surrounding cells to finally orchestrate
their cellular microenvironment and to inhibit the development of an
efficient antitumor immune response. Within this scenario, the role of
extracellular vesicles (EVs) released by HRS cells which can communi-
cate with other cells in trans has not been addressed yet. Recently, we
demonstrated that EVs released by HRS cells impact on the formation
of a tumor supportive niche by stimulating IL-8 release. Here, we inves-
tigate the role of tumor cell-derived vesicles on fibroblast activity and
thus their impact on creating a tumor favorable surrounding. With single
and co-cultures of the malignant cells and healthy stromal cells, the
reciprocal effects on their cellular functions were analyzed. Using
Fibroblast mediated eotaxin as a marker we could show that the bi-
directional cross-talk is not entirely cell-cell contact dependent. Not
only soluble factors, but also EVs had a positive effect on migration and
chemotaxis, showing concentration depending effects. EVs released by
malignant cells are internalized by fibroblasts and induce an inflamma-
tory phenotype, which resembles the phenotype of cancer associated
fibroblasts (CAFs). As a result of EV exposure, fibroblasts show selective
changes in the secretome with enhanced expression of pro-inflamma-
tory cytokines and hits related to NF B-Signaling. Further experiments
indicate that in this context, NF B-Signaling is induced by TNF- trans-
ported via Evs Results are further supported by in vivo experiments using
a HL Xenograft model.
P027
PROGNOSTIC IMPLICATIONS OF AN ACTIVE, INNATE OR ANERGIC IMMUNE RESPONSE
IN THE HODGKIN LYMPHOMA TUMOR MICROENVIRONMENT
P. Hollander1, K. Rostgaard2, K.E. Smedby3,4, D. Molin1, A. Loskog5,
P. de Nully Brown6, G. Enblad1, R.-M. Amini7, H. Hjalgrim2, I. Glimelius1,3
1Experimental and clinical oncology, Department of Immunology, Genetics and
Pathology; Uppsala University, Uppsala, Sweden; 2Department of Epidemiology
Research; Statens Serum Institut, Copenhagen, Denmark; 3Clinical Epidemiology
Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;
4Hematology Center, Karolinska University Hospital, Stockholm, Sweden;
5Clinical Immunology, Department of Immunology, Genetics and Pathology;
Uppsala University, Uppsala, Sweden; 6Department of Haematology,
Rigshospitalet, Copenhagen, Denmark; 7Clinical and Experimental Pathology,
Department of Immunology, Genetics and Pathology; Uppsala University,
Uppsala, Sweden
The classical Hodgkin lymphoma (cHL) tumor microenvironment
includes a variable inflammatory response consisting of eosinophils,
mast cells, macrophages, regulatory T lymphocytes (Treg) and active
lymphocytes. We counted these inflammatory cells in tumor tissue
from 459 patients with cHL from Sweden and Denmark, with complete
clinical data available for 409 patients (Figure 1). Depending on the pre-
dominant cell types and their immunologic function we categorized
the immune profile into an active, anergic or innate immune response
with the aim to investigate if a specific tumor immune profile can pre-
dict survival. Time to progression (TTP) (primary progression, relapse
or cHL death) and overall survival (OS) were analyzed using Cox pro-
portional hazards regression. During follow-up (median 12.9 years) 49
patients had disease progression and 78 patients died. A high proportion
of Treg (an anergic immune response) conferred shorter TTP when
adjusted for age (hazard ratio (HR)=2.25; 95% confidence interval (CI)
1.15-4.41), especially in advanced stages (HR=2.83; 95%CI 1.25-6.40).
In addition, a low proportion of Treg combined with a high proportion
of macrophages conferred superior TTP when adjusted for age, stage,
albumin and bulky tumor (HR=0.23; 95%CI 0.07-0.77). This is the first
study to show that a tumor microenvironment characterized by an
anergic immune response corresponds to a shorter TTP in cHL, indi-
cating a reduced ability of an anergic immune system to attack the
tumor cells. The programmed death receptor 1 (PD-1) is expressed by
Treg, and these results warrant further investigation to determine if
Treg is a predictor of response to PD-1 blocking drugs.
Figure 1. Univariate analysis for Time to Progression. (A) Kaplan-Meier
estimates according to upper quartile Treg (Blue) and below upper quartile
Treg (Red). (B) Kaplan-Meier estimates according to active (Red), anergic
(Blue), innate (Black), and mixed immune responses (Green). (C) Kaplan-
Meier estimates according to below upper quartile Treg and upper quartile
macrophages combined (Blue), and upper quartile Treg and below upper
quartile macrophages combined (Red). 
P028
STUDYING THE ROLE OF ONCOGENIC miR-24-3P IN HODGKIN LYMPHOMA
Y. Yuan, J. Kluiver, J. Koerts, D. de Jong, B. Rutgers, A. Diepstra, L. Visser,
A. van den Berg
Department of Pathology & Medical Biology, University of Groningen, University
Medical Centre Groningen, Groningen, the Netherlands
Introduction. Micro (mi)RNAs negatively regulate gene expression at
the transcriptional level by binding to complementary regions in the
3’-UTR. They play important roles in biological processes such as pro-
liferation, metabolism, differentiation and apoptosis. Aberrant expres-
sion of miRNAs contributes to several diseases including cancer.
Although several miRNAs have been implicated in the pathogenesis of
Hodgkin lymphoma (HL), the function of most of the aberrantly
expressed miRNAs is unknown. Therefore, the aim of this study is to
investigate the role of miRNAs and the underlying mechanism in HL.
Results. Small RNA-seq revealed 84 significantly differentially expressed
miRNAs in HL cell lines as compared to GC-B cells, including 55 up-
and 29 downregulated miRNAs. QRT-PCR validation confirmed the
differential expression pattern as observed with small RNA sequencing
for 15 out of 19 selected miRNAs. Among the upregulated miRNAs,
miR-23a, miR-24 and miR-27a were transcribed from one primary miR-
NA transcript. Loss-of-function analysis for these 3 miRNAs and their
family members resulted in decreased growth upon miR-24 inhibition
in L428, L1236 and KMH2 and upon inhibition of miR-27a/b in L1236.
No effect on cell growth was observed upon inhibition of miR-23a/b.
Apoptosis analysis upon miR-24 inhibition revealed increased percent-
age of apoptosis cells, indicating that the decreased cell growth upon
miR-24 inhibition was at least in part caused by an increase in apoptosis.
To identify the target genes of these miRNAs we performed argonaute
2 (AGO2)-IP in four HL cell lines. This revealed 1,142 consistently
AGO2-enriched genes. Gene set enrichment analysis revealed signifi-
cant enrichment of the miR-23a/b, miR-24 and miR-27a/b miRNA tar-
get gene sets in the IP fraction. Furthermore, 51 out of 1,142 genes were
predicated targets of miR-24 based on Targetscan, including 4 out of 5
proven miR-24 targets. Functional annotation analysis revealed a func-
tion related to cell growth, cell death and/or apoptosis for 15 out of the
52 genes. Western blotting for 2 of these genes, i.e.CDKN1B and MYC,
showed downregulation at the protein level upon miR-24 inhibition.
haematologica | 2016; 101(s5) | 3
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Conclusions.A total of 84 miRNAs were significant differently expressed
in HL cell lines compared to GC-B cells. MiR-24 has an oncogenic role
in HL by inhibiting apoptosis.
P029
CHARACTERIZATION OF HODGKIN LYMPHOMA CLONOGENIC CELLS USING A NEW L428
IN VIVO XENOGRAFT MODEL IN IMMUNODEFICIENT NOD/SCID-GAMMAC-/- MICE
AND PERIPHERAL LYMPHOCYTES STUDY IN HODGKIN LYMPHOMA PATIENTS 
C. Cuceu1, M. Al Jawhari1, L. Morat1, M. Frenzel1, D. Lewandowski2,
S. Junker2, F. Pflumio3, J. Bourhis4, T. Girinsky5, L. Sabatier1, P. Carde6,
R. M’kacher1-7
1Laboratoire de Radiobiologie et d’Oncologie, IRCM/DSV/CEA Fontenay aux
Roses, France; 2CEA/DSV/iRCM/LRTS, Fontenay-aux-Roses, France;
3CEA/DSV/iRCM/,LSHL, Fontenay-aux-Roses, France; 4INSERM 1030, Insti-
tut Gustave Roussy Villejuif, France; 5Department of radiation oncology, Institut
Gustave Roussy, Villejuif France; 6Department of Hematology, Intitut Gustave
Roussy, Villejuif France; 7Cell Environment Oncology section Paris France 
The characterization of the cells at the origin of Hodgkin and Reed
Sternberg cells in Hodgkin lymphoma (HL) is hampered mostly because
of the poor growth of HL cells in vitro and in vivo. Investigation of cell
markers and signaling pathways specific to HL clonogenic cells may
lead to progress in therapy and improve the prognosis of patients with
HL. Using a newly developed murine in vivo L428 xenograft model and
circulating lymphocytes of HL patients before treatment, we attempted
to determine the immunophenotype and cytogenetic profile of the
clonogenic cells. Materials and Methods. L428 HL cell line was used to
establish an in vivo xenograft model in immunodeficient NOD/SCID-
gammac-/- mice. In vitro and in vivo clonogenic cells derived from L428
cell line and circulating lymphocytes of 50 HL patients were character-
ized using immunofluorescence, immunochemistry and cytogenetic.
Chromosomal instability was also investigated. Telomere maintenance
mechanisms (telomerase activity (TA) and Alternative Lengthening
Telomere (ALT)) were explored. Results. We confirmed previous data
that L428 cell line contained small (<2%) subpopulations that lacked
CD30 and CD15 expression and had greater clonogenic potential in
vitro than the corresponding CD30+ and CD15+ cells. These cells were
also clonogenic in vivo in NOD/SCID gamma -/- mice. Immunopheno-
type characterization of the first cells harvested from the mice demon-
strated a CD30, CD15 and CD14 negative profile. Over time, the cells
acquired CD14 followed by CD15 and finally CD30 surface markers.
Cytogenetic analysis confirmed the diploid origin of the cells that grow
in the mice. Cell sorting of negative cells in HL cell lines was performed
to validate this hypothesis and demonstrate their clonogenic potential
to recover the parental cell line. These cells were characterized by a
higher telomere instability associated to the presence of higher fre-
quency of dicentric chromosome. A high TA was detected in these cells
as well as in the circulating lymphocytes in 10 out of 50 HL patients.
Conclusions.We better characterized the origin of the cells which grow
in the L428 xenograft model, and their different steps of transformation
from “clonogenic cells” to monocytes/macrophages and finally to
Hodgkin and HRS cells due to the unique microenvironment of HL.
The assessment of TA could be used as a biomarker of the prevalence
of clonogenic cells in circulating lymphocytes. 
P030
THE LYMPHOID CELL SPECIFIC TRANSCRIPTION FACTOR ELF-1 IS TRANSCRIPTIONALLY
DOWNREGULATED AND RECURRENTLY DELETED IN CLASSICAL HODGKIN LYMPHOMA
M. Giefing1,2, N. Zemke1, M. Bodnar2,3, E. Domanowska3, J. Janiszewska1,
J. Paczkowska1, A. Ustaszewski1, J.I. Martin-Subero4, O. Ammerpohl5,
W. Klapper6, A. Marszalek3,7, R. Siebert5,8
1Institute of Human Genetics, Polish Academy of Sciences, Department of Cancer
Genetics, Poznan, Poland; 2Department of Otolaryngology and Laryngological
Oncology, Poznan University of Medical Sciences, Poznan, Poland; 3Department
of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus
Copernicus University in Torun, Bydgoszcz, Poland; 4Institut d’Investigacions
Biomédiques August Pi i Sunyer (IDIBAPS), Department of Anatomic Pathology,
Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain;
5Institute of Human Genetics, Christian-Albrechts-University Kiel, Kiel,
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ELF-1 and ELF-2 belong to the ETS-family of transcription activators
or repressors implicated in processes recurrently deregulated in human
neoplasms. Recently, we have shown that genes hypermethylated in
cHL are enriched for binding sites of ETS-family members ETS-1 (1.28
fold), ELF-1 (1.07 fold) and ELF-2 (1.91 fold). We hypothesized that hyper-
methylation of genes in cHL might be secondary towards genomic alter-
ations of these B-cell related transcription factors. In line, we have recent-
ly reported recurrent alterations and significant downregulation of ETS-
1 expression in cHL. Encouraged by this finding, here we analyzed the
two other ETS family members in cHL. We show significant downreg-
ulation of ELF-1 (8.82 fold, p<0.0001, tag 40067_at) and 1.36 fold of ELF-
2 (tag 507_s_at) in cHL cell lines (n=4) compared to GCB pools (n=20)
(U95 microarray). This was further validated for ELF-1 in primary biop-
sies where using immunohistochemistry (AB99401) we observed loss or
downregulation of the protein in HRS cells in 26/35 (74%) cases but not
in no-tumor bystander cells. In case of ELF-2 no reduction of protein
abundance was observed. To identify the underlying mechanism we
sequenced the ELF-1 coding region in 7 cHL cell lines but no mutations
were identified. In contrast, we analyzed copy number (CN) alterations
of the ELF-1 locus in primary biopsies using combined immunopheno-
typing and in situ hybridization (FICTION) and identified deletions in
5/11 (45%) analyzed cases. Similarly, deletions or LOH were found in
4/7 (57%) cHL cell lines (Affymetrix SNP 6.0 array). Also epigenetic
mechanism may contribute to ELF-1 downregulation as using next-gen-
eration miRnome sequencing we observed 3.26 fold overexpression
(p=0.0018) of the hsa-miR-330-3p in cHL cell lines (n=7) compared to
non-Hodgkin lymphomas (n=10). Hsa-miR-330-3p shows significant
affinity (p=0.0013) towards the 3’UTR region of ELF-1 basing on in silico
analysis (miRWalk). In conclusion, we show recurrent loss of ELF-1
expression in HRS cells that at least in part is attributable to the genomic
deletions and overexpressed hsa-miR-330-3p. Moreover, our data support
the concept, that downregulation of the ELF-1 transcription factor may
lead to consequent hypermethylation and silencing of its target genes
contributing to the loss of B-cell phenotype of HRS cells.
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MUTATIONS IN CD58 AND MYB IN HODGKIN LYMPHOMA
F.R. Abdul Razak, A. Diepstra, D. Jong, J. Koerts, B. Rutgers, J. Kluiver,
L. Visser, A. van den Berg
Department of Pathology & Medical Biology, University of Groningen, Univer-
sity Medical Center Groningen, The Netherlands
Hodgkin lymphoma (HL) is characterized by constitutive activation
of several signaling pathways and expression of a distinct set of tran-
scription factors. This characteristic phenotype is partly caused by
gene mutations as determined by targeted and whole genome sequenc-
ing approaches on cell lines and microdissected HRS cells. Here we
studied CD58 and MYB, 2 genes we previously identified by whole
exome sequencing (WES) in HL cell lines. CD58 gene mutations
observed in 3 HL cell lines were confirmed by Sanger sequencing at
the DNA and RNA level. CD58 protein expression as determined by
flow, western blot and IHC was absent in all 3 HL cell lines with muta-
tions and present in 4 HL cell lines with wild type CD58. In primary
tissue samples, loss of CD58 expression was observed in 11% of the
patients. Lack of CD58 was specifically observed in patients who
developed a relapse. This suggests that loss of CD58 is a potential
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immune escape mechanism of HRS tumor cells, especially in clinically
aggressive disease. Frame shift mutations resulting in a truncated MYB
protein were found in L428 and SUPHD1 cells. The mutation in L428
causes complete loss of most of the C-terminal domain whereas the
mutation in SUPHD1 results in a MYB protein with a partial loss of
the C-terminal domain. We confirmed the mutations at the DNA and
RNA level and confirmed presence of a truncated protein by Western
blot with C-terminal and N-terminal domain specific antibodies. RT-
PCR with primers specific for each of the alternatively spliced exons,
indicated that these were not included in the MYB transcript in any of
the HL cell lines. In tissue samples, staining of MYB in HL cases
revealed no staining with both antibodies in the vast majority of the
cases, indicating complete loss of the MYB protein. Inhibition of MYB
by shRNA constructs induced negative effects on cell growth in HL
cell lines with wild type MYB (L540 & KMH2) and no or limited effects
in HL cell lines with truncated MYB (L428 & SUPHD1). Microarray
analyses of L540 & KMH2 cells treated with non-targeting and MYB
shRNA constructs revealed 63 consistently MYB induced and repressed
genes. In conclusion, we show that loss of CD58 expression is common
in HL cell lines and restricted to the HRS cells of tissue samples of
relapsed HL. For MYB, strong oncogenic effects were observed espe-
cially for the HL cell lines with wild type MYB.
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RE-FUSION OF SMALL MONONUCLEATED HODGKIN CELLS LEADS TO GIANT
MULTINUCLEATED REED-STERNBERG CELLS IN HODGKIN LYMPHOMA
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F. Schmid1, K. Warner4, S. Hartmann1, T. Schroeder5, R. Küppers6,
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The multinucleated Reed-Sternberg (RS) cells are pathognomonic for
classical Hodgkin lymphoma (HL) and their presence is essential for
diagnosis. However, the development of these giant tumor cells is con-
troversially discussed. It was postulated that RS cells arise from
mononucleated Hodgkin cells via endomitosis. Conversely, continuous
single cell tracking of HL cell lines by long-term time-lapse microscopy
showed that cell fusion is the main route of RS cell formation. In con-
trast to growth-induced formation of giant Hodgkin cells, fusion of
small mononuclear cells followed by size increase gives rise to giant RS
cells. Importantly, we nearly exclusively observed fusion of cells origi-
nating from the same ancestor, termed re-fusion. In the majority of cas-
es, re-fusion of daughter cells was preceded by an incomplete cytoki-
nesis, visualized by a microtubule bond between the cells. We confirm
at the level of individual tracked cells that giant Hodgkin and RS cells
have little proliferative capacity, further specifying small mononuclear
Hodgkin cells as the proliferative compartment of the HL tumor clone.
In addition, sister cells showed a shared propensity for re-fusion, which
provides evidence of early RS cell fate commitment. Thus, RS cell gen-
eration is neither due to cell fusion of unrelated Hodgkin cells nor to
endomitosis, but is mediated by re-fusion of daughter cells that under-
went mitosis. This surprising finding indicates the existence of a novel
mechanism for the generation of multinuclear RS cells, which might
have implications beyond HL, as RS-like cells are frequently observed
in several other lymphoproliferative diseases.
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MOLECULAR CHARACTERIZATION OF BRUTON’S TYROSINE KINASE INHIBITOR IN
HODGKIN’S LYMPHOMA: CELLULAR AND ANIMAL MODELS
I. Muqbil1, A. Aboukameel1,2, A.S. Azmi1, R.M. Mohammad1,
R. Ramchandren1
1Department of Oncology, Karmanos Cancer Institute, Wayne State University
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Janssen Services, LLC
Abstract. Classical Hodgkin Lymphoma (cHL) is a malignancy of
mature (post germinal center) B-lymphocytes that afflicts almost
20,000 individuals annually in North America and Europe alone. While
the majority of patients diagnosed with HL are cured with multi-agent
chemotherapy, 15% of patients are refractory to conventional
chemotherapy and almost half of patients with high-risk disease
relapse. Only 2 agents have been approved in the last 30 years for
relapsed HL and novel therapies are needed. Bruton’s Tyrosine Kinase
(BTK) is a member of the TEC family and plays a central role in B-cell
signaling, activation, proliferation and differentiation. Several studies
have shown that BTK is upregulated in a proportion of Reed-Sternberg
cells and has been associated with PI3K, mTOR, FAS and NF- B sig-
naling. Furthermore, pathways upregulated in cHL such as CD40 lig-
and binding, elevated chemokines such as IL-6 and activation of toll
like receptor (TLR) pathways have been associated with BTK upreg-
ulation. Thus, BTK inhibition may have therapeutic potential in cHL.
Methods. The BTK inhibitor Ibrutinib at 0-15 micro molar doses was
incubated for 72 hrs. with a panel of HL cell lines (KM-H2, L1236, L-
428). Cell viability was evaluated using trypan blue. Apoptosis was
analyzed using annexin V FITC and histone DNA ELISA. Protein
expression was analyzed using western blotting with RNA post ibru-
tinib treatment subjected to RT PCR. Results. Ibrutinib suppressed via-
bility of these HL cell lines in a dose dependent manner (IC50s ~5-7.5
µM in KM-H2, L1236 and L-428). The drug induced statistically sig-
nificant apoptosis in the responsive cell lines in a dose dependent
manner (>50% apoptosis at IC50 doses). Molecular analysis using
western blotting and RT-PCR revealed significant induction of apop-
totic markers and down-regulation of pro-survival markers. Further
characterization of the effect of Ibrutinib on PI3K, mTOR, FAS and
NF-kB signaling is ongoing. Ibrutinib is now being evaluated in ICR
SCID mice with sub-cutaneous xenografts of KM-H2 and L1236. A
pre-clinical efficacy trial using maximum tolerated dose (MTD) given
by gavage is ongoing. Conclusions. These are the first studies showing
in vitro and ex vivo effects of BTK inhibitors in HL and may provide
support for further clinical investigation.
P034
FUNCTIONAL ANALYSIS TO ELUCIDATE THE SUSCEPTIBILITY MECHANISMS OF SNPs AT
THE REL, GATA3 AND TCF3 LOCI IN CLASSICAL HODGKIN LYMPHOMA
R. Veenstra, J. Kluiver, D. de Jong, J. Koerts, L. Visser, A. Diepstra,
A. van den Berg
University of Groningen, University Medical Center Groningen, Department of
Pathology & Medical Biology, Groningen, Netherlands
Introduction. Genome Wide Association Studies (GWAS) revealed
significant associations for SNPs mapping at the REL, GATA3 and
TCF3 loci with cHL susceptibility. In this study, we aim to elucidate
the susceptibility mechanism of these associations by establishing
possible expression quantitative trait loci (eQTL) effects. Methods.
EQTL analysis was performed in EBV transformed lymphoblastoid
cell lines (LCLs) generated from 96 controls and 70 former cHL
patients as well as in three previously published large gene expression
studies of HRS cells and total HL tissue samples. Results. An eQTL
effect for REL was found using cHL total tissue array data with
increased REL expression levels for individuals carrying the homozy-
gous risk allele. No significant effects were observed for the HRS cell
data and for the LCLs. For GATA3 a significant association was found
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in the patient derived LCLs with lower GATA3 levels in LCLs of
homozygous risk allele carriers, while no effect was observed for the
control LCLs, or the HRS cell and the cHL total tissue array data. Only
In the control LCLs lower TCF3 expression levels were found for indi-
viduals homozygous for the risk allele. To identify the downstream
targets of these three transcription factors we performed gene expres-
sion arrays of cHL cell lines infected with shRNA constructs. We iden-
tified 1805, 1052, 1602 differentially expressed genes for REL, GATA3
and TCF3, respectively. eQTL analysis of the array data focusing only
on these downstream targets is ongoing. Conclusions. For REL, GATA3
and TCF3 we observed an eQTL effect in at least one of the studied
groups. For REL and TCF3 the eQTL pattern is consistent with the
proposed susceptibility effects of these genes, i.e. higher REL levels
stimulating cell growth and lower TCF3 levels supporting the loss-
of-B-cell phenotype for the risk alleles. Surprisingly, for the T-helper
2 specific transcription factor GATA3 the risk allele is associated with
decreased levels in B-cells, but apparently not in T-cells. Our data sup-
port a functional rol for the risk and protective SNP alleles in cHL sus-
ceptibility.
P035
IGH-MEDIATED TRANSLOCATIONS, RECURRENT IN CLASSIC HODGKIN LYMPHOMA,
FREQUENTLY CORRELATE WITH AN AGGRESSIVE BEHAVIOR 
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Cytogenetic features of classic Hodgkin lymphoma (cHL) remain
largely unknown. Interphase FISH (iFISH) studies, however, suggest that
IGH-mediated t(14q32) are recurrent in cHL (PMID: 17079453,
18940474). Recently, we have identified t(14;18)(q32;q21)/IGH-BCL2
and inv(14)(q11q32)/IGH-CEPBE in two patients with nodular sclerosis
HL (NSHL) analyzed at time of relapse. To identify additional cHL cases
with t(14q32/IGH) and check whether these rearrangements correlate
with clinical outcome, we screened by iFISH: (i) 46 relapsed cHL, (ii) 40
cHL with a long-term remission, and (iii) 60 prospective cases. Alto-
gether, IGH rearrangements were detected in 28 patients, including 17
representing the former group (35.4%), 4 cases representing the second
group (10%) and 7 prospective cases (11.6%). LSI IGH FISH pattern sug-
gested a reciprocal t(14q32/IGH) in 20 cases, nonreciprocal t(14q32/IGH)
in 4 cases, inv(14q32/IGH) or ins(14q32/IGH) in 3 cases and interstitial
del(14q32/IGH) in one case. Twenty six cases were further analyzed by
iFISH with break-apart (BA) assays for BCL2, BCL3, BCL6 and MYC. In
3 cases with likely inv(14)/ins(14), CEPBE BA was applied. Altogether,
we have identified the IGH-BCL2 rearrangement in two cases, including
the index case with t(14;18), and the IGH-CEPBE rearrangement in the
case with inv(14). All the remaining cases showed a non-rearranged sta-
tus of the examined loci. The majority of patients (18/28) with
t(14q32/IGH) were diagnosed with NSHL. There were 18 male and 10
female patients in age ranging from 18 to 91 years (mean 50). Patients
presented with both early (10/26) and advanced (16/26) stage (two not
staged). All were treated with chemotherapy with or without radio-
therapy, except for two patients who were subjected to a palliative treat-
ment. After induction therapy, complete and partial remission was
achieved in 17 and 5 patients, respectively. Thirteen patients are alive
(11 without disease and 2 with disease); 13 patients died, including 11
whose death was related with a disease, and two are lost for follow up.
In summary, we confirmed that chromosomal aberrations involving
14q32/IGH occur recurrently in cHL. These rearrangements rarely target
BCL2 and CEPBE, and do not affect BCL3, BCL6 and MYC. Interestingly,
17 out of 21 (81%) patients with t(14q32/IGH) showed an aggressive
behavior. Our study allows a new insight into the pathogenesis of cHL
and might help in further stratification of cHL patients.
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TIGHTLY REGULATED FOXO3 EXPRESSION IS CRITICAL FOR THE MAINTENANCE OF cHL
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Wuhan, China
FOXO (forkhead box O) transcription factors regulate genes involved
in cell cycle arrest, apoptosis, or oxidative stress response. Recently,
we have shown that FOXO1 is specifically repressed in classical
Hodgkin lymphoma (cHL) and thus acts as a tumor suppressor in this
tumor entity. In contrast, FOXO3 was reported to be markedly
expressed in the malignant Hodgkin and Reed-Sternberg (HRS) cells of
cHL, but not in other B-cell lymphoma subtypes. We confirmed a high
FOXO3/FOXO1 ratio in cHL by analysing publically available gene
expression profiling (GEP) data and found that this ratio is similiar to
those of plasma cells (PC) and multiple myeloma (MM). Of note, cHL
FOXO3 expression was higher than in non-HL, but still less than in
terminally differentiated MM cell lines. These intermediate FOXO3
levels might reflect the “abortive PC differentiation” phenotype of cHL.
Moreover, analysis of GEP data of microdissected HRS cells revealed a
positive correlation between FOXO3 and PRDM1 expression, the mas-
ter regulator of PC differentiation and a tumor suppressor in cHL. This
is similar to our previously published findings showing that FOXO1
regulates PRDM1, the active isoform of PRDM1. Using ChIP, we next
proved that FOXO3, too, directly binds to the PRDM1 promoter in
cHL. To further investigate this interaction, we overexpressed a consti-
tutively active variant of FOXO3 (FOXO3(A3)ER) in cHL cell lines.
FOXO3 activation increased PRDM1 expression levels and inhibited
proliferation of cHL cell lines. So far, frequent genomic deletions are
known to restrict FOXO3 levels in cHL. Aiming to identify additional
factors involved in the tight regulation of FOXO3 in cHL, we found
that miR-155 negatively influences FOXO3 expression. Paradoxically,
knockdown of FOXO3 with the help of a specific shRNA also showed
an antitumor effect in two of three cHL cell lines, whereas FOXO1
downregulation was not toxic. Our data suggest that intermediate lev-
els of FOXO3 contribute to abortive PC differentiation of cHL and that
tightly regulated FOXO3 expression might be critical for the oncogenic
program of cHL.
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IN VITRO AND IN VIVO PRECLINICAL ACTIVITY OF EDO-S101 IN HODGKIN LYMPHOMA
M. Al Jawhari1, C. Cuceu1, M. Frenzel1, L. Stimmer2, S. Junker3, J. Bosq4,
P. Carde5, T. Mehrling6, L. Sabatier1, F. Pflumio7, R. M’kacher1,8
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of Aarhus, Aarhus, Denmark; 4Departement of Anapathology, Institut Gustave
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Background. EDO-S101 is an alkylating histone-deacetylase inhibitor
(HDACi) fusion molecule that combines the strong DNA damaging
effect of Bendamustine, with a fully functional pan-HDAC inhibitor,
vorinostat. In this work, we investigated the preclinical rationale for
the use of EDO-S101 in Hodgkin lymphoma (HL). Materials and Meth-
ods. In vitro, a panel of 8 HL cell lines was used to study the cytotoxicity
of EDO-S101 alone and combined with radiation therapy, and to inves-
tigate its cellular and molecular effects. In vivo, we investigated in
immunodeficient NOD/SCID-gammac-/- mice xenografted with the
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L428 the antitumor effect of EDO-S101 alone . This evaluation, based
on organ infiltration and survival, was performed following one single
(60mg/kg or 80mg/kg) dosing or a repeat- dose (60mg/kg) of EDO-S101.
Results. In vitro, the IC50 of EDO-S101 ranged between 1.6 to 6.3 M in
8 Hl cell lines after a 48 h-exposure. All HL cell lines showed a high
sensitivity to EDO-S101; a clonogenic survival assay confirmed these
observations. Multiple mechanisms of action of EDO-S101 were iden-
tified. In one group of HL cell lines (L428-L428-s, L540, SUP-HD, L591
and KMH2), activation of apoptosis was independent of the P53 status.
The combination of EDO-S101 with irradiation demonstrated a dra-
matical enhancement of apoptotic cell death via G2 arrest. In a second
group (L1236 and HDLM2), with the higher sensitivity to EDO-S101,
resistance to apoptosis was associated with a higher frequency of chro-
matid aberrations involved in mitotic cell death. The effect of radiation
was marginal in this group. In vivo, in mice engrafted with the L428
cells, treatment with EDO-S101 reduced drastically L428 cells infiltra-
tion, and prolonged survival of EDO-S101 treated mice in comparison
with those untreated. Histological evaluation of the infiltration of
tumoral cells after EDO-S101 treatment showed a significant reduction
of tumor cell infiltration, more pronounced after a single dose of 80
mg/kg EDO-S101 than after two administrations of 60mg/kg. We
observed a high liver weight heterogeneity in untreated mice, contrast-
ing with homogeneous weight in treated mice. The absence of necrotic
cells and cell degeneration in treated mice could be correlated to the
anti-tumoral effect of EDO-S101 confirming the efficacy of EDO-S101.
Conclusions. Our results show the antitumoral activity of EDO-S101 in
pre-clinical models of HL, both in vitro and in vivo. 
P038
HODGKIN REED-STERNBERG CELLS IN CLASSICAL HODGKIN LYMPHOMA ARE
SURROUNDED BY T REGULATORY CELLS WHILE LYMPHOCYTE PREDOMINANT CELLS OF
NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA ARE SURROUNDED BY T
FOLLICULAR HELPER CELLS
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Department of Pathology and Medical Biology, University of Groningen,
University Medical Center Groningen, Groningen, The Netherlands
While it is clear that there is an important role for the microenviron-
ment in Hodgkin lymphoma (HL), the composition and functionality is
still a matter of discussion. Both a Th2 and a Th1 phenotype has been
described in classical HL (cHL), irrespective of the Epstein Barr virus
(EBV) status of the tumor cells. A systematic comparison between cHL
and nodular lymphocyte predominant HL (NLPHL) has not been per-
formed before and studies on the composition of the cells in- versus
outside of the tumor area are missing. We compared the composition
of the microenvironment of 14 cHL (7 EBV+ and 7 EBV-) and 10 NLPHL
suspensions by flowcytometry. CD26 expression was used to identify
cells in- (CD26-) and outside (CD26+) the tumor cell area. Results. In
EBV+ cHL there were more CD56+CD16+ NK cells, and more CD69+,
Granzyme B+ and TIA-1+ CD8+ cells than in EBV- cHL. We saw no
differences between EBV+ and EBV- cHL when looking at the location
of the cells. Compared to cHL, NLPHL contained more PD-1+ CD4+
cells and PD-1+CD57+CD4+ cells, while cHL showed more
CCR7+CD45RA+CD4+, FoxP3+CD4+, CD25+CD4+,
CXCR5+ICOS+CD4+, CXCR3+CD8+ and CD56+ cells. In cHL, we
found more CD69+CD4+ and FoxP3+CD4+ cells inside, and more
CD25+CD8+ cells outside the tumor cell area. In NLPHL, the distribu-
tion of CD69+CD4+ cells and CD25+CD8+ cells was similar to cHL.
In addition, we found more CD69+CD8+, and more PD1+CD4+ cells
inside, and more FoxP3+CD25+CD4+ cells outside the tumor cell area.
Both HL subtypes are characterized by high numbers of CD69+CD4+
cells inside the tumor cell area, and a shift of CD25+CD8+ cells from
in- to outside the tumor cell area. Conclusions. PD-1+CD4+ T follicular
helper cells normally provide help to germinal center B cells and the
increase in the tumor cell area of NLPHL indicates a similar function
for LP cells. In cHL, the increase of FoxP3+ T regulatory cells might pro-
vide an immune suppressive environment for the HRS cells. Both types
of HL depend on different cells in the direct tumor cell environment,
fitting the different nature of the tumor cells.
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THE INCIDENCE OF BLEOMYCIN INDUCED LUNG TOXICITY IS INCREASED IN HODGKIN
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Background. In Hodgkin lymphoma (HL) the risk of developing
bleomycin pulmonary toxicity (BPT) is well described. A number of
factors that could potentially increase the risk of this condition have
been suggested e.g. increasing age, bleomycin dose, smoking history.
The use of granulocyte-colony stimulating factor (G-CSF) has also been
proposed as a potential risk factor for BPT. In the present study, we
have investigated the incidence of BPT in the face of possible risk factors
in a cohort of HL patients treated at our institution between 1990 and
2014. Methods. Information on clinico-pathological parameters including
the occurrence of BPT, the use of filgrastim/pegfilgrastim and smoke
habits was obtained from clinical records. BPT was defined as pul-
monary symptoms occurring during the course of chemotherapy, pres-
ence of infiltrates on chest X-ray or CT-scan and absence of infection.
Patient characteristics were correlated to the presence of BPT and use
of G-CSF using the chi2-test. Overall- and progression-free survival (OS
and PFS), were analyzed by the Kaplan-Meier method. Results. 413
patients with a median age of 38.5 yrs (range: 16-86 yrs) were analyzed.
The M:F ratio was 1,3. A total of 155 patients (38%) had disseminated
disease. B-symptoms and bulky lesions were present in 48% and 31%
of the patients, respectively. A history of smoking was reported in 47%
of all patients. A total of 36 patients (9%) were diagnosed with BPT.
The incidence of BPT was found to be higher among patents with high
stage (p<0,001) and among those presenting with B-symptoms
(p=0.008), i.e. the subsets that were likely to have received the largest
amounts of bleomycin. A trend was found towards a higher incidence
with increasing age (p=0.06). No correlation was found between BPT
and a smoking history (p=0,37). Patients presenting with BPT were
more likely to have been exposed to the use of G-CSF (p=0,03). Inter-
estingly, the highest number of BPT events was observed among the
patients exposed to the PEGylated forms of G-CSF (p=0,02). When
stratifying the analysis according to age, the above correlations
remained significant in the age group above 45 years, but did not seem
to impact the younger patients. Conclusions. In the present study, the
occurrence of BPT was correlated to the presence of disseminated dis-
ease and B-symptoms at the time of diagnosis. We also found a higher
incidence of BPT among the patients that were exposed to G-CSF dur-
ing the course of chemotherapy. 
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CLASSICAL HODGKIN LYMPHOMA INCLUDED IN A PROSPECTIVE STUDY OF THE
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Benite, France; Unite de Prevention et d’Epidemiologie Genetique - UMR UCBL
CNRS 5558, Centre Leon Berard, Lyon, France; INSERM U917, Hematology
Laboratory, Universite de Rennes 1, Hopital Pontchaillou, Rennes, France;
Department of Hematology, CHU Dijon, Dijon, France
Introduction. Classical Hodgkin Lymphoma (CHL) is characterized
by PD-L1/L2 deregulation with the effectiveness of PD-1 blockage
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treatment. Pre-treatment level of soluble PD-L1 (sPD-L1) was more
elevated in diffuse large B-cell lymphoma (DLBCL) patients than in
controls and was associated with overall survival. We evaluated pre-
treatment sPD-L1 level of 126 CHL patients included in a prospective
study of the Lymphoma Study Association (LYSA) and 37 controls.
Methods. The cohort consisted in 126 CHL patients enrolled between
1998 and 2002 in a prospective study of the LYSA assessing the prog-
nostic values of plasma cytokines and soluble receptors. A peripheral
blood sample for plasma was collected from all patients at diagnosis
before any treatment. The protein expression of sPD-L1 was evaluat-
ed in duplicate using an ELISA kit. A Zero-Inflated Binomial-Negative
regression model was used to compare sPD-L1 levels in CHL patients
and controls. Correlation between log-transformed sPD-L1 level and
clinical characteristics, EBV status and cytokine levels measured
before any treatment (IL-10, TNF, TNF-R1, TNF-R2, IL-6, IL-1R,
sCD30), response to initial treatment and progression-free survival
(PFS) were investigated. Results. the median age of the 126 CHL
patients was 33 years (range, 15-93), 68% had an Ann Arbor stage I-
II and 71% had an IPS score of 0-2. Nodular sclerosis was the main
histologic subtype (83%). The EBV status was positive in 18 (27%)
patients. 67% patients were treated with ABVD, 14% of patients pro-
gressed or relapsed and 11% died. sPD-L1 mean level in CHL patients
was 3.56 times more elevated in cases than in controls (95% CI: 2.66-
4.76, p= 8.2e-13; estimated means for cases and controls: 869 vs 3093
pg/ml; medians: 549 vs 1954 pg/ml). No statistically significant corre-
lation/association was found between sPD-L1 level and age, Ann
Arbor stage, ECOG-PS, IPS, lymphocyte count, EBV status, the dif-
ferent evaluated cytokines, response to treatment and PFS. Conclusions.
CHL patients have a PD-L1 level in plasma which is higher than con-
trols and DLBCL patients. Further studies are needed to decipher the
prognostic role of sPD-L1 level in larger cohort including patients with
more advanced stages and treated with immune checkpoint
inhibitors.
P041
PROTEASOME INHIBITOR THERAPY IN HODGKIN LYMPHOMA: LEVERAGING SYSTEMS
BIOLOGY ANALYSES FOR CELL-SPECIFIC TRANSCRIPTOME ALTERATIONS AND OPTIMUM
COMBINATORIAL THERAPY
F.C. Passero Jr., A. Beheshti, R. Dashnamoorthy, A.M. Evens
Division of Hematology Oncology and Molecular Oncology Research Institute,
Tufts Medical Center, Boston, Massachusetts, USA
Introduction.NF- B has been shown to be critical for HL cell survival.
Ixazomib is a new oral PI with favorable pharmacodynamic and phar-
macokinetics; we recently reported activity of ixazomib in HL cells
and in vivo SCID xenografts (Ravi et al. Cancer Research. 2016). SBA
favored tumor inhibition via downregulation of MYC and CHK1 with
CHK1 involved in Myc alteration through chromatin modification &
histone H3 acetylation. Continued dissection of cell-specific transcrip-
tome changes with PIT is needed and potential combination therapy
with ixazomib should be explored. Methods.We examined ixazomib-
induced transcriptome changes in L540 & L428 cells that were ixa-
zomib sensitive and also with generated resistance. Key genes were
derived from overlapping Ingenuity Pathway Analysis (IPA) and Gene
Set Enrichment Analysis (GSEA). SBA were used to identify genes
related to treatment response; and based upon the aforementioned
results, we studied the HDAC inhibitor (HDACi), belinostat, com-
bined with ixazomib. Results.On GSEA (Figure 1A), ixazomib induced
downregulation of mitotic cell cycle in L540 cells, while L428 cells
had noted upregulation. Chromatin architecture was downregulated
in L540, while L428 had no change. Catabolic activity and vesicular
function linked to protein localization and transport were upregulated
in L540 & L428 cells. Furthermore, analysis of “key genes” predicted
greater ‘tumor promotion’ in ixazomib-resistant L428 vs ixazomib-
sensitive L428 and L540 cells (Figure 1B and 1C). Among 66 common
key genes in L540 & L428, the most connectivity was seen between
CDKN1A (p21), JUN, GADD45A, ATF4, HSPA8, SQSTM1 (p62),
CSF2, CEBPB and its inhibitory binding partners DDIT3 and TRIB3
(associated with cell cycle, apoptosis, response to oxidative stress &
autophagy). For combination studies, ixazomib+belinostat was highly
synergistic with combination index <0.5. On Western blot, ixa-
zomib+belinostat resulted in increased p21, cleaved caspases,
decreased autophagy (ie, proteins p62 and cathepsin) and also
decreased Myc, which had previously been implicated with ixazomib.
Conclusions. Ixazomib alone has prominent in vitro and in vivo activity
in HL, and via SBA, we identified rational synergistic therapy with
HDACi. In addition, we identified HL cell-specific transcriptome
changes affecting varied and distinct pathways involving cell cycle,
autophagy and apoptosis. Continued understanding of cell and drug-
specific omic alterations are warranted.
Figure 1.
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TELOMERE MAINTENANCE MECHANISMS AND TUMOR MICROENVIRONMENT ARE KEY
FACTORS IN THE OUTCOME OF CLASSIC HODGKIN LYMPHOMA
R. M’kacher1,2, C. Cuceu1, L. Morat1, M. Al Jawhari1, M. Frenzel1,
G. Shim1, A. Lenain1, M. Ricoul1, W. Hempel1, E. Guilotto3, S. Junker4,
T. Girinsky5, C. Badie7, B. Colicchio8, A. Dieterlen8, E. Jeandidier9,
O. Moralès10, S. Renaud10, Z. Van de Wyngaert11, P. Carde6, N. Delhem10,
L. Sabatier1
1Laboratoire de Radiobiologie et d’Oncologie, IRCM/DSV/CEA Fontenay aux
Roses, France; 2Cell Environment Oncology Section Paris France; 3Laboratory of
Cellular and Molecular Biology, University of Pavia, Italy; 4Institute of Human
Genetics University of Aarhus Hospital, Denmark; 5Departement of Radiation
Therapy, Gustave Roussy Institut, Villejuif, France; 6Departement of Medicine,
Gustave Roussy Institut, Villejuif, France; 7Biological Effects Department, Centre
for Radiation, Chemical and Environmental Hazards, Public Health England,
Didcot, UK; 8Laboratoire MIPS - Groupe TIIM3D Université de Haute-Alsace,
Mulhouse, France; 9Cytogenetic Service, Centre Hospitalier de Mulhouse, Mul-
house, France; 10Université Lille, CNRS, Institut Pasteur de Lille, Siric OncoL-
ille,UMR 8161 - M3T – Mechanisms of Tumorigenesis and Target Therapies,
Lille, France; 11Hematology department, CHRU de Lille, Lille, France
Background. About 15-20% of patients with advanced stage
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Hodgkin lymphoma (HL) still die following relapse or progressive dis-
ease and a similar proportion of patients are over-treated, leading to
treatment-related late sequelae, including solid tumors and organ dys-
function. We analyzed telomere maintenance mechanisms (TMMs)
of HL cell lines as well as the samples from HL patients treated with
standard therapy and compared the TMMs with favorable and unfa-
vorable clinical outcome. Materials and Methods. Frozen lymph node
samples obtained from 38 HL patients during diagnostic lymph node
biopsy and from 24 patients with lymphadenitis were entered in this
study. All HL patients were stage I (84.2%) and II (15.8%) with mean
age of 36.7 years and 94.7% were nodular sclerosis. Seven HL cell
lines were used as a positive control. Telomerase activity (TA) and
alternative lengthening telomere (ALT) profile were assessed as well
as Epstein Barr Virus (EBV) status and protein expression levels. The
TMMs were correlated to clinical outcomes of patients (10.3 years)
as well as to radiation sensitivity of HL cell lines. Results. The major
finding of this study is the presence of both TA and ALT mechanisms
in selected lymph nodes of HL patients. This TMMs heterogenei ty
was confirmed in HL cell lines. Hodgkin and Reed Sternberg (HRS)
cells demonstrated an ALT profile, while the small cells exhibited a
higher telomerase activity. We identified in the same tumor lymph
node HRS cells containing ALT-associated PML bodies, a hallmark of
ALT, and separate small cells expressing telomerase. Similarly, in HL
cell lines, a high level of TA was detected in L428 and SUP-HD1. L1236
cell line demonstrated a lower TA and presented an ALT profile. The
latent membrane protein (LMP1) staining revealed the presence of
EBV genome in HRS cells in 13 lymph nodes (34.2%). A higher expres-
sion of TRF2/PML (ALT profile) and CD68 in EBV positive patients
was correlated with Overall Survival (p=0.02), Freedom From Progres-
sion (p=0.02) and Event Free Survival (p=0.003). ALT HL cell lines
demonstrated a lower radiation sensitivity as compared to TA HL cell
lines. Conclusions. The presence of both TMMs (TA and ALT) in HL
lymph nodes and HL cell lines is a singular oncology phenomenon.
TMMs, related to tumor microenvironment in HL lymph nodes, are
associated with treatment response and survival of HL patients. 
P043
PHENOTYPIC CHARACTERIZATION OF CIRCULATING LYMPHOCYTES IN HODGKIN’S
LYMPHOMA WITH FOCUS ON T CELLS
M. Palma1,2, K. Heimersson2, B. Näsman-Glaser2, L. Hansson1,2
1Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;
2Department of Oncology & Pathology, Karolinska Institutet, Stockholm, Sweden
Background. The malignant cells in HL comprise only a small fraction
of the total tumor population but orchestrate an inflammatory
microenvironment of reactive cells that sustains tumor cell survival
and growth. HL patients (pts) have high systemic levels of inflamma-
tory cytokines and chemokines and low lymphocyte count
(<0.6x109/L) is a well-established prognostic factor in advanced dis-
ease. The aim of this pilot study was to characterize the phenotype
of circulating lymphocytes in HL pts. Materials and Methods. Peripheral
blood samples were obtained from 10 HL pts and 12 sex- and age-
matched healthy controls. Nine pts had classical HL and 1 had nodular
lymphocyte predominance (NLP) HL. Five pts had limited (stage I-
IIA) and 5 had advanced (IIB-IV) disease. Pts with ongoing acute EBV
infection were excluded. All pts had negative serology for HIV.
Absolute numbers of CD19+, CD3+, CD4+, CD8+, NK and NKT cells,
functional T helper subpopulations (Th1/Th2/Th17), CD4+ and CD8+
memory cell subsets and expression of CTLA-4, PD-1, CD69 and Ki-
67 on CD4+ and CD8+ T cells were assessed by flow-cytometry.
Results. HL pts with advanced disease had lower lymphocyte counts
compared to controls (median 0.9 vs 1.7x109/L, p=0.01) while no dif-
ference was observed for pts with limited disease. Compared to con-
trols, HL pts had lower CD19+ cell numbers irrespective of disease
stage (0.075 vs 0.05x109/L in pts with limited and advanced disease vs
0.19x109/L in controls, p=0.009 and p=0.0003, respectively). Pts with
advanced disease had also significantly lower numbers, compared to
controls, of CD3+ (median 0.78 vs 1.36x109/L, p=0.04), CD4+ (median
0.3 vs 0.5x109/L, p=0.04), Tregs (median 0.008 vs 0.017x109/L,
p=0.004), Th2 (median 0.18 vs 0.28x109/L, p<0.05) and Th17 cells
(median 0.03 vs 0.08x109/L, p=0.006), while no difference was
observed for Th1. HL pts had lower numbers of naive CD8+ cells irre-
spective of disease stage, while central memory CD4+ cells were low-
er in advanced disease. No difference was observed with regard either
to the numbers of proliferating (Ki67+) or PD-1- and CTLA-4-express-
ing CD4+ and CD8+ cells. On the other hand, CD69+CD4+ cells were
significantly higher in pts with limited disease compared to controls
(median 0.04 vs 0.01x109/L, p=0.04) (Figure 1). Conclusions. These
observations suggest that the immune microenvironment in HL plays
a role that is far from being only local. Further studies are ongoing in
larger cohorts of pts.
Figure 1.
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SIP-F1: A NEW GRAY ZONE LYMPHOMA CELL LINE?
B. Rengstl1, S. Hartmann1, S. Eberth2, C. Döring1, C. Pommerenke2,
P.S.A. Becker3, C. Weiser1, K. Warner1, C. Doering1, C. Seidl3, R. Küppers4,
H. Abken5, R.A. MacLeod2, H.G. Drexler2, M.-L. Hansmann1,*,
S. Newrzela1,*
1Dr. Senckenberg Institute of Pathology, Goethe-University of Frankfurt, Medical
School, Theodor-Stern-Kai 7, Frankfurt am Main, Germany; 2Leibniz Institute
DSMZ, German Collection of Microorganisms and Cell Cultures, Braunschweig,
Germany; 3Institute for Transfusion Medicine and Immunohematology, Red Cross
Blood Donor Service, Baden-Württemberg-Hessen, Frankfurt,
Germany; 4Institute of Cell Biology (Cancer Research), University of Duisburg-
Essen, Medical School, Essen, Germany; 5Center for Molecular Medicine
Cologne, University of Cologne, and Department I of Internal Medicine,
University Hospital Cologne, Cologne, Germany
*Shared last authorship
Lymphoid cancers are mainly classified according to their clinical
presentation, morphology, immunology and molecular genetic fea-
tures. Diagnosis of Hodgkin lymphoma (HL) is mainly based on
pathognomonic Hodgkin and Reed-Sternberg cells (HRS). However,
in the group of non-Hodgkin lymphomas (NHL), diffuse large B-cell
lymphoma (DLBCL) can resemble typical features of HL. In some cas-
es, a diagnostic pitfall exists at the interface of HL and DLBCL, so
that, morphological overlaps and missing clear-cut diagnostic criteria
complicate classification of these so-called gray zone lymphomas
(GZL). In a recent study, we analyzed a newly established GZL cell
line (SIP-F1) derived from a lymph node biopsy of a male 20-year-old
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lymphoma patient. Histological sections of the primary GZL were
characterized by striking pleomorphism of in part multinuclear blast
infiltrates and areas of necrosis. Immunohistochemistry revealed
tumor cell positivity for the markers CD15, CD20 and CD30. SIP-F1
presented clonal Ig gene rearrangement and flow cytometry analysis
showed expression of B-cell markers as well as 50-60% positivity for
HL marker CD30. In addition, we observed tumor growth of SIP-F1
in a xenograft mouse model, morphologically resembling the primary
tumor with lacunar HRS-like cells growing in sheets. For closer char-
acterization, we performed gene expression profiling (GEP) and com-
pared SIP-F1 to several B-cell lymphoma cell lines. The GEP of SIP-F1
did not cluster with any of the compared entities. Interestingly, but
yet quite surprisingly, cytogenetic analysis revealed a normal kary-
otype. As SIP-F1 is positive for EBV, the cell line probably displays
more a transformed B-cell clone than a GZL cell line. The patient,
SIP-F1 is derived from, showed fast tumor rejection after initialization
of chemotherapy. We were able to receive T cells for a co-culture
study and could show that his immune system regained anti-tumor
strength. In conclusion, considering the paucity in prospective differ-
entiation of GZL cases, their distinct clinical behavior and treatment,
we think that SIP-F1 could be a helpful tool to study morphological
and molecular features of GZL and to better understand the biology
of these unusual cases, although we are still tackling the question,
what is the real tumor cell clone.
P045
CD4 LYMPHOPENIA AS A PROGNOSIS FACTOR IN PREVIOUSLY UNTREATED HODGKIN
LYMPHOMA
T. Bogatyreva, G. Neprina, I. Zamulaeva, A. Terekhova, S. Smirnova,
N. Orlova, M. Daniliva, V. Pavlov
A.F. Tsyb Medical Radiological Research Centre - Branch of the National
Medical Research Radiological Centre of the Ministry of Health of the Russian
Federation
Peripheral lymphopenia (PL) is included in IPS for advanced Hodgkin
lymphoma (HL). Prognostic value of PL in stages I-II of HL as well as
lymphocyte subsets responsible for PL have to be clarified. To evaluate
the influence of baseline lymphocyte count on the treatment efficacy
in HL total of 838 patients were included in the study. Flow cytometry
was done in 83 patients, 47 (57%) had PL defined as lymphocyte count
less than 1000/mm3. CD4 counts were available in additional 72
patients. Progression-free survival (PFS) and overall survival (OS) were
analysed with reference to lymphocyte count at diagnosis and CD4
content. Results PL was found in 116/838 (14%) HL patients: 1,4% in
early favorable (Gr.1), 7,5% in early unfavorable (Gr.2) and 18,6% in
advanced HL(Gr.3). Flow cytometry data of 47 patients with PL
revealed low T-cell counts in 41(87%) of cases, mixed T- and B-cell
lymphopenia in 25/41 (61%) cases, B-cell lymphopenia in 6/47 (13%)
of cases. Deep CD4 lymphopenia (less than 200/mm3) was observed
in 24(16%) out of 155 patients; it was associated with age ≥45
(p=0.017), lymphoid depletion (p=0.13), advanced stage (p=0.061) and
IPS score ≥4 (p=0.000). At a median follow up of 60 months, PFS rate
and OS were significantly impaired in 58 patients with low CD4 count
(less than 400/mm3). In Gr.1 progression occurred in one of the two
patients who had both PL and CD4 lymphopenia; OS was 100%. In
Gr.2, six patients with low CD4 counts at diagnosis had PFS 50% vs
95% in the rest, p=0.007; OS was 30% vs 100%, p=0.001. In 115
patients from Gr.3 those with low CD4 count (n=49) had PFS 72% vs
89%, p=0.037; OS was 75% vs 95%, p=0.003. Subset analysis in 91
patients with stages III-IV and IPS 0-3 supported negative impact of
CD4 lymphopenia (PFS 79% vs 90%, p=0.266; OS 84% vs 97%,
p=0.018). Conclusion The study shows that absolute lymphopenia is
an independent adverse factor for stages I-II and for advanced HL
patients with IPS 0-3. These results may justify alternative therapeutic
strategies, including early antiCD30 therapy to account for CD4 lym-
phopenia at diagnosis.
P046
CAN PLASMA CHEMOKINES AND SOLUBLE RECEPTOR MONITORING PREDICT OUT-
COME IN CLASSICAL HODGKIN’S LYMPHOMA PATIENTS?
A. Stamatoullas1, A. Perdrix2, E. Lemasle1, C. Thill3, V. Camus1,
L. Veresezan2, J.M. Picquenot2, A.L. Menard1, P. Lenain1, N. Contentin1,
H. Lanic1, S. Lepretre1, O. Brehar1, N. Cardinael1, M.L. Fontura1,
C. Fronville1, F. Jardin1, C. Bastard2, H. Tilly1
1INSERM U918, Hematology Department; 2Biopathology Department, Centre
Henri Becquerel, Rouen, France; 3Centre de traitement des Données du Can-
céropole Nord Ouest (CTD-CNO), Centre François Baclesse, Caen, France
The usual prognostic scores used in cHL fail to identify some patients
with worst outcome either in early or advanced stage HL. Pre-treatment
cytokines, soluble receptor, cytokine signature (Casasnovas JCO 2007)
and TARC profile have been described as biological markers correlated
to tumour burden, to response and outcome. To evaluate the impact of
TARC, IL6, IL1-RA, sCD30 and TNF-R1 levels on response and out-
come, we collected plasma from 50 newly diagnosed cHL patients at
baseline, during therapy and at the end of chemotherapy. We also
analysed the correlation of usual prognostic factors with cytokines and
soluble receptor level. Between April 2010 and November 2013, 50 cHL
patients were enrolled (26 M/ 24F), median age was 31 years (18,5-63).
Main clinical characteristics were as follow: stage I-II in 24 patients
(according to EORTC classification: favourable: 7 and unfavourable:
17) and stage III-IV in 26 patients (IPS 1-2: in 15 patients). Thirty five
patient were treated with ABVD and 15 patients with eBEACCOP.
Radiotherapy was added in 24 patients. Mean TARC level was 281
pg/ml (27-83098), mean IL6 level was 2.9 pg/ml (0,6-175), mean IL1-
RA was 252 pg/ml (0,9-6609), mean sCD30 level was 33 U/ml (8,8-
1007), and mean TNR-F1 level was 2129,5 ng/ml (314-8463). Baseline
cytokines level or cytokines signature did not correlate significantly
with any clinical or biological factors nor with FDG-PET response. Ten
patients disclosed relapse or progressive disease (R/R), only two
patients died. With a median follow-up of 48 months, the event free
survival (EFS) and overall survival (OS) at 3 years are 82% (95% CI 68-
90) and 96% ( 95% CI 85-99) respectively. None of the classical prog-
nostic factors as early response evaluated with FDG-PET were corre-
lated with PFS. Neither baseline cytokines levels nor cytokine signature
or early reduction of IL1-RA, sCD30, TNR-F1 level impacted signifi-
cantly the outcome, but a trend was noted with early reduction of
TARC and IL6. The decrease of TARC and IL6 seems to predict
response to therapy and EFS. Unfortunately we failed to demonstrate
any correlation between baseline cytokines or cytokine signature with
biological or clinical characteristics, and outcome in this population.
Surprisingly none of the usual prognostic factors predict outcome.
These results could be perhaps explained by the small number of
patients and should be confirmed in a larger prospective study.
P047
EXPRESSION AND PROGNOSTIC IMPACT OF INDOLEAMINE 2,3-DIOXYGENASE IN
HODGKIN’S LYMPHOMA
I. Kryachok1, O. Novosad1, T. Skrypets1, K. Ulianchenko1, I. Tytorenko1,
N. Khranovska2, O. Skachkova2, N. Svergun2, O. Gorbach2
1Oncohematology; 2Experimental Oncology, National Cancer Institute, Kiev,
Ukraine
Background. Indoleamine 2,3-dioxygenase (IDO) catalyzes the rate-
limiting step in the metabolism of tryptophan along the kynurenine
pathway. IDO is a key factor maintaining immune tolerance and expres-
sion correlates with poor clinical outcome in different types of cancer
and hematological malignancies. Nowadays, not enough attempts have
been made to evaluate IDO expression and its prognostic score value.
We assessed the impact of the IDO expression on clinical outcome in
patients with Hodgkin lymphoma (HL). Methods.The case group includ-
ed 23 patients (5 male and 18 female) with HL (median age: 19-60 years,
range: 39.5). With early stage were diagnosed 52.2% and 47.8% with
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advanced. Only 26% cases had B-symptoms. ABVD or BEACOPP
(14/esc) were administered as a first-line therapy. In 65.2% and 34.8%
cases, achievement remission and progression disease after treatment,
respectively. The relative mRNA expression levels of IDO were meas-
ured in pre-treatment tumor tissue specimens from HL patients using
real-time qPCR analysis. Results. The mRNA expression of IDO was
found in 15 cases (65.2%) and further this group was considered as IDO-
positive. The presence of IDO expression was significantly associated
with advanced stage of disease and B-symptoms (p<0.05). The relapse
was more frequently found in cases with IDO+ compared IDO- HL
(30.47% versus 4.3%, p<0.05). 13% patients with IDO+ expression died
and had an early relapse or refractory disease. ROC analysis revealed
that IDO+ expression in the tumor is an important marker which is
associated with reduced progression-free (PFS) and overall survival (OS)
in HL patients (Se=87.5%; Sp=78%; AUC=0.85). 5-year PFS for patients
with IDO+ expression was 44% versus 89% of IDO- expression
(p=0.0003). Two-sample comparison between the IDO+ versus IDO-
expression was done by the Cox F-test. The difference was significant
for PFS and OS (p=0.03) (Figure 1). Conclusions.The obtained results sug-
gest that the IDO-positive expression can predict clinical outcome in
patients with HL and seems to be promising for the future studies.
Figure 1.
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REED-STERNBERG CELLS ON BONE MARROW CYTOLOGY: THE VERY EARLY FEATURE ON
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS ASSOCIATED TO HODGKIN LYMPHOMA
L. Niero-Melo1, L.A. Lustri1, B.F. Polegatto2, C. Del Castanhel1,
L.O. Cantadori1, C.C. Oliveira3, R.D. Gaiolla1
1Hematology, Department of Internal Medicine, Botucatu School of Medicine,
Sao Paulo State University - UNESP, Sao Paulo, Brasil; 2Department of Internal
Medicine, Botucatu School of Medicine, Sao Paulo State University - UNESP,
Sao Paulo, Brasil; 3Department of Pathology, Botucatu School of Medicine, Sao
Paulo State University - UNESP, Sao Paulo, Brasil
Introduction. Hemophagocytic lymphohistiocytosis (HLH) is a hyper-
inflammatory disorder resulting from primary or acquired immune dys-
function. In adults, HLH is most frequently associated to infections,
autoimmune diseases, and lymphomas, although Hodgkin lymphoma
(HL) has been less frequently described. This immune activation leads
to a variety of clinical and laboratory features, including pancytopenia,
which makes bone marrow examination an important tool in order to
identify possible trigger factors for HLH. Case Report. A 53 year-old
white female, was referred to the Hospital das Clínicas de Botucatu –
UNESP (São Paulo, Brazil) with a 4-day history of mental confusion.
She had no palpable lymphadenomegaly, hepatosplenomegaly or
abdominal mass. Complete blood count showed markedly pancytope-
nia. Lactate dehydrogenase was normal and serum ferritin was 9.621
mg/dl. Bone marrow (BM) cytology evaluation showed markedly
hemophagocytosis and some large cells were identified as “Owl Eye
Cell” and “Mononuclear Hodgkin’s Cells”. The bone marrow clot eval-
uation showed frequent epithelioid granulomas, without necrosis, and
bi-nucleated and mononuclear cells with large nuclei and evident nucle-
oli, featuring classic Reed-Sternberg cells and Hodgkin’s cells. Immuno-
histochemistry confirmed the diagnosis of bone marrow infiltration by
HL with granulomatous reaction. The Ziehl-Neelsen and Grocott-
Gomori stains were negative (Figure 1). Discussion. BM cytological eval-
uation is immediately required in cases of pancytopenia for diagnostic
purpose, regardless the level of blood counts. Especially in HLH, it is
part of a systematic front-line clinical investigation for possible immune
triggers. Epithelioid granulomas in BM or lymph nodes of patients with
a nonspecific clinical presentation is a diagnostic challenge as it can be
associated with a variety of autoimmune, inflammatory and neoplastic
conditions. HL can present with granulomas in about 14% of cases,
although it is unusually seen in BM biopsy. In this context, a careful
morphological analysis with immunohistochemistry study is highly
recommended considering that the absence of a typical HL presentation
can sometimes postpone diagnosis and compromise disease outcome.
Conclusions. This case highlights the importance of prompt investigation
of pancytopenia in the context of HLH, with an early diagnosis of HL




A NOVEL PTPN1 SPLICE VARIANT REGULATES JAK/STAT ACTIVITY IN CLASSICAL
HODGKIN’S LYMPHOMA CELLS
M. Zahn*, R. Marienfeld*, I. Melzner, J. Heinrich, A. Rehm, T.F. Barth,
K. Dorsch, S. Brüderlein, P. Möller
Institute of Pathology, Ulm University, Ulm, Germany
*Equal contribution
Background. Chronic activation of the Janus kinase (JAK)/ Signal Trans-
ducer and Activator of Transcription (STAT) signaling pathways is a
hallmark of a variety of B cell lymphomas including the classical
Hodgkin’s lymphoma (cHL). Constitutive JAK/STAT signaling is crucial
for survival and proliferation of Hodgkin/Reed-Sternberg (HRS) cells,
the malignant cells of cHL. Although the exact molecular basis of this
constitutive JAK/STAT signaling in cHL has not been understood com-
pletely, accumulating reports highlight the role of an inactivation or
reduced expression of negative JAK/STAT regulators like Silencer of
Cell signaling 1 (SOCS1) or Protein-Tyrosine Phosphatase 1B (PTP1B)
haematologica | 2016; 101(s5) | 11
Cologne, Germany, October 22-25, 2016
ISHL_2016_S5_Abstract book_indice nomi ok.qxp  19/09/16  12:05  Pagina 11
in this process. Given the essential role of PTP1B and SOCS1 for the
constitutive JAK-STAT signaling in cHL, the identification and charac-
terization of the regulatory mechanisms controlling the activity of these
negative JAK/STAT regulators is crucial for the understanding of their
role for the pathogenesis of cHL. Here, we report the expression of dif-
ferent truncated PTP1B mRNA variants identified in cHL cell lines and
primary cHL tumor samples lacking either one or several exon
sequences. We describe the expression of a shorter PTP1B isoform in
cHL as a novel negative control mechanism for PTP1B involved in the
dis-regulation of the JAK-STAT pathway. Methods. PTP1B mRNA of
cHL cases and cell lines was isolated and sequenced by Sanger sequenc-
ing. PTP1B protein expression was determined by western blot and
immunohistochemistry analyses. Expression analysis of PTP1B mRNA
variants was done by qPCR. To determine the role of PTP1BD6 for
JAK/STAT signaling, stably transfected L428 cell clones either express-
ing PTP1BWT, PTP1BC215S, or PTP1BD6 were generated. Functional analy-
sis of the novel PTP1BD6 variant was achieved by western blot analysis
using phospho-STAT antibodies, luciferase reporter analysis and EMSA.
The impact of the PTP1B variants on cell proliferation was examined
by MTS assays. Results. In order to determine the molecular basis of
the reduced or absent PTP1B expression in selected cHL cases, we iso-
lated and sequenced the PTP1B mRNA. In contrast to the previously
published study highlighting inactivating point mutations in the PTP1B
gene of PMBL and cHL cases, we obtained a set of PTP1B variants
which lack different exon sequences. One of these novel PTP1B vari-
ants, lacking exon 6 (PTP1BD6), was found to be expressed at low levels
in cHL cell lines. However, serum stimulation of cHL augmented the
expression of PTP1BD6 significantly. Functional characterization of
PTP1BD6 revealed a positive impact on IFN and IL-4 induced JAK/STAT
activity in HEK293 or HEK293-STAT6 cells, and on the basal STAT
activity in stably transfected L-428 and U-HO1 cHL cell lines. Further-
more, PTP1BD6 expression increased the proliferation of L-428 and U-
HO1 cells and the reduced cytotoxic effect of the chemotherapeutical
agents gemcitabine and etoposide distinctively. Conclusions. Collective-
ly, these data suggest that the activity of PTP1B in cHL is regulated by
different molecular mechanisms including the expression of shorter
PTP1B variants like the novel PTP1BD6 variant which acts as a positive
regulator of JAK/STAT signaling in cHL.
Early Stages
T010
LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE FAVORABLE
HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP
HD7 AND HD10 TRIAL
S. Sasse*, P.J. Bröckelmann*, H. Görgen, A. Plütschow, H. Mueller,
S. Kreissl, C. Bürkle, S. Borchmann, M. Fuchs, P. Borchmann, A. Engert
Department I of Internal Medicine and German Hodgkin Study Group
(GHSG), University Hospital of Cologne, Germany
*Contributed equally
Background. Combined modality treatment (CMT) is considered as
standard of care in patients with early-stage favorable HL. During the
years, a gradual toxicity reduction through balancing extent and inten-
sity of radiotherapy (RT) and chemotherapy was achieved. Long-term
follow-up (FU) of the pivotal trials is needed, to ensure the applied ther-
apies are safe and beneficial for our patients. Methods. We analyzed
updated FU data of 1817 patients who were treated for early-stage
favorable HL in previously published GHSG trials between 1993 and
2003. In the HD7 trial patients were randomized to either 40Gy extend-
ed-field (EF)-RT only or CMT with 2xABVD, and in HD10 to either 4x
or 2xABVD and 30 or 20Gy involved-field (IF)-RT respectively. Pro-
gression-free (PFS) and overall survival (OS) were analyzed according
to the Kaplan-Meier method. Cumulative incidences of secondary neo-
plasias (SN) were compared using Pepe & Mori’s test. The level of sig-
nificance was set to 0.05. Results. The median FU was 120 and 98
months for patients in HD7 (n=627) and HD10 (n=1190), respectively.
New FU data beyond the last evaluation were available for <50% of
patients and last information was obtained from population registries
in 18-30%. In HD7, CMT was superior to EF-RT with 15-year PFS esti-
mates of 72.8% vs 52.2% and a hazard ratio (HR) of 0.45 (95% confi-
dence interval CI: 0.33-0.61). No significant differences were observed
regarding OS or SN. In HD10, non-inferiority of 2xABVD+20Gy IF-RT
to more intensive treatment was confirmed with HRs of 1.0 (CI:0.6-
1.5) and 0.9 (CI:0.5-1.6) and 10-year estimates of 87.2% and 94.1% for
PFS and OS, respectively. No significant differences in SN were
observed.
Summary: Long-term FU data of HD7 and HD10 confirm the current
treatment-standard in early-stage favorable HL consisting of 2xAB-
VD+20Gy IF-RT. In order to assess the risk of secondary neoplasia and
long-term organ toxicity a prolonged follow-up period is required.
T011
PROTON RADIOTHERAPY FOR MEDIASTINAL HODGKIN LYMPHOMA: SINGLE INSTITUTION
EXPERIENCE
K. Dědečková1, H. Móciková2, J. Marková2, Ľ. Gahérová2, I. Kantorova3,
B. Ondrova1, V. Vondracek1, P. Vitek1, J. Kubes1
1Proton Therapy Department, Proton Therapy Center Czech, Prague, Czech
Republic; 2Department for Internal Medicine and Hematology, Faculty Hospital
Kralovske Vinohrady and Third Faculty of Medicine, Charles Univesity in
Prague, Czech Republic, 3Nuclear Medicine Department, Proton Therapy Center
Czech, Prague, Czech Republic
Introduction. Conventional radiotherapy (RT) based on photons has
achieved its physical limits. Proton beam offers promising dosimetric
benefits compared to photons, due to its potential to decrease unintended
healthy tissue irradiation. Mediastinal proton RT can be safely provided
with the awareness of targeting to a moving structure. The technological
progress in proton RT allows solving this issue. It can be reasonably man-
aged via pencil beam scanning technique with repainting and/or the use
of deep inspiration breath hold method. We present our preliminary clin-
ical experience with this technique. Methods. Between May 2013 and
June 2016, 39 patients (pts) with Hodgkin lymphoma (HL) underwent
12 | haematologica | 2016; 101(s5)
10th International Symposium on Hodgkin Lymphoma
ISHL_2016_S5_Abstract book_indice nomi ok.qxp  19/09/16  12:05  Pagina 12
mediastinal proton RT. Pencil beam scanning technique was used in all
pts. Overall 33 of 39 pts were evaluable for acute toxicity and early
response. Proton RT was indicated in the first-line treatment in 30 pts, 3
pts were re-irradiated after previous photon RT. Median age at the time
of RT was 32 years (range, 13-59 years). RT volume definition: involved
field 9 pts, residual disease 10 pts, involved site 14 pts. RT to PET negative
disease was indicated in 23 pts as a part of combined modality of treat-
ment after chemotherapy. RT to PET positive disease after chemotherapy
was performed in 10 pts. Median total dose was 30 GyE (range, 19.8-40
GyE). Overall 17 pts underwent RT in deep inspiration breath hold, the
rest of pts received RT in free breathing after 4D control of mediastinal
structures movement. Results.Of evaluable pts, 31 are in complete remis-
sion. Two pts with multiple sites of progression achieved a local control
of disease. Acute and subacute RT toxicity was mild (pharyngeal mucosi-
tis gr. 2 in 3 pts, leukopenia gr.3 in 1 pt, leukopenia gr 2 in 1 pt, radioder-
matitis gr.2 in 1 pt). No case of radiation pneumonitis or Lhermitte sign
was observed. No pt required growth factor application or hemosubsti-
tution during RT. Conclusions. Proton RT offers promising and safe option
for most pts indicated for mediastinal RT. Proton irradiation has low
acute toxicity profile and a potential to decrease the risk of significant
late toxicity. Proton RT should be considered in all HL patients indicated
for mediastinal RT or re-irradiation.
Support. This work was supported by grant awarded by AZV 16-
29857A, Ministry of Health in Czech Republic and Research project P
27/2012 awarded by Charles University in Prague, 3rd Faculty of Med-
icine, Prague, Czech Republic
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RESULTS OF US INTERGROUP TRIAL OF RESPONSE-ADAPTED CHEMOTHERAPY OR
CHEMOTHERAPY/RADIATION THERAPY BASED ON PET FOR NON-BULKY STAGE I AND II
HODGKIN LYMPHOMA (CALGB/ALLIANCE 50604) 
D. Straus1, B. Pitcher2,*, L. Kostakoglu3,*, J.C. Grecula4,*, E.D. Hsi5,
H. Schöder6,*, S.-H. Jung2,*, L. Popplewell7, J.E. Chang8,
C. Moskowitz6, N. Wagner-Johnson9,*, J. Leonard10, J.W. Friedberg11,
B.S. Kahl12, B.D. Cheson13, N.L. Bartlett14
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer
Center, New York, NY, USA; 2Alliance Statistics and Data Center, Duke
University, Durham, NC, USA; 3Mount Sinai Medical Center, New York, NY,
USA; 4Ohio State Univeristy, Columbus, OH, USA; 5Cleveland Clinic,
Cleveland, OH, USA; 6Memorial Sloan Kettering Cancer Center, New York,
NY, USA; 7City of Hope, Duarte, CA, USA; 8University of Wisconsin, Madison,
WI, USA; 9Washington University, Saint Louis, MO, USA; 10Weill Cornell
Medical College, New York, NY, USA; 11University of Rochester, Rochester,
NY, USA; 12Washington University, Saint Louis, MO, USA; 13Lombardi
Comprehensive Cancer Center, Georgetown University Hospital, Washington,
DC, USA; 14Siteman Cancer Center, Washington University School of Medicine,
Saint Louis, MO, USA
*For Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology
Group, and Southwest Oncology Group
Interim positron-emission tomography (PET) following 1-3 cycles of
doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in new-
ly-diagnosed, non-bulky stage I and II HL patients (pts) is a useful bio-
marker that predicts relapse rates of ≤10% for PET- pts. Relapse rates
are higher in pts who are PET+. Interim PET thus provides an opportu-
nity to minimize treatment for the majority of pts who are interim PET
- and only intensify treatment for those who are PET+. This strategy
could reduce short and long term treatment toxicity for the majority of
pts. To test this hypothesis, the US Intergroup conducted a phase II
clinical trial, CALGB/Alliance 50604, for newly-diagnosed non-bulky
stage I and II HL pts. Between 5/15/10 and 5/4/12, 164 previously
untreated pts with non-bulky stages I/II HL were enrolled. Pts received
2 cycles of ABVD followed by PET. Deauville scores 1-3 were negative
(≤liver uptake), while scores of 4-5 were positive, based on central
review. PET- pts received 2 more cycles of ABVD, and PET+ pts received
2 cycles of escalated BEACOPP+3060 cGy involved-field radiation ther-
apy (IF RT). Median age was 31 years (18-58). There were 88 males
and 76 females. Pt. stages were IA (16), IB (4), IIA (90), IIB (35), IIAE (4),
and IIBE (3). All pts were PET+ prior to treatment. 144/164 patients had
cycle 2 PET and adequate follow-up for assessment: 131 (91%) were
PET- and 13 (9%) PET+. Of 20 not analyzed, 13 were excluded (6 never
treated and 2 treated with <2 cycles) and 7 had insufficient follow up.
At a median follow-up time of 2 years, 8/131 (6%) PET- pts relapsed or
progressed with an estimated 3-year progression-free-survival (PFS) of
92%. 4/13 (31%) PET+ pts. failed (3 relapsed, 1 suicide) with an esti-
mated 3-year PFS of 66%. By Cox model, observed hazard ratio com-
paring PET- and PET+ PFS for pts is 6.04 (1.82, 20.08). There was 1
death (suicide). These early results demonstrate that the 91% of pts
PET- after 2 cycles of ABVD had an excellent PFS with total of 4 ABVD
cycles (Figure 1). Updated results will be presented.
Support. Supported in part by U10CA180821, U10CA180820, and
U10CA180888.
Figure 1. Kaplan Meier Plot of PFS for PET-negative and PET-positive
patients.
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LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE UNFAVORABLE
HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP
HD8 AND HD11 TRIAL
S. Sasse*, P.J. Bröckelmann*, H. Görgen, A. Plütschow, H. Mueller,
S. Kreissl, C. Bürkle, S. Borchmann, M. Fuchs, P. Borchmann, A. Engert
Department I of Internal Medicine and German Hodgkin Study Group (GHSG),
University Hospital of Cologne, Germany
*Contributed equally
Background.Combined modality treatment (CMT) is currently consid-
ered standard of care in patients with early-stage unfavorable HL. By
gradually increasing chemotherapy intensity an improvement of treat-
ment efficacy and by reducing radiotherapy intensity a reduction of tox-
icity were attained. Long-term follow-up (FU) is needed to ensure the
safety and efficacy of the applied therapies. Methods.We analyzed updat-
ed FU data of 2459 patients with early-stage unfavorable HL treated in
the HD8 and HD 11 trial. In HD8 patients were randomized to either
30Gy IF- or extended-field (EF)-RT after 2xCOPP/ABVD and in HD11
patients received 20 or 30Gy IF-RT after 4xABVD or 4xBEACOPPbase-
line. Progression-free (PFS) and overall survival (OS) were analyzed
according to the Kaplan-Meier method. Cumulative incidences of sec-
ondary neoplasias (SN) were calculated and compared between groups
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using Pepe & Mori’s test. Results. The median FU was 153 and 106
months for patients in HD8 (n=1064) and HD11 (n=1395), respectively.
New FU data were available for less than 50% of patients and last infor-
mation was obtained from population registries in 23-27%. In HD8, non-
inferiority of IF- compared to EF-RT was confirmed with HRs of 0.98
(95% confidence interval CI: 0.76-1.25) and 0.88 (CI:0.66-1.16) for PFS
and OS, respectively. We observed a non-significant trend towards more
SN (15-year cumulative incidence 17.1% versus 14.2%, respectively,
p=0.3) and deaths from SN after EF-RT versus IF-RT. In HD11, no differ-
ence in PFS was found with BEACOPPbaseline compared to ABVD when
followed by 30Gy IF-RT (HR: 1.1 (CI: 0.7-1.5)). In contrast, there was a
significant difference in 10-year PFS rates estimated at 77.6% versus
83.3% in ABVD-treated patients who had received 20Gy instead of 30Gy
IF-RT with a HR of 1.5 (CI: 1.0-2.1). After BEACOPPbas, 20Gy were
non-inferior to 30Gy IF-RT with a HR of 1.0 (CI: 0.7-1.5) for PFS. No dif-
ferences in terms of OS or SN were observed. Summary.Moderate inten-
sification of chemotherapy does not improve the outcome but might
facilitate the reduction of IF-RT-dose. Continued FU is necessary to assess
long-term toxicity of the applied treatment strategies. 10-year PFS and
OS estimates in early-stage unfavorable HL treated with 4xABVD+30Gy
IF-RT leave room for improvement.
P050
FINAL RESULTS OF A QUALITY ASSURANCE PROGRAM WITHIN THE GERMAN HODGKIN
STUDY GROUP HD13/14 TRIAL – A REPORT FROM THE RADIOTHERAPY REFERENCE
PANEL INTEGRATING MODERN GUIDELINES
H.T. Eich1, J. Kriz1, R. Engenhart-Cabillic2, U. Haverkamp1, K. Herfarth3,
P. Lukas4, H. Schmidberger5, S. Staar6, A. Plütschow7, M. Fuchs7,
A. Engert7, C. Baues8
1Department of Radiation Oncology, University Muenster, Germany; 2Department
of Radiation Oncology, University Marburg, Germany; 3Department of Radiation
Oncology, University Heidelberg, Germany; 4Department of Radiation Oncology,
University Innsbruck, Germany; 5Department of Radiation Oncology, University
Mainz, Germany; 6Department of Radiation Oncology, Bremen Mitte, Germany;
7Department of Internal Medicine, University Cologne, Germany; 8Department
of Radiation Oncology, University Cologne, Germany
Introduction. Since the foundation of the German Hodgkin Study
Group (GHSG) in 1978 a central radiotherapy (RT) reference centre
was established to evaluate and to improve the quality of treatment.
During the study generations the quality assurance programs (QA) were
continuously adapted and refined. The purpose of this analysis is to
show the results of the work within the fifth study generation
(HD13/14) and to demonstrate the establishment of a QA including
modern RT-techniques e.g. intensity modulated RT (IMRT), image guid-
ed RT (IGRT) and involved node RT (IN-RT). Methods.With the fourth
study generation (HD10-12) a central prospective review of all diag-
nostic imaging to create an individual treatment plan for every study
patient was established in early stages and the quality of involved field
RT was evaluated by an expert panel of radiation oncologists retro-
spectively. In the era of modern conformal RT this QA-program had to
be adapted fundamentally and within several meetings a new process
of evaluation has been developed. The findings were compared to the
results of the QA within the fifth study generation (HD13-15). Results.
The expert panel analyzed the RT-parameters of 1037 (28%) patients
(HD13 n=465, HD14 n=572). In 85% simulation films and in 87% ver-
ification films were available. RT was assessed as unacceptable in 46%
(HD13= 38%, HD14=52%), acceptable in 9% (HD13= 9%, HD14=
9%) and according to the protocol in 45% (HD13= 52%, HD14= 38%).
These findings were compared to a data set of eleven patients treated
within the sixth study generation (HD16-18) which was reviewed using
the “new” revised QA-program including criteria for conformal tech-
niques. Conclusions. The value for QA of RT within the GHSG trials is
well known. To develop a QA-program of modern RT the expert panel
defined criteria for analyzing current RT-procedures. With this schedule
the QA of the GHSG serves as a model for other study groups.
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CLINICAL OUTCOME OF PATIENTS WITH EARLY STAGE FAVORABLE HODGKIN LYMPHOMA
TREATED WITH ABVDX2 CYCLES FOLLOWED BY PET/CT RESTAGING AND 20 GY OF
INVOLVED-SITE RADIOTHERAPY
S.C. Kamran1, H.A. Jacene2, Y.-H. Chen3, P.M. Mauch4, A.K. Ng4
1Harvard Radiation Oncology Program; 2Department of Radiology; 3Department
of Biostatistics and Computational Biology; 4Department of Radiation Oncology,
Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA, USA
The publication of the GHSG HD10 trial changed the treatment par-
adigm for early-stage, favorable Hodgkin lymphoma (HL). Two cycles
of ABVD followed by 20 Gy of involved-field radiotherapy (IFRT) has
become a widely accepted treatment strategy for these patients. How-
ever, PET/CT is now increasingly used for response assessment after
chemotherapy, and IFRT has largely been replaced by involved-site radio-
therapy (ISRT). In this study, we describe our experience of 2 cycles of
ABVD followed by PET/CT assessment, and ISRT to 20 Gy for patients
with early-stage, favorable HL. With IRB approval, records of 20 patients
(11 females, 9 males) with early-stage, favorable HL per the GHSG cri-
teria, treated between 2008-2015, were reviewed. All patients underwent
PET/CT for initial staging and for restaging after 2 cycles of ABVD. This
was followed by ISRT to 20 Gy in 10 fractions, using 3-dimensional con-
formal technique. PET-response after 2 cycles of ABVD was independ-
ently assessed by a nuclear medicine physician with Deauville score
assignment. Actuarial rates of relapse-free survival (RFS) and overall sur-
vival (OS) were calculated. RFS was defined as the time from start of
chemotherapy to relapse or death, whichever occurred first. The median
age at diagnosis was 33 years (range 20-82). All but 2 patients were with-
out B symptoms, and 50% had 1 site of disease. Median ESR was 10
(range 1-16). Median maximal tumor dimension was 38 mm (range 12-
80 mm). After 2 cycles of ABVD, 95% of patients had a Deauville score
of 1-2, and 1 patient had a score of 3. Median follow-up is 46.9 months.
As of this analysis, all patients are alive without disease. One patient had
an out-of-field relapse, but was salvaged with chemotherapy followed
by autologous stem cell transplant. This patient had 80 mm disease at
time of diagnosis and a Deauville 2 score after chemotherapy. The 4-
year RFS rate is 90.9% (95% CI: [50.8, 98.7]). Figure 1 shows RFS in this
20-patient cohort. Our results showed that with careful patient selection
based on initial disease characteristics and PET-response to chemother-
apy, the use of a more restricted radiotherapy treatment volume of ISRT
to 20 Gy following ABVDx2 is associated with an excellent outcome
with no local recurrences or marginal misses.
Figure 1.
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OPTIMIZED “BUTTERFLY” VMAT REDUCES MEAN DOSE TO CORONARY ARTERIES FOR
EARLY STAGE HL PATIENTS UNDERGOING MEDIASTINAL RADIOTHERAPY
A.R. Filippi, M. Levis, A. Girardi, C. Fiandra, C. Piva, I. Donegani,
R. Ragona, U. Ricardi
Department of Oncology, Radiation Oncology, University of Torino, Italy
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Background and Objectives. A linear correlation was shown between
the occurrence of coronary artery disease (CAD) and radiation dose
received by coronary arteries for Hodgkin’s lymphoma (HL) patients,
derived by mean heart dose/long-term follow-up datasets. The pur-
pose of this study was to delineate coronary arteries and optimize
radiation planning on these substructures by using an optimized mul-
ti-arcs volumetric arc therapy (VMAT) solution, then to compare it to
standard 3D-CRT with the aim of showing a potential dosimetric
benefit for VMAT. Materials and Methods. We compared the plans of
14 HL patients (3 males and 11 females) with stage I-IIA mediastinal
disease without axillary involvement, treated with involved site radio-
therapy (ISRT); 11 had a bulky presentation at diagnosis. In every
patient, a deformable fusion was performed with a dedicated software
between the planning CT and the pre-ISRT contrast enhanced CT
scan. The following structures were delineated: whole heart; left main,
left descending, circumflex and right coronary arteries; aortic, pul-
monary, mitral and tricuspid valves; right and left atria; right ventricle,
left ventricle and interventricular septum; left ventricular apex, mid
cavity, base and lateral wall. Two experienced radiation oncologists
contoured target volumes (CTV), and heart substructures, after a val-
idation session with a cardiologist and a heart radiologist. The VMAT
approach consisted of multi non-coplanar arcs (the so-called “butter-
fly” VMAT or B-VMAT) and was compared with 3D-CRT. Mean and
max dose received by the coronary arteries were compared by Stu-
dent’s T test. Results. Maximum doses to coronary arteries resulted
similar; conversely, lower mean doses were delivered by using B-
VMAT, reaching a significant difference for the left main trunk
(p=0.002), the circumflex coronary artery (p=0.014) and the right coro-
nary artery (p=0.002). Most significant findings are illustrated in the
Figure 1. Discussion. This study suggests that an optimized intensity
modulated RT solution (B-VMAT) is able to reduce the dose to coro-
nary arteries for HL patients with mediastinal disease. As the dose-




BIOLOGICAL EVALUATION IN THE TREATMENT PLANNING. IS THERE A USE FOR PATIENTS
WITH HODGKIN’S LYMPHOMA?
J. Kriz, U. Haverkamp, N. Pepper, K. Elsayad, K. Kröger, G. Reinartz,
M. Glashörster, C. Kittel, H.T. Eich
Department of Radiation Oncology, University of Muenstere, Germany
Introduction. The aim of the present analysis is to evaluate the value
of a biological treatment planning for patients with Hodgkin’s Lym-
phoma (HL). Because patients with HL have become longtime sur-
vivors the main goal of ongoing studies is to minimize treatment relat-
ed late toxicity. Especially for patients with mediastinal involvement
the use of IMRT should be considered carefully with regard to pul-
monary toxicity. Methods. We included 27 patients with mediastinal
involvement of HL. All patients received chemotherapy followed by
30.6 Gy Involved-Field RT. 20 patients were treated with APPA, 5
patients with a 5-field IMRT (5F-IMRT) and 3 patients with a 7-field
IMRT (7F-IMRT). To compare the different techniques we calculated
3 treatment plans for every patient. We evaluated Dmean, V5, V10,
V15, V20 and V30 of the lung, Dmax of the spinal cord and V50 of
the body. To determine the probability of pneumonitis we used a bio-
logical evaluation of Eclipse© by Varian and compared them to values
we calculated using the parameters of Quantec. We analyzed the fol-
low-up CTs of all patients to test whether they had a radiogenic pneu-
monitis. Results. A total of 81 plans were calculated. The 7F-IMRT
achieves the highest values with respect to Dmean, V5, V10, V15 and
V20 of the lung. Regarding V30 APPA is inferior (14.9 Gy APPA vs 2.9
Gy 7F-IMRT median). With respect to Dmax of the spinal cord the
7F-IMRT is superior to 5F-IMRT and APPA (32.1 Gy APPA, 24.9 Gy
5F-IMRT and 19.9 Gy 7F-IMRT median). The 7F-IMRT achieves the
highest NTCP-values: Left lung: (range 0.0-2.1%); 5F-IMRT (range
0.0-4.0%) and 7F-IMRT (range 0.0 – 5.1%). Right lung: APPA (range
0.0-2.1%); 5F-IMRT (range 0.0-2.9%) and 7F-IMRT (range 0.0-8.0%).
The values calculated by using the Quantec-parameters were as fol-
lows: Left lung: APPA (range 1.4-12.2%); 5F-IMRT (range 1.6-15%)
and 7F-IMRT (range 1.7 – 16.4%). Right lung: APPA (range 2.3-12.6%);
5F-IMRT (range 2.4-13.9%) and 7F-IMRT (range 2.3-18.2%). No
patient had radiologic signs of pneumonitis by reviewing the follow
up CTs. Conclusions. APPA is superior to IMRT with respect to the
mean lung doses. This finding is underlined by the NTCP-values. If
the local doses (e.g. V30) in the field of the PTV are observed, IMRT
is superior. The calculated values show an increased risk by using the
7F-IMRT. The biological evaluation achieves remarkable results in
both cases, that are usefull in the judgement of treatment plans. 
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THE EFFECT OF DEEP INSPIRATION BREATH HOLD INTENSITY-MODULATED RADIATION
THERAPY ON SPARING HEALTHY TISSUES IN THE TREATMENT OF LYMPHOMA INVOLVING
THE MEDIASTINUM
B. Eastman, J. Uhl, V. Mosienko, J. Murphy, P. Sanghvi
University of California, San Diego, USA
Survivors of Hodgkin’s lymphoma (HL) have an increased risk of devel-
oping secondary malignancies and cardiovascular disease. This risk is
directly correlated to the amount of radiation exposure and is significant
even with the use of modern radiation therapy modalities. Deep inspira-
tion breath hold (DIBH) techniques have been shown to lead to the deliv-
ery of lower amounts of radiation to organs at risk (OARs) during the
treatment of breast cancer and Hodgkin’s lymphoma. In this study, we
evaluated the ability to DIBH techniques to decrease the amount of radi-
ation exposure of OAR in 16 consecutive HL lymphoma patients with
mediastinal involvement. Majority of patients had Stage II bulky disease.
For each patient four different plans were calculated – two utilizing deep
inspiration breath hold technique and two with free breathing with IMRT
and APPA plans created for both breathing modalities. DIBH plans deliv-
ered significantly decreased mean doses to the heart with Dmean of
474.5cGy (DIBH-IMRT) and 779.0cGy (DIBH-APPA), compared to the
free breathing plans with 1125.6cGy (FB-IMRT) and 1709.3cGy (FB-
APPA). In addition, specific cardiac substructures such as the coronary
arteries and the aortic valve also received reduced mean doses of radia-
tion. The coronary arteries in DIBH-IMRT plans received on average
Dmean of 888cGy, DIBH-APPA plans -1528Gy, FB-IMRT 1921cGy and
DIBH-APPA – 2529cGy. Similar trend is present within the average dose
delivered to the aortic valve with average Dmean for DIBH-IMRT plans
of only 894cGy, compared to average Dmean of 1694cGy for DIBH-APPA
plans, 2718cGy for FB-IMRT plans, and 2874cGy for FB-APPA plans.
Mean dose of lung exposure for DIBH-IMRT plans is also significantly
lower than FB-IMRT plans (p=0.003). The volume of lung tissue receiving
low dose radiation is significantly decreased in the DIBH-IMRT plan
compered to the FB-IMRT plan, however the volume receiving 2000cGy
is comparable between the DIBH and FB plans. These findings are con-
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sistent with previous reports and suggest that utilizing DIBH could great-
ly decrease the radiation exposure of OAR and decrease the long-term
complications young cancer survivors face. 
Figure 1.
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MULTICENTRIC ITALIAN EXPERIENCE IN TREATMENT OF NODULAR LYMPHOCYTE
PREDOMINANT HODGKIN LYMPHOMA IN THE RITUXIMAB ERA
M. Gotti1, F. Merli2, A. Re3, C. Rusconi4, A. Pulsoni5, L. Rigacci6,
M. Merli7, M. Liberati8, V. Ferretti1, V. Zoboli1, A. Fama2, D. Dalceggio3,
E. Meli4, G. Annechini5, B. Puccini6, A. Ferrario7, V. Appolloni8,
R. Sciarra1, M. Frigeni1, L. Arcaini1, M. Bonfichi1
1Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo,
Pavia, Italy; 2Hematology Unit, Arcispedale S Maria Nuova-IRCCS of Reggio
Emilia, Italy; 3Department of Hematology, Spedali Civili, Brescia, Italy;
4Department of Haematology, Niguarda Ca’ Granda Hospital, Milan, Italy;
5Department of Cellular Biotechnologies and Hematology, “La Sapienza”
University, Roma, Italy; 6Department of Haematology, ”Careggi“ Hospital,
Firenze, Italy; 7Division of Hematology, University Hospital Ospedale di Circolo
& Fondazione Macchi, Varese, Italy; 8Onco-Hematology Departmant, S. Maria
Hospital, Terni, Italy
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is
characterized by the expression of B-cell associated antigen CD20. Due
to this characteristic it has been proposed the use of the anti-CD20 anti-
body but at now, there is no consensus on which chemotherapy regimen
should be used. In patients with stage IA two prospective studies evalu-
ated the role of the anti-CD20 antibody in monotherapy (GHSG and
Stanford); both of them concluded that rituximab cannot be recommend-
ed as a first-line therapy and ESMO guidelines recommend radiotherapy
for this subset of patients. In other stages chemotherapy is generally rec-
ommended, but there is no consensus on whether classical HL-directed
regimens, such as ABVD (doxorubicin, bleomycin, vinblastine, dacar-
bazine), or B-cell lymphoma-directed regimens, such as R-CHOP (ritux-
imab, cychlophosphamide, doxorubicin, vincristine, prednisone) should
be used. In order to plan clinical trials and to test our potential accrual
we performed a retrospective analysis of patients treated between 2000
and 2016 in 8 Italian hematologic centers. We identified 113 pts affected
by NLPHL (41 stage I without symptoms, 40 stage II, 21 stage III, 11
stage IV). 11 patients had extranodal disease (pancreas, intestine, skin,
lung, liver, bone marrow, muscle), 14 had spleen involvement and 9 had
B symptoms. Median age at diagnosis was 43, male:female ratio was 2.9.
Median follow-up is 62 months (range 1-199 months). 5yr-OS and 3yr-
EFS were respectively 95.5% and 85.9%.13 patients had relapse of
NLPHL, 5 patients had transformation to DLBCL at a median of 14
months, 4 patients died (1 from acute myelogenous leukemia, 1 from
progression of disease, 1 from stomach cancer and 1 for interstitial pneu-
monia during ABVD). Treatments for non-stage I pts were as follows: 29
ABVD ± IFRT (II 19, III 6, IV 4), 13 R-ABVD (II 5, III 5, IV 3), 24 R-CHOP
± IFRT (II 10, III 10, IV 4) and 6 other (2 observation, 2 IFRT, 1 Rituximab,
1 CHOP like).3-years event-free survival are as follows: 78.5% (58-90)
for ABVD±RT, 100% for R-ABVD and 74% for R-CHOP (48-88). No
statistically significant difference was observed in terms of EFS neither
for therapy regimen (p 0.512), nor for stage and spleen involvement (p
0.33). Our data do not show any difference among classical HL-directed
regimens, B-cell lymphoma-directed regimens or composite approach.
A prospective randomized large cohort evaluation should be taken into
account.
P056
CONSTRUCTION OF A DECISION MODEL TO AID TREATMENT CHOICES FOR EARLY STAGE
HODGKIN LYMPHOMA: BRINGING SURVIVORSHIP FORWARD
M.J. Kelly1,2 S.K. Parsons2,3,4, J.T. Cohen3,5, S.M. Castellino6, K. Kelly7,
F. Keller6, T.J. Henzer3, A. Kumar4, P. Johnson8, R.M. Meyer9,
L.M. Morton10, J. Radford11, J. Raemaekers12, D.C. Hodgson13,
A.M. Evens4
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Tufts MC, Boston, Massachusetts, USA; 6Aflca Cancer Center and Blood Dis-
orders Center, Children’s Hospital of Atlanta, Emory University School of Med-
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Cancer Institute, Buffalo, New York, USA; 8Cancer Research UK Centre,
Southampton, United Kingdom; 9Departments of Oncology, Medicine and Com-
munity Health and Epidemiology, NCIC Clinical Trials Group, Queen’s Uni-
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and Human Services, Bethesda, Maryland, USA; 11Institute of Cancer Sciences,
University of Manchester, United Kingdom; 12Department of Hematology, Rad-
boud University Medical Center, Nijmegen, the Netherlands; 13Radiation Med-
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Introduction.Decision-making for the treatment of ES HL patients con-
tinues to involve consideration of the tradeoff between shorter-term pro-
gression-free survival (PFS) and the impact of late effects (LE) on overall
survival (OS). To evaluate the complex decision process arising from
these factors, there is a desire to obtain integrated data that assimilates
short-term outcomes, LE, and quality adjusted life expectancy (QALE)
to help aid treatment choices. Methods.We analyzed PFS and OS from 4
large, modern randomized trials comparing chemotherapy alone with
combined modality therapy (CMT) for ES HL (Meyer NEJM 2012; Wold-
en JCO 2012; Raemaekers JCO 2014; Radford NEJM 2015). We con-
structed a detailed Markov model comparing QALE after initial therapy
for ES HL using chemotherapy alone vs CMT. The model incorporated:
3-year PFS from PET- patients; quality of life associated with relapse and
cure; cure rates after relapse; 15-year latency period before onset of
increased mortality from LE; and “discounting” of future life years. We
also performed sensitivity analyses to determine the amount that CMT
(with contemporary radiotherapy) must increase LE-associated mortality
for that impact to outweigh its early PFS advantage. Results. All 4 trials
demonstrated that short-term PFS was superior with CMT, including
PET response-adapted paradigms, however OS was at least equivalent
in each study. Collectively, the analyses showed that if CMT-associated
LE increased deaths >15-20% (relative) compared with chemotherapy
alone, then treatment with the latter was associated with overall
improved QALE. This finding was consistent across a range of patient
ages and among varied estimates for SMR after cure for those treated
with chemotherapy alone (see Figure 1). Furthermore, sensitivity analyses
demonstrated that these findings were most sensitive to assumptions
regarding the impact of CMT on mortality after cure, and insensitive to
moderate changes in the assumed short-term impact of CMT on PFS.
Conclusions.We identified the “break-even point” whereby chemotherapy
alone was associated with superior QALE vs CMT (ie, 15-20% relative
increased death from LE). This model provides the base analytic frame-
work to aid the complex decision of treating ES HL. Future model itera-
tions may incorporate patient & tumor characteristics, patient prefer-
ences, and cost-effectiveness of varied therapeutics in order to help guide
individualized decisions for providers and patients with HL.
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Figure 1. Quality-adjusted life expectancy (QALE) examining varied SMR
values and delayed effect. The Y-axis of the figure shows the gain in QALE
when treating with a strategy of chemotherapy alone compared with com-
bined modality therapy (CMT). Negative values indicate that CMT is asso-
ciated with superior QALE, while positive values indicate that chemother-
apy alone is associated with superior QALE. The X-axis plots the relative
standardized mortality ratio (SMR) after cure when treating with CMT com-
pared with chemotherapy alone. For example, a relative of SMR of 1.2
means that treatment with CMT is associated with a 20% higher risk of
death from late effects than treatment with chemotherapy alone. We per-
formed the analysis three times, each time choosing a different SMR for
those treated with chemotherapy alone (1.0, 1.1, and 1.5) and adjusting
the relative CMT for those treated with CMT.  Additionally, we performed
the analysis two different ways: 1) assuming that the SMR after cure is
incorporated into the model immediately after subjects enter the cured
state – depicted as dashed lines (representing the immediate onset of an
increased susceptibility to deaths from late effects); and 2) holding the
SMR at 1.0 for 15 years after subjects enter the cured state and then incor-
porating the SMR after 15 years (to represent the latency period of approx-
imately 15 years until there is an observed increase in deaths from late
effects). We assumed a base case age of the subjects to be 25 years old.
Altogether, the figure illustrates that the “break-even point” (i.e., where
the curves cross the horizontal axis) are nearly the same under the afore-
mentioned set of assumptions and that it holds true in all three scenarios
(i.e., for chemotherapy alone with SMRs of 1.0, 1.1, and 1.5). Thus, if there
is expected to a be a 15-20% or greater increase in deaths from late effects
after treatment with CMT, then treatment with chemotherapy alone is asso-
ciated with superior QALE.
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DOSES TO ORGANS AT RISK AT DIFFERENT MODES OF 3D-CONFORMAL RADIOTHERAPY
FOR MEDIASTINAL STAGE II HODGKIN LYMPHOMA
N.V. Ilyin, J.N. Vinogradova, E.I. Ivanova
FSBI “Russian Research Center for Radiology and Surgical Technologies” of the
Ministry of Health care, St. Petersburg, Russian Federation
Purpose. In this study we evaluated the doses for organs at risk (lungs,
heart, spinal cord) and CTV-PTV volume at 3D-conformal radiotherapy
(3DCRT, ISRT) and intensity-modulated radiotherapy (IMRT) for
mediastinal stage II HL (30-36Gy). Patients and Methods. From March
2014 to March 2015 63 patients with mediastinal stage II HL had
chemotherapy 3-4 cycles ABVD than there was 3DCRT: 52 patients –
involved site radiation therapy (ISRT) and 11 patients – IMRT. We
compared CTV-PTV volumes and the doses to organs at risk in these
groups. Results.CTV volume was not distinguished (401±15,0 cm3 and
385±61,5 cm3). PTV was significantly more at ISRT than IMRT-groupe
(1270±84,0 cm3 and 604±89,0 cm3, p<0,01). Besides, at IMRT-groupe
were less compared with ISRT-groupe V20 left lung (24,0±3,8% and
33,5±1,4%, p<0,05), right lung (28,0±1,3% and 16,6±2,4%, p<0,05),
V30 heart (50,0±4,4% and 8,1±2,2%, p<0,01), mean heart dose
(29,4±3,8 Gy and 7,0±1,5 Gy, p<0,001). Mean dose for spinal cord was
similar in these groups. Conclusions. IMRT compared to 3DCRT (ISRT)
substantially reduces V20 lungs, V30 heart and mean dose for heart
without compromising the dose to the target in patients with medi-
astinal stage II HL.
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RESIDUAL SITE RADIATION THERAPY: AN OPPORTUNITY TO INCREASE SAFETY OF
COMBINED MODALITY THERAPY FOR EARLY STAGE HODGKIN LYMPHOMA
D. Straus, O. Cahlon
Memorial Sloan Kettering Cancer Center New York, NY, USA
In randomized controlled trials, the addition of RT to chemotherapy
increases the progression-free survival but not overall survival in early
stage HL. Extended field (EF) and involved field (IF) RT are both asso-
ciated with late morbidity and mortality, particularly due to second
malignancies and cardiovascular events. There do not appear to be safe
doses of RT that will remain therapeutic, Doses as low as 20 Gy in
CMT do not seem to reduce the risk of second cancers below that seen
with traditionally therapeutic doses of 35-45 Gy. The risk of coronary
heart disease is increased by 7.4% per Gy in median heart dose. Like-
wise the reduction of radiation therapy portals from EF to IF RT has
not reduced the risk of second cancers. The latest iteration of IF RT is
involved site RT (IS RT)  (Figure 1).
Figure 1.
However, despite the early observation that initially bulky nodal
sites are at higher risk for recurrence than non-bulky sites following
adequate chemotherapy, all initial nodal sites are still treated regardless
of whether or not they resolve with chemotherapy despite their initial
size. Involved site RT still results in large fields encompassing the pre-
chemotherapy extent of disease, and as a result, in substantial off-
target radiation exposure to adjacent organs. There is no data indicating
that lowering the RT dose further in CMT will remain therapeutic.
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Given the paradigm of treating all initial nodal sites of involvement, it
will also be difficult to further substantially reduce off-target radiation
exposure, even with new techniques such as three-dimensional con-
formal RT, intensity modulated RT, deep inspiratory breath hold, or
even proton beam RT. Because of these considerations, we propose a
change in the paradigm of treating all initial nodal sites of involvement
when administering adjuvant RT following adequate chemotherapy.
It is unclear whether initial nodal sites that have completely resolved
with chemotherapy are at increased risk for recurrence. Rather, we
propose clinical trials to test the concept of only treating the PET-neg-
ative residual remaining masses on CT imaging following chemother-




BEACOPP-ESCALATED FOLLOWED BY RADIOTHERAPY OF INITIAL BULK OR RESIDUAL
DISEASE IN ADVANCED-STAGE HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP OF THE
GHSG HD9 AND HD12 TRIALS
B. von Tresckow*, S. Kreissl*, H. Haverkamp, S. Sasse, V. Diehl,
A. Engert, P. Borchmann
University Hospital of Cologne, Internal Medicine I, German Hodgkin Study
Group (GHSG), Cologne, Germany
*Both first authors contributed equally
Introduction. The HD9 trial had established 8xBEACOPPescalated fol-
lowed by radiotherapy (RX) of initial bulk or residual tumors as standard
of care for advanced Hodgkin Lymphoma (HL) at that time. The succes-
sor study of HD9, HD12, evaluated a reduction of chemotherapy and
RX. Since the long-term safety and efficacy of BEACOPPescalated and
RX has been debated, we report the HD9 and HD12 long-term follow-
up. Patients and Methods. All patients had advanced HL. 1,282 HD9-
patients were randomized between 8xCOPP/ABVD, 8xBEACOPPbase-
line, and 8xBEACOPPescalated. 1,670 HD12-patients were randomized
between 8xBEACOPPescalated, and 4xBEACOPPescalated followed by
4xBEACOPPbaseline (“4+ 4”), both with or without RX to initial bulk
and residual disease. Results. In HD9-patients treated with COPP/ABVD,
BEACOPPbaseline, and BEACOPPescalated, the 15-year progression-free
survival (PFS) was 57%, 66.8%, and 74% with overall survival (OS) rates
of 72.3%, 74.5%, and 80.9%, respectively. BEACOPPescalated remains
significantly better than COPP/ABVD in terms of PFS (P<0.0001) and OS
(P=0.02). A total of 123 second malignancies corresponding to 15-year
cumulative secondary malignancy incidences of 7.2%, 13%, and 11.4%
were reported for COPP/ABVD, BEACOPPbaseline, and BEACOPPesca-
lated, respectively, without a difference between COPP/ABVD and BEA-
COPPescalated (p=0.5). Standardized incidence ratios (SIR) with 95%-
CI were 2.0[1.2-3.2], 2.6[1.9-3.4] and 2.6[1.9-3.4]. The 10-year PFS and
OS rates in the two HD12 chemotherapy groups were not significantly
different with 82.6% and 87.3% in the BEACOPPescalated group and
80.6% and 86.8% in the 4+4 group, respectively. However, omitting RX
resulted in an significantly inferior 10-year PFS of 83.5% in no RX patients
with initial bulk/residual disease compared to RX (88.6%, difference -
5.1%; 95%-CI,-9.9% to -0.4%, hazard ratio [HR] 1.47; Figure 1) and a
trend towards inferior OS in no RX patients (RX 93%; no RX 90.2%;
difference -2.7%; 95%-CI,-6.5% to 1%).
Figure 1.
Patients with residual lesions without RX had an inferior OS as com-
pared to patients with RX (as treated comparison: RX 94.4%; no RX
88.4%; difference -6%; 95%-CI,-11.4% to -0.5%). Conclusions. The
superiority of BEACOPPescalated to COPP/ABVD is confirmed by this
HD9 long-term analysis. The HD12 long-term analysis shows an infe-
rior PFS and trend towards inferior OS in patients in the no RX groups,
particularly in patients with residual lesions.
18 | haematologica | 2016; 101(s5)
10th International Symposium on Hodgkin Lymphoma
ISHL_2016_S5_Abstract book_indice nomi ok.qxp  19/09/16  12:05  Pagina 18
T002
OVERALL SURVIVAL IMPACT OF BEACOPP VERSUS ABVD IN ADVANCED HODGKIN
LYMPHOMA: A POOLED ANALYSIS OF 4 RANDOMIZED TRIALS
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Introduction. In 4 individual randomized trials comparing ABVD and BEA-
COPP in advanced HL, BEACOPP significantly improved disease control
but not OS. We explored the potential OS benefit of BEACOPP in a pooled
analysis of these 4 trials. Methods. The primary objective was to assess the
impact of BEACOPP on OS by one-stage individual patient data meta-
analysis stratified for trial. Secondary endpoints were PFS, early toxicities,
second malignancies and use of hematopoietic stem cell transplantation
(HSCT). Results. Four trials representing a total of 1227 patients (622 ABVD
and 605 BEACOPP) were included (IIL Viviani 2011, LYSA H34 Mounier
2014, EORTC 20012 Carde 2016, HD2000 Merli 2016). Patients character-
istics: median age: 32 yrs, male 64%, nodular sclerosis 78%, stage II-III-IV:
13-32-55%, B symptoms: 77%, Bulky disease: 38%, IPS>3: 66%. With a
median fup of 4.9 yrs, the 5-yrs OS is 86.59% for ABVD (95%CI=83.0-
89.3) vs 90.8% for BEACOPP (95%CI=88.0-93.0). The data indicated that
the HR is not constant over time (P<0.05) preventing the use of a simple
Cox model. Per analysis plan, two time periods (< and ≥18m) were defined
from the observed survival and hazard curves. In the first 18 months
(N=1227, 54 events), no difference was detected (HR:0.75, 95%CI=0.41-
1.23). After 18 months (N=1083, 68 events), the risk of death appeared
higher in patients in ABVD arm than in BEACOPP arm (HRABVD vs BEA-
COPP=2.52, 95%CI=1.48-4.28, p<0.001). Further adjustment for IPS
showed that both treatment (p<0.001) and IPS group (p=0.0326) effects
are significant. The 5-yr PFS was 72.0% for ABVD (95%CI=67.3-76.1) vs
82.9% for BEACOPP (95%CI=78.7-86.4) (p<0.001). Grade 3-4 toxicities
(ABVD vs BEACOPP): anemia: 4.3% vs 24.2%; leukopenia: 23.2% vs
76.8%; thrombocytopenia: 1.7% vs 26.4%; infection: 7.9% vs 34.2%. After
ABVD, 17 second malignancies (0 AML) (2.7%) were reported and 21(7
AML)(3.6%) after BEACOPP. After ABVD, 86 patients (13.8%) received
HSCT vs 39 (6.4%) after BEACOPP. Conclusions. This pooled analysis of 4
studies with increased power, indicated a non-constant treatment effect
over time. A statistically significant OS benefit of BEACOPP was observed
from 18 months after randomization. Frontline use of BEACOPP increased
PFS, early hematological toxicity, secondary leukemia incidence but halved
the need of HSCT. Further follow-up is needed to explore the impact of
BEACOPP on fertility, second malignancies and long term survival.
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LONG-TERM FOLLOW-UP OF SWOG S0816: RESPONSE-ADAPTED THERAPY OF
ADVANCED STAGE HODGKIN LYMPHOMA USING EARLY INTERIM FDG-PET IMAGING
J.W. Friedberg, H. Li, H. Schöder, D. Straus, C. Moskowitz,
M. LeBlanc, L.M. Rimsza, N.L. Bartlett, A.M. Evens, E.S. Mittra,
A. LaCasce, J. Sweetenham, P.M. Barr, M.A. Fanale, M.V. Knopp,
A. Noy, E.D. Hsi, J.R. Cook, M.J. Lechowicz, R.D. Gascoyne,
J. Leonard, B.S. Kahl, B.D. Cheson, R.I. Fisher, O.W. Press
United States National Clinical Trials Network: SWOG, Alliance, ECOG-
Acrin and AIDS Malignancy Consortium 
S0816 was the first US intergroup clinical trial using early interim FDG–
PET imaging to determine the utility of response-adapted therapy for
adults with stage III–IV classical Hodgkin Lymphoma. After 2 initial cycles
of ABVD, PET2-negative patients (Deauville 1-3) received an additional
4 cycles of ABVD, while PET2+ patients (Deauville score 4-5) switched
to eBEACOPP for 6 cycles. Among 336 eligible and evaluable patients,
the median age was 32 (18-60), with 52% stage III, 48% stage IV, and
49% IPS 0-2, 51% IPS 3-7. Central review of the interim PET2 scan was
performed in 331 evaluable patients, with 271 (82%) PET2-negative and
60 (18%) PET2+. Of 60 eligible PET2+ patients, 49 switched to eBEA-
COPP as planned and 11 declined. The median follow-up of patients last
known alive now exceeds 45 months (range 2.1-76 months). Eighty-two
patients have either progressed or died, for an estimated 2-year progres-
sion-free survival of 79% (95%CI: 73.8%-82.7%). There were 61 failures
in the PET2-negative group (2-year PFS 82%) and 20 failures in the PET2+
group (2-year PFS 64%), see Figure 1. In the entire trial, only 19 patients
died, for estimated 2-year overall survival of 98%. Long-term or late (post
therapy) grade 3 adverse events on ABVD arm were uncommon including
1 case each of neuropathy, heart failure, DVT, diarrhea and prolonged
neutropenia. There was one case of late grade 3 osteonecrosis on the
eBEACOPP arm. Six patients (1.4%) have developed secondary malig-
nancies, including 3 cases (1%) on ABVD (non-Hodgkin lymphoma, renal
cell carcinoma, and melanoma) and 3 cases (6%) on eBEACOPP (non-
Hodgkin lymphoma, renal cell carcinoma and skin cancer). We conclude
that response-adapted therapy based on interim PET imaging after two
cycles of ABVD appears promising and durable with a high 2-year PFS
for PET2+ patients (64%), and outstanding overall survival. However,
surprisingly, with prolonged follow-up, the majority of failures have
occurred in PET2-negative patients, indicating the limitations to a PET-
adapted approach. To further improve ABVD using precision medicine,
we need to further refine predictive markers of failure at the time of
Hodgkin lymphoma diagnosis.
Support. National Cancer Institute (NCI), National Clinical Trials Net-
work (NCTN) grants CA180888, CA180819, CA180821, CA180820,
CA121947.
Figure 1.
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SEQUENTIAL BRENTUXIMAB VEDOTIN AND ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE
FOR OLDER PATIENTS WITH UNTREATED HODGKIN LYMPHOMA: FINDINGS FROM A PHASE
II WINDOW STUDY
A.M. Evens1, P.A. Hamlin2, C. Nabhan3, R. Advani4, M. Fanale5,
A. Petrich6, S. Smith3, G. Bociek7, J. Winter6, L.I. Gordon6
1Tufts University School of Medicine, Boston, MA, USA; 2Memorial Sloan Ket-
tering Cancer Center, New York, NY, USA; 3University of Chicago, Chicago,
IL, USA; 4Stanford University Medical Center, Stanford, CA, USA; 5University
of Texas, MD Anderson Cancer Center, Houston, TX, USA; 6Northwestern
University Feinberg School of Medicine, Chicago, IL, USA; 7University of
Nebraska, Omaha, NE, USA
Introduction. Outcomes for older patients (pts) with HL remain sub-
optimal. We initiated a multicenter study examining sequential bren-
tuximab vedotin (BV) given before and after AVD chemotherapy
(NCT01476410). Methods. Pts ages ≥60 years with stage II-IV, untreated
HL were eligible. All pts received 2 “lead-in” cycles of single-agent BV
1.8 mg/kg (q 3 weeks), followed by 6 cycles of standard AVD
chemotherapy. Responding pts then receieved consolidation therapy
(Tx) with BVx4 cycles. Study design is Simon two-stage with plan of
48 total pts. The primary endpoint is complete remission (CR) rate after
AVD (ie, prior to BV consolidation) using FDG-PET. If ≥12 CRs were
observed among 20 evaluable pts, accrual continued to the 2nd stage.
Results. 26 pts enrolled to the first study stage, of which 20 were evalu-
able for response. Characteristics for all pts included: median age 69
years (60-88); median ECOG PS of 1 (0-2); 92% stage III/IV disease;
IPS 3-7 in 54%; and median CIRS co-morbidity score 5 (0-19). 6 pts
were non-evaluable for response (n=3 withdrew consent/refused fur-
ther therapy; n=2 toxicity; and n=1 death due to pancreatitis). Among
20 evaluable pts, overall response rate (ORR) to BV lead-in was 85%
with 30% CR. After 3 AVD cycles, ORR and CR rates were 95% and
70%, respectively. The best ORR (including after BV consolidation ther-
apy) was 95% with a CR rate of 90%. By intent-to-treat, best ORR
and CR rates were 81% and 77%, respectively. Grade 3/4 AEs occurring
in >1 pt were infection (15%), pancreatitis (4%), and peripheral neu-
ropathy (PN) (4%); 31% of pts experienced grade 2 PN. Reasons for
discontinuation of Tx included: 7/26 (27%) completed Tx; 7/26 (27%)
on active Tx; 4/26 (15%) due to toxicity (grade 2: infusion reaction,
hepatic, pneumonitis; and grade 3 wound infection); 3/26 (12%) refused
additional Tx; 3/26 (12%) discontinued for PN (all grade 2 status-post
cycles 6, 8,10); 1/26 (4%) due to lack of response; and 1 (4%) death
(due to pancreatitis). At median follow-up of 22 months, 92% of all pts
are alive, the progression-free survival is 85%, and notably, 95% of all
evaluable pts are disease-free. Conclusions. Sequential integration of BV
before and after standard AVD chemotherapy for newly diagnosed old-
er HL pts is feasible and highly promising. The planned interim analysis
confirmed the requisite CR rate needed for continuation to the 2nd
stage of this multicenter phase II study. Updated results will be reported
at the meeting. 
P002
PRELIMINARY RESULTS OF A PHASE II STUDY OF BRENTUXIMAB VEDOTIN USING A
RESPONSE ADAPTED DESIGN IN THE FIRST LINE TREATMENT OF PATIENTS WITH
HODGKIN LYMPHOMA UNSUITABLE FOR CHEMOTHERAPY DUE TO AGE, FRAILTY OR
CO-MORBIDITY (BREVITY)
A. Gibb1, S. Pirrie2, K. Linton1,3, K. Paterson2, A. Davies4, G. Collins5,
T. Menne6, P. McKay7, P. Fields8, F. Miall9, E. Nagy2, K. Wheatley2,
V. Warbey10, S. Barrington10, J. Radford1,3
1The Christie NHS Foundation Trust, Manchester, UK; 2CRCTU, University
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ation Programme; 3University of Manchester, Manchester, UK; 4Cancer Research
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Health Partners, UK
Introduction. Results of standard treatment for older patients (pts) with
classical Hodgkin lymphoma (cHL) are sub-optimal and alternative
approaches are required. Brentuximab vedotin (BV) is a CD30 targeted
antibody-drug conjugate which in the pivotal* phase 2 trial in
relapsed/refractory cHL produced an objective response rate of 75%,
complete remission rate of 34% and manageable toxicity. BREVITY is
a study of efficacy/tolerability of BV in older, frail or comorbid pts with
previously untreated cHL. Methods. This was a phase II, Simon 2-stage,
single arm study requiring 30 evaluable pts. Primary outcome was com-
plete metabolic response rate (CMR, Deauville Score 1-3) by centrally
reviewed PET-CT after 4 cycles of BV. Secondary outcomes included
PFS, OS, toxicity and comorbidity assessment (CIRS-G). Inclusion cri-
teria were previously untreated cHL stage 2 (with B symptoms and/or
mediastinal bulk) or stages 3/4 with cardiac/respiratory compromise
(at any age) or an ECOG score 1-3 and considered unfit for standard
chemotherapy (in pts ≥60 yrs). BV dose was 1.8 mg/kg every 3 weeks,
reduced to 1.2 mg/kg for toxicity. Pts in CMR/PMR after 4 doses BV
continued to a total of 16 cycles if CT and/or PET-CT every 4 cycles
confirmed ongoing response. PFS/OS data is not mature. Results. 38 pts
were recruited Feb 2014-Oct 2015 at 12 UK centres; demographics are
shown in Table 1.
Table 1.
35 pts were treated and evaluable for toxicity, 31 are evaluable for
response. Median follow-up for alive pts is 11.6(range 0.9, 21.4) months.
A median of 4 cycles were given per pt (range 1, 16). 28(12%) cycles in
14 pts were modified due to toxicity and 11 pts stopped treatment due
to adverse events (AEs). 695 AEs were reported of which 601(86%)
were grade 1/2. 26(74%) pts had at least 1 AE ≥grade 3, most commonly
infection, myelosuppression or neuropathy. CMR rate at PET4 was
25.8%(95% CI 13.7, 43.2) and combined CMR/PMR rate was
83.7(95%CI: 67.4, 92.9). To date 21(67.7%) pts have progressed. Dis-
cussion. In this study BV monotherapy produced a high objective
response rate although the CMR rate after 4 cycles did not meet the
pre-specified 40% level. Toxicity was greater than in the pivotal* study
where pts were younger/fitter and led to treatment termination in some
pts. Nevertheless BV is effective in this older comorbid population. A
follow-on study incorporating BV at lower dose in combination with
other agents and growth factor support aimed at improving the CMR
rate is in development.
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CAUTION IN THE ELIMINATION OF RADIOTHERAPY FROM THE TREATMENT OF PATIENTS
WITH STAGE III CLASSICAL HODGKIN LYMPHOMA: A SURVEILLANCE, EPIDEMIOLOGY,
AND END RESULTS DATABASE ANALYSIS
J.E. Bates1, S. Dhakal2, A. Mazloom3, C. Casulo4, L.S. Constine2
1Department of Radiation Oncology, University of Florida, Gainesville, FL, USA;
2Department of Radiation Oncology, Wilmot Cancer Institute, University of
Rochester Medical Center, Rochester, NY, USA; 3Tacoma Valley Radiation Oncol-
ogy Center, Tacoma, WA, USA; 4Department of Medical Oncology, Wilmot Can-
cer Institute, University of Rochester Medical Center, Rochester, NY, USA
Background. The role of radiotherapy (RT) in the primary manage-
ment of advanced stage classic Hodgkin lymphoma (HL) remains con-
troversial based on conflicting study results. While the definition for
advanced stage is widely agreed upon as patients with stage III or IV
disease, the difference in disease distribution and burden, as well as the
difference in overall survival, between these stages may make RT more
beneficial to patients with stage III disease. Methods. We queried the
Surveillance, Epidemiology, and End Results (SEER) database, restricting
our search to patients with stage III classical HL diagnosed from 2004 -
2012, to examine the difference in overall and cause-specific survival
(OS and CSS) between patients who did or did not receive RT in com-
bination with chemotherapy. Results. Patients treated with RT had
improved OS and CSS relative to those treated without RT (5-year OS
91.6% with RT compared to 71.4% without RT, HR=0.34, p <0.001)
and CSS (5-year OS 95.4% with RT compared to 84.7% without RT,
HR=0.32, p <0.001). A benefit in OS and/or CSS was seen in both pedi-
atric and adult patient subgroups, and patients with B symptoms and/or
extranodal disease (Table 1).
Table 1. Multivariate Analysis of Treatment Outcomes in Patients with
Stage III Classical Hodgkin Lymphoma (n=4,108).
Conclusions. This large, hypothesis-generating, population-based study
of the effect of radiotherapy in the treatment of stage III HL shows a
benefit to radiotherapy across most subgroups. This supports a cau-
tionary approach to omitting radiation therapy from treatment strate-
gies for patients with advanced stage HL.
P004
GRAY ZONE LYMPHOMA WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE
B-CELL LYMPHOMA AND CLASSICAL HODGKIN LYMPHOMA: DIAGNOSTIC EXPERIENCES
AND CHALLENGES FROM A MULTICENTER STUDY
M. Pilichowska1, S. Pittaluga2, J.A. Ferry3, J. Hemminger4, G. Gupta1,
A. Kritharis5, R.D. Gascoyne6, A.M. Evens5, E.S. Jaffe2
1Department of Pathology, Tufts Medical Center, Boston, Massachusetts, USA;
2Laboratory of Pathology, Center for Cancer Research, National Cancer Institute,
Bethesda, Maryland, USA; 3Department of Pathology, Massachusetts General
Hospital, Boston, Massachusetts, USA; 4Department of Pathology, The Ohio
State University, Wexner Medical Center, Columbus, Ohio, USA; 5Division of
Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts, USA;
6Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC,
Canada, USA
Background. GZL (B-cell lymphoma, unclassifiable, with features
intermediate between DLBCL and cHL) was described in 2005 and
included in the 2008 WHO classification. Most cases present with medi-
astinal disease and share features with cHL and primary mediastinal
large B-cell lymphoma (PMBCL). Non-mediastinal lymphomas with
similar pathologic features have also been reported. Because of rarity
and diagnostic complexity, data on GZL are limited and further study
of this entity is desired.
Figure 1. Outcomes in gray zone lymphoma (GZL). The 2-year (A) progres-
sion-free survival (PFS) and overall survival (OS) rates for 112 patients
with GZL were 40% and 88%, respectively. (B) Outcome based on the pres-
ence of a mediastinal or non-mediastinal mass. Outcome (C) based on
frontline therapeutic regimen: 2-year PFS for patients who received a stan-
dard frontline DLBCL regimen (i.e., CHOP+/-R and DA-EPOCH-R) versus
ABVD+/-R were 52% versus 23%, P=0.03. Kaplan-Meier survival curves (D)
for patients who received rituximab as a part of frontline therapy versus
not; 2-year PFS were 51% versus 22%, respectively, P=0.01. 
Methods.Clinical data from cases originally diagnosed as GZL were col-
lected from 19 academic centers across the US and Canada (Evens AM
et al. Am J Hematol 90:778-83, 2015). To further characterize the diag-
nostic features and correlations, 73 cases (majority from the above series
and n=4 subsequent cases) were submitted for central pathology review
using criteria of the 2016 revised WHO classification. Initial diagnostic
samples were evaluated with a panel comprising CD20, CD79a, PAX5,
OCT2, BCL6, MUM1, CD30, CD15, CD3 and EBV by in situ hybridiza-
tion (EBER). Beyond the tumor cell immunoprofile, diagnostic criteria
included tumor cell density and morphology, necrosis, and the microen-
vironment. cHL nodular sclerosis grade 2 (cHL-NS2) were classified
according to prior criteria (MacLennan K. et al. Cancer 64: 1686-93,
1989). 5 cases were rejected for insufficient material/technical issues;
68 cases were evaluated by 5 hematopathologists and consensus diag-
nosis was reached at multiheaded scope review. Results. Of 68 cases
submitted with an original diagnosis of GZL, only 26 cases were con-
firmed as GZL on consensus review (14M/12F, median age 38 years,
range 19-69). 11/26 biopsies were mediastinal in origin, and in an addi-
tional 4 cases, a mediastinal mass was present clinically; 11 had only
peripheral lymphadenopathy (ie, non-mediastinal). 42 cases were re-
classified as follows: NS cHL, n=27 (n=10 of which were cHL-NS2);
DLBCL NOS, n=4; nodular lymphocyte predominant HL (NLPHL), n=3;
EBV positive LBCL, n=3; PMBCL, n=2; lymphocyte-rich cHL, n=1; and
B-cell lymphoproliferative disorder, n=1. Most cases of cHL diagnosed
as GZL had strong CD20 expression. Furthermore, cHL-NS2 was fre-
quently misdiagnosed as GZL typically due to confluent growth of lacu-
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nar cells (Figure 1). Conclusions. Diagnosis of GZL remains a challenge.
Rarity of the cases, and overlap with cHL-NS2, contribute to the diffi-
culty. Further biologic and clinical analyses may contribute to improved
understanding.
P005
HODGKIN LYMPHOMA IN SWEDEN SINCE 2000: BETTER SURVIVAL ONLY IN ELDERLY
WOMEN - A SWEDISH LYMPHOMA REGISTRY STUDY
B.E. Wahlin1, N. Övergaard2, S. Peterson3, E. Digkas4, I. Glimelius2,
I. Lagerlöf5, A.-S. Johansson6, M. Palma1, L. Hansson1, J. Linderoth7,
C. Goldkuhl8, D. Molin2
1Department of Hematology, Karolinska University Hospital, Stockholm, Swe-
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Lund University, Lund, Sweden; 8Department of Oncology, Sahlgrenska Uni-
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Two major areas of dispute in Hodgkin lymphoma are treatment of
advanced stages and of elderly patients. For advanced stages the debate
is whether BEACOPPesc/14 or ABVD is to be considered standard.
ABVD is standard in many countries, especially for those with IPS 0-2.
There is no golden standard for therapy in elderly patients. In Sweden
CHOP has been the standard treatment in patients >70 years during
the study period. Outcome is also inferior in elderly compared with
younger patients. We have analysed data from all 2345 Hodgkin lym-
phoma patients (1257 men and 1088 women, median age 42, range 16-
99) diagnosed from 2000 through 2014 in the Swedish Lymphoma Reg-
istry. Median follow-up was 6.7 years. Overall survival (OS) at 3 and 5
years were 83% and 79%, without any differences between calendar
periods (2000-2004, 2005-2009, and 2010-2014). In the most recent cal-
endar period (2010-2014), longer survival was observed among patients
≥61 years (P=0.027), but not among those <61 (P=0.49). This improve-
ment was restricted to women with advanced stage disease (P=0.005).
Stage IV disease was more common in the most recent calendar period
(2010-2014) compared to the first (2000-2004), both in women (22%
vs 15%, P=0.003) and in men (28% vs 21%; P=0.006), likely explained
by the increasing use of PET-CT. In multivariate analysis, adjusted for
all factors significant in univariate analysis, of patients ≥61 years, CHOP
(compared with ABVD) was an independent adverse factor for OS (HR
1.7; 95% CI, 1.1-2.7; P=0.027). Patients <61 with advanced stages treat-
ed with BEACOPPesc/14 and ABVD showed identical OS in univariate
and multivariate analysis (P=0.51). In conclusion, outcome was not
improved over time except in elderly women. The implementation of
FDG-PET/CT has resulted in a stage migration with an increased pro-
portion of patients with stage IV disease. ABVD seems superior to
CHOP for elderly who tolerate this regimen. BEACOPP and ABVD
show equal OS in younger patients with advanced stage disease, sup-
porting the use of PET/CT-adapted ABVD as initial therapy.
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ADVANCED HODGKIN LYMPHOMA IN THE EAST OF ENGLAND CANCER NETWORK:
A 10 YEAR COMPARATIVE ANALYSIS OF OUTCOMES FOR ABVD AND ESCALATED
BEACOPP TREATED PATIENTS AGED 16-59
A. Collins1, A. Fowler2, M. Karanth3, C. Saha4, J. Russel5,
V. Shyamsundar1, S. Docherty6, K. Maw7, J. Padayatty4, A. Hodson5,
J. Wimperis6, S. Sadullah7, N. Grigoropoulos1, B. Uttenthal1, G. Follows1
1Cambridge University Hospitals, Cambridge, UK; 2Peterborough Hospital,
Peterborough, UK; 3West Suffolk Hospital, UK; 4Kings Lynn Hospital, Kings
Lynn, UK; 5Ipswich Hosptial, Ipswich, UK; 6Norfolk and Norwich University
Hospital, Norwich, UK; 7James Paget University Hospital, Norfolk, UK
The majority of young patients presenting with advanced stage
Hodgkin lymphoma (HL) in the UK are managed with ABVD. Howev-
er, following the 2009 HD9 trial publication, escalated BEACOPP (escB)
was introduced as a treatment option in certain UK cancer centres. Here
we present the data from advanced stage HL patients aged 16 to 59,
who presented between 2004 and 2014 in the East of England Anglia
Cancer Network with a referral population of 2.64 million. 250 cases
were diagnosed, giving an incidence of 0.95 cases per 100,000 which is
in-line with expected incidence of advanced HL in this age group. Six
of the eight Anglia cancer centres introduced escalated BEACOPP for
patents as determined by physician and patient choice. Over this 10
year period, 44 patients were managed with escB, 202 with ABVD, 3
with an alternative regimen and 1 patient died pre-treatment. The 5
year progression free survival (PFS) for all patients was 82% and 5 year
overall survival (OS) was 92%. There was a clinician / patient prefer-
ence for escB for worse prognosis patients as escB patients had a higher
international prognostic score (IPS) than patients treated with ABVD
(IPS3+: escB 75% vs ABVD 38%, p<0.0001). For the whole cohort, PFS
was better for patients treated with escB compared with ABVD (5 year
PFS 95% vs 80%; HR 4.3 (95%CI:1.97-9.7), p=0.0261)), but there was
no OS difference (5 year OS 97% vs 92%; HR 2.6 (95%CI:0.69-10.4),
p=0.312). However, patients with IPS 3+ had both a PFS and OS advan-
tage when treated with escB compared with ABVD (5 year PFS 96% vs
74%; HR 9.24 (95%CI:3.43-24.89), p=0.012: 5 year OS 100% vs 84%;
p=0.0325). The use of consolidation radiotherapy(RT) was equal
between regimens with 11% of patients receiving RT with both escB
and ABVD. 29 ABVD-treated and 3 escB-treated patients had at least
one subsequent transplant procedure (including 6 allografts post ABVD
and 3 allografts post escB, including one allograft for tAML/MDS). Of
the 20 pre-menopausal women treated with escB, 11 of 14 aged <30
regained menstrual periods (5 pregnancies) but only 1 of 6 aged >30
regained menstrual periods which were not sustained beyond 3 years.
Our data reflect clinical trials results which indicate a first remission
PFS but not OS advantage for unselected young advanced stage HL
patients treated with escB compared with ABVD. However, our data
strongly suggest that patients with a poor IPS score derive a PFS and
OS benefit from treatment with escB compared with ABVD.
P007
SUPERIORITY OF MODIFIED PROGRESSION FREE SURVIVAL TO EVALUATE
CHEMOTHERAPY EFFECTIVENESS FOR ADVANCED STAGE HODGKIN LYMPHOMA
J.M. Connors, A.S. Gerrie, D.W. Scott, L.H. Sehn, D. Villa, K.J. Savage
From the BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, British
Columbia, Canada
Background. Assessment of the effectiveness of chemotherapy for
advanced stage Hodgkin lymphoma may be obscured by the incorpo-
ration of radiotherapy in primary treatment when standard endpoints
such as progression free survival (PFS) are used. Ineffective chemother-
apy may be “rescued” by the addition of radiotherapy residual PET-
positive masses. Use of a modified PFS endpoint (mPFS), in which addi-
tion of radiotherapy after the conclusion of chemotherapy is scored as
an event, more accurately assesses chemotherapy effectiveness. Meth-
ods. We examined the records of 207 consecutive adult patients (age
16-82 y, median 36; males 55%) with advanced stage HL (IIIA, 23%;
IIIB, 24%; IVA, 17%; IVB, 36%) treated between 2004 and 2015 with
ABVD with or without involved field radiotherapy (IFRT). Standard
PFS events were the first of relapse or progression (REL/PROG) despite
primary treatment (ABVD +/- IFRT) or death from any cause; mPFS
events were the first of radiotherapy given after ABVD if the post-
ABVD PET was positive (PET-RT), relapse or progression after primary
treatment (REL/PROG) or death from any cause. Results.We observed
56 PFS events (REL/PROG, 54; death 2) and 64 mPFS events (PET-RT,
17; REL/PROG 45; death 2). Thus, 8/64 (13%) of the relevant events
(failure of the primary chemotherapy to cure the lymphoma) were
unappreciated using the standard PFS endpoint. This resulted in an
overestimate of the effectiveness of primary chemotherapy (2-y PFS
78%; 2-y mPFS 72%) and of the duration of survival free of death,
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relapse or progression (time to 25% treatment failures using standard
PFS=2.8 y; using mPFS=1.1 y) (Figure 1). These overestimates occur
because the addition of radiotherapy to the primary chemotherapy “res-
cues” patients whose primary chemotherapy has failed (PET positive
residual disease still present after completion of the primary chemother-
apy) and creates the appearance of successful treatment. Conclusions.
Use of the mPFS endpoint provides a superior assessment compared to
standard PFS if the goal of a clinical trial testing treatment for advanced
stage Hodgkin lymphoma is to identify the most effective chemother-
apy regimen. This is particularly important in an era when post-
chemotherapy evaluation with PET has become standard and major
efforts are being made to determine the potential benefit of adding nov-




TREATMENT RESULTS FOR HODGKIN LYMPHOMA IN BRAZIL: FIRST REPORT FROM THE
BRAZILIAN PROSPECTIVE HODGKIN’S LYMPHOMA REGISTRY
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Introduction.Data about Hodgkin Lymphoma (HL) in developing coun-
tries are scarce. In 2009, a prospective registry of HL was implemented
in Brazil. Methods. Twenty institutions take part in the registry. Clinical,
treatment and outcome data were prospectively collected in a web-
based platform, and are reported here for the first time. Results. 756 HL
patients (pts) with diagnosis until December 31, 2014 were identified.
Twenty-one pts with nodular-predominant HL, 11 pts younger than 13
years-old and 38 pts with HIV were excluded, with 686 pts available
for this analysis. Median age was 30 years-old (13-90); 67 (10%) pts
were older than 60. Females comprised 346 pts (50%). Median time
from onset of symptoms to diagnosis was 6 (0-60) months. Forty-four
(7%) pts had limited disease, 180 (26%) had intermediate disease and
445 (65%) had advanced disease by GHSG criteria. Stage IVB was pres-
ent in 26%, B symptoms in 69%, low albumin in 63% and a high-risk
IPS score in 38%. Median time from diagnosis to beginning of treatment
was 0.72 months (0-10.87 months). Median follow-up was 37 months
(0.53-94) for all patients, and 40 months (4-94) for patients alive. ABVD
was the first-line treatment in 93% of pts. Twenty-one patients died
during treatment. After completed treatment, the complete remission
(CR) rate was 73%, unconfirmed CR was 12%, partial remission was
4%, stable disease was 2% and progressive disease was 9%. Among
those who received ABVD, the median number of cycles was 4 for lim-
ited and intermediate and 6 for advanced disease. Radiotherapy (RT)
was used in 33% of advanced disease pts, 65% of intermediate disease
pts, and 77% of limited disease pts. The median dose of RT was 36 Gy
for localized disease, and 32 Gy for advanced disease. The median time
from the end of chemotherapy to the beginning of RT was 1.7 months.
The 3-year OS and 3-year PFS were 90% and 74%, respectively. The
3-y PFS in limited disease, intermediate disease and advanced disease
were 95%, 88% and 66% (p<0.0001), respectively. The 3-year OS for
limited disease, intermediate disease and advanced disease were 100%,
96% and 86% (p=0.0001), respectively. Conclusions.Advanced stage and
poor risk patients predominated. Radiation doses used for localized dis-
ease appear higher than current recommendations. Outcomes for
advanced disease appear to be 5-10% lower than in developed coun-
tries, in part due to very advanced disease at diagnosis, and to an excess
of deaths during treatment.
P009
DOSE-DENSE/DOSE-INTENSE ABVD IN ADVANCED-STAGE HODGKIN’S LYMPHOMA:
A LONG-TERM FOLLOW UP STUDY
F. Russo1, L. Aloj2, G. Svanera3, P. Fimiani4, S. Lastoria2
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Clinica Stabia, Castellammare di Stabia (NA), Italy
One-hundred forty-three patients with advanced-stage HL were treat-
ed with a dose-dense three-weekly version of the ABVD regimen, which
was also dose intensified, in the first 4 cycles, by escalating doxorubicin.
Specifications are contained in the published article (Russo F BHJ
166,1,118, 2014). Twelve patients (8.4%) received radiotherapy (RT) on
residual mediastinal or extramediastinal bulk disease. Results were com-
pared with a historical series of 111 patients treated with standard
ABVD+/-RT. The demographics and clinical characteristics are in Figure
1. Ninety-six percent of patients completed the planned 6 cycles (median
time=16.8 weeks). Median actual dose intensities were 20.87 (23.11
cycles 1-4), 6.72, 3.89 and 248 mg/m2/week for doxorubicin, bleomycin,
vinblastine and dacarbazine, respectively. This corresponded to a 66.9%
(85.0%, cycles 1-4) increase in dose intensity for doxorubicin, (total dose
380 mg/m2) and of 32% for the other agents, over standard ABVD. Inten-
sified ABVD confirmed to be highly tolerated with low rates of hospi-
talization during treatment, a low incidence of G3/ G4 events, low post-
treatment cardiac and pulmonary toxicities and a very low rate of
gonadic toxicity. Only two cases of second cancer were recorded. One-
hundred-eleven out of 143 (79%) showed a PET normalization at the
end of 2nd cycle. Comparison between intensified and standard ABVD
showed complete remission (CR) rates 93.7% in intensified ABVD and
80.2% in standard ABVD, respectively (p=0.002). EFS and OS rates at 7
years were 85.7% vs 68.1% and 93.9% vs 76.3%. At univariate analysis
the predictive factors of low CR rate were IPS≥3 ( p=0.032), and PET2pos
(p <0.001). At multivariate analysis PET2pos (p<0.001) was the only
independent risk factor predictive of low CR rate. Seven-yr EFS was sig-
nificantly better in patients with PET2neg (log rank 13.2, p<0.001) and
in patients with IPS 0-2 (log rank 4.3, p=0.032). At Cox regression analy-
sis PET2 was the only independent factor predictive of EFS. As on
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09/2015, one-hundred-thirty-five out of 143 are alive with 131 free of
disease (123 in 1stCR,8 in 2ndCR). Intensified ABVD seems to be ade-
quately powered to exploit early disease chemo-sensitivity yielding high
percentage of PET2neg, high rate of response and survival, without new
severe or critical short and long-term toxicities. Selective use of low dose
RT in residual PET+ tissue seems to rescue a subset of patients with
bulky disease and suboptimal response. 
Figure 1.
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THE SWITCH FROM ABVD TO eBEACOPP AS FRONT-LINE THERAPY FOR HIGH-RISK
STAGE III-IV CLASSICAL HODGKIN LYMPHOMA PATIENTS RESULTS IN AN INVERSION OF
EVENT-FREE SURVIVAL OF PROGNOSTIC GROUPS
I. Aurer, S. Basic-Kinda, D. Dujmovic, I. Radman, B. Dreta, S. Dotlic,
L. Galunic-Bilic, M. Dobrenic, M. Kralik, P. Roncevic
University Hospital Centre Zagreb and Medical School, University of Zagreb,
Croatia
When ABVD is used as the chemotherapy backbone for newly diag-
nosed cHL, patients with favorable stage I-II (EF), unfavorable stage I-
II (EU), favorable stage III-IV (Hasenclever index 0-2) (AF) and unfavor-
able stage III-IV (Hasenclever index ≥3) (AU) differ in EFS with the
latter having the worst prognosis. GHLSG has reported that the intro-
duction of eBEACOPP-based chemotherapy for EU and advanced stage
groups annuls this difference. To our knowledge, no other group has
reproduced these findings.
Since 2010, after the end of accrual into the EORTC 20012 trial, we
recommend eBEACOPP as front-line therapy for AU. During 2014/5
this recommendation was extended to AF and EU patients. Here we
analyze the outcome of different prognostic groups of newly diagnosed
cHL patients below 60 years of age treated at our institution during the
period of almost 5 years when eBEACOPP was used as initial treatment
only for AU patients. There were 13 patients in the EF group, one was
treated with ABVD only, one with radiotherapy (RT) only, and 11 with
the combination of ABVD and RT. None relapsed or died. 38 patients
were in the EU group. All started ABVD, two switched to eBEACOPP
because of interim PET positivity; 33 received RT and five chemother-
apy only. Two progressed immediately after RT, additional 8 relapsed,
2 died. EFS at three years was 72% and OS 97%. 20 patients were in
the AF group. All received ABVD, three switched to eBEACOPP
because of interim PET positivity; four received additional RT. Two
patients died, one due to sepsis after switching to eBEACOPP and one,
treated with ABVD, due to bleomycin-related pneumonitis; additional
two relapsed. EFS at three years was 79% and OS 90%. 34 patients
were in the AU group. 30 started treatment with eBEACOPP and 4
with ABVD, one switched to eBEACOPP because of interim PET pos-
itivity; 10 received additional RT. One patient died during treatment,
presumably due to pulmonary embolism; one relapsed. EFS at three
years was 94% and OS 97%. The difference in EFS between EU and
AF is statistically significant (p=0.023) (Figure 1). If eBEACOPP is used
for front-line treatment only in patients with high-risk advanced stage
disease, this results in paradoxical inversion of EFS between prognostic
groups. eBEACOPP should be considered for all newly diagnosed HL
patients younger than 60, except those in the lowest risk group.
Figure 1.
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HALO STUDY: A PHASE 1/2 CLINICAL TRIAL OF BRENTUXIMAB-VEDOTIN AND
BENDAMUSTIN IN ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED
HODGKIN LYMPHOMA. PRELIMINARY DATA
S. Viviani1, B. Fontanet2, A. Rambaldi3, A. Perrot4, C. Patti5, L. Gastaud6,
R. Sorasio7, C. Debaigt6, E. Chamorey6, A. Gallamini6, A. Thyss6
1Istituto Nazionale dei Tumori, Milano, Italy; 2Institut Bergonié, Bordeaux,
France; 3Ospedale Papa Giovanni XXII, Bergamo, Italy; 4CHU Nancy-Brabois,
Vandoeuvre-lès-Nancy, France; 5Ospedale Riuniti Villa Sofia e Cervello, Paler-
mo, Italy; 6Centre Antoine-Lacassagne, Nice, France 7Ospedale Santa Croce,
Cuneo, Italy
Treatment of elderly patients with HL remains a difficult challenge
as results and tolerance of the standard treatment with ABVD remains
very inferior to adults. Bendamustine (Be), andwith Brentuximab
Vedotin (BV), are active drugs, which have demonstrated a good toler-
ance and an high level of response in relapsing/refractory HL. To assess
the safety and the efficacy of the combination of this two drugs in eld-
erly HL, we conduct a prospective multicentric open-label stydy of
Brentuximab-Vedotin (BV): 1.2 mg/kg D1 and Bendamustin (Be) 90
mg/m2/day, D1 and D2, every 3 weeks up to 6 cycles, for patients from
60 to 80 years of age, with advanced HL, stage 2B to 4,. Ten centers, 5
from Italy and 5 from France, participate to the study. A total of 60
patients are planned to be included. An evaluation by TEP-Scan will be
performed after the 2nd cycle and treatment will be pursued until the
6th cycles for patients in CR according to Lugarno’s criteria. A supple-
mentary control by TEP-scan is planned after the 4th cycle for patients
in PR after 2 cycles. . Patients with progressive disease at any time or
not in CR after 4 cycles will receive salvage therapy according the
choice of the local investigator. A final evaluation by PET-Scan is
planned for all patients after the 6th cycle. A centralized review of all
TEP-Scan is planned. . The patients will be followed up for 3 years.
The study is divided in 2 phases: the phase 1 with 12 patients with the
main objective to evaluate the tolerability and toxicity of Be-BV and
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the phase 2 with 48 patients, with the primary objective to evaluate
the efficacy in terms of response rate after treatment completion. The
secondary objectives of the phase 2 are to evaluate the efficacy in terms
of PFS, EFS and OS at 3 years, to evaluate the efficacy in terms of com-
plete response rate after two cycles of Be-BV and to evaluate the feasi-
bility of the treatment. Currently, we have enrolled 14 patients: 9
patients have performed the first TEP-Scan evaluation after 2 cycles: 7
were in complete response and 2 in partial responses according to local
evaluation. The 2 patients in PR after 2 cycles were in CR at the evalu-
ation by PET-Scan after 4 cycles. None unexpected toxicity has been
observed and the trial remains open to inclusions. The precise design
of the study and updated results will be presented for the symposium.
Support. Study is supported by a grant of Millenium US/Takeda
France.
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TRANSFORMATION OF NODULAR HODGKIN’S LYMPHOMA WITH LYMPHOCYTE
PREDOMINANCE TO T-CELL-RICH LARGE B-CELL LYMPHOMA
T. Moiseeva, L.S. Al-Radi, E.I. Dorokhina, S.R. Goryacheva,
O.V. Margolin, A.U. Magomedova, H.L. Julhakyan, S. Kravchenko
National Reserch Center for Hematology, Moscow, Russian Federation
Aim. To describe clinical features of transformation of nodular
Hodgkin’s lymphoma (HL) with lymphoid predominance (NLHLP) to
T-cell-rich large B-cell lymphoma (TCRLBCL), to evaluate the effective-
ness of therapy program BEACOPP-14 in this group of patients. Mate-
rials and Methods.During the period from 2010 to 2016 the transforma-
tion NLHLP to TCRLBCL was diagnosed in 15 patients. Male to female
ratio 4: 1, median age 40 (23-68) years. NLHLP diagnosis was based on
histological and immunohistochemical study of the biopsy of the tumor,
the stage of disease - by standard for LH methods. Results. Of the 46
patients with NLPLH observed in National Reserch Center for Hema-
tology, transformation NLHLP to TCRLBCL was diagnosed in 15 (33%)
patients (13 untreated patients with a long history of lymphadenopathy,
and 2 patients with relapsed Hodgkin’s lymphoma after 3 years and 21
years). All patients had advanced stages of disease. All untreated
patients had previous long-term asymptomatic lymphadenopathy. B -
symptoms were noted in 11 (73%) cases. Extranodal involvement had
12 (80%) patients: liver damage - in 7 (47%), lung involves - in 5 (33%),
spleen involves - in 10 (67%), bone marrow lesions was found in 9
(60%) patients and was proved by histological and immunohistochem-
ical study. Follow-up of the 15 patients: 1 patient with transformation
to TCRLBCL in relapse (in 21year after the end of LH treatment) was
not treated (refusal of treatment, death), 1 patient received ABVD and
achieved complete remission, the remaining 13 patients received BEA-
COPP-14, complete remission was achieved in 11 (85%), partial remis-
sion - in 2 (15%) patients. In one young patient with transformation
NLHLP to TCRLBCL with aggressive clinical presentation of disease
complete remission was consolidated by high-dose chemotherapy fol-
lowed by autologous peripheral blood stem cells transplantation. Con-
clusions. The clinical features of transformation NLHLP to TCRLBCL
are advanced stages of disease with presence of B-symptoms, frequent
involvement of extranodal sites and bone marrow. Therapy by BEA-
COPP-14 program can lead to complete remission in 85% of patients.
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ABVD AS THE TREATMENT OPTION IN HODGKIN LYMPHOMA WITH LARGE MEDIASTINAL
TUMOR
B. Andjelic1,2, L.J. Jakovic1, D. Antic1,2, M. Todorovic1,2, J. Bila1,2,
V. Djurasinovic1, A. Sretenovic1, V. Vukovic1, J. Jelicic1, M. Smiljanic1,
B. Mihaljevic1,2
1Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia; 2Faculty of
Medicine, University of Belgrade, Belgrade, Serbia
Background. Large mediastinal tumor is considered as an unfavorable
prognostic factor for Hodgkin’s lymphoma (HL). Patients with
advanced Ann Arbor clinical stages (CS III and IV) are considered as
advanced disease. Nevertheless, some study groups are also stratifying
patients with large mediastinal tumor as advanced disease. Aim. The
aim of this study was to assess the outcome of ABVD treated HL
patients with large mediastinal tumor, as well to identify risk factors
for poor outcome. Patients and Methods.A study was performed on 173
HL patients with large mediastinal tumor (more than one-third of the
maximum horizontal chest diameter on CXR) diagnosed between 1997
and 2011. The standard initial treatment was 6-8 cycles of ABVD +/-
radiotherapy. Beside the patients with advanced CS, this study also
included patients wirh CS II who were according to institutional guide-
lines treated the same as patients with advanced CS. Results. The medi-
an age was 29 (range 16-68). The median follow up was 94 months.
Five-year event free survival (EFS) was 62% and 5-year overall survival
(OS) was 76%. In univariate analysis, there was no difference in sur-
vival based on CS, both in OS (log rank; p=0.180) and EFS (log rank;
p=0.126). Worse OS was found only in patients with IPS≥3 (5-year OS
62.5% vs 82.1%; log rank, p=0.011), while presence of age>45, male
gender, ESR≥50 mm/h, B symptoms or EN disease didn’t influence OS
(log rank; p=0.499, p=0.145, p=0.631, p=0.111, p=0.900, respectively).
Worse EFS was found in patients with IPS≥3 (5-year EFS 51.8% vs
67.6%) and males (5-year EFS 54.8% vs 66.7%) (log rank; p=0.037,
p=0.016, respectively), while presence of age>45, ESR≥50 mm/h, B
symptoms or EN disease didn’t influence EFS (log rank; p=0.960,
p=0.885, p=0.295, p=0.887, respectively). The multivariate Cox regres-
sion analysis identified IPS≥3 as the independent prognostic factor for
OS (p=0.023; RR=1.982; 95% CI 1.100-3.570) and male gender for EFS
(p=0.011; RR=1.852; 95% CI 1.153-2.974). Conclusions. The initial
approach in patients with CS II and large mediastinal tumor shouldn’t
be different from advanced clinical stages. More effective approach
seems to be required, especially in males and patients with high IPS. 
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PERIPHERAL BLOOD EOSINOPHILIA IS A GOOD RISK FACTOR IN POOR
PROGNOSIS GROUP: ADVANCED HODGKIN LYMPHOMA WITH LOW ALC/AMC
L.R. Jakovic1,2, B. Mihaljevic1,2, B. Andjelic1,2, A.D. Bogdanovic1,2,
M.D. Perunicic Jovanovic3, V.Z. Bumbasirevic4
1Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia; 2Faculty of
Medicine, University of Belgrade, Serbia; 3Department of Histopathology, Clin-
ical Center of Serbia, Serbia; 4Institute of Histology and Embryology, Faculty of
Medicine University of Belgrade, Serbia
We studied the prognostic significance of the absolute neutrophil/lym-
phocyte ratio (ANC/ALC), the absolute lymphocyte/monocyte ratio
(ALC/AMC), absolute eosinophil count (AEoC) and their contribution
to prognostic value of the International Prognostic Score (IPS) in 361
advanced Hodgkin lymphoma (HL) patients. The receiver operating
characteristic curve identified the best cut-off values as 4.3 for ANC/ALC
and 2.0 for ALC/AMC. Univariate analysis showed that all analyzed
factors were associated with lower OS: ANC/ALC>4.3 (OS5yrs
with/without risk factor 72% vs 85%, respectively, p<0.01);
ALC/AMC<2 (OS5yrs with/without risk factor 64% vs 86%, respec-
tively, p<0.01); AEoC<0.5x10e6/L (OS5yrs with/without risk factor 76%
vs 88%, respectively, p<0.01); IPS >2 (OS5yrs with/without risk factor
66% vs 86%, respectively, p<0.01). Apart from AEoC, these factors also
had a significant impact on EFS - ANC/ALC>4.3 (EFS5yrs with/without
risk factor 55% vs 72%, respectively, p<0.01); ALC/AMC <2 (EFS5yrs
with/without risk factor 46% vs 73%, respectively, p<0.01); IPS >2
(EFS5yrs with/without risk factor 51% vs 71%, respectively, p<0.01).
Overall survival multivariate analysis identified ALC/AMC<2, IPS>2
and AEoC<0.5x10e6/L as prognostic factors for poor OS (p<0.01; p<0.01;
p<0.01 respectively). In a respective model for EFS, ALC/AMC<2 and
IPS>2 were also significant (p<0.01; p<0.05, respectively). After evalu-
ating ALC/AMC and IPS, we stratified patients into 3 progressively-
worse-outcome groups (low-risk: 0; intermediate: 1 risk factor; high: 2
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risk factors) both for OS (91%; 74%; 56%, p<0.01) and EFS (77%; 58%;
41%, p<0.01). Furthermore, we observed that patients with eosinophil-
ia, AEoC>0.5x10e6/L had significantly better OS in group with
ALC/AMC<2 (82% vs 58%, p<0.01), as well as in low IPS group (97%
vs 84%, p<0.05), but not in group with high IPS (75% vs 64%, p>0.05).
Our study encourages the combination of ALC/AMC with IPS, thus
providing an improved risk prediction in advanced HL patients. More-
over, present peripheral blood eosinophilia separates patients with better
prognosis in poor prognostic group.
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LOWER SOCIOECONOMIC STATUS IS ASSOCIATED WITH SHORTER SURVIVAL IN HL
PATIENTS - AN ANALYSIS FROM THE BRAZILIAN HODGKIN LYMPHOMA REGISTRY
I. Biasoli1, N. Castro2, M. Delamain3, T. Silveira4, J. Farley5,
B. Pinto Simões6, C. Solza7, M. Praxedes8, O. Baiocchi9, R. Gaiolla10,
F. Franceschi11, C. Bonamin12, C. Boquimpani13, N. Clementino14,
G. Perini15, K. Pagnano3, G. Steffenello16, J. Tabacof17, G. de Freitas Colli2,
A. Soares7, C. de Souza3, C.S. Chiattone4, R. Raggio18, C. Milito1,
J.C. Morais1, N. Spector1
1School of Medicine, Universidade Federal do Rio de Janeiro, Brasil; 2Hospital de
Cancer de Barretos, Brasil; 3Hematology and Hemotherapy Center, University of
Campinas, Brasil; 4São Paulo Santa Casa Medical School, Brasil; 5Liga Norte
Rio Grandense Contra o Cancer, Brasil; 6USP-Ribeirão Preto, Brasil; 7Universi-
dade do Estado do Rio de Janeiro, Barsil; 8Universidade Federal Fluminense, Brasil;
9Federal University of São Paulo, Brasil; 10Universidade Estadual Paulista, Brasil;
11Fundação Amaral Carvalho, Jaú, Brasil; 12Universidade Federal do Paraná,
Brasil; 13HEMORIO, Rio de Janeiro, Brasil; 14Universidade Federal de Minas
Gerais, Brasil; 15Hospital Albert Einstein, São Paulo, Brasil; 16Universidade Federal
de Santa Catarina, Brasil; 17ESHO - Centro Paulistano de Oncologia, Brasil
Introduction. Socioeconomic status (SES) is a well-known determinant
of outcomes in cancer. We have previously reported that Hodgkin’s
lymphoma (HL) patients (pts) with a lower SES had inferior survival in
a different cohort from Rio de Janeiro. Methods. SES stratification was
done using an asset/education-based household index widely used in
publicity and political polls in Brazil. Results. 624 classical HL pts with
diagnosis until December 31 2014, ≥13 y-old and HIV-, treated with
ABVD, were analysed. The median follow-up was 35.6 months for all
pts, 67% (390/578) were classified as higher SES and 33% (188/578) as
lower SES. The 3-y PFS in higher and lower SES were 78% and 64%
(p<0.0001), respectively. The 3-year OS in higher and lower SES were
94% and 82% (p<0.0001), respectively. Lower SES pts were more likely
to be ≥60 years (16% vs 8%, p=0.003), to have a poor performance sta-
tus (20% vs 10%, p=0.001) and high risk IPS (44% vs 31%, p=0.004),
to present with advanced disease (71% vs 58%, p=0.003) and to have
histopathology other than nodular sclerosis (31% vs 19%, p=0.002).
Also, time to diagnosis >4 months was more frequent in lower SES pts
(69% vs 53%, p=0.0001). After adjustments for potential confounders
(age, PS, advanced disease, IPS, histopathology and time to diagnosis),
lower SES remained associated with poorer survival (HR=3.15 [1.8-5.2]
for OS and HR=1.67 [1.2-2.31] for PFS). Twenty-one patients died dur-
ing treatment, accounting for a death rate of 7.5% and 1.3% for lower
and higher SES (p=0.0001). Infections and treatment toxicity accounted
for 81% of deaths during treatment. No differences were found accord-
ing to the distance and travel time from residence to hospital, or to
availability of someone to transport pts to hospital in an emergency.
Independent factors associated with death during treatment were: age
≥60 year, poor PS, advanced disease, lower SES and low educational
level. Deaths after the conclusion of treatment occurred in 48 patients,
mostly due to progressive disease. However, follow-up is still short for
analysis of long-term outcomes. Conclusions. SES is an independent fac-
tor associated with shorter survival in Brazil. Along with age, advanced
disease, and poor PS, SES and educational level allow the identification
of vulnerable patients who might benefit from a program of intensive
medical and social supervision, or from management modifications to
reduce serious infections and drug toxicity during treatment.
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THE IMPACT OF OUTCOME OF INTERIM PET/CT ON ADVANCED HODGKIN LYMPHOMA
TREATED WITH EACOPP-14 
E. Medvedovskaya1, A. Leontjeva1, E. Demina1, J. Ryabukhina1,
G. Tumyan1, N. Kokosadze1, O. Trofimova1, V. Larionova1,
M. Dolgushin1, A. Odzharova1, O. Mukhortova2, I. Aslanidis2,
D. Osmanov1
1N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; 2A.N.
Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, Russia
Introduction. To assess the role of interim positron emission tomogra-
phy/computed tomography (PET/CT) and compare its with PET\CT
results after the end of treatment the patients (pts) with advanced stages
classical Hodgkin lymphoma (cHL). Methods. 114 newly diagnosed cHL
pts received 6 cycles EACOPP every 14 days (doxorubicin 50 mg\m2,
cyclophosphamide, etoposide, procarbazine, vincristine, prednisone).
Consolidation radiotherapy was given to 78 (68%) pts. Interim PET/CT
(iPET) imaging after 2 cycles was done in 54 (48%) pts. Results.With a
median follow-up 35 months, 3-year progression-free survival (3-PFS)
were 85%, overall survival - 92%. In 33 pts (61%) the iPET was nega-
tive - Deauville score 1-2 (DS 1-2). The residual uptake was higher than
the mediastinal blood pool (MBP) uptake but below the liver uptake
(DS 3) in 17 pts (31%) and 4 pts (8%) were PET-positive (DS 4-5).
omplete metabolic response (CMR) after 2 cycles predicted higher 3-
PFS compared PETpos (100% vs 75%; p=0,0035 - Figure 1).
Figure 1. 3-PFS in patients with advanced stage cHL according results of
iPET.
Patients with residual metabolic activity had equally good outcomes
(100% vs 92%; p=0,1). Of the 60 pts who not done iPET, 24 (40%) were
performed PET\CT after the end of 6 EACOPP-14. There is not difference
of outcome between 19 pts with CMR after the end of chemotherapy
and 36 pts with CR\uCR according chest\abdominal\pelvic CT with con-
trast of diagnostic quality (3-PFS 78% vs 91%; p<0,1). Conclusions. The
intensive EACOPP-14 program showed good and early response for pts
with advanced stage cHL. Predictive value of metabolic response after 2
cycles was higher than PET-negativity after the end of chemotherapy. 
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ADVANCED HODGKIN LYMPHOMA - A RISK STRATIFICATION OF ABVD TREATED
FEMALES IN GENERATIVE AGE
B. Andjelic1,2, L.J. Jakovic1, D. Antic1,2, M. Todorovic1,2, J. Bila1,2,
V. Djurasinovic1, A. Sretenovic1, V. Vukovic1, J. Jelicic1, M. Smiljanic1,
B. Mihaljevic1,2
1Clinic for Hematology, Clinical Center of Serbia, Belgade, Serbia; 2Faculty of
Medicine, University of Belgrade, Belgrade, Serbia
Background. Recent trials demonstrated that treatment results of
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BEACOPPesc are likely better than ABVD for advanced Hodgkin Lym-
phoma (HL). However, BEACOPPesc is associated with more toxic
effects, with post treatment infertility as one of the major concerns.
Aim. The aim of this study was to identify females in generative age
with advanced HL who do not require more aggressive approach than
ABVD. Patients and Methods. This study was performed on 147 females
younger than 40 years with advanced HL, diagnosed between 1997
and 2011. The initial treatment was 6-8 cycles of ABVD +/- radio-
therapy. Prognostic relevance of IPS, ESR≥50 mm/h, as well presence
of B symptoms, bulky disease and extranodal disease (EN) were exam-
ined. Results. For the whole group 5-year overall survival (OS) was
81% and 5-year event free survival (EFS) was 66%. Based on exam-
ined parameters, in univariate analysis worse OS had patients with
IPS≥3 (5-year OS 61.1% vs 87.3%; log rank, p=0.000) and EN (5-year
OS 71.9% vs 83.5%; log rank, p=0.036). Worse EFS had patients with
IPS≥3 (5-year EFS 41.7% vs 73.9%) and EN (5-year EFS 40.6% vs
73.0%) (log rank; p=0.000, p=0.000, respectively). The multivariate
analysis identified IPS≥3 as the independent prognostic factor both
for OS (p=0.002) and EFS (p=0.023), as well as EN for EFS (p=0.027).
Subsequently, we analyzed the subgroup of 111 patients with low
IPS. Thirty patients without bulky disease (27.0% of low IPS patients,
20.4% of the entire group) had better OS (5-year OS 100% vs 82.7%,
log rank, p=0.028) and trend toward better EFS (5-year EFS 90% vs
67.9%, log rank; p=0.06), with only 2 deaths until the end of follow
up. Based on IPS score (0, 1, 2), presence of ESR≥50 mm/h, B symp-
toms and EN there was no difference both in OS (log rank; p=0.166,
p=0.359, p=0.459, p=0.865, respectively) and EFS (log rank; p=0.098,
p=0.933, p=0.383, p=0.187, respectively). Moreover, bulky disease in
this subgroup retained its prognostic significance in multivariate
analysis for OS (p=0.044; RR=4.577; 95% CI 1.042-20.106). Conclu-
sions. ABVD is very effective for females with advanced HL younger
than 40 years with low IPS and without bulky disease. 
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ADVANCED STAGE HODGKIN LYMPHOMA IN MOROCCAN ADULTS: CLINICO-PATHOLOGICAL
FEATURES AND THERAPEUTIC OUTCOMES
W. Kaddouri, S. Anoun, N. Khoubila, S. Cherkaoui, M. Lamchahab,
M. Quachouh, M. Rachid, A. Madani, A. Quessar
Hematology and Oncology Pediatric Unit, 20 August Hospital, Ibn Rochd UH,
Hassan II Univerity, Casablanaca, Morocco
Introduction.Advanced stage Hodgkin lymphoma (ASHL) is still a major
concern to face in both developed and developing countries. Five-year
survival rate ranges between 51% and 94.6% in Western literature. How-
ever, few is known about the features of ASHL in developing countries.
The purpose of this study is to describe the clinic-pathological features
of ASHL in Morocco. Methods. Retrospective descriptive study of diag-
nosed ASHL carried over a period of 6.5 years from January 2007 to
August 2013 in a single Moroccan University Hospital, including all
patients with ASHL (stage III and IV of Ann Arbor) aged over 18. Patients
with retroviral infections and secondary HL were excluded. The diagnosis
was based on histological examination of biopsy and immunohistochem-
istry. Patients were classified according to the classification of Ann Arbor,
and stratified according to the score of IPS. Results. Four hundred and sev-
enty-eight patients were diagnosed with HL (all stages) during the period
study, among them 200 patients ASHL account for 46.3. The age was
ranged between 18 and 91 years old (yo) with a median age of 32 yo. Sex
ratio H/F was 1.66. Seventy three percent of ASHL patients didn’t have
medical insurance and 47% were jobless. the median time to diagnosis
was 6 months [1-52]. Lymphadenopathy was the most common presen-
tation (61.5%). Eighty three patients (41,5%) were stage III, 117 patients
(58,5%) were stage IV. Eighty two percent of the patients reported B
symptoms. Nodular sclerosis was the predominant histological presen-
tation of ASHL in adult (60.5%) followed by mixed cellularity (17.5%).
Ninety nine percent of lymphoma’s biopsies were CD30+, 82.5% were
CD15+ and LMP-1 was positive in 33.6%. Bulky disease was present in
37% of the ASHL. IPS score was ranged between 0 and 6 with a median
of 3, 42,5% patients had a score less than 2. Survival was rated in patients
treated with 8 cycles of ABVD +/- Radiotherapy (150 patients fulfilled
the inclusion criteria). Twenty-one percent of patients were treatment
failure, 12% relapsed. The death rate was 20.6% of which 45% was by
progression disease. The 5-years overall survival and event free survival
of ASHL patients were 70,9% and 41,7% respectively. Conclusions. This
current pattern for epidemiological features and outcomes of ASHL
enables delineate key populations in order to explore risk factors for ASHL
and strategies to improve treatment outcomes, especially intensification
strategies.
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GENERAL POPULATION-DERIVED SPECIFIC SURVIVAL APPLIED TO HODGKIN LYMPHOMA
P. Gobbi1, M. Bellei2, L. Marcheselli2, T. Chisesi3, F. Merli4,
S. Galimberti5, E. Iannitto6, S. Luminari2, M. Manni2, C. Stelitano7,
P. Musto8, V. Pavone9, U. Vitolo10, M. Federico2
1Clinica Medica I, Università di Pavia, Fondazione IRCCS Policlinico S. Matteo,
Pavia, Italy; 2Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pub-
blica, Università di Modena e Reggio Emilia, Modena, Italy; 3SOLCA, Instituto
Oncológico Nacional Dr. Juan Tanca Marengo, La Atarazana, Guayaquil,
Ecuador; 4Ematologia, AO Arcispedale S. Maria Nuova, IRCCS, Reggio Emilia,
Italy; 5UO Ematologia, Dipartimento di Medicina Interna e Sperimentale, Uni-
versità di Pisa, Pisa, Italy; 6UO Ematologia, AOU Policlinico Paolo Giaccone,
Palermo, Italy; 7UOC Ematologia, AO Bianchi Melacrino Morelli, Reggio Cal-
abria, Italy; 8IRCCS-CROB, Rionero in Vulture (Potenza), Italy; 9Ematologia e
Centro Trapianti Midollo Osseo, AO Cardinal Panico, Tricase (LE), Italy; 10Divi-
sione di Ematologia, AOU Città della Salute e della Scienza, Torino, Italy
Mortality of patients (pts) affected with cancer can be partially unre-
lated to tumor, while accurate clinical investigation must be focused
mainly on that tumor related. Specific survival (SS) is obtained by sub-
tracting expected mortality (EM) – inferred from national or regional
mortality tables – to the observed one. The expected survival (ES) is
that enjoyed in the absence of tumor. ES corresponds to the time still
at patients’ disposal in case of hypothetical full recovery and repre-
sents an absolute ceiling of maximal mean attainable SS for a given
tumor in a given time. SS limits of variability clinically correspond to
full recovery and death, and SS can be evaluated by the measure of
how much, in a given time/site, a group of pts has approached the
potentially attainable ES. On this full range of prognostic variability
relies the comparability of SS, whatever time/site are involved. The
number of years lost with respect to those expected represents a useful
additional measure. ES and SS are subjected to the same conditioning
factors, being contextualized into the evolving conditions of the health
services, and depending on customs and behaviours. SS allowed com-
parison of the effectiveness of some chemotherapy regimens admin-
istered to pts with advanced-stage (IIB-IV) Hodgkin lymphoma (HL),
whatever histologic subtype, age 16-65 years, of two randomized tri-
als of the past decades. The IIL-HD9601 (1996-2000) enrolled 355 pts
in three different arms: ABVD, Stanford-V and MOPPEBVCAD
(MEC). The GISL-HD2000 (2000-2007) randomized 307 pts into three
arms: ABVD (identical to IIL-HD9601), BEACOPP and COPPEBVCAD
(CEC), a variant of MEC adopting cyclophosphamide instead of
mechlorethamine at the dose considered with identical anti-lym-
phoma activity. CEC, ABVD and MEC showed the smallest ratio of
expected/observed deaths. BEACOPP, ABVD and MEC allowed the
relatively minimal loss of years of life per patient. The evaluation of
the curves of ES confirmed the starting prognostic homogeneity of
each arm of randomization (12-year ES from 0.965 [MEC] to 0.987
[BEACOPP]). The 12-year SS was 0.88, 0.81, 0.79, 0.79 for CEC,
ABVD, BEACOPP, Stanford-V and MEC, respectively. The estimation
of SS inferred from national or regional mortality tables allows a
potentially unbiased comparison between treatments adopted in dif-
ferent time-spans, since it takes into account the social and health sta-
tus along time. This method could be extended to other neoplasia.
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P020
THE DIAGNOSTICS AND THERAPY OF HODGKIN LYMPHOMA IN PREGNANCY,
THE EXPERIENCES OF ONE CENTER
Ľ. Gahérová, H. Móciková, J. Marková
Department of Internal Medicine of Hematology, University Hospital Královské
Vinohrady, Prague, Czech Republic
Hodgkin lymphoma is one of the most frequently diagnosed malig-
nancies in pregnancy. In the group of nine patients of one center with
manifestation of Hodgkin lymphoma in pregnancy we demonstrate the
management of diagnostic and therapeutic procedures. Seven patients
were diagnosed in 20-30th week of pregnancy; one with progressive lym-
phadenopathy already before confirmation of pregnancy and one patient
with the diagnosis in 7th week. Only in one case there was induced abor-
tion, and in one case the corticotherapy was started in the third trimester,
in the rest of patients (7) the therapy was started after the delivery.
Although there are some publications about therapy with single vin-
blastin, respectively combination chemotherapy ABVD in the second
half of pregnancy, our experiences are based on preferation of thorough
observation in pregnancy and indication of specific chemotherapy after
delivery.
Support. This work was supported by grant awarded by AZV 16-
29857A, Ministry of Health in Czech Republic and Research project P
27/2012 awarded by Charles University in Prague, 3rd Faculty of Med-
icine, Prague, Czech Republic.
P021
DIFFICULTIES IN DISTINGUISHING SYNCYTIAL VARIANT OF NODULAR SCLEROSIS
CLASSICAL HODGKIN’S LYMPHOMA FROM DIFFUSE LARGE B-CELL LYMPHOMA AND
COMPLETE REMISSION AFTER INTENSIVE CHEMOTHERAPY
T. Okatani1, H. Asaoku1, M. Fujiwara2, Y. Sato3, M. Seto4
1Division of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Sur-
vivors Hospital, Hiroshima, Japan; 2Division of Pathology, Hiroshima Red Cross
Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan; 3Department
of Pathology,Okayama University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences, Okayama, Japan; 4Department of Pathology, Kurume
University School of Medicine, Fukuoka, Japan
Case report.A 31-year-old woman presented at a primary care physician
with a dry cough and a sore throat that had persisted for one month. A
cold was diagnosed, but dyspnea gradually developed. A chest X-ray and
computed tomography (CT) revealed a bulky mediastinal mass and sev-
eral enlarged lymph nodes. Positron emission tomography/computed
tomography (PET-CT) imaging showed increased 18-fluoro-deoxyglu-
cose uptake in the bilateral supraclavicular, axillary, mediastinal, hilar,
and paraaortic lymph nodes (maximum standardized uptake value
[SUVmax], 13.4). A lymph node biopsy showed destruction of the basic
structure, hyperplastic fibrous connective fibrous tissue and cohesive
clusters and sheets of large malignant cells with a clear, vacuolated cyto-
plasm and sharply-defined borders. Flow cytometry could not determine
the phenotype of the tumor cells. Immunostaining at our hospital
showed that the tumor cells expressed CD15, CD30, and CD79a but not
CD2, CD3, CD10, or CD20. We initially diagnosed clinical stage 3,
CD20-negative diffuse large B-cell lymphoma (DLBCL) and started the
patient on the original intensive treatment protocol for advanced, aggres-
sive lymphoma (ML5 protocol). The patient partially responded to the
first CHOP-like regimen (doxorubicin 40mg/m2 day1,5,9, vindesine
3mg/body day1,5,9, cyclophosphamide 1000mg/m2 day2,6,10, pred-
nisolone 60mg/m2 day1-10) and then an etoposide-based second regi-
men(etoposide 100mg/m2 day1-3, 8-10, mitoxantrone 8mg/m2 day1, 8,
cyclephosphamide 400mg/m2 day2, 9, prednisolone 60mg/m2 day1-3, 8-
10, procarbazine 100mg/m2 day1-10) resulted in a complete response
(CR) on PET-CT images. The Department of Pathology, Okayama Uni-
versity, Japan found that the tumor cells were CD79a-, Bob.1-, Oct.2-,
indicating a syncytial variant of nodular sclerosis classical Hodgkin lym-
phoma (NSCHL). Discussion. A syncytial variant of NSCHL has been
described in Cancer (1990), and this disease is statistically more advanced
at diagnosis and often accompanied by huge mediastinal masses that
require treatment after diagnosis. We applied the intensive chemotherapy
used for DLBCL to our patient, but seven of eight other patients achieved
CR after the administration of MOPP (mechlorethamine, vincristine, pro-
carbazine, prednisolone) or ABV (doxorubicin, bleomycin, vinblastine)
regimens. Therefore, awareness of this variant is needed at initial diag-
nosis to ensure appropriate treatment.
P022
SYSTEMIC HODGKIN’S DISEASE WITH OSSEOUS INVOLVEMENT
A. Banti, E. Papadakis, A. Kioumi
Hematology Department, Papageorgiou Hospital, Thessaloniki Greece
Hodgkin’s Disease most commonly presents with progressive painless
enlargement of peripheral lymph nodes. At diagnosis, osseous involve-
ment is rare (<2%) and even in refractory or relapsing disease only 1/3
of the patients have any bony involvement. Systemic Hodgkin’s Disease
with skeletal involvement is considered to have worse prognosis. We
present a 26-year-old female, who admitted to our orthopedic depart-
ment with complaints of deformity and pain in the left shoulder. Upon
examination, mild local tenderness was noted with no neurological find-
ings. Patient also had involvement of adjacent axillary and supraclavian
nodes. Regarding laboratory tests, mild anemia and leukocytosis along
with increased ESR and CRP were noted. Left shoulder X-Ray showed
osteolytic lesion of capita arm extended to the upper third of diaphyseal
humeral. Magnetic resonance imaging (MRI) showed lesions of the capita
arm and diaphyseal humeral (low T1/high T2) with surrounding soft tis-
sue mass. CT scanning revealed left axillary/supraclavian and mediastinal
lymphadenopathy. Lymph node and bone mass biopsies confirmed the
diagnosis of Hodgkin’ Disease (nodular sclerosis).The patient received 8
courses of ABVD with PET positivity after completion in left humerus
(18FDG suv max : 3.8). Subsequently involved field radiotherapy
(4000cGy) was given with no additional treatment benefit. The patient
was then deferred to transplantation unit and underwent ASCT, resulting
in long term complete remission (PET negative-4,5 years). Osseous
involvement in systemic Hodgkin’ Disease is rare but warrants intensive
treatment in order to achieve sustained remission.
P023
BRENTUXIMAB VEDOTIN ALONE AND IN COMBINATION WITH DACARBAZINE OR
BENDAMUSTINE IN PATIENTS AGED ≥60 YEARS WITH NEWLY DIAGNOSED HODGKIN
LYMPHOMA: INTERIM RESULTS OF A PHASE 2 STUDY 
J.W. Friedberg1, A. Forero-Torres2, V.J.M. Cline-Burkhardt3,
R.E. Bordoni4, D. Patel-Donnelly5, P.J. Flynn6, R. Chen7, A. Fong8,
C.A. Yasenchak9
1University of Rochester Medical Center, Rochester, NY, USA; 2University of Ala-
bama at Birmingham, Birmingham, AL, USA; 3Texas Oncology-Round Rock
Seton Williamson, Round Rock, TX, USA; 4Georgia Cancer Specialists, Marietta,
GA, USA; 5Virginia Cancer Specialists, Fairfax, VA, USA; 6Minnesota Oncol-
ogy, Woodbury, MN, USA; 7City of Hope National Medical Center, Duarte,
CA, USA; 8Seattle Genetics, Inc., Bothell, WA, USA; 9Willamette Valley Cancer
Institute and Research Center/US Oncology Research, Eugene, OR, USA
Background. Treatment-related mortality and inferior responses to
chemotherapy lead to poorer outcomes for patients aged ≥60 years
with newly diagnosed Hodgkin lymphoma (HL). This phase 2, front-
line, open-label study is evaluating safety, efficacy, and durability of
response to treatment with brentuximab vedotin (BV) as monotherapy
and in combination with dacarbazine (DTIC) or bendamustine. The
primary endpoint is objective response rate (ORR) (NCT01716806).
Methods. Patients with classical HL who were ineligible for or declined
initial conventional chemotherapy and had ECOG ≤3 were eligible.
The study evaluated cohorts of 1.8 mg/kg BV (16 cycles), 1.8 mg/kg
BV+375 mg/m2 DTIC (12 cycles), and 1.8 mg/kg BV+90 or 70 mg/m2
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bendamustine (starting dose reduced to improve tolerability after 10
patients treated) (6 cycles). Patients with clinical benefit could subse-
quently continue BV treatment. Responses were assessed per the
Revised Response Criteria for Malignant Lymphoma (Cheson 2007).
Results. Enrollment was completed sequentially (treated patients: n=27
BV; n=22 BV+DTIC; n=20 BV+bendamustine), all patients are off treat-
ment, and 44 remain in long-term follow-up (n=16 BV; n=18 BV+DTIC;
n=10 BV+bendamustine). Overall, median age was 76 years (range, 62–
92). At baseline, 70% of patients had Stage III-IV HL, 13% presented
with bulky disease, 41% had B symptoms, 25% had ECOG 2-3, and
72% were ineligible for frontline chemotherapy. Treatment was dis-
continued for adverse events (n=35; mostly peripheral neuropathy,
n=24), progressive disease (PD; n=15), or other reasons (n=19). Although
no specific safety signal was identified, the sponsor suspended treat-
ment with bendamustine because the tolerability did not meet the study
goal of defining a low toxicity regimen for this patient population (Table
1). Median number of treatment cycles, median observation time, ORR,
complete remission (CR) rate, median progression-free survival (PFS),
and overall survival (OS) are presented by cohort (Table 1). Conclusions.
Both BV monotherapy and BV+DTIC appear tolerable and yield high
response rates (ORR 92-100%) in this fragile patient population. Fur-
thermore, the combination with DTIC appears to increase the durabil-
ity of response without increasing toxicity; and therefore, may represent
a reasonable frontline treatment option for elderly HL patients. Other




HODGKIN LYMPHOMA INFILTRATING T CELLS: CONSIDERING VARIOUS MEANS OF
TUMOR EVASION
F. Wein1, K. Stock2, S. Hartmann2, M.-L. Hansmann2 R. Küppers1
1Institute of Cell Biology (Cancer Research), Medical Faculty, University of
Duisburg-Essen, Essen, Germany; 2Dr. Senckenberg Institute of Pathology,
Goethe-University of Frankfurt, Medical School, Frankfurt am Main, Germany
The cellular microenvironment in classical Hodgkin lymphoma (cHL)
is dominated by a mixed infiltrate of inflammatory cells with typically
only one or a few percent of Hodgkin and Reed/Sternberg (HRS) tumor
cells. HRS cells orchestrate this infiltrate by the secretion of a multitude
of chemokines and direct cell–cell interactions. T cells are usually the
largest population of cells in the HL tissue, encompassing T helper (Th)
cells, regulatory T (Treg) cells and cytotoxic T cells. Helper and regula-
tory T cells presumably provide essential survival signals for the HRS
cells, and the regulatory T cells also play an important role in rescuing
HRS cells from cellular immune response. Here, we investigate the sig-
nificance of the cHL-specific T cell infiltrate in regard to its role in tumor
evasion. Comparing the global gene expression profiles of T cells iso-
lated from cHL lymph nodes (LN) and reactive human tonsils revealed
substantial phenotypical differences. Performing gene expression pro-
filing, the T cell compartment in the cHL microenvironment featured
an activated, highly proliferative and yet immunosuppressive pheno-
type. However, the nature of the regulative phenotype in both cHL
CD4+ T cell subsets (Th: CD25- and CD127+; Tregs: CD25+ and
CD127-) differs to the corresponding tonsillar Treg subset that com-
prises a purer population of natural FOXP3+ T cells. The ability of HRS
cells to induce suppressive T cells was analyzed with an in vitro model
system using human CD4+ peripheral blood (PB) T cells that were co-
cultured with cHL cell lines. Co-cultured, naive T cells displayed an
induced, CD25+ subpopulation and upregulated levels of FOXP3,
CTLA4 and IRF4. Moreover, the exposure to HRS cells caused a damp-
ened Th1 specific immune response. As for specific means of tumor
evasion, the purinergic pathway seems an attractive co-factor. In vitro
observations support a HRS dependent generation of environmental
adenosine. Additionally, we observed an increase expression of the sur-
face molecules BTLA and CD200R in cHL-infiltrating T cell subsets.
Regarding their corresponding binding partners, typically expressed on
tumor cells, most cHL cell lines were positive for HVEM and CD200.
Taken together, we provide a novel perspective on the complex HRS -
T cells interaction, verify its immunosuppressive nature and provide
further insights into various means of tumor evasion in cHL. 
T008
CCR5 BLOCKING BY MARAVIROC INHIBITED RECRUITMENT, PROLIFERATION AND
PRO-TUMOR EFFECTS OF MESENCHYMAL STROMAL CELLS AND MONOCYTES IN 2D
AND 3D MODELS OF HODGKIN LYMPHOMA MICROENVIRONMENT
N. Casagrande, C. Borghese, M. Celegato, D. Aldinucci
Department of Experimental Oncology 2, CRO Aviano National Cancer Institute,
Aviano (PN) Italy
In classical Hodgkin Lymphoma (cHL), the tumor microenvironment
(TME) is dominated by an extensive mixed cellular inflammatory infil-
trate that plays a decisive role in the pathobiology of the disease. CCL5
and its main receptor CCR5, expressed by cHL cells and by bystander
cells including stromal cells and macrophages, are increased in cHL
lymph nodes respect to normal lymph nodes. Recently, CCL5 and
CCR5 have been implicated in cancer progression. Our hypothesis is
that CCL5 secreted by cHL cells could recruit Mesenchymal Stromal
cells (MCS) and monocytes, which in turn educated by tumor cells may
affect tumor progression. To demonstrate the involvement of CCL5 in
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the cross-talk of cHL cells with the TME we used neutralizing anti-
CCL5 antibody and the CCR5 antagonist Maraviroc. We found that
CCL5 secreted by L-1236, L-428, KM-H2 and HDLM-2 cHL cell lines,
recruited and increased the proliferation of MSCs from Bone Marrow
and Adipose Tissue. In turn, tumor-educated MSCs (E-MSCs) secreted
higher amounts of CCL5, which increased the proliferation, the clono-
genic growth and the movement/spread of cHL cells. Both E-MSCs and
cHL cells by secreting CCL5 were able to recruit monocytes purified
from Peripheral blood, suggesting that monocytes may be recruited
directly by tumor cells and indirectly by E-MSCs. Treatment of mono-
cytes with L-1236-conditioned medium (CM) enhanced the surface
expression of CCR5, the proliferation and induced the secretion of
CCL5. In turn, tumor-educated monocytes, by secreting CCL5,
increased the proliferation and the clonogenic growth of L-1236 and
HDLM2 cells. Only CM from tumor-educated monocytes inhibited the
proliferation of PHA activated peripheral blood mononuclear cells.
Finally, using a new tridimensional (3D) approach (mixed organoids)
to mimic the TME, we found that the cocultivation of L1236 and
HDLM-2 cells with monocytes, MSCs and especially the combination
cHL/monocytes/MSCs increased the survival/proliferation of tumor
cells. Treatment with Maraviroc not only decreased cHL cell
survival/proliferation due to the cocultivation with MSCs and mono-
cytes, but also disrupted the 3D mixed organoids. Taken together our
results suggest that CCL5 secreted by cHL cells, as well as by tumor-
educated MSCs and monocytes, may build the protective TME and
suggest a potential for Maraviroc as adjuvant therapy to block TME
formation and tumor cell proliferation due to CCR5 ligands.
T009
DISTURBED ANTIGEN PRESENTATION IN CLASSICAL HODGKIN LYMPHOMA; IMPLICATIONS
FOR IMMUNE CHECKPOINT INHIBITOR THERAPY?
M. Nijland1, L. Visser2, R. Veenstra2, K. Kushekhar2, G. van Imhoff1,
A. van den Berg2, A. Diepstra2
1Department of Hematology; 2Department of Pathology & Medical Biology,
University of Groningen, University Medical Center Groningen, the Netherlands
Immune checkpoint inhibitors are being tested in clinical trials and
show great promise in the treatment of classical Hodgkin lymphoma
(cHL). The proposed mechanism of action of these inhibitors consists
of reactivating T lymphocytes that have become unresponsive as a con-
sequence of inhibitory mechanisms exerted by the tumor cells. These
reactivated T cells are expected to kill tumor cells after recognizing
tumor cell derived antigens that are presented by Human Leukocyte
Antigens (HLA) at the tumor cell surface. Consequently, lack of tumor
cell surface expression of HLA may be one of the explanations why
immune checkpoint inhibitor therapy does not always result in a com-
plete remission in cHL. We evaluated expression of HLA class I, HLA
class II and HLA-DM in primary diagnostic tissue in a large population
based cohort of cHL, by using immunohistochemistry. HLA class I cell
surface expression was lacking in tumor cells in 229 out of 361 cases
(63.3%), more often in EBV- cHL (83.2%) than in EBV+ cHL (27.4%).
HLA class II cell surface expression was missing in 147 out of 361 cHL
cases (40.8%; EBV- 46.8% and EBV+ 29.7%). In addition, we scored
lack of cytoplasmic expression of the non-polymorphic HLA-DM. This
molecule is essential in the intracellular assembly of HLA class II-anti-
genic peptide complexes. HLA-DM displaces the invariant chain pep-
tide CLIP from the antigen binding groove of HLA class II molecules,
to make this groove accessible for loading of antigens. We show that
in the absence of HLA-DM, CLIP is not displaced and is aberrantly
expressed on the cell surface of Hodgkin tumor cells in frozen sections
(n=8). We found that in HLA class II cell surface expressing tumor cells,
HLA-DM expression was lacking in 44 out of 89 cases of cHL (49.4%),
indicating that no immunogenic peptides are being presented. Com-
bined results for HLA class I, class II and DM show that only 12.4% of
cHL cases show HLA expression that is compatible with normal antigen
presentation. In conclusion, antigen presentation is often disturbed in
cHL. It is expected that this will influence the success of immune check-
point inhibitors. We therefore propose to take tumor cell HLA expres-
sion into account in the evaluation of (lack of) clinical response to these
inhibitors.
P059
TUMOR INFILTRATING HLA-MATCHED CD4+ T CELLS RETARGETED AGAINST HODGKIN
AND REED-STERNBERG CELLS
B. Rengstl1, F. Schmid1, C. Weiser1, C. Döring1, T. Heinrich1, K. Warner1,2,
P.S.A. Becker3, R. Wistinghausen1, S. Kameh-Var1, E. Werling1,
A. Billmeier1, C. Seidl3, S. Hartmann1, H. Abken2, R. Küppers4,
M.-L. Hansmann1,*, S. Newrzela1,*
1Dr. Senckenberg Institute of Pathology, Goethe-University of Frankfurt, Medical
School, Frankfurt am Main, Germany; 2Center for Molecular Medicine Cologne,
University of Cologne, and Department I of Internal Medicine, University Hos-
pital Cologne, Cologne, Germany; 3Institute for Transfusion Medicine and
Immunohematology, Red Cross Blood Donor Service, Baden-Württemberg-Hes-
sen, Frankfurt, Germany; 4Institute of Cell Biology (Cancer Research), University
of Duisburg-Essen, Medical School, Essen, Germany
*Shared last authorship
Hodgkin lymphoma (HL) presents with a unique histologic pattern.
Pathognomonic Hodgkin and Reed-Sternberg (HRS) cells usually
account for less than 1% of the tumor and are embedded in a reactive
infiltrate mainly comprised of CD4+ T cells. HRS cells induce an
immunosuppressive microenvironment and thereby escape anti-tumor
immunity. To investigate the impact of interactions between HRS cells
and T cells, we performed long-term co-culture studies that were fur-
ther translated into a xenograft model. Surprisingly, we revealed a
strong anti-tumor potential of allogeneic CD4+ T cells against HL cell
lines. HRS and CD4+ T cells interact by adhesion complexes similar to
immunological synapses. Tumor-cell killing was likely based on the
recognition of allogeneic major histocompatibility complex class II
(MHC-II) receptor, while CD4+ T cells from MHC-II compatible donors
did not develop any anti-tumor potential in case of HL cell line L428.
However, gene expression profiling of co-cultured HRS cells as well as
tumor infiltration of matched CD4+ T cells indicated cellular interac-
tions. Moreover, matched CD4+ T cells could be activated to kill
CD30+ HRS cells when redirected with a CD30-specific chimeric anti-
gen receptor. Our work gives novel insights into the crosstalk between
HRS and CD4+ T cells, suggesting the latter as potent effector cells in
the adoptive cell therapy of HL.
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Minimal Residual Disease and Prediction
T013
PLASMA VESICLE-ASSOCIATED miRNAs AS THERAPY RESPONSE BIOMARKERS IN
HODGKIN LYMPHOMA
D.M. Pegtel1,*, E. Drees1, M.A.J. van Eijndhoven1, N.J. Groenewegen1,
S. van Niele1, R. Prins1, S.R. Baglio1, J.M. Zijlstra2, H. van der Voorn3,
S.F.W.M. Libregts4, M.H. Wauben4, R.X. de Menezes5,
J.R.T. van Weering6, R. Nieuwland7, A. Diepstra8, A. van den Berg8,
D. de Jong1
1Department of Pathology, Exosomes Research Group, VU University Medical
Center, Amsterdam, The Netherlands; 2Department of Hematology, VUmc,
Amsterdam, The Netherlands; 3iZON Science, Oxford, UK; 4Department of
Biochemistry & Cell Biology, Utrecht University, Utrecht, The Netherlands;
5Department of Epidemiology and Biostatistics, VUmc, Amsterdam, The
Netherlands; 6Department of Functional Genomics, Center for Neurogenomics
and Cognative Research, Neuroscience Campus Amsterdam, VU University,
Amsterdam, The Netherlands; 7Department of Clinical Chemistry, Academic
Medical Center Amsterdam, The Netherlands; 8Department of Pathology &
Medical Biology, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands
Cure rates for classical Hodgkin Lymphoma (CHL) patients are gen-
erally high. CHL patients that are cured remain at risk for long-term
side effects from the aggressive radiation/chemotherapy regimens and
relapses occur. Upcoming treatment strategies aim towards personal-
ized therapy by early assessment of the effectiveness of active treatment
by measuring vital tumor tissue with FDG-PET/CT imaging. Apart from
radiation burden, imaging is costly and reported positive predictive val-
ues are suboptimal. Studies suggest that tumors actively secrete small
extracellular vesicles (EVs) that encapsulate tumor-derived nucleic acids,
including 22nt non-coding microRNAs (miRNAs). Here we identified
with RNAseq, CHL-associated miRNAs in circulating EVs as defined
biosource, using size-exclusion chromatography (SEC) as isolation
method. Apart from miR-21-5p and miR-155-5p oncomiRs already
implicated in lymphomagenesis, we identified let7-a-5p, miR-24-3p and
miR-127-3p as circulating CHL biomarkers. Notably, a high abundance
of these miRNAs in circulation of CHL patients pre-therapy, correlated
with a high concentration of 100nm EVs, as determined with tunable-
resistive pulse sensing (TRPS). Using logistic regression modeling we
determined that EV-associated miR-127-3p levels alone can distinguish
primary and relapse CHL patients from healthy controls. Importantly,
the calculated AUC for miR127-3p in vesicles outperform ROC calcu-
lations using unfractionated (total) plasma. Finally, in serial samples of
individual CHL patients, during- and after treatment but also in long-
term follow up, we measured robust and consistent decreases in EV-
miRNA levels that corresponded with FDG-PET/CT outcome . Thus
defined EV-miRNAs in circulation reflect the presence of vital tumor
tissue. This liquid biopsy method may proof suitable for early respsonse
and relapse monitoring, MRD detection and guiding therapy decisions.
Upcoming studies in serial samples are ongoing to determine whether
RNAseq-generated small RNA signatures are useful for diagnosis, prog-
nosis and prediction in CHL.
T014
MID-TREATMENT TARC AND MID-TREATMENT FDG-PET PREDICT FOR PROGRESSION
FREE SURVIVAL IN CLASSICAL HODGKIN LYMPHOMA
W.J. Plattel1, A. van den Berg2, L. Visser2, A. Glaudemans3, A. Diepstra2,
G. van Imhoff1
1Department of Hematology, University Medical Center Groningen, The Nether-
lands; 2Department of Pathology and Medical Biology, University Medical Center
Groningen, The Netherlands; 3Department of Nucleair Medicine and Molecular
Imaging, University Medical Center Groningen, The Netherlands
Background. Plasma or serum CC-chemokine ligand 17 (CCL17) /
Thymus and Activation Regulated Chemokine (TARC) is a highly spe-
cific biomarker for classical Hodgkin lymphoma (cHL) disease activity.
Serial TARC levels correlate with treatment response as early as after
one cycle of chemotherapy. In the current study we compared predic-
tive value of mid-treatment TARC with mid-treatment FDG-PET for
modified progression free survival (mPFS) in primary cHL patients.
Patients and Methods. Serial serum or plasma samples were prospectively
obtained from 112 newly diagnosed (65 early stage and 57 advanced
stage) cHL patients. Patients were mainly treated with ABVD or eBEA-
COPP based treatment regimens. TARC levels were quantified using
ELISA. FDG-PET results were quantified and reassessed according to
the Lugano classification including Deauville five point score. Events
for mPFS were scored in case of death due to any cause, progression of
cHL or start of second line treatment. Patients without elevated TARC
at pre-treatment and patients with active atopic dermatitis were exclud-
ed for survival analysis on TARC. Results. Median follow-up was 45
months for the entire cohort. Out of 112 patients, 103 (92%) achieved
a complete remission, 8 patients (7%) had a partial response and one
patient (1%) had progressive disease. Of 92 patients with a mid-treat-
ment FDG-PET scan 16 (17%) were positive (Deauville ≥4). Mid-treat-
ment FDG-PET positive patients had significantly reduced mPFS com-
pared to mid-treatment FDG-PET negative patients (56% versus 93%
at 3 years, p<.001, Figure 1A). Pre-treatment TARC levels were elevated
in 100/112 patients (89%) of which two patients had active atopic dis-
ease. Of 92 patients with a mid-treatment plasma or serum sample,
TARC was elevated (>900 pg/ml) in 8 (9%). mPFS at 3-years was 25%
for patients with high mid-treatment TARC and 92% for patients with
low mid-treatment TARC levels (p<.001, Figure 1B). Elevated mid-treat-
ment TARC levels were associated with mid-treatment Deauville score
of 5. In multivariate analysis both mid-treatment FDG-PET and mid-
treatment TARC independently predicted for mPFS. Conclusions. Ele-
vated levels of TARC at mid-treatment are highly predictive for inferior
mPFS. Both negative and positive predictive value of mid-treatment
TARC are at least as good or even better than mid-treatment FDG-PET
imaging. TARC might serve as a substitute for mid-treatment FDG-PET
imaging in future response evaluation.
Figure 1.
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A COMPREHENSIVE ANALYSIS OF HODGKIN LYMPHOMA SEASONALITY ACROSS VARIOUS
GEOGRAPHIC REGIONS
S. Borchmann, H. Müller, A. Engert
First Department for Internal Medicine, University Hospital of Cologne, Köln,
Germany
Introduction. Seasonal variations in incidence and mortality after a
Hodgkin lymphoma (HL) diagnosis have been previously described
with partly conflicting results. The goal of this study is to comprehen-
sively analyze seasonal variation in incidence and mortality risk of HL
with a focus on geographic differences. Methods. HL cases diagnosed
between 1973 and 2012 in the 18 Surveillance, Epidemiology, and End
Results (SEER) registries were eligible (n=50,179). Cases with missing
data for at least one of the analyzed variables (n=8,700) and from the
two SEER registries “Alaska natives” (n=17) and “Rural Georgia” (n=57)
were excluded, leaving 41,405 cases for the study. Seasonality of inci-
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dence was analyzed using cosinor analysis. The risk of overall mortality
within 3 years following a HL diagnosis in winter (Sep.-Feb.) vs summer
(Mar.-Aug.) was analyzed by employing a Cox proportional-hazards
model with correction for known risk factors. Results. HL shows a sea-
sonal incidence pattern with a peak in March and a trough in September
(p<0.001). In predefined subgroup analyses, cases of the mixed cellu-
larity (p<0.001), nodular sclerosis (p<0.001) and lymphocyte depleted
subtype (p=0.002) showed a seasonal incidence pattern. Seasonality
was particularly pronounced in the age groups 20-29, 30-39 and 60-69,
coinciding with age groups of increased HL incidence. Cases from lower
(<38.05°N) latitudes showed a decreased seasonality of incidence
(amplitude=0.055) compared to cases from higher (≥38.05°N) latitudes
(amplitude=0.102) (p(diff.)=0.023). The risk of dying in winter vs sum-
mer is increased at higher latitudes (HR: 1.082[1.009;1.161], p=0.027),
whereas no seasonal difference in mortality was observed for cases
from lower latitudes (HR: 0.990[0.926;1.059], p=0.772). A multiplicative
interaction term showed interaction between the latitude and a diag-
nosis in winter on mortality risk (HR(interaction): 1.119[1.009;1.241],
p=0.033). Conclusions. HL exhibits a seasonal incidence and mortality
pattern in this most comprehensive analysis performed to date. The
seasonal effect on incidence is exacerbated at and the effect on mortality
restricted to higher latitudes. As latitude is closely linked to seasonal
variations in Vitamin D serum levels, a protective effect of Vitamin D
in HL is a possible explanation. Evidence on the direct association
between Vitamin D levels and the clinical course of HL should be col-
lected to improve the understanding of Vitamin D in HL.
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EVALUATION OF SERUM TARC LEVELS IN PATIENTS AT RISK OF PROGRESSION
FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT FOR HODGKIN LYMPHOMA:
RESULTS FROM THE AETHERA TRIAL
V. Bachanova1, A. Carella2, T. Masszi3, J. Holowiecki4, S. Viviani5,
D. Huebner6, N. Hunder7, E. Larsen7, J. Odegard7, M. Onsum7,
C. Moskowitz8
1University of Minnesota Medical Center, Minneapolis, MN, USA; 2IRCCS
Azienda Ospedaliera Universitaria San Martino-Ist, Genova, Italy; 3Szent
Istvan & Szent Laszlo Corporate Hospital Hematology & Stem Cell Dept.,
Budapest, Hungary; 4Department of Bone Marrow Transplantation & Onco-
hematology, Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland;
5Istituto Nazionale dei Tumori, Milano, Italy; 6Millennium Pharmaceuticals,
Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceuticals
Limited; 7Seattle Genetics, Inc., Bothell, WA, USA; 8Memorial Sloan-Kettering
Cancer Center, New York, NY, USA
Background. In patients with Hodgkin lymphoma (HL), serum con-
centrations of thymus and activation-regulated chemokine (TARC) and
other cytokines may have prognostic significance in both the front-line
and salvage therapy settings. The potential utility of TARC to predict
relapse or progression of HL following autologous hematopoietic cell
transplant (AHCT) is unknown. AETHERA (NCT01100502) is a phase
3, randomized, placebo-controlled trial that demonstrated improved
progression-free survival (PFS) in patients with high risk HL who
received post-AHCT consolidation treatment with brentuximab
vedotin (BV) (hazard ratio [HR]=0.57, P=0.001), and an acceptable safe-
ty profile. Methods. In this exploratory analysis, we measured baseline
serum TARC levels in patients enrolled in AETHERA, and evaluated
impact of TARC on outcomes after AHCT with or without BV consol-
idation therapy. Additional serum biomarkers under analysis include
sCD30, sCD163, IL-6, sIL-2R, and sCD68. Descriptive statistics were
used to characterize baseline TARC concentrations as a function of
baseline clinical characteristics, and Kaplan-Meier analysis was used to
assess PFS over 24 months of follow-up. Results. Among 329 patients
enrolled, 312 (156 BV and 156 placebo) had available serum samples
collected between days 28-45 post-AHCT. The median (range) baseline
TARC concentration was 472 (18-18,092) pg/mL, and was similar
among patients in the BV (481 [18-18,092] pg/mL) and placebo (446
[43-9,756] pg/mL) arms. Median TARC levels were higher among
patients with (vs without) established risk factors for progression; these
included B symptoms (537 vs 414 pg/mL), extranodal involvement (501
vs 450 pg/mL), FDG-avid PET status (543 vs 433 pg/mL), and incomplete
response to salvage therapy (532 [stable disease] vs 474 [partial remis-
sion] vs 404 [complete remission] pg/mL, respectively). The median
TARC level was also higher among patients with ≥2 risk factors vs those
with 1 risk factor (487 vs 410 pg/mL). PFS at 12 months decreased pro-
gressively with increasing TARC among patients who received placebo,
but not among those who received BV consolidation (Figure). PFS at 24
months was more similar across TARC levels within each treatment
arm. Conclusions. Overall, these data suggest that serum TARC may




VALIDATION OF A CLINICAL/BIOLOGICAL PROGNOSTIC MODEL IN A LARGE COHORT OF
ELDERLY PATIENTS WITH A CLASSICAL HODGKIN LYMPHOMA
V. Safar1, M. Morelle2, P. Brice3, C. Rossi4, J. Dupuis5, A. Perrot6,
A. Stamatoullas7, S. Garciaz8, S. Carras9, J. Lazarovici10, H. Ghesquières1
1Hematology Department, Centre Hospitalier Universitaire de Lyon Sud, Pierre
Bénite, France; 2Biostatistics Department, Centre Léon Bérard, Lyon, France;
3Hematology Department, Hôpital Saint-Louis, Paris, France; 4Hematology
Department, Hôpital Le Bocage, Dijon, France; 5Lymphoid Malignancies Unit,
Groupe Hospitalier Henri Mondor-Albert Chenevier, Créteil, France; 6Hematology
Department, Hôpital de Brabois, Nancy, France; 7Hematology Department,
Centre Becquerel, Rouen, France; 8Hematology Department, Institut Paoli-
Calmettes, Marseille, France; 9Hematology Department, Centre Hospitalier
Universitaire, Grenoble, France; 10Hematology Department, Institut Gustave
Roussy, Villejuif, France
Introduction. Our goal is to investigate the external validity of two
previously developed prognostic models for overall survival (OS) and
progression free survival (PFS) using a scoring system counting unfa-
vorable risk factors (age, performans status, bone marrow involvement,
gamma globulin level and fibrinogen level) in elderly patients with a
classical Hodgkin lymphoma (cHL). Methods. The performance of the
prediction models was evaluated on a retrospective cohort of patients
≥59 years with newly diagnosed cHL treated in eight hospitals in
France. Model discrimination was evaluated by computing hazard ratio
(HR) across risk groups. A comparison with the International Prognostic
Score (IPS) was performed using ROC curves. Results. 288 patients were
included (November 1990 –June 2015): median age at diagnosis was 70
years (range, 59-93), 55% were male, 53% presented with B symptoms,
25% had a PS>2, 61% had Ann Harbor stage III/IV, 26% had at least
one comorbidity scored 3 or 4 on CIRS. Median follow up is 64 months
(0-232). 25% of patients have progressed or relapsed and 103 patients
died, 40% within the first year of treatment. OS and PFS at 36 months
were 72.1% [95% CI: 66.2%; 77.1%] and 63.5% [57.5%; 68.9%],
respectively. On 188 evaluable patients, HR for PFS were 8.2, 7.9, and
9.6 for the presence of 1, 2, and 3/4 factors respectively
(reference=absence of factor). On 215 evaluable patients, HR for OS
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were 1.3, 2.2 and 4.0 for the presence of 1, 2 and 3 factors respectively.
Patients with 0, 1, 2 and 3 factors had a 3 years OS of 82.3, 77.3, 69.5
and 38.1% respectively (p=0.001). The areas under the curve were not
significantly different (p=0.9754) for OS between our score and IPS.
Conclusions. These results provide evidence of a satisfactory discrimi-
nation ability of the prediction model for OS, with a predictive power
similar to IPS. A larger evaluable cohort is required to have a better
prognostic model for PFS. This study is a first step in establishing the
external validity of these models before use in clinical practice, together
with geriatric assessment, in order to offer adequate treatment to
patients.
P062
OUTCOMES AND PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA – A SINGLE CENTER
EXPERIENCE
A. Pinto, D. Mota, M. Santos, R. Guilherme, M. Gomes, L. Ribeiro
Clinical Hematology Department, Coimbra University Hospital Center, Coimbra,
Portugal
Background. Identification of patients with Hodgkin lymphoma (HL)
at risk of treatment failure remains an important unsolved question.
Several prognostic models have been proposed to define risk-adapted
therapeutic strategies, avoiding overtreatment and identifying in whom
standard treatment is not sufficient. Aims. To test validated prognostic
factors and identify other predictors of survival in a cohort of patients
with classical HL (cHL) in a tertiary health institution. Methods. Retro-
spective analysis of patients with cHL treated between 1990 and 2015.
Univariate analysis was performed and significant predictors at the level
of 0.05 were used to adjust a multivariate Cox regression model. Results.
We included 355 cHL patients, mainly males (55.2%) with a median
age at diagnosis of 29 years (12-80). The most prevalent histological
subtype was nodular sclerosis (78.3%). Ann Arbor stage III/IV was
observed in 41.1% (n=146) patients, B symptoms in 54.6% (n=194) and
bulky disease in 22.8% (n=81). According to GHSG criteria, 50.1%
(n=178) had advanced disease of which 49.4% (n=88) had an IPS≥3.
Among the 344 patients treated, ABVD was performed in 210 (59.2%);
MOPP/ABVD in 78 (21.9%); MOPP/MOPP like in 30 (8.5%); BEACOPP
in 25 (7.0%); other regimens in 17 patients (4.8%) and radiotherapy
alone in 11 (3.1%). Overall response rate was 83.9% (77.2% of com-
plete responses). With a median follow-up of 100.1 months (0.3-316.0),
overall survival (OS) at 5, 10 and 20 years was 84.3%, 78.1% and 67.8%
and progression free survival (PFS) was 71.6%, 67.3% and 57.9%,
respectively. We analyze the prognostic significance of several factors
accepted previously with regard to survival. On multivariate regression
analysis only 3 factors were associated with impact on OS: age (HR
1.04; 95%CI 1.02-1.06, p<0.001); hemoglobin level (HR 0.78; 95%CI
0.66-0.93, p=0.005) and LDH>2xULN (HR 2.13; 95%CI 1.06-4.28,
p=0.034). Four factors were predictors of PFS: age (HR 1.02; 95%CI
1.01-1.04, p<0.004); lymphocyte count (HR 0.60; 95%CI 0.39-0.92,
p=0.02), LDH>2xULN (HR 2.55; 95%CI 1.31-4.97, p=0.006) and Ann
Arbor stage III/VI (HR 2.40; 95%CI 1.18-4.86, p=0.015). Conclusions.
This data provides evidence for age, hemoglobin and LDH as independ-
ent predictors of OS and age, lymphocyte count, LDH and Ann Arbor
stage as predictors of PFS in patients with cHL. Further work in larger
groups is warranted to create an accurate predictive model for adequate
stratification of newly diagnosed patients.
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COMBINED PROGNOSTIC ROLE OF TARC PROTEIN AND PET/CT IN PATIENTS WITH
HODGKIN LYMPHOMA
K. Husi1, Á. Illés1, Á. Jóna1, B. Nagy2, Z. Fejes2, S. Barna3, Z. Miltényi1
1Department of Hematology; 2Department of Laboratory Medicine; 3University
of Debrecen, Faculty of Medicine; Scanomed Ltd, Debrecen, Hungary
Introduction. It is well known that long-term survival of Hodgkin lym-
phoma (HL) patients is very favourable, that is why we have to detect
those high-risk patients in time who don’t respond to first-line therapy
on a desirable way. Nowadays interim and restaging PET/CT is wide-
spread, but there are some biomarkers in addition, which may help us
to choose the best way of therapy and to avoid undertreatment. Patients
and Methods.We examined HL patients who were treated in our insti-
tute from September 2013 to March 2016. Our aim was to detect
whether serum TARC (Thymus and Activation- Regulated Chemokine)
protein alone or combined with PET/CT is appropriate for being a help-
ful biomarker in HL patients or not. Results. During this period we col-
lected serum samples from 39 patients treated with Hodgkin lym-
phoma. We have got samples from 3 different times (before treatment,
after 2 cycles of chemotherapy and after 6 cycles of chemotherapy) in
the case of 20 patients. The mean age of the 20 patient ( 11 males and
9 females) was 42,4 years (18-75 years) at the time of the diagnosis.
Three of them were in an early stage and 17 of them were in advanced
stage. According to our results the activity of TARC protein measured
before treatment is fit for indicating extranodal manifestations, the pres-
ence of bulky disease, and the extension of the disease, but neither it’s
activity after 2 cycles of chemotherapy, nor at the end of treatment
indicated refractory disease nor alone, neither combined with interim
PET/CT. Conclusions. Nevertheless, Hodgkin lymphoma is one of the
best curable malignancies; there are no methods except PET/CT which
may help us to identify high-risk patients in time. The exact role of bio-
markers needs further investigations. 
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WHOLE BODY FUNCTIONAL AND ANATOMICAL MRI: ACCURACY IN STAGING AND
TREATMENT RESPONSE MONITORING IN CHILDHOOD AND ADOLESCENT HODGKIN’S
LYMPHOMA COMPARED TO CONVENTIONAL MULTIMODALITY IMAGING
(CRUK C23580/A12707)
S. Daw, S. Punwani, A. Latifoltojar, P.D. Humphries, L. Menezes,
D. Neriman, A. Shankar, B. Popova, P. Smith, K.M. Condne, A. Lopes,
S.A. Taylor
Cancer Research UK and UCL Cancer Trials Office, University College
London, London, UK; Centre for Medical Imaging, University College London,
London, UK; Institute of Nuclear Medicine, University College London, London,
UK; University College London Hospital, London, UK
This is a single centre cohort trial to compare whole body MRI (WB-
MRI) & conventional investigations for staging & treatment response
monitoring in childhood Hodgkin’s lymphoma. A total of 50 patients
(32 male, median age 16, range 6-19) prospectively underwent WB-
MRI in addition to conventional CT and PET CT at initial staging and
during response assessment (n=37) after 2 chemotherapy cycles. WB-
MRI included axial/coronal FS T2/T1 TSE, axial FS DWI (5 b values 0
to 800), & dynamic contrast enhanced T1 FLASH through the
liver/spleen. The reference standard disease status at 30 sites (17 nodal,
13 extra nodal) & Ann Arbour stage was assigned by a multidisciplinary
committee using PET CT and CT, based on EURONET trial criteria
(nodal positivity >2cm and/or focal 18-FDG uptake above background).
Treatment response (progression, none, partial inadequate (PRi), partial
adequate (PRa) and complete) was defined using nodal volume change
& FDG avidity. WB-MRI was read in consensus by 2 radiologists blind-
ed to conventional imaging. Based on pilot data, nodal positivity was
defined as >2cm &/or mean ADC <1.2 x10-3mm2 s-1. Nodes 1 to 2cm
with ADC 1.2-1.8 were equivocal. Treatment response was assigned
using nodal volume change and rise in ADC (cut off of 70% to differ-
entiate between PRi & PRa). Agreement between WB-MRI and the ref-
erence was expressed as percentage concordance for all reported disease
sites and kappa statistics. Equivocal sites were treated as disease posi-
tive. Results are uncorrected for discrepancies in nodal site description.
A total of 44 (88%) patients were concordant for at least 80% of nodal
sites, although only 12 (24%) achieved 100% concordance between
WB-MRI and the reference standard. Equivalent results for extra nodal
disease were 48 (96%) and 34 (68%) respectively. There was 72%
agreement for stage (36/50), (kappa 0.56-moderate), with 10 (20%)
patients under staged by WB-MRI and 4 (8%) over staged. There was
68% agreement for response classification (25/37) (kappa 0.34-fair) with
response over estimated by WB-MRI in 4 (11%) & under estimated in
8 (22%). In conclusion, WB-MRI holds promise as an alternative to con-
ventional staging modalities using ionising radiation, but levels of dis-
cordance suggest it is not ready to fully replace them. WB-MRI is attrac-
tive as a staging modality for paediatric lymphoma but disagreement
with standard modalities suggests caution must be applied before intro-
ducing into staging algorithms.
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PHASE III STUDY OF RESPONSE ADAPTED THERAPY FOR THE TREATMENT OF CHILDREN
WITH NEWLY DIAGNOSED VERY HIGH RISK HODGKIN LYMPHOMA (STAGES IIIB/IVB)
(AHOD0831): A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP 
K. Kelly1, P.D. Cole2, L. Chen3, K.B. Roberts4, D.C. Hodgson5,
K. McCarten6, S.Y. Cho7, C.L. Schwartz8
1Roswell Park Cancer Institute; 2Montefiore Medical Center; 3Children’s Oncology
Group; 4Yale Cancer Center; 5Princess Margaret Cancer Centre; 6Brown
University; 7University of Wisconsin Carbone Cancer Center; 8UT MD Anderson
Cancer Center
Purpose.AHOD0831 tested a response-based treatment approach for
children with very high risk Hodgkin lymphoma (HL). Central review
following 2 cycles by FDG-PET was used to assign consolidation
chemotherapy and radiotherapy (RT). As many patients with relapsed
HL can be successfully cured with retrieval therapy, 2ndEFS (freedom
from 2nd relapse or malignancy) was used as a surrogate for long term
HL-related cause of death. AHOD0831 tested whether this treatment
would maintain 4yr 2ndEFS ≥95%. Methods. Patients ≤21 with stage
IIIB/IVB HL were nonrandomly assigned to receive two 21-day cycles
of ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, pred-
nisone, cyclophosphamide). Rapid Early Response (RER) was defined
by FDG-PET without activity above background, irrespective of resid-
ual masses. RER received 2 additional cycles of ABVE-PC. Slow early
responders (SER) received 2 cycles of ifosfamide/vinorelbine and 2 more
ABVE-PC. Sites of initial bulky involvement (large mediastinal mass,
nodal aggregate >6cm, splenic macronodules) and regions of SER
received RT 21 Gy. 2nd events were defined as relapse/PD of HL or
SMN, new SMN or death after a 1st event (relapse/PD, SMN, biopsy
proven HL at end of chemotherapy). Results. The 165 eligible patients
were: median age 15.8 yrs (5.2-21.4), 61% male, 43% stage IIIB. 50%
were RER. Median follow-up was 42 mos. 1st events: 29 relapse/PD, 1
SMN, 1 fungal death. 4yr 1stEFS rates 80.2% (73%-85.6%). 4yr OS
95.9% (90%-98.4%). 12 SER were persistently PET+ at end of
chemotherapy; 8 had clinical evidence of active HL: 3 biopsy-proven
HL, 2 PD by clinical or radiographic criteria, and 3 relapsed. 20 patients
were excluded from 2ndEFS analysis due to premature termination or
deviation of protocol therapy. 2ndEFS at 4yrs is 89.8% (95% CI:80.8%-
94.8%). 4yr 2ndEFS was 91.9% (76.3%-97.4%) for RER, 87.8% (75.8%-
94.1%) for SER (n=68) and 89.6% (76.3%-95.7%) for stage IVB. Con-
clusions. Among pediatric patients with VHR HL, a response directed
approach with limited chemotherapy and risk-directed RT achieved
EFS and OS rates comparable with results of recent trials for this pop-
ulation (POG 9425: IIIB/IVB, n=88: 4yr EFS 81.7%; 4 yr OS 92.9%)
despite reduction in RT volumes. The similar EFS/2ndEFS for RER and
SER supports therapeutic tailoring based on response. Persistent PET
at end of chemotherapy identifies a cohort at especially high risk for
relapse/early PD. Novel approaches are needed for this group.
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OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA TREATED
ON US COOPERATIVE GROUP PROTOCOLS: AN ADULT INTERGROUP (E2496)
AND CHILDREN’S ONCOLOGY GROUP (COG AHOD0031) COMPARATIVE ANALYSIS
T.O. Henderson1, S.K. Parsons2, K. Wroblewski3, L. Chen4, F. Hong5,
S. Smith6, J. McNeer1, R. Advani7, R.D. Gascoyne8, L.S. Constine9,
S. Horning10, N.L. Bartlett11, B. Shah12, J.M. Connors8, J. Leonard13,
B.S. Kahl11, K. Kelly14, C.L. Schwartz15, D. Friedman16, L.I. Gordon17,
A.M. Evens2
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10Genentech, San Francisco, CA, USA; 11Washington University School of
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WI, USA; 13Department of Medicine, Cornell Weill School of Medicine, New
York, NY, USA; 14Roswell Park Cancer Institute, Buffalo, NY, USA; 15Division
of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA; 16Department
of Pediatrics, Vanderbilt University, Nashville, TN, USA; 17Northwestern
University Feinberg School of Medicine, Chicago, IL, USA
Introduction. The optimal therapeutic approach for AYAs with HL
remains unclear. We examined AYAs treated on 2 recent, randomized
pediatric and adult North American HL studies. Methods. The charac-
teristics, failure free survival (FFS) and overall survival (OS) of 114 AYA
HL patients (pts) [17-21 years(yr)] treated on E2496 (ABVD vs Stanford
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V [SV], Gordon JCO 2013) were compared with pts >21 years on E2496.
The characteristics, FFS and OS of these ECOG AYAs were compared
with 391 AYAs (17-21 yr) treated on COG AHOD0031 (ABVE-PC back-
bone, Friedman JCO 2014). Stratified log-rank tests and propensity score
analysis were utilized to compare outcome differences. Results. In
E2496, the 5-year FFS and OS rates for AYAs were 68% and 89%,
respectively, with significant variations identified by pt age (Table).
There was no FFS difference between ECOG AYAs treated with ABVD
vs SV (P=0.66). FFS in AYAs were inferior to those ages 21 to 44 yr (P
=0.005) but appeared more similar to patients aged 45-59 yr. There was
no significant difference in sex, race, or histology in COG or E2496
AYAs. Due in part to trial design differences, a larger proportion of
E2496 AYAs were stage III or IV vs COG AYAs (63% vs 29%, P<0.001)
and had B symptoms (63% vs 27%, P<0.001); fewer E2496 pts had bulk
disease (33% vs 77%, P<0.001). There was no significant difference in
extralymphatic disease, anemia or low albumin. More COG AYAs
received radiotherapy (76% vs 66%, P=0.03), though in smaller doses
(21 Gy vs 36 Gy). The 5-year FFS and OS for COG AYAs were 80% and
97%, respectively. COG AYAs appeared to have superior FFS compared
with E2496 AYAs (P=0.001). In multivariable analyses (controlled for
stage, anemia, bulk), E2496 AYAs appeared to have worse FFS compared
with COG AYAs in all strata except among those with stage I/II without
anemia. Propensity score analysis matched on stage, anemia, and bulk
disease confirmed inferior FFS for E2496 compared with COG AYAs
(P=0.004). The AYA survival disparity across studies persisted after addi-
tional covariates were incorporated into the propensity score (ie, age,
gender, B symptoms and hypoalbuminemia; P=0.026). Conclusions.AYA
HL pts treated on E2496 had inferior outcomes compared with older
pts (22-44 yr) on same study, and to similarly matched AYA pts treated
on COG AHOD0031. This may reflect differing treatment regimens,
risk profiles, biology, or other factors. Prospective examination of these
issues in AYA HL pts is warranted.
Table 1. Survival outcomes within E2496 by age.
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FIRST INTERNATIONAL INTER-GROUP STUDY FOR CLASSICAL HODGKIN LYMPHOMA IN
CHILDREN AND ADOLESCENTS: EuroNet-PHL-C1. REPORT OF THE LATEST INTERIM
ANALYSIS
J. Landman-Parker1, H. Wallace2, D. Hasenclever3, W. Balwierz4,
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Dose-intensive chemotherapy regimens combined with radiotherapy
have demonstrated high efficacy in classical Hodgkin Lymphoma (cHL)
in children and adolescents with about 90% EFS after 10 years. Never-
theless these results are hampered by long-term adverse events like
radiotherapy-induced malignancies or procarbazine-induced male infer-
tility. The primary objectives of the EuroNet-PHL-C1 trial aimed at
demonstrating a 90% 5-year EFS in patients who were PET-negative
after the two OEPA (vincristine, etoposide, prednisone,doxorubicine)
induction chemotherapy cycles and thus received no radiotherapy (RT).
In addition, patients in intermediate and advanced stages have been
randomized between COPP (cyclophosfamide, vincristine, prednisone,
procarbazine) and COPDAC (cyclophosfamide, vincristine, prednisone,
dacarbazine) consolidation chemotherapy to demonstrate whether pro-
carbazine could be replaced by dacarbazine without impairing treat-
ment results. From January 2007 to January 2013, 2111 patients at medi-
an age of 14.3 years were enrolled in 16 European countries. 716
patients were classified as early stages (IA/IB-IIA) (treatment group 1,
TG-1), 490 as intermediate stage (IIAE-IIB-IIIA)(TG-2) and 905 as
advanced stages ( IIEB,IIIB,IVA/B) (TG-3). RT was assigned to 1114 pts
(52%). In the randomized part of the trial 473 pts TG-2 and TG-3 pts
received COPP and 468 pts COPDAC. At the latest interim analysis
the 48 months OS/EFS are 98% and 88%, EFS- TG1, EFS-TG2 and EFS-
TG3 are 87.5%, 91% and 86.6% respectively ( p=0.08). The EFS in
patients with or without RT is 88% and 87%. EFS did not differ
between the COPP and the COPDAC arm in TG2 and TG3. In TG1
ESR >30 or bulky disease was associated with inferior EFS . Conclusions.
in this trial RT could be avoided in about 50% of patients without
impairing treatment results by using an early response PET-based strat-
egy. Dacarbazine could safely replace procarbazine in the COPP con-
solidation cycle, rendering COPDAC as standard consolidation.
EuroNet PHL-C2 will further focus on reducing RT indication by pro-
posing a moderate increase of chemotherapy burden in a randomized
fashion.
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JOINT PEDIATRIC HODGKIN AND NON-HODGKIN LYMPHOMA STUDY GROUP ON GREY
ZONE LYMPHOMA IN CHILDREN AND ADOLESCENTS
B. Burkhardt1,*, O. Makarova1,*, D. Koerholz2, M. Zimmermann3,
S. Mueller1, F. Knoerr2, I. Oschlies4, W. Klapper4, W. Woessmann2,
C. Mauz-Körholz2
1Pediatric Hematology and Oncology, University Children’s Hospital, Münster,
Germany; 2Pediatric Hematology and Oncology, Justus Liebig University,
Giessen, Germany; 3Pediatric Hematology and Oncology, Medical School Han-
nover, Hannover, Germany; 4Pathology, Hematopathology Section and Lymph
Node Registry, Christian-Albrechts-University Kiel and University Hospital
Schleswig-Holstein, Campus Kiel, Kiel, Germany
Background. In the current version of the WHO classification of lym-
phoid tumors the term ‘grey zone lymphoma’ (GZL) was introduced for
the first time. The cases of GZL with characteristics of Hodgkin lym-
phoma (HL) and Non-Hodgkin lymphoma (NHL) are poorly character-
ized in children and adolescents and need further improvement of diag-
nostic and treatment approaches. Patients and Methods. We evaluated
patient’s characteristics, treatment and outcome of young GZL patients
reported to the German Pediatric Hodgkin lymphoma study center
and/or to the NHL-Berlin-Frankfurt-Muenster study center. Results.
Between 2003 and 2015, 27 children and adolescents with GZL, com-
prised of 22 boys and 5 girls, with a median age of 15 years, were iden-
tified. The GZL was identified at the time of initial diagnosis in 19
patients, in six patients the diagnosis was established at the time of
relapse by comparing initial and relapse samples, and in two patients by
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a reference pathology panel which reviewed primary mediastinal B-cell
lymphoma (PMLBL) cases. GZL between classical Hodgkin lymphoma
(cHL) and diffuse large B-cell lymphoma (DLBCL) was diagnosed in
eleven patients, GZL between cHL and PMLBL in three cases, GZL of
lymphocyte predominant Hodgkin (LPHL) and T-cell rich B-cell lym-
phoma (TCBCL) in eleven and in two cases grey zone between LPHL
and DLBCL. Fifteen patients received frontline treatment according to
protocols for HL, ten patients had treatment for mature B-NHL and two
had DA-R-EPOCH. Seventeen of the 27 patients relapsed. Among them,
nine patients with cHL/DLBCL - four after HL treatment, four after B-
NHL treatment and one after DA-R-EPOCH; both patients with
cHL/PMLBL - one after HL and one after B-NHL treatment; and six with
LPHL/TCRBCL - five after HL and one after B-NHL treatment. Five of
the eleven patients with GZL between LPHL and TCRBCL stayed in
remission after frontline treatment, compared to only three of fourteen
patients with GZL between cHL and DLBCL or PMLBL. Both patients
with GZL between LPHL and DLBCL stayed in remission after frontline
treatment. Conclusions. The diagnosis of GZL requires expert reference
pathology and centralized review of staging and response evaluation.
Since the relapse incidence of GZL is higher than in each of both “pure”
entities HL and NHL, implementation of optimized treatment strategies
for GZL is urgently needed. Therefore, global cooperative initiatives
have to be undertaken, since GZL is a rare entity.
P066
HODGKIN LYMPHOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS- 
A COMPARATIVE STUDY OF CLINICAL PRESENTATION AND TREATMENT OUTCOME 
A. Englund1,*, I. Glimelius2,3,*, K. Rostgaard4, S. Eloranta2, D. Molin3,
T. Kuusk1, P. de Nully Brown6, P. Kamper7, K.E. Smedby2, H. Hjalgrim4,
G. Ljungman1, L. Lyngsie Hjalgrim4,5
1Department of Women’s and Children’s Health, Uppsala University, Uppsala,
Sweden; 2Clinical Epidemiology Unit, Department of Medicine, Karolinska
Institutet, Stockholm, Sweden; 3Experimental and Clinical Oncology, Depart-
ment of Immunology Genetics and Pathology, Uppsala University, Sweden;
4Statens Serum Institut, Department of Epidemiology Research, Copenhagen S,
Denmark; 5The Child and Youth Clinic, Department of Paediatric Haematology
and Oncology, Rigshospitalet, Copenhagen, Denmark; 6Department of Haema-
tology, Rigshospitalet, Copenhagen, Denmark; 7Department of Haematology,
Aarhus University Hospital, Denmark
*Both first authors contributed equally
Hodgkin lymphoma (HL) treatment protocols for adolescents and
young adults traditionally vary by age, but the biological and clinical
rationale for this remains uncertain. Our aim was to investigate clinical
presentation and outcome in different age groups (0-9, 10-17, 18-24
years) and to compare prognosis among patients treated in pediatric or
adult departments. Patients and Methods. 1345 classical HL (cHL) 0-24
years were diagnosed in Denmark 1990-2010 and Sweden 1992-2009.
Disease characteristics and treatment outcome were available for 1083
cHL patients treated in pediatric (n=325) or adult departments (n=758).
Outcome was estimated as event free survival (EFS) and overall survival
(OS) and using Cox regression. Patients treated in adult departments
were mainly treated with ABVD (doxorubicine, bleomycin, vinblastine,
dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicine,
cyclophosphamide, vincristine, procarbazine, prednisone) +/- radio-
therapy (RT) and the majority of the pediatric patients with
OPPA/OEPA (vincristine, etoposide vs procarbazine, prednisone, dox-
orubicine) and COPP/COPDAC (cyclophosphamide, vincristine, pred-
nisone, procarbazine vs dacarbazine) +/- RT. Results. Children0-9yrs
had male predominance and presented with lower stage disease and
lower frequency of B-symptoms and extra nodal disease. Five-year EFS
was lower among Danish paediatric patients (0-14 years) [0.81 (95%
confidence interval (95%CI):0.72-0.88)] than among Danish adults [0.85
(0.81-0.88)], Swedish pediatric patients (0-17 years) [0.89 (0.85-0.93)]
and adults [0.90 (0.86-0.92)] (Figure 1A). There was no difference in 5-
or 10-year OS (Figure 1B). Danish pediatric patients received RT (32%)
less frequently than Swedish pediatric patients (71%), p<0.002, while
in adults the difference was not as pronounced (Denmark 67%, Sweden
56%). In analyses adjusted for sex, stage and country, EFS and OS did
not vary among patients treated in pediatric compared to adult depart-
ments. Conclusions. Children 0-9yrs had a different clinical presentation
in several aspects, whereas adolescents 10-17yrs and young adults 18-
24yrs shared similar features. There was no difference in treatment
outcome between pediatric and adult departments overall. Patients in
Denmark treated in pediatric departments had lower EFS than patients
in Swedish pediatric departments and Swedish and Danish adult
departments. This correlated to a lower use of RT in primary treatment.
OS was equal between the groups.
Figure 1.
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PHARMACOKINETICS, IMMUNOGENICITY AND SAFETY OF WEEKLY DOSING OF
BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA
J. Flerlage1, M. Metzger1, J.C. Panetta2
1Department of Oncology, St. Jude Children’s Research Hospital and the
University of Tennessee Health Sciences Center, Memphis, TN, USA;
2Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital
and the University of Tennessee Health Sciences Center, Memphis, TN, USA
Background. To improve the success of treatment for Hodgkin Lym-
phoma (HL) the novel agent brentuximab vedotin (anti-CD30 agent)
was developed as CD30 is highly expressed in both HL and anaplastic
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large cell lymphoma. Based off the success of phase 1 and II trials it is
now used as a frontline agent in a high-risk pediatric HL trial HLHR13.
Purpose. The primary goal of this study was to evaluate the variability
of pharmacokinetics for weekly dosing of 1.2 mg/kg of brentuximab
vedotin, determine factors that may explain this variability, compare
our drug exposure with published data for the recommended 1.8 mg/kg
every 3 week dosing and evaluate toxicity with this novel agent in the
pediatric population. Methods. Serum samples for brentuximab vedotin
levels were collected at day 1 pre and post infusion, 48 hours and day 8
pre-infusion for 16 patients. A compartmental pharmacokinetic model
was fit to the data using non-linear mixed effects modeling methods.
Serum concentration of anti-therapeutic antibody was measured prior
to the first 3 courses and at the end of therapy. Results. Brentuximab
vedotin and MMAE clearance and volume were significantly correlated
with weight (p<1e-10) and accounting for weight explained 75%, 84%,
61%, and 94% of the inter-individual variability in the ADC clearance,
ADC volume, MMAE apparent clearance, and MMAE apparent volume
respectively. The ADC clearance and volume differed by gender; clear-
ance and volume were higher in male vs female patients (17%; p=0.08,
and 17%; p=0.03, respectively) and explained an additional 11% and
36% of the inter-individual variability in the ADC clearance and volume
respectively compared to the weight-normalized model. The ADC AUC
and Cmax in our pediatric study were lower compared to those reported
in adult studies (25% and 11%, respectively at 1.2 mg/kg and 35% and
16%, respectively at 1.8 mg/kg). Toxicity was comparable to that pub-
lished for the standard of care backbone. All 16 patients remained neg-
ative for anti-therapeutic antibodies during and at the end of therapy.
Conclusions.As in previous studies, weight continues to be the most sig-
nificant factor explaining brentuximab vedotin pharmacokinetic vari-
ability in pediatric patients. Exposure with weekly dosing appeared safe
and tolerable in pediatric patients. Given the promising clinical results
of brentuximab vedotin, more studies are warranted to demonstrate
safety and allow for increased use in the pediatric population. 
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APPROACH AND FEASIBILITY OF PATIENT-REPORTED OUTCOMES IN A PHASE III CLINICAL
TRIAL FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN CHILDREN
AND ADOLESCENTS 
S.M. Castellino*, T.O. Henderson*, F. Keller, K. Kelly, R. Curtis,
R.M. Conti, S.K. Parsons
Emory University, Children’s Healthcare of Atlanta, Atlanta, GA, USA; The
University of Chicago, Chicago, IL, USA; University of Buffalo School of
Medicine, Buffalo, NY, Roswell Park Cancer Institute; Tufts Medical Center,
Boston, MA, USA
*Co-first authors
Objectives. We describe the feasibility of embedding PROs for
chemotherapy-induced peripheral neuropathy (CIPN) and cost effec-
tiveness (CEA) in a randomized, multi-institutional Phase III study
(NCT02166463), evaluating the efficacy of the novel agent, Brentux-
imab vedotin, for advanced cHL in children and adolescents. Methods.
Recruitment for PROs of interest is targeted for 250 of the planned 600
trial participants. Participation in the trial includes prospective collection
of patient- and parent proxy-reported outcomes. CIPN is evaluated with
the 11- item FACT-GOG-NTX and paired with the 9-item CHRIs-Glob-
al to serially evaluate health-related quality of life (HRQL) consequences
of CIPN from initial diagnosis to 12 months off therapy. For CEA, US-
based participants are queried from diagnosis through 36 months off
therapy with the 4-item Stanford Healthcare Utilization Questionnaire
(parent-report), the Health Utilities Index (HUI) 2/3, and the 23-item
Caregiver Work Limitations Questionnaire (parent-report) as a measure
of productivity loss. A study-designated research assistant is charged
with contacting site personnel at study entry and at each scheduled
assessment. All data are tracked for completion and uploaded into a
web-based relational database for future analysis. Units of healthcare
utilization will be monetized with unit costs from US-based adminis-
trative databases, including claims from public and private payers, based
on site of care and diagnostic and/or procedure codes. Total costs will
be calculated by study arm and expressed as cost per quality-adjusted
life year, derived from the HUI 2/3. Results. The clinical trial, activated
in March 2015, has enrolled 137 participants; accrual is ongoing at 170
participating institutions. Among participants 95% have completed the
baseline CIPN and CEA assessments and >90% have completed subse-
quent measures. Monetization of significant adverse events and utiliza-
tion is in progress. Discussion.We demonstrate feasibility of embedding
PROs evidenced by high acceptance and completion rates of assess-
ments for prospective evaluation of CIPN, HRQL, and healthcare uti-
lization in a multi-institutional trial of children with advanced HL. Our
experience serves as a proof of principle to cooperative groups regarding
the resources and the feasibility of incorporating necessary PRO and
health utilization outcomes into Phase III clinical trials as a component
of cancer care delivery research.
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PREDICTION OF PRIMARY TREATMENT RESPONSE AND OUTCOME IN PEDIATRIC
HODGKIN LYMPHOMA USING DIGITAL GENE EXPRESSION PROFILING
A. Mottok1,2, R.L. Johnston1,3, F. Chun Chan1,3, D.W. Scott1,4,
D. Friedman5, C.L. Schwartz6, K. Kelly7, T.M. Horton8, C. Steidl1,2
1Department of Lymphoid Cancer Research and Centre for Lymphoid Cancer,
British Columbia Cancer Agency, Vancouver, Canada; 2Department of Pathology
and Laboratory Medicine, University of British Columbia, Vancouver, Canada;
3Bioinformatics Training Program, University of British Columbia, Vancouver,
BC, Canada; 4Department of Medicine, University of British Columbia,
Vancouver, Canada; 5Vanderbilt Ingram Cancer Center, Nashville, TN, USA;
6University of Texas, MD Anderson Cancer Center, Houston, TX, USA;
7Department of Pediatrics, Roswell Park Cancer Institute and University at
Buffalo, Buffalo, NY, USA; 8Baylor College of Medicine and Texas Children’s
Cancer Center, Houston, TX, USA
Introduction. Hodgkin lymphoma (HL) is a common pediatric malig-
nancy, and although considered highly curable, treatment success comes
at a high cost in the form of long-term toxicity and morbidity. To over-
come this challenge clinical trials have evaluated risk-adapted treatment
regimens aiming to maintain high survival rates and reduce treatment-
related toxicity. However, risk stratification is currently limited to the
use of clinical factors as there are no validated molecular biomarkers
that can be employed as predictors for treatment outcome in pediatric
HL. Therefore, we aimed to perform gene expression profiling (GEP)
to uncover disease biology underlying treatment response and develop
a prognostic model to tailor first-line therapy in pediatric HL. Methods.
We selected specimens from patients enrolled in a phase 3 clinical trial
(AHOD0031) of the Children’s Oncology Group (COG) randomizing
patients dependent on CT imaging-based early response criteria (slow
early response, SER; rapid early response, RER). We performed inter-
mediate density GEP (784 genes) using NanoString on RNA extracted
from pre-treatment formalin-fixed, paraffin-embedded tissue biopsies.
Results.Of the 206 tissue samples obtained, 185 (89.8%) passed quality
assurance testing. We applied our previously published 23-gene predic-
tor - developed to predict OS in adult HL patients - to the pediatric
cohort. This assay failed to predict outcomes, with patients in the “high-
risk” group, as assigned by the assay, trending to have superior out-
comes than the “low risk” patients. Therefore, we sought to develop a
novel EFS predictive model for pediatric patients. Using penalized Cox
regression, we developed a 16-gene model to predict EFS in a training
cohort. This model was applied to an independent cohort of 117 spec-
imens from the same clinical trial which were enriched for treatment
failure (no EFS event to EFS event ratio=1:1). Using this validation
cohort, the 16-gene model separated high-risk and low-risk groups with
significantly different EFS in the SER (p=0.034), but not in the RER
group (p=0.81). Conclusions. Failure of the GEP-based model developed
in adult HL suggests distinct biology underlies treatment failure in the
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pediatric age group, although differences in therapy may also be a con-
tributing factor. We describe the development of a novel predictive
model for EFS in intermediate-risk pediatric HL patients which suc-
cessfully risk-stratifies patients in the SER subgroup. 
P070
DOES INVOLVED FIELD RADIOTHERAPY IMPROVE SURVIVAL RATES IN PEDIATRIC
CLASSIC HODGKIN’S LYMPHOMA? A RETROSPECTIVE STUDY OF 694 CHILDREN
M.S. Zaghloul, H. Akoush, A. El Haddad, E. Attia, H. Taha,
M. El Wakeel, W. Omar, S. El Sayed
Children’s Cancer Hospital, Egypt & National Cancer Institute, Cairo University,
Cairo, Egypt
Background. Pediatric Hodgkin’s lymphoma represents survival success
story, however late toxicity remains as a big consideration issue. Patients
and Methods.During the period July 2007 and December 2014, 694 pedi-
atric classic Hodgkin’s lymphoma patients were treated according to
risk-adapted protocol consisted of 4-8 ABDV chemotherapy courses and
involved field radiotherapy (IFRT). Out of them 543 (78.2%) received
IFRT with a dose of 19.8 Gy, while the other 151 (21.8%) did not receive
radiotherapy for different reasons. Results. The 5-year overall (OS) and
event-free survival (EFS) for the low risk patients were 99.7% and 92.6%
respectively. These rates were 93.1% and 83.9% for the intermediate
risk and 95.4% and 75.3% for the high risk respectively. The 5-year OS
and EFS for those received IFRT were 98.0% and 86.9% respectively,
while those who receive chemotherapy only were 92.9% and 77.8%
respectively (p 0.001 for each). Radiotherapy could improve the 5-year
EFS in the advanced (intermediate and high-risk) patients from 76.6%
to 79.4% with marginal statistical significance (0.073). On the other
hand, the OS improved from 94.5% to 96.0% though this difference
did not reach the level of significance. Only one out of 318 low-risk
patients died and 14 relapsed and could be salvaged. Only 25 low-risk
patients did not receive IFRT and those did not show OS nor EFS differ-
ences from the 293 patients who received IFRT. Two patients developed
acute myeloid leukemia & one developed thyroid cancer as second pri-
mary (0.43%). All of them received chemotherapy and IFRT. Conclusions.
Involved field radiotherapy marginally improved the EFS in intermediate
and high-risk pediatric Hodgkin’s lymphoma significantly, while its
improvement in OS in such patients did not reach the significant statis-
tical level. Low-risk patient needs prospective randomized trial to thor-
oughly investigate this issue.
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CHIPS AS A PREDICTOR OF OUTCOME IN RADIATED VS UNRADIATED HL 
C.L. Schwartz1, S. Wolden2, L.S. Constine3, L. Chen4, D. Friedman5
1University of Texas M. D. Anderson Cancer Center, Houston, TX, USA;
2Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3University of
Rochester Medical Center, Rochester, NY, USA; 4Children’s Oncology Group,
Monrovia, CA, USA; 5Vanderbilt University School of Medicine, Ingram Cancer
Center, Nashville, TN, USA
Purpose. To evaluate the CHIPS (Childhood Hodgkin International
Prognostic score) in patients with intermediate risk (IR) Hodgkin Lym-
phoma (HL) randomized to +/- 21 Gy of involved filed radiation (IFRT)
after completing 4 cycles of ABVE-PC. These patients had achieved a
rapid early response (RER) to 2 cycles of ABVE-PC (RER) and complete
response (CR) at the end of chemotherapy. Methods. Patients enrolled
on COG AHOD were <21 years with IR HL. The CHIPS score was
derived from clinical data on 1103 patients who had received 4 ABVE-
PC and radiation. Four factors (fever, low albumin, large mediastinal
adenopathy, stage 4) were identified as independent predictors of EFS.
CHIPS was then examined in the cohort of RER who achieved CR and
were randomized to receive or not receive IFRT. Results. There were
664 RER/CR patients with CHIPS scores available; 329 were random-
ized to no RT and 335 were randomized to RT. 4 year EFS was similar
between CHIPS cohorts except for CHIPS 1. CHIPS 1 patients showed
an advantage to the addition of IFRT (p=0.035). CHIPS 0 patients did
well with or without IFRT. CHIPS 3 patients had poor outcomes with
or without RT (Table 1). Conclusions. CHIPS was derived based on
patients treated on COG protocol AHOD0031 who received IFRT after
ABVE-PC chemotherapy. For this report, we compared CHIPS in the
RER/CR cohort randomized to IFRT vs no IFRT. Although the overall
randomization to +/- RT (Friedman, JCO 2015) did not detect any
advantage to the addition of IFRT, this sub-analysis shows that 1)
CHIPS was predictive of outcome in both the radiated and the un-irra-
diated cohort and 2) there may be a benefit for IFRT in the CHIPS 1
cohort. As in the overall cohort, CHIPS 2 and 3 patients should be con-
sidered for augmented therapy. 
Table 1.
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CYCLOOXYGENASE-2 EXPRESSION AS A PROGNOSTIC FACTOR IN PEDIATRIC CLASSICAL
HODGKIN LYMPHOMA
A.H. Algammal1, Y. Elborai1, A. Salama2, M. Fawzy1, E.D. El-Desouky3,
L.M. Shalaby1
1Pediatric Oncology Department, National Cancer Institute, Cairo University,
Cairo, Egypt; 2Pathology Department, National Cancer Institute, Cairo Uni-
versity, Cairo, Egypt; 3Biostatistics and Cancer Epidemiology Department,
National Cancer Institute, Cairo University, Cairo, Egypt
Introduction. Cyclooxygenase-2 (COX-2) is an inflammatory enzyme
and it was proved to have a role in tumor initiation, angiogenesis, and
proliferation. It has been demonstrated that COX-2 expression increases
in many tumors as a negative prognostic parameter. Objectives.We inves-
tigated the prognostic value of COX-2 expression among pediatric Clas-
sical Hodgkin Lymphoma patients. Methods. It is a retrospective analysis
of group of pediatric patients (n=131), who were diagnosed as Classical
Hodgkin Lymphoma and treated in the Pediatric Oncology department,
National Cancer Institute, Cairo University, Egypt during the period from
January 2005 till June 2013. and all of them were followed up till August
2015. We analyzed the relation of COX-2 expression to the most recog-
nized clinical variables and its impact on outcome. Results. COX-2 was
expressed in Reed-Sternberg cells in 37.4% of the whole group. The fre-
quency of expression was found to be more among patients with bulky
disease in comparison to non-bulky and the same applies to B symptoms,
high ESR, extranodal extension, and advanced stage without statistical
significance. With a mean follow-up period of 54.4 months, 5-year overall
survival and progression free survival was lower in COX-2 positive cases
than that in COX-2 negative cases; 85.3% and 78.6% versus 96% and
84.3%; respectively but still without statistical significance. The impact
on prognosis was observed in male group of patients. 5-year overall sur-
vival in COX-2 positive cases was lower than that in COX-2 negative
cases (82.9% versus 100%) (P value: 0.045). And there was tendency for
statistical significant regarding 5-year progression free survival (75.7%
versus 90.2%) in positive and negative cases respectively (P value: 0.06)
(Figures 1 and 2). Conclusions. COX-2 was expressed on Reed-Sternberg
cells in 37.4% of pediatric C-HL patients. It was found to be an unfavor-
able prognostic factor in males and might be a therapeutic target. How-
ever, further studies including larger numbers of HL patients are needed
to investigate that COX-2 may be a major prognostic variable in HL.
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Figure 1. Five-year overall survival for cases with B symptoms in relation
to COX-2.
Figure 2. Five-year progression free survival for cases with B symptoms
in relation to COX-2.
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HODGKIN LYMPHOMA IN ADOLESCENTS AND YOUNG ADULTS: RESULTS FROM
A SINGLE-TERTIARY-CENTER PROSPECTIVE COHORT OF 349 PATIENTS
C. Bigenwald1, J.E. Galimard2, S. Amorim1, C. Thieblemont1, N. Boissel1,
M. Resche-Rigon2, P. Brice1
1Hematology, Hopital Saint Louis APHP, Paris Diderot University, Paris, France;
2Department of Biostatistics and Medical Information, CRESS INSERM U1153,
Hopital Saint Louis, France
Background. Adolescents and young adults (AYA) represent one third
of patients affected with Hodgkin lymphoma (HL). Clinical presentation
at diagnosis differs among some subgroups of patient: children, adults,
elderly, and patients with immunodeficiency. However, specific features
of HL in AYA remain unclear. We conducted a single-center study to
describe the characteristics of HL in AYA and to define associated factors
with disease progression and/or death. Methods.All consecutive patients
newly diagnosed with HL were prospectively recruited before the ini-
tiation of treatment from one tertiary academic center (Saint Louis Hos-
pital, Paris, France). Clinical characteristics and outcomes of patients
aged from 15 to 25 years old were retrospectively computed. The pri-
mary endpoint was the occurrence of an event defined as progression
of the disease or death from any cause. June 2005 was chosen as thresh-
old for the analysis as it constitutes the advent of TEP-TDM in current
practice. Uni- and multivariate survival analyses were performed using
a Cox model. Results. 349 patients were included between 1979 and
2013, with a median follow-up of 7 years. Nodular sclerosis was the
most representative histologic subtype (86.3%). According to Ann
Arbor classification, patients had a disseminated disease in 45% of cas-
es. 289 (83%), 97 (28%) and 140 patients (56%) had a mediastinal
lymph node, a bulky mediastinum and an extra-nodal involvement,
respectively. No significant difference in terms of clinical presentation
was noticed between patients younger than 21 year-old compared to
older, except a more frequent EBV association after 21. Patients diag-
nosed after June 2005 presented more frequently a disseminated disease
(36% vs 46.2%, p=0.04). 10 year-event free survival rate was estimated
at 81% (95CI [76,7-85,5]). The first cause of mortality was HL. In mul-
tivariate analysis, stage 3 and 4 according to Ann Arbor classification
were independently associated with the occurrence of event. Converse-
ly, nodular sclerosis subtype was associated with a favourable outcome.
Conclusions. Our large prospective cohort revealed interesting features
of HL in AYA. Considering data from the literature, our study suggests
a more frequent mediastinal involvement and a more advanced stage
of disease in AYA compared to children and adults. Despite these pejo-
rative features, relapse rate and mortality rates remain low.
P074
PROGNOSTIC VALUE OF ‘INTERIM’ POSITRON EMISSION TOMOGRAPHY AMONG
CHILDREN WITH ADVANCED HODGKIN LYMPHOMA IN DEVELOPING COUNTRIES;
CHILDREN CANCER HOSPITAL EGYPT EXPERIENCE
R. Khedr1, A. Hamouda1, S. Naguib2, M. Khalaf3, S. Fikry4, A. El Sayed5,
H. Taha6, M. Saad Zaghloul7, I. Attia1
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Department, National Cancer Institute, Cairo University Children, Cancer Hos-
pital 57357, Cairo, Egypt; 7Radiation Therapy Department National Cancer
Institute, Cairo University Children, Cancer Hospital 57357, Cairo, Egypt
Rationale and Aim of the Study. This is a retrospective, single center study
was done to assess the prognostic role of ‘interim’ positron emission
tomography (PET) performed during treatment of advanced stages HL
with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in pedi-
atrics patients. Patients and Methods.Three hundred and eighty one patients
with newly diagnosed Hodgkin lymphoma were enrolled. One hundred
sixty five patients with early unfavorable and 216 with advanced-stage
disease were treated with ABVD ± involved-field radiotherapy (IFR). PET
scan was performed at baseline and after two cycles of chemotherapy.
Treatment was not changed according to the results of the interim scan.
PET scans reports was used using the Deauville five-point scale, blinded
to treatment outcome. Results. Eighty-seven scans out of 336 were scored
as positive (17.3%) and 249 (82.7%) as negative. The 5- years overall sur-
vival (OS) was 94% (95% Confidence Interval (CI) :91.5 – 96.6), 86.2%
(95% CI :78.3 - 94) for patients with interim positive scans and 97% (95%
CI:94.2 - 99.3) for patients with interim negative scans (P<0.0001). The 5-
year Event-free survival (EFS) rate was 80% (95% CI :74.3 – 84.4) for the
whole study population, 63.2% (95% CI :48.6 – 77.4) for patients with
interim positive scans and 82.6% (95% CI :76.3 – 88.8) for patients with
interim negative scans (P<0.0001). EFS in correlation with patients who
received IFR was 82.4% (95% CI: 74.3-90.4) and in those who did not
receive IFR was 71.9% (95% CI: 63.6-76.1) (Figure 1).
Figure 1.
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Conclusions. The prognostic role and validity of using the interim PET
scan response have been confirmed to be strongly related to treatment
outcome by the present study. These results confirm that ABVD with
or without IFR is an adequate treatment for more than 70% of patients
in advanced stages HL.
P075
LONG-LASTING REMISSION IN AN ADOLESCENT WITH REFRACTORY HODGKIN LYMPHOMA
AFTER BRENTUXIMAB VEDOTIN–CONTAINING TREATMENT. A CASE REPORT
A. Fedorova, A. Markavets, L. Hushchina, O. Aleinikova
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology,
Minsk, Belarus
Background. Despite the high cure rate of childhood Hodgkin lym-
phoma (HL) patients with refractory HL remain incurable with standard
therapies. Autologous or allogeneic heamotopoietic stem cell transplan-
tation (HSCT) is considered the most effective method of consolidation
in relapsed or refractory HL treatment. Brentuximab vedotin (BV) is an
anti-CD30 antibody-drug conjugate that has become the preferred ther-
apy option for adults with HL who have relapsed after or are ineligible
for auto HSCT, but data relating to pediatric patients are very limited.
Objectives.We aimed to report a case of effective and tolerable BV-con-
taining treatment in an adolescent with refractory HL. Case Report. A
17-year-old female with enlarged cervical, supra-/subclavicular, axillary,
mediastinum lymph nodes and multiple lesions in both lungs was
admitted to our hospital. FDG-PET/CT and lymph node biopsy were
performed and nodular sclerosis HL stage IVA was diagnosed. Treat-
ment was administered according to modified DAL-HD-95 protocol,
and consisted of 6 courses of chemotherapy (2OPPA/4COPP) plus radi-
ation therapy of the involved fields (20 Gy). Partial response was
achieved after the 2nd cycle OPPA and stable disease was observing
during the all remaining treatment. One month after the end of treat-
ment the patient showed disease progression in mediastinum and lungs,
confirmed by FDG-PET/CT and lung biopsy. Positive response was
obtained after the two courses (IEP, ABVD) of second-line therapy, but
patient remained PET-positive. Treatment was continued with 3 cycles
VV (BV 1.8 mg/kg/bendamustine/dexamethasone), PET-negative com-
plete remission was achieved and autoHSCT (conditioning regimen
consisted of BEAM) with allogeneic bone marrow-derived mesenchy-
mal stem cells cotransplantation was subsequently performed. Further
the patient received adjuvant monotherapy with BV 1.2 mg/kg every
3 weeks (a total of 12 doses). The only evident side effect seen in BV
treatment was deteriorating peripheral neuropathy. Patient remains in
PET-negative complete remission for 14 months after autoHSCT and 4
months after the last dose of BV. Conclusions. Our experience should
encourage to use BV in combination with chemotherapy or even alone
in pediatric patients with refractory HL.
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OVERVIEW AND SURVIVAL OF PEDIATRIC ADVANCED STAGE HODGKIN LYMPHOMA
TREATED IN DEVELOPING COUNTRIES; CHILDREN CANCER HOSPITAL EGYPT EXPERIENCE
A. Hamouda1, R. Khedr1, S. Naguib2, M. Khalaf3, S. Fikry4, A. El Sayed5,
H. Taha6, M. Saad Zaghloul7, I. Attia1
1Pediatric Oncology Department, National Cancer Institute, Cairo University
Children, Cancer Hospital 57357, Cairo, Egypt; 2Clinical Research Department,
Children Cancer Hospital 57357, Cairo, Egypt; 3Radiodiagnosis Department,
National Cancer Institute, Cairo University Children, Cancer Hospital 57357,
Cairo, Egypt; 4Clinical Pharmacy, Children Cancer Hospital 57357, Cairo,
Egypt; 5Nuclear Medicine Department, National Cancer Institute, Cairo
University Children, Cancer Hospital 57357, Cairo, Egypt; 6Surgical Pathology
Department, National Cancer Institute, Cairo University Children, Cancer
Hospital 57357, Cairo, Egypt; 7Radiation Therapy Department National Cancer
Institute, Cairo University Children, Cancer Hospital 57357, Cairo, Egypt
Background and Aim of the Study. The major challenge in advanced
stage Hodgkin Lymphoma is to optimize the balance between overall
survival and treatment related toxicity. The aim of the study was to
describe the pediatric population with advanced Hodgkin lymphoma
(HL) in our country and their treatment outcome. Patients and Methods.
This is a retrospective single center study. Data analysis for children
with advanced stage HL (IIB or IIIB with bulk disease, or stage IV) as
done. Demographic data, staging, number of cycles (doxorubicin,
bleomycin, vinblastine and dacarbazine (ABVD)) received and whether
or not consolidation radiotherapy (RTH) was administered. Positron
emission tomography (PET) was performed baseline and after the sec-
ond cycle to detect early response without any change to treatment
plan. Results. Three hundred and eighty-one patients with newly diag-
nosed Hodgkin lymphoma were enrolled in the data analysis. Male
(283) to female (98) ratio 3:1. B-symptoms was present in 60% of
patients. Ann Arbor staging distribution was as follows; 68 (17.8%)
IIB, 97 (25.5%) IIIA, 96 (25.2%) IIIB, 55 (14.4%) IVA, 65 (17.1%) IVB.
the prevalent pathological subtype was the nodular sclerosis accounting
for 54% (203/381) followed by the mixed cellularity 148/ 381 ( 39%)
.One hundred sixty-five patients with early unfavorable and 216 with
advanced-stage disease were treated with ABVD ± RTH. One hundred
twenty- nine (34%) patient did not receive RTH. The Five-years Overall
survival (OS) and the Event free survival (EFS) in these patients was
90.7 (95% CI: 85.4-95.9 and 71.9% (95% CI: 63.6-76.1) (p value 0.006)
respectively. The OS and EFS of patient with advanced stage HL in the
whole study population was 94.1 (95% CI: 91.5-96.6) and 79.4 (95%
CI 74.3-84.4) respectively. Conclusions. More than 90% of patients are
cured with risk-based combined-modality therapy, yet these therapies
are frequently associated with risks for significant long term toxicities;
innovative approaches are needed for those patients who have a high
risk of failure with current therapies.
Figure 1.
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Positron Emission Tomography
T019
ONLY FOCAL BONE MARROW FDG UPTAKE IN BASELINE FDG-PET SCAN HAS A DIAGNOSTIC
AND PROGNOSTIC IMPACT IN HODGKIN LYMPHOMA: RESULTS FROM AN INTERNATIONAL
COLLABORATIVE STUDY
C. Zwarthoed1, T.C. El-Galaly2, M. Canepari3, M.J. Ouvrier1,
S. Viviani4, L. Rigacci5, L. Trentin6, C. Rusconi7, S. Luminari8,
M. Cantonetti9, S. Bolis10, A. Borra3, F. Salvi11, E. Subocz12, J. Tajer13,
W. Kulikowski14, B. Małkowski15, J.M. Zaucha16, M. Ettaiche17,
A. Gallamini17, J. Darcourt1
1Nuclear Medicine Department, A. Lacassagne Cancer Center, Nice, France;
2Hematology Department, Aalborg University Hospital, Denmark; 3Hematology
Department, S.Croce Hospital, Cuneo, Italy; 4Hematology Department and Pae-
diatric Onco-Haematology, National Tumour Institute, Milan, Italy; 5Hematology
Chair University of Florence, Policlinico Careggi,, Florence, Italy; 6Hematology
Section, Department of Medicine, Padua University, Padua, Italy; 7Hematology
Department Ca-Granda Niguarda Hospital, Milan, Italy; 8Hematology Depart-
ment Modena and Reggio Emilia University, Reggio Emilia, Italy; 9Hematology
Department Tor Vergata University, Rome, Italy; 10Hematology Department San
Gerardo Hospital Monza, Italy; 11Hematology Department S. Antonio and Bia-
gio Hospital, Alessandria, Italy; 12Hematology Department, Military Institute of
Medicine, Warszawa, Poland; 13Lymphoproliferative Disease Department,
Maria Sklodowska-Curie Memorial Institute, Warszawa, Poland; 14Hematology
Department, Interior Ministry Hospital, Warmia and Mazury Medical Univer-
sity, Olsztyn, Poland; 15Nuclear Medicine Department, Oncology Center, Byd-
goszcz, Poland; 16Gdynia Oncology Center and Department of Oncological
Propaedeutic, Medical University of Gdansk, Gdansk, Poland; 17Research, Inno-
vation and Statistics Department, A. Lacassagne Cancer Center, Nice, France
Background. PET/CT-ascertained bone marrow involvement (BMI) is
the most frequent reason for Hodgkin Lymphoma (HL) upstaging by
baseline PET/CT (PET-0). However, shared rules for BMI detection in
PET/CT still lack. This study analyzed the diagnostic and prognostic
value of BM FDG uptake pattern in PET-0. Patients and Methods. 186
early unfavorable and advanced stage HL patients (pts), enrolled in two
International studies on the role of interim PET (PET-2) in HL, were ana-
lyzed. Treatment (Tx) was ABVDx6 cycles (advanced) or x4 cycles plus
IF radiation (early unfavorable). No Tx adaptation on PET-2 was allowed.
Two reviewers blinded to Tx outcome independently reviewed PET-0;
discordant results were jointly discussed. Focal BM lesions (fPET+) were
defined as focally increased FDG-uptake >liver uptake (with or without
CT abnormalities), visible in ≥2 slices of fused images. Diffusely
increased FDG-uptake was defined as a diffuse uptake >liver (dPET+).
No uptake (nPET+) was defined as absent or faint (<liver) diffuse uptake.
Results. After a median follow-up of 33.8 (16.6 – 109.4) months, 40 pts
(21.5%) progressed or relapsed, and 9 (4.9%) died. The 3-Y OS and PFS
was 98.0% and 83.8%, respectively. In 33/40 (82.5%) pts with a fPET+
all the PET-0 focal lesions had disappeared in PET-2. Half of pts (90/186:
48.4%) had a nPET+. dPET+, recorded in 56 (30.1%) pts, correlated with
younger age, low hemoglobin, leukocytosis, low albumin and diffuse
FDG spleen uptake. Notably, dPET+ had an identical 3-Y PFS to nPET+
pts: 83.2% and 81.6%, respectively (p=0.732). Out of 40 (21.5%) fPET+
pts, 11 had unifocal and 29 multifocal (≥2) lesions, with a 3-y PFS of
70.1% and 67.0%, respectively. Multifocal fPET+ pts had a worse PFS
compared to dPET+ p. (p=0.05). BM biopsy (BMB) was positive in 6/40
(15%) of fPET+ and 0/56 (0%) of dPET+ pts. In univariate analyses,
bulky disease (HR 2.4, p=0.008), IPS (HR 3.4, p=0.0001), and PET-2 (HR
11.0, p<0.0001) were significantly associated with PFS, but only PET-2
was still significant in multivariate analysis (p<0.0001). The kappa-value
for inter-observer agreement was 0.83 for focal and 0.78 for diffuse
uptake. Conclusions. The study confirms that (1) FDG-PET scan is a reli-
able tool for BMI assessment in HL; (2) only focal FDG uptake in PET-0
has an adverse prognostic value and should be considered to represent
BMI; (3) BMI could be detected with high accuracy and inter-observed
agreement in routine HL staging with PET/CT.
T020
STRONG PREDICTIVE VALUE OF PET BASED METABOLIC TUMOR VOLUME ON SURVIVAL
AFTER AUTOLOGOUS HCT FOR HODGKIN LYMPHOMA
V. Procházka1, R.R. Gawande2, Z. Cayci2, J.W. Froelich2, Q. Cao3,
V. Bachanova4
1Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky
University, Olomouc, Czech Republic; 2Department of Radiology, University of
Minnesota Twin Cities, MN, USA; 3CTSI Biostatistics, University of Minnesota
Twin Cities, MN, USA; 4Division of Hematology, Oncology and Transplanta-
tion, University of Minnesota Twin Cities, MN, USA
Background.High-dose chemotherapy with autologous hematopoietic
cell transplant (AHCT) is a standard treatment for relapsed/refractory
Hodgkin lymphoma patients (R/R HL); however, 40-50% fail therapy.
Metabolic FDG-PET is a powerful tool to predict treatment responses
in HL. The value of more precise quantitative measurements combining
volume with the metabolic activity in patients having residual HL
before AHCT is unknown. Aim. To determine the predictive value of
total metabolic volume (TMV) and total lesion glycolysis (TLG) in R/R
HL patients undergoing AHCT. Methods. We analyzed 96 consecutive
patients with R/R HL undergoing AHCT in 2004-2014. All had PET/CT
≤4 weeks before AHCT. Two independent radiologists assessed PET
images using semi-quantitative Deauville (D) 5-point scale and selected
all hypermetabolic sites to determine regions of interests. Analytic soft-
ware was used to calculate TMV and TLG. Results.Median age at trans-
plant was 33.1 years (range 18.0-71.3); 51% of patients were males.
Patients were limited stage (60%) or advanced, commonly with extra-
nodal (32%) and bone marrow (11%) disease. Nodular sclerosis (86%)
was most common. Most patients (69%) relapsed in <1 year or were
refractory to front-line therapy. PET negativity (neg) was achieved in
61 patients (63.5%), whereas 35 remained PETpos, with D1-2 (n=61),
D3 (n=11), D4 (n=19), and D5 (n=5). Median TMV was 8.0 cm3 (range
1.3-102.1), median TLG was 23.7 (range 4.0-813.1), and median
SUVmax was 5.2 (range 2.7-23.2). Two-year PFS in PETneg patients
(63%; 95% CI 50-74%) was significantly better than in PETpos patients
(35%; 19-51%; p=0.014). In Cox regression analysis, D4-5 was associ-
ated with a 3.7-fold increased risk of failure compared to D1-3 (HR
3.73; 95% CI 1.92-7.28; p<0.01). PETpos patients with high TMV
(>8 cm3) had significantly lower 2-year PFS than those with low TMV
(11% vs 53%; p=0.03). High TLG (>24) identified patients with poor 2-
year PFS (12% vs 57%; p=0.04). Conclusions. Patients with R/R HL and
low MTV and TLG prior to AHCT have similar outcomes to PETneg
patients. Quantitative pretransplant PET may identify subgroups of
very poor AHCT responders in whom alternative therapies should be
considered.
Support. Supported by the Fulbright commission grant.
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SEMI-QUANTITATIVE PARAMETERS TO IMPROVE THE INTERIM FDG-PET/CT POSITIVE
PREDICTIVE VALUE IN HODGKIN LYMPHOMA
A. Cuccaro1, S. Annunziata2, E. Galli1, S. Bellesi1, F. D’Alò1,
M.L. Calcagni2, A. Giordano2, V. Rufini2, S. Hohaus1
1Institute of Hematology; 2Institute of Nuclear Medicine, Catholic University of
the Sacred Heart, Rome, Italy
Interim FDG-PET/CT (iPET), according to the 5-point Deauville score
(5p-DS) is the strongest predictor for outcome in Hodgkin Lymphoma
(HL). In PET-guided treatment approaches, iPET-positive patients are
candidates for more intensive and potentially more toxic treatments.
Nevertheless, recent studies have shown that the positive predictive
value (PPV) of iPET visual analysis with 5p-DS has still some limitations
to optimally identify patients at different prognosis. Semi-quantitative
parameters could improve PPV of iPET. Aim of this retrospective study
is to compare PPV of visual and semi-quantitative analysis of iPET in
HL patients treated with ABVD. We studied 67 HL patients (median
age 39 years; 30 females, 37 males; 38 limited Stage, 29 advanced) at
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our Institution between 2007 and 2013, who were treated with ABVD.
iPET was performed after 2 cycles of ABVD. For visual analysis, the
5p-DS was used, setting different cut-points at 5p-DS>3 and 5p-DS>4
as positive. For semi-quantitative analysis, we evaluated the ratio
between lesion and liver SUVmax (rPET); the ratio between lesion and
mediastinal blood pool SUVmax (mPET); the ratio between lesion SUV-
peak and liver SUVmean (qPET). Primary endpoint was two-year pro-
gression-free survival (PFS). ROC analysis was used to determine the
best cut-point of semi-quantitative parameters to identify treatment
failures. In visual analysis, 25/67 patients had 5p-DS >3, and 5p-DS
was >4 in 14/67 patients. PFS according to 5p-DS>3 and 5p-DS>4 was
53% and 27%, respectively and their PPV was 40% and 57%, respec-
tively. The semi-quantitative parameters between residual lesion and
the different backgrounds rPET, mPET and qPET were prognostic fac-
tors in our population (p<0.01). The most accurate cut-point in predict-
ing adverse events for rPET, mPET and qPET were 1.14, 2 and 1.46,
respectively. For values higher than these cut-point, PFS were 15%,
25% and 20% and the PPV were 70%, 63% and 80%, respectively.
iPET semi-quantitative parameters appear to perform better than visual
analysis for outcome prediction in HL. In particular, ratios between
residual lesion and background SUV (liver or mediastinal blood pool)
could improve the predictive value of relapse or progression. 
P077
THE IMPORTANCE OF BONE MARROW 18F-FDG UPTAKE AND FOCAL SKELETAL LESIONS
ON SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED HODGKIN LYMPHOMA
M.A. Pedersen1, L.C. Gormsen1, P. Kamper2, A. d’Amore2, G. Enblad3,
D. Molin3, C. Wassberg4, F. d’Amore2
1Department of Nuclear Midicine & PET-centre. Aarhus University Hospital,
Denmark; 2Department of Haematology. Aarhus University Hospital, Denmark;
3Department of Immunology, Genetics and Pathology. Uppsala University
Hospital, Sweden; 4Consultant Radiologist and Nuclear Medicine. Karolinska
University Hospital, Huddinge, Stockolm, Sweden
Background. 18F-FDG-PET/CT is an established method for staging
patients with newly diagnosed Hodgkin Lymphoma (HL). It has a high
ability to detect skeletal and bone marrow involvement. It has been
discussed whether diffusely increased bone marrow uptake (BMU) of
18F-FDG indicates bone marrow involvement or not. In addition, the
importance of unifocal versus multifocal bone lesions on survival is
under debate. Thus, the aim of our study was to examine the prognostic
value of BMU and compare it with that of uni- and multifocal lesions. 
Materials and Methods. 217 patients from Aarhus and Uppsala uni-
versity hospitals (mean age 42, range 8-83) with newly diagnosed HL
were included. BMU was calculated as SUVmax in the vertebral column
(L3/L4) divided by liver SUVmax. In case of focal 18F-FDG-uptake in
bone, patients were categorized as having uni- or multifocal lesions.
For survival analysis, patients were divided into four groups: Patients
with BMU below the median and no focal lesions (lowBMU), patients
with BMU higher than the median and no focal lesions (highBMU),
patients with a single bone lesion (unifocal), and patients with multi-
focal bone lesions (multifocal). Results. Median BMU was 1.15 (range
0.52–5.56). 42/217 (19.4%) patients had either unifocal (21/217) or mul-
tifocal lesions (21/217). With a median follow-up time of 41 months,
3-year PFS was 87% (lowBMU), 88% (highBMU), 67% (unifocal), and
58% (multifocal). The presence of focal bone lesions (uni- or multifocal)
was associated with a significantly inferior PFS (log-rank p=0.00046),
but no significant difference in PFS between unifocal and multifocal
lesions was observed (log-rank p=0.35). Multivariate analysis (Cox
regression) on a subset of patients (n=183), showed that presence of
bone lesions, age, and leukocyte count were independent predictors of
PFS whereas gender, haemoglobin, albumin, and sedimentation rate
were not (Figure 1). Conclusions. Diffusely increased BMU at initial stag-
ing was not associated with a poor prognosis. The presence of focal
bone lesions was associated with significantly inferior prognosis,
regardless of whether they were uni- or multifocal, and should there-
fore be considered equally important risk factors. Whether this bone
lesion-associated clinical picture of HL also correlates to specific bio-
logical features, remains to be clarified.
Figure 1.
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INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA: CLINICAL FEATURES AND OUTCOMES
F. Gaudio1, T. Perrone1, P. Sindaco1, F.E. Laddaga1, C. Pasciolla1,
A. Franco1, A.N. Asabella2, P. Pedote3, G. Specchia1
1Hematology, University of Bari, Bari, Italy; 2Nuclear Medicine, University of
Bari, Bari, Italy; 3Radiology, University of Bari, Bari, Italy
Introduction. Hodgkin’s lymphoma (HL) is a highly curable disease
and 5-year survival is improving, being currently 86%. Cure rates of
more than 90% for early HL and more than 70% for those with
advanced HL are expected. Performing a positron emission tomography
(FDG-PET), after two cycles of therapy, has proven to be a reliable tool
in the prediction of patients’ outcomes, but not all patients with positive
interim PET have poor outcomes. Patients and Methods. In this single
center retrospective study we collected clinical data of positive interim
PET cases among all the 213 patients with a diagnosis of classic
Hodgkin lymphoma admitted to our unit from 2006 to 2015. Results. A
positive interim PET was reported in 48/213 patients (22.5%); 24 (50%)
patients were classified as having 3-4 stage disease. Median age was
29 years (14-79); 20 (42%) patients were male. The presence of B symp-
toms was described in 25 (53%) patients and 23 (47.9%) patients had
bulky disease. ESR was high in 33 (68.8%) patients; 2 (4.2%) patients
had an infiltrated bone marrow biopsy; 15 (31.3%) patients presented
with extranodal disease. After the first line therapy, 17 (35%) patients
experienced disease progression or a relapse. Progression Free Survival
at 40 months was 62.2% (Figure 1); Overall Survival was 95,7%, with
a median follow-up of 38 months. 65% of our patients with a positive
interim PET did not develop relapse/refractory disease, in contrast with
the known prognostic value. We focused on clinical features in this
population. A scleronodular histotype was present in 96% of patients,
7 (26.9%) were male. ESR was high in 20 (76.9%) patients. 24 patients
(92%) had no disease at bone marrow biopsy. 6 (23.1%) patients had
extranodal disease; 18 (69.2%) were younger than 45. Stages 3 or 4
were present in 11 (42.3%) patients, 14 (53.8%) presented with B symp-
toms, and 14 (53.8%) patients had bulky disease. We performed chi
square test to compare clinical features of positive/negative PET pop-
ulations, but none demonstrated a statistically relevant difference. Con-
clusions. Patients with interim PET positive in 65% of cases presented
a responsive disease. Further studies could identify a series of clinical
features in the interim PET positive population which may predict a
better outcome. Novel approaches aim to individualise therapeutic
choices, and to minimise toxicity while maximising response, above
all in the era of new immunological and molecular targeting agents.
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Figure 1. Progression free survival in patients with Hodgkin’s lymphoma
and Interim PET positivity.
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IS FDG-PET THE MOST SENSITIVE TOOL TO DIAGNOSE BLEOMYCIN INDUCED PNEUMONITIS
IN HODGKIN’S LYMPHOMA?
E. Öztürk, O. Falay, Y. Bölükbaşı, T. Gümü, S. Örnek, M. Özbalak,
O. Demirkol, B. Ferhanoğlu
Clinic of Hematology, Koç University Hospital Istanbul, Istanbul,Turkey; Clinic
of Nuclear Medicine, Koç University Hospital Istanbul, Istanbul,Turkey; Clinic
of Radiaton Oncology, Koç University Hospital Istanbul, Istanbul,Turkey; Clinic
of Radiology, Amerikan Hospital Istanbul, Istanbul,Turkey
Bleomycin is an antineoplastic agent which may cause fatal pul-
monary toxicities where early diagnosis of bleomycin induced pneu-
monitis (BIP) is crucial. In clinical practice, formal pulmonary function
testing with inclusion of carbon monoxide diffusion capacity, is quite
unpredictable at isolating patients at risk for major bleomycin toxicity.
In small numbered case series, FDG PET/CT scan have shown to be
helpful to reveal the inflammation secondary to the BIP, but FDG is not
known to be specific to diagnose this fatal side effect. We analyzed
FDG-PET/CT scans of 77 Hodgkin Lymphoma (HL) patients retrospec-
tively to evaluate BIP. Thirteen patients have augmented abnormal FDG
activity at their lungs after the exclusion of lymphoma involvement of
the lung or pleura, radiation pneumonitis, infection, or cardiogenic pul-
monary edema. Median age of the study population was 41 years and
the average bleomycin dose was 134 mg. The FDG activities on the
lungs were predominantly diffuse, bilateral, and mostly localized at the
lower lobes and subpleural places. Interim PET revealed BIP in 8 of
these 13 patients. Six of the 13 patients (46%) were asymptomatic dur-
ing PET imaging. One of the patients without any clinical symptoms
related to BIP continued to take bleomycin despite findings of FDG-
PET, and ultimately lost secondary to bleomycin toxicity. The rest of
the patients that bleomycin was omitted from the treatment regime
and methylprednisolone was administered as routine approach demon-
strated a favorable clinical course. Clinical and radiologic findings of
BIP have been completely resolved. This study results suggest that rou-
tine interim or end of treatment PET/CT scan could have an additional
benefit in clinic by alarming the diagnosis of asymptomatic BIP patients. 
Relapsed Hodgkin Lymphoma
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CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN
LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION
P.L. Zinzani1, A. Engert2, A. Younes3, A. Santoro4, S. Ansell5,
J. Timmerman6, G. Collins7, P. Armand8, K.J. Savage9, M. Trneny10,
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Background. Nivolumab (nivo), a fully human IgG4 immune check-
point inhibitor monoclonal antibody targeting programmed death
receptor-1 (PD-1), is approved in the USA for classical Hodgkin lym-
phoma (cHL) that has relapsed or progressed after autologous
hematopoietic stem cell transplantation (ASCT) and post-transplanta-
tion brentuximab vedotin (BV). CheckMate 205 is a multicohort inter-
national phase 2 trial (NCT02181738) of nivo that treated 243 pts with
cHL after failure of ASCT in 3 cohorts: A (BV-naïve pts), B (pts with BV
treatment after ASCT), and C (pts who received BV prior to and/or
after ASCT). With a minimum 6-mo follow-up in Cohort B, ORR per
independent radiologic review committee (IRRC) was 66% and 6-mo
PFS was 77%, with an acceptable safety profile (Younes et al. Lancet
Oncol 2016 [in press]) Here we present preliminary results of pts from
Cohort C, with a minimum follow-up of 6 mo. Aim. Assess efficacy
and safety of nivo in previously unreported Cohort C pts, including
those who received BV prior to ASCT (not tested in Cohort B).
Table 1.
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Methods. Pts in Cohort C received nivo 3 mg/kg IV q2 wk until disease
progression, unacceptable toxicity, or investigator-assessed complete
response (CR) lasting 1 yr. Pts who discontinued nivo with CR could
re-initiate nivo if they relapsed ≤2 yr from discontinuation. The primary
endpoint was ORR per IRRC using 2007 International Working Group
criteria, based on CT and PET imaging. Pts were divided into subgroups
by timing of prior BV treatment relative to ASCT. Results. 100 pts were
treated, with a median age of 32 (range 19-69), and a median of 4 (range
2–9) prior lines of therapy. ORR by IRRC after a median follow-up of
8.8 mo was 73% overall, and >69% in all BV subgroups (Table 1). 6-
mo PFS was 77% overall, and >71% in all subgroups (Table 1). Median
time to response in the entire cohort was 2.1 mo (range 0.8–6.5), and
median duration of response was 7.0 mo (95% CI 6.7, NA). 6-mo OS
was 93.9% (95% CI 86.9%, 97.2%). 68% of pts had drug-related AEs
between first dose and 30 days after last dose of nivo, most commonly
fatigue, diarrhea, and infusion reactions (11% each). 19% had G3-4
drug-related AEs. At present, no pt has discontinued study therapy due
to persistent CR lasting 1 yr. Conclusions.Nivo had clinically meaningful
antitumor activity and acceptable safety in heavily pretreated cHL pts,
regardless of the timing of prior BV relative to failure of ASCT.
Funding. BMS. Medical writing: Caudex, funded by BMS.
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PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA:
MULTICOHORT, PHASE 2 KEYNOTE-087 STUDY
C. Moskowitz,1 P.L. Zinzani,2 M.A. Fanale,3 P. Armand,4 N. Johnson,5
V. Ribrag,6 J. Radford,7 B. von Tresckow,8 A. Tomita,9 M. Shipp,4
Y. Wang,10 A.D. Ricart,10 A. Balakumaran,10 R. Chen11
1Memorial Sloan Kettering Cancer Center, New York, USA; 2Institute of
Hematology “Seràgnoli”, University of Bologna, Bologna, Italy; 3The University
of Texas MD Anderson Cancer Center, Houston, USA; 4Dana-Farber Cancer
Institute, Boston, USA; 5Jewish General Hospital, Montreal, Canada; 6Gustave
Roussy, Villejuif, France; 7Christie Hospital NHS Foundation Trust, Manchester,
UK; 8Uniklinik Koln, Cologne, Germany; 9Fujita Health University School of
Medicine, and Nagoya University, Toyoake, Japan; 10Merck & Co., Inc.,
Kenilworth, USA; 11City of Hope National Medical Center, Duarte, USA
Background. In the phase 1b KEYNOTE-013 study, PD-1 blockade
with pembrolizumab demonstrated high antitumor activity (65% ORR)
in heavily pretreated cHL patients. KEYNOTE-087 (NCT02453594) is
a phase 2 study designed to further evaluate the clinical activity of pem-
brolizumab in patients with R/R cHL. Methods. Patients were enrolled
into 3 cohorts: R/R cHL after autologous stem cell transplantation
(ASCT) and subsequent brentuximab vedotin (BV) therapy (cohort 1);
ineligible for ASCT because of chemotherapy resistance (no response
to salvage chemotherapy) and BV therapy failure (cohort 2); or R/R cHL
after ASCT, but not treated with BV after ASCT (cohort 3). Patients
received pembrolizumab 200 mg Q3W. Primary end point was ORR,
with response assessed Q12W according to Revised Response Criteria
for Malignant Lymphoma. A prespecified interim analysis, based on
investigator-assessed response, was performed after 30 patients in
cohorts 1 and 2 reached the first response assessment. Results. At the
time of data cutoff (April 8, 2016), 90 patients were enrolled (30 in each
cohort). Median (range) age was 36 (19-64) years in cohort 1, 33 (20-
71) years in cohort 2, and 30 (18-67) years in cohort 3. 42% had primary
refractory disease (no response to frontline therapy), and 57% received
>3 prior lines of therapy. By investigator review, ORR was 73% (95%
CI, 54%-88%) in cohorts 1 and 3, and 83% (95% CI, 65%-94%) in
cohort 2. Complete remission rates (residual mass permitted if PET
negative) were 27% in cohort 1 and 30% in cohorts 2 and 3. With a
median of 9 treatment cycles, the most common treatment-related AEs
(TRAEs) were pyrexia (13%), diarrhea (10%), and cough, fatigue, and
neutropenia (8% each). There were 8 grade 3-4 TRAEs occurring in 4
patients (grade 3 neutropenia, colitis, diarrhea, cytokine release syn-
drome, herpes zoster infection, increased amylase, lichenoid keratosis,
and grade 4 increased lipase). There were no treatment-related deaths.
Conclusions. Pembrolizumab showed frequent responses in heavily pre-
treated patients with cHL, and provided a high ORR (83%) in patients
who were not candidates for ASCT and failed previous BV therapy.
T024
TRANSPLANT BRaVE:COMBINING BRENTUXIMAB VEDOTIN WITH DHAP AS SALVAGE
TREATMENT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA. A PHASE 1
DOSE-ESCALATION STUDY
A. Hagenbeek1, J.M. Zijlstra2, P. Lugtenburg3, G. van Imhoff4,
M. Hutchings5, R. Liu1, M. Spiering1, H. van Tinteren6, M.J. Kersten1
1Academic Medical Center, Amsterdam, The Netherlands; 2Free University
Medical Center, Amsterdam, The Netherlands; 3Erasmus Medical Center, Rot-
terdam, The Netherlands; 4University Medical Center Groningen, Groningen,
The Netherlands; 5Rigshospitalet, Copenhagen, The Netherlands; 6Netherlands
Cancer Institute, Amsterdam, The Netherlands
Achieving a PET-negative CR with salvage chemotherapy prior to
ASCT in r/r HL is a strong predictor for longterm progression-free survival
(PFS). This phase 1 dose-escalation study explored the toxicity and fea-
sibility of adding Brentuximab Vedotin (BV) to DHAP and established
the recommended Dose Level (DL) for a phase 2 study. Final objective:
to increase the metabolic CR rate after BV-DHAP and to make more
patients eligible for auto-SCT with curative intent. BV was given at the
standard dose of 1.8 mg/kg and combined with 3 courses of DHAP q 3
weeks at 3 DL in 3 patients per DL (3+3 design), i.e. dexamethasone 40
mg iv d1-4, Cisplatin (CP) and Cytarabine at 75%=DL1; CP75% and
Cytarabine 100%=DL2 and CP 100 mg/m iv d1 and Cytarabine 2x2g/m
iv d2 (full dose DHAP)= DL3 (6 patients). Out of 12 patients (8 F, median
age 30.5 yr) 2 were primary refractory and 10 were in 1st relapse. 1st line
induction: ABVD (n=9) or BEACOPPesc (n=3). Median time between
response to 1st line treatment and the first course of BV-DHAP: 9.2 mo
(range:2-134.5). Neutropenia grade 4 more than 10 days (causing 1 week
delay of BV-DHAP): 2 out of 3 patients at DL1. Neulasta became manda-
tory after course 1 and 3, reducing the duration of neutropenia. Stem
cells were harvested after the 2nd course (median yield:5.3x10E6
CD34+/kg;range:3.0-25.9). Seven AE’s gr3-4 were observed: neutropenia
gr4 (n=2), neutropenia gr3 and trombopenia gr4 (n=1), thromboembolism
gr3 (n=1), elevated transaminases gr3 (n=1) and hypokalemia gr4 (n=1).
SAE’s occurred in 4 patients, all at DL3: CVC-related infection gr3, zoster
infection gr3, fever gr3 (n=1), elevated transaminases gr3 (n=1), reduced
kidney function gr3, pneumonitis gr3 (n=1), hypokalemia gr4, fever gr3,
acute liver failure gr4 lasting longer than 14 days (likely related to antibi-
otics), atrial fibrillation gr3 (unlikely related;n=1).These last two SAE’s
were classified as DLT’s. Sensory PNP gr1-2 was seen in 4 patients which
fully resolved in 2. 11/12 patients reached a PET- complete metabolic
remission after 3x BV-DHAP. In one PET+ PR a biopsy did not show HL.
Thus, 12/12 achieved a CR. With a median FU of 15.4 mo (range:8.4-
22.7) all patients are alive and in CR. In conclusion, BV-DHAP given at
full doses is feasible with acceptable toxicity with G-CSF support and
this dose will be used in the phase 2 part of the study. The CR rate,
although assessed in only 12 patients, is 100%.
Support. This study is supported by Takeda,USA.
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A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPILIMUMAB
AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN
LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)
C.S.M. Diefenbach1, F. Hong2, R.F. Ambinder3, J.B. Cohen4,
M.J. Robertson5, T.S. Fenske6, R. Advani7, B.S. Kahl8, S. Ansell9
1New York University Perlmutter Cancer Center, New York, USA; 2Dana Farber
Cancer Institute, Boston, MA, USA; 3Johns Hopkins University, Baltimore, MD,
USA; 4Emory University, Atlanta, GA, USA; 5Indiana University Hospital,
Indianapolis, IN, USA; 6Medical College of Wisconsin, Milwaukee, WI, USA;
7Stanford University, Stanford, CA, USA; 8Washington University, Saint Louis,
MO, USA; 9Mayo Clinic, Rochester, MN, USA
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Background. Despite advances in chemotherapy, relapsed/refractory
(R/R) Hodgkin lymphoma (HL) remains an unmet medical need. HL has
a unique biology in which a small number of malignant Hodgkin Reed-
Sternberg (HRS) cells propagate an immunosuppressive microenviron-
ment. We hypothesized that using immune checkpoint inhibitor therapy
to activate the immune microenvironment, and concurrently targeting
HRS cells with the CD30 antibody-drug conjugate brentuximab vedotin
(BV), could overcome tumor cell resistance. E4412 is a phase 1 ECOG-
ACRIN sponsored study of the combination of BV and ipilimumab (IPI)
and nivolumab (NIVO) in patients with R/R HL. Here we present the
updated safety and response data on the full cohort of patients treated
with BV+IPI. Methods. Patients were treated with BV 1.8mg/kg and IPI:
1 mg/kg or 3mg/kg, followed by an expanded cohort of BV+IPI 3mg/kg.
BV was administered every 21 days for 16 cycles; IPI every 21 daysx4
and then every 3 months for one year. Results. As of 5/26/16: 23 planned
patients have been treated; 21 patients were eligible for response assess-
ment. The median age was 32 years (range: 20-49). Patients were heavily
pretreated with a median of 4 prior therapies (1-13). Four patients had
prior treatment with BV; 10 had prior SCT. BV+IPI was well tolerated,
with no DLTs noted. The most common treatment-related adverse events
(AEs) were: rash, diarrhea, and peripheral sensory neuropathy. Grade 3
and 4 AEs included: grade 3 infusion reaction, rash, vomiting, peripheral
sensory neuropathy, and 1 grade 4 thrombocytopenia. For 21 evaluable
patients, the overall response rate (ORR) for BV+IPI was 71% with a
complete response (CR) rate of 48%. An additional 2 patients had stable
disease (SD). The median progression free survival (PFS) is 1.02 years
with a median follow-up of 0.48 years; the median overall survival (OS)
has not been reached with a median follow-up of 1.16 years (Figure 1).
Conclusions.Our data confirms the tolerability and activity of BV+IPI in a
heavily pretreated R/R HL patient population. Optimization of this com-




BENEFIT OF TANDEM STEM CELL TRANSPLANTATION FOR HIGH RISK RELAPSED/
REFRACTORY HODGKIN LYMPHOMA PATIENTS: A FRENCH PROSPECTIVE MULTICENTER
OBSERVATIONAL STUDY ON 120 PATIENTS
B. Deau1, S. Amorim2, A. Perrot3, P. Quittet4, J. Cornillon5, D. Chaoui6,
J.P. Marolleau7, L.-M. Fornecker8, M. Robin2, P. Brice2
1Hopital Cochin, Paris, France; 2Hopital Saint Louis, Paris, France; 3CHU
Nancy, Vandœuvre-lès-Nancy, France; 4CHU Montpellier, Montpellier, France;
5Institut Cancerologique de la Loire, Saint-Priest-en-Jarez, France; 6CH Argen-
teuil, Argenteuil, Francia; 7CH Amiens, Amiens, France; 8CHU Strasbourg,
Strasbourg, France
Tandem stem cell transplantation (SCT) is an option for High Risk
relapsed/refractory Hodgkin Lymphoma (HR R/R HL) patients. We con-
ducted a prospective multicenter observational study to evaluate the
feasibility of tandem SCT in the routine clinical practice. HR R/R HL
patients have primary refractory disease, or stage III/IV disease with
early (<12 months) relapse. Inclusion criteria were : HR R/R HL, age 55
or younger, eligibility for salvage chemotherapy and SCT. 18FDG PET
CT/scan (PET) performed after 2 or 3 cycles of salvage chemotherapy,
stem cell harvesting after the first cycle of salvage chemotherapy, and
investigation for HLA-matched donor were required. We included 120
HL patients over a 5 years period. Median age was 26 (14-56 y) and
57% of patients were female. 61 (51%) patients had refractory disease
and 59 (49%) had relapsing HL. 60 (50%) had a HLA-matched donor
including 27 (47%) with sibling donors. Among our patients, 39 (33%)
had chemosensitive disease as defined by PET negativity (Deauville
score 1-2-3) after 2-3 cycles of first line salvage therapy. Before trans-
plant, complete metabolic remission (CR) was achieved in 72 (60%)
patients, partial response occurred in 38 (32%) patients, and PET posi-
tivity concerned 10 (8%) patients. Overall, 50 (66%) patients received
Brentuximab Vedotin (BV) before SCT. 115 (96%) patients received
high-dose chemotherapy by BEAM followed by autologous SCT. 73
(61%) patients received a second SCT : 42 (58%) had a reduced-inten-
sity conditioning allogenic SCT and 29 (40%) had a second autologous
SCT conditioned by BAM. Reasons for not performing a second trans-
plant were: progression (n= 22), stem cell mobilization failure (n= 5),
patient decision (n=4), toxicity (n= 4) and investigator decision (n=7).
The median follow-up was 43 months (4,8-73,7). Progression-Free Sur-
vival (PFS) was 57% (95% CI 47-66%) at 2 year. Disease control before
the first SCT (CR and PR) was associated with a better 2-y-PFS of 59,3%
(95% CI : 49-68%) compared to 20% (95% CI 3,1-47,5%) for stable or
progressive disease (p=0,007). Patients who underwent two SCT had a
2-y-PFS of 69% compared to 31% for patients treated with a single
transplant (HR: 0.30; 95% CI 0.17-0.52; p<0.001). The 2-year overall
survival of our patients was 82% (95% CI: 73-88). 29 (24%) patients
died and 91 (76%) were alive. Causes of death were : GVH (n=2), LEMP
(n=1), sepsis (n=5), allo toxicity (n=2), SDRA (n=1), progression (n=7)
(missing n=11) (Figure 1).
Figure 1.
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BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN
FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
A. LaCasce1, G. Bociek2, A. Sawas3, P. Caimi4, E. Agura5, J. Matous6,
S. Ansell7, H. Crosswell8, M. Islas-Ohlmayer9, C. Behler10, E. Cheung11,
A. Forero-Torres12, J. Vose2, O.A. O’Connor3, N. Josephson13, R. Advani14
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Conventional salvage therapy for patients (pts) with relapsed/refrac-
tory (R/R) Hodgkin lymphoma (HL) is associated with variable complete
remission (CR) rates (19%-60%) and substantial toxicity. Brentuximab
vedotin (BV) and bendamustine are active as single agents in pts with
R/R HL (34% and 33% CR rates, respectively), with manageable safety
profiles. This phase 1/2 open-label study was designed to evaluate the
safety and efficacy of BV in combination with bendamustine in pts with
primary refractory disease or in first relapse (NCT01874054). Pts
received BV (1.8 mg/kg on Day 1) plus bendamustine (90 mg/m2 on
Days 1 and 2) in 3-week cycles (up to 6 cycles total). Pts could undergo
autologous stem cell transplant (ASCT) any time after Cycle 2 and could
receive BV monotherapy (up to 16 total doses) post-ASCT, or after com-
pletion of combination therapy if not proceeding to ASCT. Response
was assessed by the investigator per Cheson 2007. A total of 55 pts
(51% refractory; 49% relapsed) were enrolled. Median age was 36 years
(range 19-79), 56% were female, and median time from HL diagnosis
was 14 months (range 3-98). Pts received a median of 2 cycles (range 1-
6) of the combination and 11 cycles (range 1-14) of BV monotherapy.
Infusion-related reactions (IRRs) were reported in 58% of pts; however,
a protocol amendment requiring premedication with corticosteroids and
antihistamines during combination therapy reduced the IRR-related dis-
continuation rate from 24% (6/25 pts) to 7% (2/30 pts). Common IRR
symptoms (≥10%) were pyrexia (26%), chills (20%), dyspnea (16%),
nausea and flushing (15% each), and hypotension and pruritus (11%
each). The CR rate of the combination was 74% (39/53 pts evaluable
for response); objective response rate (CR and partial remission) was
93% (49/53 pts). Stem cell mobilization succeeded with 1st-line agents
in 39/41 pts (95%); median yield was 4.2x106 CD34+ cells/kg. Median
follow-up was 19 months (range 1-33). To date, 17 progression events
have occurred in 53 pts: 11 in 40 pts who underwent ASCT and 6 in 13
pts who did not. The estimated 24-month progression-free survival was
68% for the ASCT population (95% CI: 48%, 82%) and 61% for the
overall population (95% CI: 44%, 75%). Of 3 deaths, 2 were attributed
to HL progression and 1 to septic shock after ASCT. Overall, these data
demonstrate that the outpatient regimen of BV plus bendamustine is an
active salvage therapy for pts with HL in first relapse and can be used
prior to ASCT (Figure 1).
Figure 1.
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PET ADAPTED DOSE ESCALATION OF BRENTUXIMAB VEDOTIN AS FIRST LINE SALVAGE
THERAPY IN RELAPSE/REFRACTORY HODGKIN LYMPHOMA
R. Chen, J. Palmer, A. Herrera, B. Chen, N. Tsai, S. Armenian,
N. Kennedy, J.-L. Cai, A. Nademanee, M. Mei, L. Kwak, S. Rosen,
S. Forman
City of Hope National Medical Center, Department of Hematology and
Hematopoietic Cell Transplantation, Duarte, CA, USA
Background. Brentuximab vedotin (BV), an antibody drug conjugate,
selectively induces apoptosis of CD30+ cells. We previously conducted
a phase II trial using 1.8 mg/kg dose showing an ORR of 68% and CR
of 36% in Hodgkin Lymphoma (HL) patients as first line salvage ther-
apy. We observed that all patients who achieved CR did so after 2
cycles of therapy. However, 3 patients who achieved PR after 2 cycles
progressed after 4 cycles of BV. We hypothesize that dose escalation
from 1.8 mg/kg to 2.4 mg/kg after cycle 2 CT/PET may convert patients
in PR/SD to CR or prevent disease progression. Patients and Methods.
This is an additional feasibility cohort added to a prospective phase II
trial in patients with relapsed/refractory HL. All patients had biopsy
proven relapsed/refractory HL post induction therapy. Patients were
treated with 1.8 mg/kg of BV intravenously every 3 weeks for 2 cycles
followed by CT/PET. Patients in CR after 2 cycles received 2 additional
cycles at 1.8 mg/kg. Patients in PR/SD after 2 cycles received dose esca-
lation of 2.4 mg/kg of BV for 2 cycles. The primary endpoint was the
CR rate according to Revised Cheson Criteria. Secondary endpoints
were toxicities assessment according to NCI CTCAE v 4.0. Results. 20
patients were accrued and evaluable for response. See Table for baseline
characteristics. The ORR with 1.8 mg/kg dose at cycle 2 was 85%, CR
was 55%, PR was 30%, SD was 10%, and PD was 5%. 8/20 patients
were in PR/SD after cycle 2 and received 2.4 mg/kgx2 doses. 1/6
patients in PR converted to CR and the rest stayed in PR. 2/2 patients
in SD stayed in SD. At the end of study, ORR was 85%, CR was 60%,
and PD was 5%. Treatment was well tolerated at both the 1.8 mg/kg
and 2.4 mg/kg cohort. There were no significant differences in toxicities
between the two cohorts and there were also no grade 4/5 toxicities.
The only grade 3 possibly-related toxicity was maculopapular rash that
occurred in 2 patients (at 1.8 mg/kg). In the 2.4 mg/kg cohort, grade 2
possibly-related toxicities >20% included fatigue (n=3), back pain (n=2),
pruritis (n=2), and rash (n=2). There were no transfusions required and
no neutropenic fevers. Conclusions. Dose escalation from 1.8 mg/kg to
2.4 mg/kg was able to convert 1/8 (12.5%) patients into CR. No patients
developed progressive disease while receiving 2.4 mg/kg. The dosage
of 2.4 mg/kg was well tolerated. Dose escalation of BV based on PET
2 is feasible and merits further investigation.
Table 1.
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VERY LATE RELAPSE >5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN LYMPHOMA:
AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP HD7-HD12 TRIALS
P.J. Bröckelmann, H. Görgen, C. Kohnhorst, M. Fuchs, P. Borchmann,
A. Engert
Department I of Internal Medicine and German Hodgkin Study Group
(GHSG), University Hospital of Cologne, Germany
Background. Patients free of HL >5 years after first diagnosis are usu-
ally considered cured. Nevertheless, VLR occur and biology, clinical
characteristics, therapeutic approaches and prognosis are currently
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poorly understood. Methods. Cumulative incidence of VLR was retro-
spectively estimated in 5149 patients of the GHSG HD7-HD12 trials,
who were observed and relapse-free for >5 years; risk factors were ana-
lyzed using Gray’s test and Cox regression. Standardized incidence ratio
(SIR) was estimated using age- and sex-specific reference values for the
German population. Overall and progression-free survival were esti-
mated according to Kaplan-Meier from first diagnosis (OS/PFS) and date
of relapse (OSr/PFSr), Hazard Ratios (HR) were obtained from Cox
regressions adjusted for relevant risk factors such as age, sex and initial
stage. Relapse localizations and therapies, OSr and PFSr were compared
with a group of 487 patients having earlier relapse. Patient characteris-
tics were analyzed descriptively. Results. With a median observation
time of 10.3 years, a total of 169 relapses >5 years were observed.
Cumulative incidences at 10, 15 and 20 years were 2.8%, 5.1% and
8.6%, respectively, with an SIR of 97.1 (95% CI: 83.0-112.9). VLR were
more frequently observed in patients with early-stage favorable than
early-stage unfavorable or advanced-stage disease at first diagnosis (15-
year cumulative incidence 8.0%, 4.4%, 4.2%, respectively, p<0.001).
Male patients and those with nodular-lymphocyte predominant sub-
type were also found at increased risk for VLR. VLR occurred more fre-
quently outside initially involved areas and radiation fields than earlier
relapse. OS was significantly worse compared to non-relapse survivors
(10-year OS: 95.9% vs 88.5%, HR: 2.4, 95% CI: 1.7-3.4, p<0.001). For
earlier relapse, we observed inferior 5-year PFSr and OSr compared to
VLR (55.7% vs 64.3% HR: 1.6, 95% CI: 1.1-2.4, p=0.03; 63.0% vs
76.3%, HR: 2.1, 95% CI: 1.3-3.4, p<0.01, respectively). Summary.
Besides therapy-associated side effects, survivors after initially success-
ful HL-therapy are at a 100-fold increased risk of re-occurrence of dis-
ease compared to German reference values. After modern risk-adapted
treatment strategies especially in early-stage favorable HL, thorough
regular follow-up is hence needed for timely detection. Prognosis of
VLR seems favorable when compared to early relapses. 
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AN INTERNATIONAL MULTICENTER PHASE I/II STUDY OF BRENTUXIMAB VEDOTIN AND
BENDAMUSTINE IN PATIENTS WITH HEAVILY TREATED RELAPSED OR REFRACTORY
HODGKIN LYMPHOMA AND ANAPLASTIC LARGE T-CELL LYMPHOMA DEMONSTRATES
MARKED DURABLE RESPONSES 
O.A. O’Connor1, A. Sawas1, J.M. Connors2, I. Turenne1, C. Rojas1,
R. Lichtenstein1, C. Deng1, J.E. Amengual1, D. Villa2, M. Crump3,
J. Kuruvilla3
1Center for Lymphoid Malignancies, Columbia University Medical Center, New
York, NY, USA; 2BC Cancer Agency, BC Cancer Research Centre Vancouver,
BC, Canada; 3Division of Medical Oncology and Hematology, Princess
Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Patients with HL or ALCL who relapsed post or are ineligible for
autologous stem cell transplant (ASCT) are incurable with standard
therapies. The anti-CD30 ADC BV is approved for such patients. B is
also active and tolerable HL. This phase I/II study evaluated the safety
and efficacy of brentuximab vedotin with bendamustine for patients
with R/R HL or ALCL. (ClinicalTrials.gov #NCT01657331). Methods.
Patients received IV BV on Day 1 with B on Days 1 and 2 of a 3-week
cycle for up to 6 cycles. In the Phase 1 portion 4 dose levels were eval-
uated: (1) Bv=1.2mg/kg; B=70mg/m2; (2) Bv=1.2mg/kg; B=80mg/m2; (3)
Bv=1.8mg/kg; B=80mg/m2; and (4) Bv=1.8mg/kg; B=90. Accrual fol-
lowed a classic Fibonacci dose escalation, with 3 patients being treated
at each dose level. Dose Limiting Toxicity (DLT) led to expansion of
the dose cohort. The recommended phase II dose was Bv 1.8 mg/kg on
Day 1 and B 90 mg/m2 on Days 1 and 2. Response was assessed by the
investigator per Cheson 2007 after cycles 2 and 6. Enrollment is nearly
complete (n=3 remaining) . In addition, plasma and serum biomarkers
are being prospectively collected for correlation with toxicity and
response. Results. Sixty-one patients (66% male) with a median age of
36 years (range, 18-70) were enrolled. Fifty-nine patients had HL and 2
ALCL; the median number of prior systemic therapies was 5 (range 1-
16); with 36 patients having had prior ASCT and 25 patients receiving
prior radiation therapy. The predominant all grade toxicity observed
with the combination was nausea (62%, grade 1-2). The observed grade
3-4 toxicities in the phase I were: neutropenia (19%), thrombocytopenia
(19%), anemia (15%) and rash (11%). The observed phase II grade 3-4
toxicities include neutropenia (8%). No DLT was observed at dose level
4 (Bv 1.8 mg/m2 and B 90 mg/m2). The maximum tolerated dose (MTD)
was not reached. A decision was made not to explore further doses
that exceeded the standard single agent doses of both drugs. Patient’s
received a median of 6 cycles (range, 1-6). To date, 52/59 patients are
evaluable for response. The overall response rate is 73%, with 10
patients (19%) attaining a complete response (CR). Nine patients had
stable disease. Among the 11 patients who received prior Bv, 6 respond-
ed (55%) (CR= 2, PR=4, SD=3, PD=2), and of the 4 patients who had
prior B, 2 responded (50%) (PR=2, SD=1, PD=1). Two patients had
received both Bv and B as single agents prior to initiation of study; one
patient achieved a PR and the other experienced PD. The ALCL patient
achieved a PR. Conclusions. In this heavily treated population of HL and
ALCL, the combination of brentuximab vedotin 1.8 mg/kg on Day 1
with bendamustine 90 mg/m2 on Days 1 and 2 of 3-week cycles repre-
sents a very effective and tolerable outpatient regimen. The regimen
has an ORR of 73% with responses ≥50% in patients who had received
either agent separately supporting the potential clinical synergy of the
combination. 
P086
POST TRANSPLANT OUTCOMES IN A MULTICENTER PHASE II STUDY OF BRENTUXIMAB
VEDOTIN AS FIRST LINE SALVAGE THERAPY IN RELAPSED OR REFRACTORY HODGKIN
LYMPHOMA PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
A. Herrera1, J. Palmer2, P. Martin3, S. Armenian4, N.-C. Tsai2, M. Mott1,
F. Sahebi1, J.-L. Cai1, T. Siddiqi1, L. Popplewell1, A. Nademanee1,
S. Rosen1, L. Kwak1, S. Forman1, R. Chen1
1City of Hope National Medical Center, Department of Hematology and
Hematopoietic Cell Transplantation, Duarte, CA, USA; 2City of Hope National
Medical Center, Department of Information Sciences, Division of Biostatistics,
Duarte, CA, USA; 3Weill Cornell Medical College, Department of Hematol-
ogy/Oncology, New York, USA; 4City of Hope National Medical Center,
Department of Population Sciences, Duarte, CA, USA
Background. Standard of care treatment for patients with relapsed or
refractory (rel/ref) Hodgkin lymphoma (HL) is salvage chemotherapy
followed by autologous stem cell transplantation (ASCT) in chemosen-
sitive patients. Brentuximab vedotin (BV) is an antibody drug conjugate
that selectively induces apoptosis of CD30+ HL cells. Here we present
updated post-ASCT follow-up in a previously reported multicenter
phase II trial evaluating BV as first line salvage therapy prior to ASCT.
Patients and Methods.We conducted a prospective, multicenter (City of
Hope, Cornell) phase II trial of BV as first line salvage therapy prior to
ASCT in patients with rel/ref HL after induction therapy. Patients
received 1.8 mg/kg of BV intravenously every 3 weeks for 4 cycles. This
analysis is limited to patients who underwent ASCT. Endpoints include
toxicities, stem cell collection, engraftment, and 2-yr post-ASCT pro-
gression-free and overall survival (PFS, OS). Results. 37 patients were
accrued and 36 were evaluable. The overall best response (CR+PR) rate
to BV was 69% with 36% CR. 32 (89%) patients proceeded to ASCT.
All 13 CR patients proceeded to ASCT without additional chemother-
apy. 3/12 PR patients proceeded directly to ASCT, while 9 received
additional chemotherapy. All patients with SD/PD received additional
chemotherapy except for 1 patient who received XRT. 23 patients were
in CR, 8 were in PR, and 1 patient had SD at ASCT. All patients were
primed with cyclophosphamide/G-CSF and 9 patients received plerix-
afor per institutional guidelines. The median stem cell collection days
was 2 and median CD34 cells collected was 5.97x106. 19 patients
received BEAM conditioning, 11 received CBV, and 2 received BEAM
plus yttrium-90 labeled anti-CD25. The median time to neutrophil and
platelet engraftment was 11 and 20 days, respectively. There were no
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Gr 3 or 4 post-ASCT toxicities through d+30. With a median follow up
of 25.7 months, the 2-yr PFS was 72%, OS was 94%, and NRM was
3%. Patients who received only BV had 2-yr PFS of 80% vs 69% in
patients who received BV followed by chemotherapy. Patients in CR
at ASCT, had 2-yr PFS of 78% vs 56% for non-CR patients (Table 1).
Conclusions. 89% of patients who received BV as first-line salvage ther-
apy successfully underwent ASCT. Outcomes compare favorably with
historical data, including patients who received BV salvage alone with-
out chemotherapy. BV is a promising first-line salvage therapy for rel/ref
HL patients undergoing ASCT.
Table 1. Patient characteristics.
P087
T CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-INFUSION
CYCLOPHOSPHAMIDE IN POOR PROGNOSIS HODGKIN LYMPHOMA
L. Castagna1, S. Bramanti1, R. Devillier2, R. Crocchiolo1, S. Furst2,
J. El Cheikh2, B. Sarina1, A. Granata2, C. Faucher2, S. Harbi2, L. Morabito1,
P.J. Weiller2, C. Chabannon3,4,5, J. Mokart6, C. Carlo-Stella1, A. Santoro1,
D. Blaise2,4,5
1Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano (MI), Italy;
2Department of Hematology, Transplantation Program; 3Cell Therapy Unit,
Institut Paoli Calmettes, Marseille, France; 4Aix-Marseille Université, Marseille,
France; 5Centre de Recherche en Cancérologie de Marseille, Institut Paoli-
Calmettes, Aix-Marseille Université, CNRS UMR, Marseille, France; 6Intensive
Care Unit, Institut Paoli Calmettes, Marseille, France 
In advanced Hodgkin lymphoma, allogeneic hematopoietic stem
cell transplantation can represents a potential curative option. In this
study, we analyzed the outcome of advanced HL patients who
received haplo-HSCT using the unmanipulated stem cell and PT-Cy.
62 consecutive HL patients undergoing T-cell replete haploidentical
transplantation with PT-Cy. ANC and platelets engraftment was
observed in 94% and 82% of patients. The 100-day cumulative inci-
dence (CI) of grade 2-4 and 3-4 aGVHD was 23% and 4%, respectively
and the CI of cGVHD (overall) was 16. The median follow-up was 32
months. The 3-year OS, PFS, relapse rate was 63%, 59%, and 21%,
respectively. The 1-year NRM was 20%. In multivariate analysis, fac-
tors negatively associated with OS were uncontrolled disease status
and higher than 2 HCT-CI. PBSC was an independent protective factor.
The same factors were predictive for PFS, except for HCT-CI 1. Disease
status other than CR was predictive of relapse. Haplo-HSCT with PT-
Cy looks particularly effective against HL cells, and it seem to work
better than other donors. However, prospective studies are needed to
confirm the these results.
P088
PET-ADAPTED THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE FOR
RELAPSED/REFRACTORY HODGKIN LYMPHOMA – LACK OF IMPROVEMENT WITH 3
VERSUS 2 CYCLES OF WEEKLY BRENTUXIMAB VEDOTIN
A.J. Moskowitz, H. Schöder, J. Yahlom, S.J. McCall, S.Y. Fox,
J. Gerecitano, R. Grewal, P.A. Hamlin, S. Horwitz, R. Kobos,
A. Kumar, M. Matasar, A. Noy, M.L. Palomba, M.-A. Perales,
C.S. Portlock, C. Sauter, N. Shukla, P. Steinherz, D. Straus, T. Trippett,
A. Younes, A. Zelenetz, C. Moskowitz
Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer
Center, New York, USA
Introduction. PET-adapted salvage therapy with brentuximab vedotin
(BV) and augmented ICE (augICE) produced a PET-negative (neg) rate of
76% (Moskowitz, AJ. Lancet Oncology 2015). In this study, 45 patients
(pts) received 2 cycles of BV (1.2mg/Kg weekly, 6 doses over 8 weeks)
and those with residual PET-avidity received 2 cycles of augICE (ifos-
famide 5000mg/m2 x2 doses, carboplatin AUC 5, etoposide 200mg/m2
x3 doses) prior to ASCT. With a median follow-up of 40 months, 44 of 45
patients proceeded to ASCT and 3-year event free survival (EFS) and over-
all survival (OS) were 80% and 93%, respectively. 27% achieved PET-
neg status following BV and received no additional chemotherapy before
ASCT. We enrolled a second cohort aimed at improving the PET-neg rate
to BV by administering 3 rather than 2 cycles. Methods.On cohort 2, pts
received 3 cycles of weekly BV (1.2mg/Kg weekly, 9 doses over 12 weeks).
PET-neg pts (by Deauville 1-2) proceeded to ASCT while those with resid-
ual PET-avidity received augICE for 2 cycles before ASCT. Transplant
conditioning included involved field radiation for eligible patients. Results.
20 pts enrolled onto cohort 2. Characteristics appear in the Table 1.
Table 1. Summary of patient characteristics and outcomes according to
treatment cohort.
After BV, 6 (30%) pts were PET-neg (by Deauville 1-2) and 7 (6 Deauville
2, 1 Deauville 3) proceeded directly to ASCT. 13 pts received additional
treatment before ASCT; 10 received augICEx2, 2 received ICEx2, and 1
received ICEx1 and augICEx1. All patients proceeded to ASCT and pre-
transplant PET was negative by Deauville 1-2 for 16 (80%) pts. The medi-
an follow-up for cohort 2 was 24 months and 2-year EFS and OS were
85% and 100%, respectively. For cohorts 1 plus 2, the PET-neg rate fol-
lowing BV and before transplant were 28% and 78%, respectively. The
2 year EFS was 82%. By multivariate analysis, factors predictive of EFS
included age>40 (p<0.001), advanced stage (p=0.001), refractory disease
(p=0.001), and pre-transplant PET (0.003). Conclusions. PET-adapted sal-
vage therapy with BV followed by augICE produces a PET-neg rate of
78%. With this treatment program, 28% patients achieved PET-neg sta-
tus and proceeded to ASCT following BV alone. Increasing the number
of weekly BV cycles from 2 to 3 did not improve the PET-neg rate
achieved with single-agent BV. Pre-transplant PET remains an important
prognostic factor for relapsed/refractory HL and achievement of PET-
negative status should continue to be the primary objective of studies
evaluating novel salvage regimens.
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BRENTUXIMAB VEDOTIN AFTER AUTOLOGOUS STEM CELL TRANSPLANT YIELDS THE
STRONGEST BENEFIT IN HODGKIN LYMPHOMA PATIENTS WITH ≥2 RISK FACTORS:
RESULTS OF A MULTIVARIATE ANALYSIS
C. Moskowitz1, J. Sweetenham2, A. Chen3, E. Ayala4, T. Masszi5,
J. Holowiecki6, P. Stiff7, A. Carella8, S. Viviani9, V. Bachanova10,
A. Sureda11, D. Huebner12, S.-Y. Lee12, N. Hunder13, L. Thomas13,
M. Uttarwar13, J. Walewski14
1Memorial Sloan-Kettering Cancer Center, New York, New York, USA;
2Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA;
3Oregon Health and Science University, Portland, Oregon, USA; 4H. Lee Moffitt
Cancer Center & Research Institute, Tampa, Florida, USA; 5Szent Istvan &
Szent Laszlo Corporate Hospital Hematology & Stem Cell Dept., Budapest,
Hungary; 6Department of Bone Marrow Transplantation & Oncohematology,
Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland; 7Loyola
University Medical Center, Maywood, Illinois, USA; 8IRCCS Azienda
Ospedaliera Universitaria San Martino-IST, Genoa, Italy; 9Istituto Nazionale
dei Tumori, Milano, Italy; 10University of Minnesota Medical Center,
Minneapolis, MN, USA; 11Institut Català d’Oncologia, Hospital Duran i
Reynals, Barcelona, Spain; 12Millennium Pharmaceuticals, Inc., Cambridge,
MA, a wholly owned subsidiary of Takeda Pharmaceuticals Limited; 13Seattle
Genetics, Inc., Bothell, WA, USA; 14Maria Sklodowska-Curie Institute and
Oncology Center, Warszawa, Poland
Background. In the phase 3 AETHERA trial, PFS was significantly
improved with brentuximab vedotin (BV) versus placebo (PB) (HR=0.57,
P=0.001) in HL patients at high risk of progression post-ASCT1. In a
previous MVA of the study population, consolidation treatment with
BV was significantly associated with improved PFS compared with
placebo after adjustment for clinical factors2. Here we present an MVA
assessing interactions between established risk factors and treatment
(BV versus PB) to identify patients who may benefit most from consol-
idation therapy. As eligibility was limited to high-risk patients, identi-
fication of risk factors for a general population was not explored. Meth-
ods. To identify qualitative treatment-subgroup interactions, Martingale
residuals from a null Cox proportional hazard (CPH) model were used
as a continuous outcome variable for a qualitative interaction tree
(QUINT3); 18 covariates were used to define potential subgroups. Some
subgroups were based on number of established risk factors present in
a patient, including relapse <12 months or refractory to frontline ther-
apy, best response of partial remission or stable disease to salvage ther-
apy, extranodal disease at pre-ASCT relapse, B symptoms at pre-ASCT
relapse, and ≥2 prior salvage therapies. As a sensitivity analysis, a mul-
tivariate CPH model with treatment-covariate interactions was devel-
oped to identify the most significant interaction (smallest p-value
<0.05). This interaction was retained in the model, and a second-round
analysis was performed to identify the next most significant interaction
among the remaining covariates. Results.The most significant qualitative
treatment-subgroup interaction identified in the QUINT model was in
the subgroup of patients with 1 versus ≥2 risk factors, with greater treat-
ment benefit for patients with ≥2 risk factors. The sensitivity analysis
confirmed this outcome (P=0.0006) and, after adjusting for this interac-
tion, found no other interaction among the covariates tested to be sig-
nificant. Analysis details will be presented with updated PFS and safety
data after ~4 years since last patient enrolled. Conclusions. Treatment
with BV appears to have the strongest impact for patients with ≥2 risk
factors. 
REFERENCES
1   Moskowitz CH et al. Lancet 2015. 385:1853.
2   Walewski J et al. J Clin Oncol 2015. 33(suppl; abstr 8519)
3   Dusseldorp E, Van Mechelen I. Stat Med 2014. 33:219.
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NIVOLUMAB RE-TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN
LYMPHOMA: SAFETY AND EFFICACY OUTCOMES FROM A PHASE 1 CLINICAL TRIAL
S. Ansell1, P. Armand2, J. Timmerman3, M. Shipp2,
M. Popa Mckiver4, L. Zhu4, A.M. Lesokhin5
1Mayo Clinic, Rochester, MN, USA; 2Dana-Faber Cancer Institute, Harvard
Medical School, Boston, MA, USA; 3Jonsson Comprehensive Cancer Centre,
UCLA, Los Angeles, LA, USA; 4Bristol-Myers Squibb, Princeton, NJ, USA;
5Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College,
New York, NY, USA 
Background. In classical Hodgkin lymphoma (cHL), malignant Reed–
Sternberg cells almost uniformly overexpress the programmed death
receptor-1 (PD-1) ligands, PD-L1 and PD-L2, through genetic amplifi-
cation at 9p24.11; therefore, cHL may be particularly sensitive to PD-1
blockade. Nivolumab (nivo), a fully human anti–PD-1 IgG4 monoclonal
antibody checkpoint inhibitor, showed acceptable safety and high effi-
cacy in a phase 1 trial (NCT01592370) of patients (pts) with
relapsed/refractory cHL-a group with limited treatment options. Among
23 pts treated with nivo, investigator-assessed ORR was 87% and PFS
at 24 weeks was 86%2. Median duration of response was not reached
after 101 weeks3. Pts who progressed after stopping nivo were eligible
for re-treatment. Aim.Assess the safety and efficacy of nivo re-treatment
in pts with progression after initial response. Methods. In this phase 1
trial, adults with relapsed/refractory cHL were treated with nivo until
progression, CR, or for a maximum of 2 years3. Pts with ongoing disease
control (CR, PR, or stable disease) after discontinuation entered a pro-
tocol-specified follow-up period. Pts with PD <1 year after discontinu-
ing nivo were eligible for re-treatment for ≤1 year. Toxicity, treatment
response, and duration of response were assessed during re-treatment.
Results. In total, 3 pts (age 26, 35, and 43 at baseline; 2 female) were re-
treated with nivo. All had prior systemic treatment (4, 3, and 15, ther-
apies, respectively) and had undergone autologous stem cell transplan-
tation; 2 had prior treatment with brentuximab vedotin. ECOG per-
formance status was 0 or 1. Nivo treatment course and outcomes are
summarized in the Table 1. All 3 pts achieved a response with re-treat-
ment. All experienced treatment-related AEs during the initial treatment
period (1 grade 3 lymphopenia; all others grade 1–2). During re-treat-
ment, 1 pt experienced treatment-related grade 2 neutropenia after 18
re-treatment cycles. Conclusions.All 3 pts re-treated with nivo responded
to treatment, with 2 achieving PR and 1 discontinuing due to CR. These
data provide preliminary evidence that re-treatment with nivo after
progression may be an option for further treatment response. 
Funding. Bristol-Myers Squibb.
Previous presentation. Preliminary data on 1 patient presented at ASH 2015.
Table 1.
REFERENCES
1 Roemer MG et al. J Clin Oncol 2016 [Epub ahead of print].
2 Ansell SM et al. N Engl J Med 2015;372:311.9.
3 Ansell SM et al. ASH 2015 [oral 583].
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STEM CELL COLLECTION AFTER FAILURE OF UPFRONT ABVD OR BEACOPP IN PATIENTS
WITH HIGH RISK ADVANCED STAGE III-IV HODGKIN’S LYMPHOMA
D. Ghez1, C. Fortpied2, N. Mounier3, P. Carde1, A. Perrot4, H. Khaled5,
S. Amorim6, S. Ramadan2, F. Le Bras7, M. Erlanson8, C. Herbaux9,
J.P. Marolleau10, E. Nicolas-Virelizier11, O. Casasnovas12,
A. Stamatoullas-Bastard13, C. Fermé1 on behalf of EORTC, LYSA,
LYMG and NLG cooperating groups
1Department of Hematology, Gustave Roussy, Villejuif, France; 2EORTC
Headquarters, Brussels, Belgium; 3Onco-Hematology Department, CHU
l’Archet, Nice, France; 4Department of Hematology CHU Nancy-Brabois,
Vandoeuvre Les Nancy, France; 5Department of Medical Oncology, National
Cancer Institute, Cairo, Egypt; 6Hopital Saint-Louis APHP, Université Paris
Diderot, Paris, France; 7Unité Hémopathies Lymphoïdes, AP-HP CHU Mondor,
Creteil, France; 8Department of Oncology, Umea Universitet, Sweden; 9Clinical
Hematology, Hôpital Claude Huriez, Université de Lille 2, Lille, France;
10Department of Hematology CHU Amiens, Université Picardie Jules Verne,
Amiens, France; 11Department of Hematology, Leon Bérard Cancer Center, Lyon,
France; 12Department of Hematology, CHU Dijon, Dijon, France; 13Department
of Hematology, Centre Henri Becquerel, Rouen, France
Treatment of relapsed/refractory (R/R) Hodgkin’s lymphoma (HL)
usually relies on high dose chemotherapy (HDT) followed by autolo-
gous stem cell transplantation (ASCT). Whether the myelotoxicity of
BEACOPP may have consequences on stem cell harvest in patients with
R/R HL has not been evaluated. Methods. Among 549 patients enrolled
in the 20012 Intergroup randomized phase III trial, which compared a4
cycles of escalated BEACOPP followed by 4 cycles of BEACOPP with 8
cycles of ABVD in high risk stage III-IV HL., we identified, 91 patients
(67 ABVD and 24 BEACOPP arm) with R/R HL. Additional data on stem
cell collection, transplantation and engraftment outcome was obtained
in 64/91 patients, 46 in the ABVD and 18 in the BEACOPP arm.
Figure 1.
Results. Mobilization was carried out in 48 patients (35 ABVD and 13
BEACOPP arm). 14 patients had no mobilization (death, refractory dis-
ease, ineligibility for HDT). Data were incomplete in 2 patients who
were excluded from analysis. One mobilization was sufficient in 91%
of ABVD and 69% of BEACOPP patients. 3 (9%) ABVD patients
required 2 mobilizations, and 31% of BEACOPP patients had ≥2 mobi-
lizations (2-5). Stem cell collection required one, two or >2 cytaphereses
(3-5) in 52%, 32% and 16% of cases In the ABVD arm and 31%, 23%
and 46% In the BEACOPP arm. A graft >3.10e6 CD34+ cell/kg was
obtained in 33 (94%) patients in the ABVD and 8 (61%) in the BEACOPP
arm. In this group, ASCT was not performed in 5 (12%) because of
refractory disease or death. In the 36 patients (88%), it proceeded as ini-
tially planned. Eight (24%) patients in the ABVD arm and 5 (63%) in
the BEACOPP arm had a double ACST. One patient was considered
unfit for a second transplant (ABVD arm). Two patients (6%) in the
ABVD arm and 5 (39%) in the BEACOPP arm had a graft <3.10e6
CD34+ cell/kg. In this group 5 patients proceeded to single ASCT and
2 did not because of death (BEACOPP arm) or insufficient graft (ABVD
arm). Two patients had engraftment failures (ABVD arm). At the time
of analysis, median overall survival from the date of randomization was
5.8 years in the ABVD and 4.3 years in the BEACOPP arm (Figure 1).
Conclusions. Stem cells harvest is more difficult after first line BEACOPP,
requiring more mobilizations and more cytaphereses. This is consistent
with the greater bone marrow toxicity of BEACOPP. Remarkably, this
had very limited impact on the strategy salvage treatment strategy as
nearly all patients could proceed to transplantation as initially planned.
P092
COMPLETE RESPONSES TO IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH
RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PREVIOUSLY TREATED WITH
5-AZACITIDINE: A POSSIBLE ROLE FOR EPIGENETIC PRIMING?
L. Falchi1, A. Sawas1, C. Deng1, J.E. Amengual1, D.S. Colbourn1,
E.A. Lichtenstein1, H.J. Dials1, K.A. Khan1, L.H. Schwartz2,
O.A. O’Connor1
1Center for Lymphoid Malignancies, Department of Medicine, Division of Hema-
tology/Oncology, Columbia University Medical Center, New York, NY, USA;
2Department of Radiology, Columbia University Medical Center, New York,
NY, USA
Background. Patients with relapsed/refractory (R/R) classical Hodgkin
lymphoma (cHL) after brentuximab vedotin (Bv) and autologous stem
cell transplantation (ASCT) have limited treatment options. Immune
checkpoint inhibitors (ICI) are active in this population, but rarely induce
complete response (CR). Evidence suggests that exposure of tumor cells
to 5-azacitidine may activate a T-cell-mediated immune responses, thus
enhancing the efficacy of ICI. We reviewed our experience with ICI in
patients with R/R cHL, and compared responses between those who
had been exposed to 5-azacitidine to those not previously esposed to a
hypomethylating agent. Methods. Eleven patients with R/R cHL received
pembrolizumab at the dose of 2 mg/kg every 3 weeks (N=9), or
nivolumab at the dose of 3 mg/kg every 2 weeks (N=2). Response was
assessed by positron emission tomography/computerized tomography
(PET/CT). Results.The patient population was very heavily treated, with
a median of 12 [3-16] prior treatments. All had received ASCT and Bv.
Six had been exposed to 5-azacitidine on a Phase 1 study. Four of them
had received it immediately prior to ICI, all of them within 14 months.
Grade ≥3 adverse events (AE) included: infusion reaction (N=1) throm-
bocytopenia (N=1), grade-5 respiratory failure (N=1), myelodysplastic
syndrome (N=2, one pre-existent), and acute kidney injury (N=1, pre-
existent). Nine patients were evaluable for response: 7 (78%) achieved
CR, one PR, and one a reduction of tumor burden. All five evaluable
patients who received 5-azacitidine prior to ICI achieved CR (one is
pending evaluation and will be reported), while only 2 of 4 who did not
receive prior 5-azacytidine achieved CR. At a median follow-up of 9.0
months [0.5-14.3], 9 patients are alive and 6 are still receiving treatment.
Conclusions. We documented an unprecedented rate of CR to ICI in
patients with heavily pre-treated R/R cHL. The most serious AE’s were
unrelated to ICI therapy. We believe this experience supports the notion
of epigenetic priming, as shown in lung cancer studies, and is now being
studied in the context of a clinical trial.
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BRENTUXIMAB VEDOTIN IN PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM
CELL TRANSPLANT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA:
A UNITED KINGDOM AND GERMANY RETROSPECTIVE STUDY
P.J. Bröckelmann1, E.A. Zagadailov2, S. Corman3, M. Hagan4,
V. Chirikov3, C. Johnson3, C. Macahilig4, B. Seal2, M.R. Dalal2, T. Illidge5
1Department I of Internal Medicine and German Hodgkin Study Group
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Background. Brentuximab Vedotin (BV) is an anti-CD30 antibody-
drug conjugate indicated for the treatment of CD30+ rrHL following
Autologous Stem-Cell Transplantation (ASCT) or following at least two
prior therapies in patients who are ASCT-ineligible. Clinical outcomes
in the ASCT-ineligible population have not yet been evaluated in a real-
world study. We aimed to describe outcomes in real-world ASCT-inel-
igible patients with relapsed/refractory Hodgkin Lymphoma (rrHL) in
two countries known to have different practice patterns in rrHL. Meth-
ods. This was a retrospective medical chart review study that enrolled
patients at 45 clinical sites representative of routine practice in Germany
and the UK. The study included patients ≥18 years old at the time of
HL diagnosis, who progressed after multi-drug chemotherapy regimens
between 1 January 2008 and 30 June 2014 and were not ASCT candi-
dates as identified by their clinicians, were subsequently treated with
BV, and were not enrolled in an HL-related clinical trial. Patient demo-
graphics, clinical characteristics, and treatment characteristics were
described. Clinical outcomes included best response to treatment, pro-
gression-free survival (PFS), overall survival (OS), and adverse events
(AEs). All outcomes were descriptive, and reported in the full study
population and by country. Results.A total of 136 patients were included
in this analysis (78 in Germany and 58 in the UK). The median age of
study patients at HL diagnosis was 70 years, and 58% were male. Near-
ly all patients had classical HL (96%), and over half had non-bulky (<5
cm) disease (55%). The most common reasons for ASCT ineligibility
were comorbidities (74%), age (57%), and disease progression (12%).
Coronary artery disease (39%), diabetes (38%), and chronic pulmonary
disease (24%) were the most common comorbidities among study
patients. Eighty-five percent of patients received at least 2 lines of treat-
ment prior to initiating BV. At the time of BV initiation, 24% of patients
had stage IV disease and 21% had extranodal involvement. The median
duration of follow-up was 3.2 years from the time of HL diagnosis.
Three fourths of patients had a partial or complete response (Table 1).
Other events of interest included leukopenia (13%; of which 53% were
serious), neuropathy (10%; 8% serious), and anemia (9%; 42% serious).
Conclusions. Progression-free and overall survival in ASCT-ineligible
patients receiving BV were 15.1 and 17.8 months, respectively, after
initiation of therapy.
Table 1. Treatment, response, and survival in ASCT-Ineligible patients
receiving Brentuximab Vedotin.
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REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN VS OTHER TREATMENTS IN
PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA POST AUTOLOGOUS
STEM-CELL TRANSPLANTATION
E.A. Zagadailov1, S. Corman2, M. Hagan3, V. Chirikov2, C. Johnson2, C.
Macahilig3, B. Sea1, M.R. Dalal1, P.J. Bröckelmann4, T. Illidge5
1Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned
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4Department I of Internal Medicine and German Hodgkin Study Group
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Background. Brentuximab Vedotin (BV) is an anti-CD30 antibody-drug
conjugate indicated for the treatment of CD30+ rrHL following Autol-
ogous Stem-Cell Transplantation (ASCT) or after ≥2 prior therapies in
patients who are ASCT-ineligible. We aimed to compare effectiveness
in post-ASCT patients with relapsed/refractory Hodgkin Lymphoma
(rrHL) receiving BV to those receiving other or no treatment in clinical
settings in Germany and the UK. Methods. This retrospective medical
chart review enrolled patients at 45 clinical sites in Germany and the
UK. The study included patients ≥18 years old at HL diagnosis, who
received ASCT between 1 January 2008-30 June 2014, had ≥12 months
of available clinical data from the start of post-ASCT treatment, and
were not enrolled in an HL-related clinical trial. This analysis included
randomly selected post-ASCT patients who subsequently relapsed, and
an augmented sample of patients who relapsed post-ASCT. Patients
were grouped according to the subsequent line of therapy (LOT) received
after post-ASCT relapse (BV, salvage chemotherapy, or no treatment).
Patient demographics, clinical, and treatment characteristics were
described, and clinical outcomes included progression-free survival (PFS),
OS, and best response. Median PFS and OS were calculated using
Kaplan-Meier methods; other outcomes were summarized using descrip-
tive statistics. Results. A total of 360 patients were included in the study
(161 in Germany, 199 in the UK). Of these, 213 received BV, 128 received
other treatments, and 19 received no treatment for post-ASCT relapse.
Groups were similar in age at diagnosis, gender, and HL type. The most
commonly applied chemotherapy regimens were gemcitabine-based
(38% and 42% in Germany and UK) and ICE (17% and 8%, respective-
ly). Patients in the BV group received a median of 7 of the recommended
16 treatment cycles (Table1 ). Median PFS was 11.7 months longer in
patients receiving BV compared to those receiving salvage chemothera-
py. Median OS from start of therapy was 32.0 months in the salvage
chemotherapy group and was not estimable in the BV group due to
>50% of patients surviving at last follow-up (P=0.014). Other events
that occurred during treatment include leukopenia (12%) and peripheral
neuropathy (10%) for BV and leukopenia (12%), anemia (6%), and diar-
rhea (6%) for salvage chemotherapy. Conclusions. In this real-world study,
rrHL patients receiving BV as the first post-relapse LOT after ASCT
relapse tended to have longer PFS and OS than patients receiving salvage
chemotherapy; however, confidence intervals were wide.
Table 1. Treatment and survival outcomes in patients with Relapsed/
Refractory Hodgkin Lymphoma after Autologous Stem-Cell Transplanta-
tion relapse.
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Background. With the advance of novel therapeutic options, RFs for
post-ASCT outcomes in patients with rrHL are of immediate interest.
Several RFs for relapse have been previously documented; however,
there are limited data with respect to the prevalence and distribution
of RFs in post-ASCT rrHL patients who have and have not had a sub-
sequent relapse. We aimed to describe the prevalence and distribution
of RFs after ASCT in patients with rrHL in a sample of real-world
patients in Germany and the UK. Methods.We retrospectively evaluated
patients who were ≥18 years old at the time of HL diagnosis, received
ASCT between 1 January 2008 and 30 June 2014, were not enrolled in
an HL-related clinical trial and treated under real-world setting at 45
clinical sites in Germany and the UK. This analysis included randomly
selected post-ASCT patients, and was augmented by patients who
relapsed post-ASCT. RFs of interest included patient age, sex, B symp-
toms, extranodal disease, bulkiness, clinical stage, ECOG performance
status, erythrocyte sedimentation rate (ESR), white blood cell (WBC)
count, lymphocyte count, hemoglobin (Hgb), and lactate dehydroge-
nase (LDH) at the time of relapse preceding ASCT (ie, pre-ASCT
relapse), number of salvage regimens prior to ASCT; response to salvage
treatment; and time to relapse after front-line treatment. Results.A total
of 398, predominantly male patients, with a median follow-up of 2.2
years post-ASCT were included (196 in Germany, 202 in the UK). The
mean age at diagnosis was 43 years. In total, 329 (83%) had a relapse
during the follow-up period. A greater proportion of patients who
relapsed were ≥45 years old, had stage IV disease, B symptoms, bulky
disease, ECOG ≥1, anemia, and elevated LDH at the time of pre-ASCT
relapse (Table 1). The median number (range) of RFs present was 3 (0-
7) in patients who relapsed and 1 (0-5) in patients who did not relapse.
Conclusions. This real-world study demonstrates the prevalence and dis-
tribution of a myriad of RFs in patients post-ASCT rrHL. RF profiles
are different in patients who did and did not have a subsequent relapse,
and, as such, clinical evaluation of RFs is critical to identify patients at
a truly increased risk of subsequent relapse.
Table 1. Table. Prevalence of risk factors in patients who did and did not
relapse after Autologous Stem-Cell Transplantation.
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VERY LATE RELAPSES OCCURING AT LEAST 5 YEARS AFTER THE INITIATION OF TREATMENT
WITH CHEMOTHERAPY OR COMBINED MODALITY THERAPY IN PATIENTS WITH HODGKIN:
INCIDENCE, RISK FACTORS AND OUTCOME
T.P. Vassilakopoulos1, G.A. Pangalis2, M.N. Dimopoulou1,
M.P. Siakantaris3, M. Dimou4, G. Boutsikas1, M. Moschogiannis2,
V. Telonis1, K. Petevi1, T. Tzenou4, X. Yiakoumis2, A. Kanellopoulos1,
G. Gainaru1, L. Papageorgiou1, K. Koutsi1, J. Asimakopoulos1,
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P. Tsaftaridis1, E. Plata1, M.C. Kyrtsonis4, P. Tsirkinidis2, E. Variamis3,
N.A. Viniou3, P. Panayiotidis4, K. Konstantopoulos1, M.K. Angelopoulou1
1Department of Haematology; 2Department of Haematology, Athens Medical
Center, Athens, Greece; 31st Department of Internal Medicine; 41st Propedeutic
Department of Internal Medicine of National and Kapodistrian University of
Athens, Laikon General Hospital, Athens, Greece
Introduction. Most relapses in HL patients (pts) occur within 5 yrs
from diagnosis. However, there are pts who do relapse later on, even
after decades. The exact incidence of VLRs, especially after CT/CMT,
is not well established. Similarly, there are very limited data on base-
line disease features associated with VLRs as well as the outcome of
these pts. Aim. The estimation of the probability of VLR in pts with
HL who remain in 1st complete remission (CR1) for 5 years after insti-
tution of CT/CMT, the identification of risk factors for VLR and the
evaluation of the outcome of VLRs. Pts/Methods. Retrospective study
of 764 HL pts in CR1 for ≥5 years. Initial CT was anthracycline-based
in 87% of pts [mainly A(E)BVD] and MOPP-like in 13%. The Kaplan-
Meier method and Cox’s model were used for univariate and multi-
variate survival analysis. Results. Among 764 pts, 44 had a VLR (2/44
had a composite HL and non-Hodgkin lymphoma): 24, 13, 4 and 3
between 5-10, 10-15, 15-20 and beyond 20 years from diagnosis.
Starting from diagnosis, the 10-year and 15-year VLR rate were 3.7%
and 8.0%. In univariate analysis, higher risk for VLR was observed
for pts treated with CT only vs CMT (p=0.0006), non-nodular scle-
rosing histologies (non-NS) (p=0.002) and age ≥45 yrs (p=0.02). In
multivariate analysis, independent predictors of VLR were non-NS
(HR 2.39, p=0.006) and CT vs CMT (HR 2.56, p=0.003). At 15 yrs
from diagnosis, the probability of VLR was 3.0%, 10.3% and 24.0%
(p<0.0001) for pts with 0, 1 and 2 risk factors (RFs). Among 663
anthracycline-treated pts, independent predictors for VLR were non-
NS histologies (HR 2.56, p=0.02) and age ≥45 yrs (HR 2.29, p=0.04).
At 15 yrs from diagnosis, the probability of VLR was 2.7%, 10.8%
and 27.3% (p<0.0001) for patients with 0, 1 and 2 RFs. Conventional
salvage therapy was given to 37 pts (mostly non-cross resistant), 4
received salvage RT only, 2 salvage with autoSCT, while 1 pt has not
received salvage therapy yet. The 5- and 10-yr survival after failure
was 70% and 42%. Conclusions. Among pts with HL who remain in
CR1 at 5 years following CT w/wo RT, approximately 3-4% relapse
within the next 5 yrs and even more thereafter. This observation if
important when counselling pts in CR1 regarding their chance of ulti-
mate cure. Younger pts with NS who receive CMT have the lowest
risk for VLR. AutoSCT should not be spared solely on the basis of a
very long CR1, since the results of conventional salvage do not appear
satisfactory.
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LONG-TERM OUTCOME OF REDUCED-INTENSITY ALLOGENEIC TRANSPLANT IN
RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA: THE TIMING OF RELAPSE AFTER
AUTOLOGOUS TRANSPLANT AND PRIMARY REFRACTORY DISEASE DO NOT IMPACT THE
LONG-TERM SURVIVAL
F. Spina1, S. Dalto1,2, C. De Philippis1,2, A. Dodero1, L. Farina1,
V. Montefusco1, S. Viviani1, P. Corradini1,2
1Division of Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan,
Italy; 2Chair of Hematology, Università degli Studi di Milano, Milan, Italy
This study analyzed a cohort of consecutive patients with
relapsed/refractory Hodgkin’s lymphoma (RR-HL) receiving reduced
intensity allogeneic transplant (alloSCT) in a single center to under-
stand whether the timing of relapse after autologous transplant
(ASCT) or primary refractory disease would change the survival after
allograft. Of 243 patients with HL referred to our division from 2001
to 2014, 105 had RR-HL (64 primary refractory). After salvage treat-
ment, 62 patients (59%) underwent alloSCT with thiotepa-based con-
ditioning, 43 patients did not receive alloSCT due to progressive dis-
ease (31), age >65 years (3) or complete remission after third line
chemotherapy and ASCT (9 patients). Multivariate analysis of
alloSCT outcomes included disease pre-transplant status (CR vs PR vs
resistant [SD or PD]), donor type (HLA identical, matched unrelated
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[MUD], or T-depleted or T-repleted haploidentical), primary refractory
disease (yes vs no) and timing of relapse after ASCT (<12 months after
ASCT vs >12 months vs no ASCT). Allografted patients had a median
of 33 years, 76% had a primary refractory disease, 25% had persistent
disease at alloSCT. Donors were HLA identical siblings (42%), MUD
(29%) or haploidentical (29%); 74% of patients relapsed <12 months,
15% relapsed >12 months after ASCT, and 11% had not received
ASCT. After a median follow-up of 5.4 years, 5-year OS was 59%
(CI95% 47-71%), PFS and relapse incidence were 46% (CI95% 34-
58%) and 38% (CI95% 26-50%). Non-relapse mortality (NRM) was
10% at 100 days (CI95% 3-17%), 17% at 1 year (CI95% 8-26%) and
subsequently for the entire follow-up. In multivariate analysis, the
timing of relapse after ASCT and primary refractory disease did not
impact the outcome after alloSCT. OS was reduced by resistant dis-
ease at alloSCT (HR=4.01, CI95% 1.34-11.97, p=0.012) and by T-
depleted haploidentical graft (HR=3.81, CI95% 1.36-10.66, p=0.010).
PFS and relapse incidence were impacted only by resistant disease
(HR=5.54, CI95% 2.13-14.37, p<0.001, and HR=6.75, CI95% 2.07-
21.96, p=0.001, respectively). NRM was significantly increased in the
T-depleted haploidentical transplant (HR=7.63, CI95% 1.07-54.31,
p=0.042). In conclusion, only the disease pre-transplant status, not
the timing of relapse after ASCT or primary refractory disease, influ-
enced OS, PFS and relapse of alloSCT. The deepest response should
be pursued before alloSCT to have the best results from it and this
might be possible in the era of novel agents.
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THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF BRENTUXIMAB
VEDOTIN IN A PATIENT UNDERGOING HEMODIALYSIS
C. Liu1, G. Jang2, R. Ramchandren1
1Department of Oncology, Karmanos Cancer Institute, Wayne State University
School of Medicine, Detroit, MI, USA; 2Seattle Genetics, Bothell, WA, USA
Abstract. Brentuximab Vedotin (BV) is an antibody drug conjugate
(ADC) approved for the treatment of relapsed classical Hodgkin lym-
phoma (cHL) and systemic anaplastic T cell lymphoma. BV consists
of a CD30 directed antibody cAC10 conjugated by a protease-cleav-
able linker to a microtubule disrupting agent, monomethyl auristatin
E (MMAE). Prior studies analyzing the pharmacokinetics (PK) of BV
in normal and impaired renal function patients indicate that the elim-
ination of the ADC and unconjugated cAC10 are through proteolytic
degradation into amino acids with the elimination of MMAE occur-
ring through the liver and kidney. However, to date no data evaluating
the PK of MMAE in the hemodialysis (HD) population is available.
Therefore, we serially obtained serum MMAE levels in a 75 year old
female patient diagnosed with relapsed cHL undergoing HD and BV
therapy to evaluate the PK and PD behavior of ADC in this popula-
tion. Methods. BV was administered at a dose of 1.2 mg/kg every 21
days. Serum samples were obtained within 15 minutes pre and post
HD (Mon,Wed, Fri) and pre and post BV. The samples were then ana-
lyzed for MMAE drug levels. Concentrations of unconjugated MMAE
were measured in plasma, by liquid chromatography and tandem
mass spectrometry(LC MS/MS). Results. The maximum observed plas-
ma MMAE level (Cmax) of 3110 pg/ml and overall decline in plasma
concentrations post dosing were similar to phase I studies evaluating
the 1.2 mg/kg dose in patients with normal renal function. Areas under
the curve (AUC) levels over 21 days also were similar to non HD
patients with normal renal function. In addition, pre and post dialysis
plasma MMAE levels were similar, indicating that the effect of HD
on MMAE levels was negligible. Conclusions. In a single patient analy-
sis of MMAE levels undergoing HD, levels were consistent with non
HD patients suggesting that BV may have similar PK, PD and clinical
activity profiles in this population. In addition, HD had minimal effect
on MMAE levels indicating little effect of HD on potential efficacy or
toxicity. Further studies of BV in patients undergoing HD are war-
ranted to further characterize drug behavior in this population. 
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IMMUNE SYSTEMS ENGAGEMENT RESULTS IN NON-CLASSICAL ANTIBODY-DRUG
CONJUGATE ANTITUMOR ACTIVITY OF BRENTUXIMAB VEDOTIN 
S.J. Gardai, R. Heiser, A. Cao, F. Li, C. Leung-Law
Seattle Genetics, Bothell, WA, USA
Brentuximab vedotin (BV) is an antibody-drug conjugate (ADC)
approved for the treatment of relapsed Hodgkin lymphoma (HL) and
systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin
is comprised of a chimeric IgG1-directed antibody against CD30 and
the small molecule, MMAE, a microtubule-disrupting agent covalently
attached to the antibody via a cleavable linker. The primary anticancer
activity of BV is believed to be the binding of the ADC to CD30-
expressing cells, followed by internalization, release of MMAE which
results in microtubule network disruption, cell cycle arrest, and apop-
totic death. In addition to classical ADC activity, the antibody and auris-
tatin drug payload components of BV have additional and distinct
modalities that may contribute to its overall function and antitumor
activity in the heterogeneous and complex immune microenvironment
of lymphoma. In addition to classical ADC activity, recent evidence
elucidates new functionality of BV including antibody-dependent cel-
lular phagocytosis (ADCP); bystander-killing of nearby CD30-negative
tumor cells in the tumor microenvironment due to MMAE release from
CD30-expressing tumor cells and macrophages; and immunogenic cell
death driven by endoplasmic reticulum (ER) stress that can promote an
antigen specific T-cell response. Decoration of CD30-expressing cells
with BV mediates macrophage recognition and phagocytosis promoting
the removal of tumor cells independent of antibody internalization and
release of the auristatin payload (MMAE). This activity occurs in vitro
and contributes to in vivo activity seen with the antibody backbone.
Furthermore, cell-permeable MMAE released from proteolytic process-
ing of BV by macrophages within the tumor microenvironment or
CD30-expressing tumor cells is able to kill antigen-negative tumor cells
in a variety of in vivo tumor models. Additionally, in vitro characterization
has demonstrated that MMAE-mediated disruption of microtubules
not only drives tumor cell apoptosis but results in ER stress leading to
surface exposure of immune-activating molecules that can drive innate
and adaptive immune response that may contribute to the overall and
long-term antitumor activity of BV. Taken together, these data provide
rationale for the activity of BV in tumors with low and heterogeneous
CD30 expression and for ongoing combinatorial trial with immuno-
oncology agents. 
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THE LONG-TERM OUTCOME OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AND
NEGATIVE INTERIM PET FAILING ABVD MIGHT BE WORSE THAN THAT OF INTERIM PET
POSITIVE PATIENTS UNDERGOING EARLY TREATMENT INTENSIFICATION WITH
ESCALATED BEACOPP
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Purpose.Despite high NPV of negative iPET in patients with HL about
10% of them relapse/progress after completion of ABVD. Here we pres-
ent clinical characteristics and outcome of such patients comparing them
to patients with positive iPET and interim treatment escalation
[iPET(+)&TE]. Patients and Methods. Data of the Polish patients were
retrieved from the prospective observational study of the Polish Lym-
phoma Research Group on the predictive role of iPET after 1 ABVD
cycle. Briefly, intermediate and advanced stage (IIB-IVB) HL patients
were treated with ABVD followed by iPET after each of the first 2 ABVD
cycles. iPET(-) patients continued with ABVD, while some iPET2(+) had
at the discretion of a local physician treatment intensification with BEA-
COPP esc. with a median of 6 (2-8) cycles. iPET(-) patients failing ABVD
had second line treatment with ICE(3), IGEV(6), DHAP(7),ESHAP(5),
BEACOPP esc(3), ABVD/MOPP(2) Brentuximab(1), IVOX(1), ASCT(1).
iPETs were interpreted according to the Deauville scale as negative(-
)(score 1,2,3) and positive (+)(score 4,5). The primary endpoints were:
overall survival (OS) and time (EFS2) to the second event (no complete
remission or allogeneic HCT at the day of last follow-up), respectively.
The secondary endpoint: time to first event (2^nd progression for
iPET1(-) or 1^st one for iPET(+)&TE after treatment escalation). Results.
After a median follow-up of 48.8 (range 15 – 84) months 29 iPET(-) fail-
ing ABVD and 26 iPET(+)&TE patients were identified. (Table 1).
Table 1. Demographics and treatment outcome of patients.
The two cohorts were not different with regard to sex, age, stage, his-
tological subtype, presence of: B symptoms, bulky mass and extranodal
disease, absolute number of lymphocytes, lymphocyte to monocyte
ratio, and type of relapse. Six(21%) iPET(-) and 4(15%) iPET(+)&TE
died. However, in the former group deaths occurred during the longer
follow-up, whereas in the latter occurred in the 25 months after treat-
ment onset (Figure1). Similarly more patients experienced S2 events in
iPET(-) group (12-41% vs 8-31%) that tended to occur within longer
time in iPET(-) patients. This translated to a significant difference
(p=0,04) in the probability of EFS2 events between the two cohorts as
shown by the landmark analysis @25 months. Conclusions. Patients with
iPET(-) interim BEACOPP escalation despite iPET(+) may experience
better long-term OS and significantly better EFS than patients with
iPET(-) failing ABVD. Markers to improve NPV of iPET are warranted.
Figure 1. The probability of overall survival (Panel A) and second event
free survival (Panel B) in patients with iPET(-) and subsequent progres-
sion, and iPET(+) and interim treatment escalation.
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Objectives. Based on excellent data of Results of the Pivotal phase II
study (Younes et al., J Clin Oncol. 2012 Jun 20;30(18):2183-9), the US
Food and Drug Administration (FDA) and the European Medicines
Agency (EMA) approved BV for the treatment of patients with HL who
have either failed autologous stem cell (ASCT) or had at least two prior
multi-agent chemotherapy regimens and who are not candidates for
ASCT. Since the approval several study groups published the results of
their experience in treating refractory/relapsed HL patients with BV.
This meta-analysis evaluated the effect of single agent brentuximab
vedotin (BV) in patients with relapsed/refractory Hodgkin lymphoma
(HL). Patients and Methods.A systematic literature search was performed
and included studies published from 1st January 2012 to 1st July 2015
investigating BV in patients with relapsed/refractory HL. Data was
extracted and reviewed by two investigators then analyzed using the
comprehensive meta-analysis version 3 software. Heterogeneity of
studies was identified according to I2 value. Studies are regarded
homogenous if I2 ≤25% and the fixed effect model of meta-analysis is
used. Results. 22 out of 4048 screened records met the eligibility criteria.
These records included 903 patients. The median age of the cohort was
31 year (range: 26-45). 86% received ≥3 previous lines of systemic ther-
apy. 529 (58.7%) and 232 (25.7%) underwent high dose chemotherapy
and autologous and/or allogeneic stem transplantation prior of BV
respectively. The overall response rate to BV was 62.7% (range: 30-
100%) (Figure 1).
Figure 1. Pooled overall response rate to Brentuximab Vedotin (Random
effect).
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The complete response, partial response, stable disease and progressive
disease rates were 31.8% (Figure 2), 35.1%, 19.5% and 11.7% respec-
tively.
Figure 2: Pooled response rate to Brentuximab Vedotin (Random effect).
The one year progression free survival and estimated one year overall
survival were 47.6% (Figure 3) and 79.5% (Figure 4) respectively. Addi-
tional fixed effect model meta-analysis showed similar results (differ-
ence: <2%) except for progressive disease (difference: 9.3%) and pro-
gression at one year (difference: 5.2%) (Table 1). Conclusions. In this
largest published pooled cohort BV produces high responses with
encouraging progression free and overall survival in relapsed/refractory
HL patients. Our results enhance the role of BV in heavily pretreated HL
patients.
Figure 3: Pooled rate of disease progression one year after treatment with
Brentuximab Vedotin (Random effect).
Figure 4: Pooled rate of mortality events one year after treatment with
Brentuximab Vedotin (Random effect).
Table 1. Results of random and fixed effect meta-analysis models.
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A ROLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL AGENTS
FOR HODGKIN’S LYMPHOMA?
C. Scheid, J. Chemnitz, M. Herling, N. Pflug, S. Theurich, A. Burst,
S. Leitzke, M. von Bergwelt-Baildon, M. Hallek, U. Holtick
Stem Cell Transplantation Program, Dept. I of Medicine, University of Cologne,
Cologne, Germany
Patients with relapsed Hodgkins lymphoma (HL) can achieve long
term remission after high-dose chemotherapy and autologous stem
cell transplantation (SCT). However the prognosis is dismal for
patients relapsing after autologous SCT. The advent of novel agents
such as brentuximab vedotin or checkpoint-inhibitors has enabled a
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large proportion of patients to achieve responses, but these remissions
are often not durable. On the other hand there have been several
attempts to use allogeneic SCT as a potentially curative treatment
modality in HL. While progress has been made to reduce the trans-
plant-related mortality, relapse after transplant remains the biggest
challenge for allogeneic SCT. In order to investigate how the avail-
ability of novel agents may have influenced the results of allogeneic
SCT we performed a retrospective single centre analysis in our insti-
tution. Thirty seven patients with relapsed/refractory HL were trans-
planted between 2005 and 2016. Median overall survival (OS) after
transplant was 4.4 years with 57% OS at 3 years. There was no dif-
ference in OS in patients transplanted before or after 2010. Remission
status before allogeneic SCT had a significant impact on 3 yr OS
which was 75% in patients transplanted in CR, 63% in PR, 66% in
SD and 22% in patients with progressive disease. Of the 20 patients
in CR or PR before transplant 2 (10%) died from transplant-related
causes. Eight patients (40%) in this group relapsed after transplant.
While four patients eventually died from relapsed HL, four patients
are long term survivors 5 – 6.6 years from transplant after being treat-
ed with novel agents such as brentuximab, everolimus or ruxolitinib.
In the era of novel agents performing allogeneic SCT in patients with
relapsed HL at the time of maximum response may provide long term
survival with acceptable transplant-related risks. In addition using
these agents to treat relapse after transplant can further improve the
long term prognosis. While more and more options are available to
optimize the remission status before transplant, new approaches will
incorporate novel agents in the early post-transplant phase before day
100, such as everolimus in our current single-centre OCTET-Ever pro-
tocol or brentuximab vedotin in a planned multi-centre protocol by
the German Hodgkin Study Group.
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SALVAGE TREATMENTS FOR RELAPSED CLASSICAL HODGKIN LYMPHOMA IN CHILDREN
AND ADOLESCENTS: A 10-YEAR EXPERIENCE IN A SINGLE CENTRE
V. Fiaccadori1, J. Roskin1, V. Sana1, B. Carpenter1, R. Hough1,
V. Grandage1, P. Humphries2, M. Klusmann2, L. Menezes3, S. Daw1
1Children and Young People’s Cancer Services, University College Hospital
London, UK; 2Department of Radiology, UCLH, London, UK; 3Department of
Nuclear Medicine, UCLH, London, UK
Background. The optimal treatment for paediatric relapsed/refractory
(R/R) classical Hodgkin lymphoma (cHL) is undefined. Standard salvage
treatment is re-induction chemotherapy followed by consolidation
with high dose chemotherapy (HDCT) / autologous stem cell trans-
plantation (ASCT). However some patients may be salvaged with
chemo-radiotherapy only thereby avoiding toxicity of transplant while
in others the standard HDCT/ASCT would be predicted to fail and
allogeneic transplant has been proposed as an alternative approach. 
Purpose: To evaluate outcomes of risk and response adapted salvage
strategies in R/R cHL in our centre. Patients and Methods. A retrospec-
tive study between 2005-16 identified 23 first relapse patients; median
age 14 (3-19) years; M:F ratio 1.6:1; median time to relapse 10 months
(1 month - 180). First line treatment was multi-agent chemotherapy
with (n=5) or without radiotherapy (n=18). Salvage was re-induction
chemotherapy in all patients followed by consolidation treatment
which was selected based on an assessment of prognostic factors and
assessment of response to salvage chemotherapy. RT consolidation
was used in 4 patients with later relapse who achieved a complete
metabolic remission (CMR) with one line of salvage. HDCT/ASCT
was used in 13 patients, all in a CMR after one (n=5), two (n=7) or
four (n=1) lines of salvage. Allo-SCT was used in 6 patients, five in
CMR [after one (n=1), two (n=2), three (n=1) or four (n=1)] lines of
salvage. Results. 4/4 consolidated with RT only (no transplant) remain
well in second remission, median follow-up 66 months. 11/13 con-
solidated with HDCT/ASCT (conditioning BEAM/LEAM) remain in
second remission, median follow-up 18 months. Only 2/6 consoli-
dated with allo-SCT (conditioning regimen BEAM-Campath in 5 and
FMC in 1) remain in second remission, median follow up of 24
months while 2/6 relapsed and 2/6 died of early treatment toxicities.
Conclusions. Only 4/23 patients experienced a second relapse. 0/4 in
the RT group, 2/13 in the HDCT/ASCT group, 2/6 in the Allo-SCT
group. Two patients died of infection / toxicity post allo-SCT. The
disease free survival (DFS) by consolidation group was 100% in the
RT group, 85% in the HDCT/ASCT group, and 33% in the allo-SCT
group. A risk and response adapted salvage approach achieved excel-
lent outcomes with RT or HDCT/ASCT consolidation but the out-
comes with allogeneic transplant are less encouraging due to relapse
and toxicity in this small study.
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SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR
REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL
TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY
J. Walewski1, A. Hellmann2, N. Siritanaratkul3, G.H. Ozsan4, M. Ozcan5,
S. Chuncharunee6, A.S. Goh7, W. Jurczak8, J. Koren9, B. Wang10,
S. Singh10, D. Huebner10, A. Engert11
1Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland;
2Medical University of Gda sk, Gda sk, Poland; 3Siriraj Hospital, Bangkok,
Thailand; 4Dokuz Eylul University, Izmir, Turkey; 5Ankara University School
of Medicine, Ankara, Turkey; 6Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand; 7Hospital Pulau Pinang, Pulau Pinang, Malaysia;
8Jagiellonian University, Kraków, Poland; 9Charles University, Prague, Czech
Republic; 10Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of
Takeda Pharmaceutical Company Ltd, Cambridge, USA; 11University Hospital
Cologne, Cologne, Germany
Background. CD30 is a cell surface antigen expressed on malignant
HL Reed-Steenberg cells and targeted by the antibody-drug conjugate
(ADC) brentuximab vedotin (ADCETRIS®), which comprises a
CD30-targeted monoclonal antibody conjugated to the microtubule
disrupting agent monomethyl auristatin E via a protease-cleavable
linker. Brentuximab vedotin has received US and European approval
for treatment of RRHL following failure of autologous SCT (ASCT)
or following ≥2 prior therapies when ASCT or multiagent chemother-
apy is not a treatment option. Treatments are limited for patients inel-
igible for ASCT or multiagent chemotherapy; results of this ongoing
Phase 4 trial (NCT01990534) will further investigate the anti-tumor
activity of brentuximab vedotin in this difficult-to-treat population.
Methods. Eligible patients are ≥18 years of age with Eastern Cooper-
ative Oncology Group performance status 0–1, RRHL after ≥1 prior
therapy, and considered ineligible for SCT or multiagent chemother-
apy due to progression within 90 days of complete response (CR) or
unconfirmed CR to multiagent frontline chemo/radiotherapy, pro-
gressive disease (PD) during frontline multiagent chemotherapy, or
relapse after ≥2 prior treatments (including salvage). Patients must
have measurable disease (≥1.5 cm) by CT scan. Patients will receive
an intravenous infusion of brentuximab vedotin 1.8 mg/kg on day 1
of 21-day cycles for up to 16 cycles or until disease progression or
unacceptable toxicity. The primary objective is overall response rate
(ORR) assessed by an independent review committee; secondary
objectives include duration of response, CR rate, progression-free sur-
vival (PFS), overall survival (OS), pharmacokinetics, immunogenicity,
safety and tolerability, and proportion of patients receiving ASCT or
allogenic SCT following brentuximab vedotin treatment. CT scans
of chest, neck, abdomen, and pelvis will be performed at baseline and
cycles 2, 4, 7, 10, 13, and 16; PET scans at baseline and cycles 4 and
7. Post treatment follow-up for PFS and OS will be performed every
3 months, for 18 months after end of treatment. OS assessment will
continue thereafter every 6 months until death or study closure. Inci-
dence and severity of adverse events will be evaluated according to
NCI CTCAE v.4.03. Enrollment has finished with 60 patients across
20 international sites. Final data will be provided at the congress.
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OUTCOME OF VERY LATE RELAPSE IN HODGKIN LYMPHOMA – A REPORT FROM
DEBRECEN, HUNGARY
L.I. Pinczés, Z. Miltényi, Á. Illés
Department of Hematology, University of Debrecen, Faculty of Medicine,
Debrecen, Hungary
Introduction.With modern risk-adapted treatment modalities 80-90%
of Hodgkin lymphoma (HL) patients can be cured, however, 30% of the
patients may relapse after the first line treatment. Late relapses, that
occurred 5 or more years after first diagnosis are rare. Neither clinical
characteristics, nor risk factors, nor optimal treatment are well described
for very late relapse (VLR) patients. Aim. To describe the incidence, clin-
ical presentation, treatment and outcome of VLR in HL patients between
1970 and 2010 at our institute. Results. Of 669 consecutive HL patients
treated at our institute between 1970 and 2010, 617 (92.2%) patients
achieved complete remission after the first line treatment. Relapse
occurred in 188 (28.1%) patients, 26 (3.8%) of them 5 or more years
after the first diagnosis. VLR were more frequently observed in patients
with mixed cellularity histological subtype and stage II/III disease at first
diagnosis. In 15 (57.7%) patients, the histologic subtype remained the
same at VLR, in 8 (30.8%) cases the region of the relapse was also iden-
tical. 24 (92.3%) patients with VLR received polychemotherapies, 5
(20.8%) of them also received involved-field radiotherapy. Primary diag-
nosis before the age of 20 and treatment with radiotherapy alone at first
diagnosis was associated with a higher risk of VLR (p=0.009 and p=0.004
respectively). Compared to early relapse we observed superior OS after
VLR. At a median of 244 (91 - 360) months of follow-up, 22 (84.6%)
patients with VLR are still alive and disease free. In addition, relapse
characteristics, therapeutic approaches, and changes in histologic sub-
type will be presented. Conclusions. VLR occurs in a small number of
patients diagnosed with HL. Besides the rarity of these cases, with ade-
quate treatment, late relapse of HL appears to have a favorable prognosis
to early relapse HL cases. Subgroup analyses suggest that treatment with
radiotherapy alone and first diagnosis before adulthood conveys worse
prognosis. Continuous investigations are needed in this setting to deter-
mine further risk factors of VLR in HL.
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LIMITED EFFICACY OF BRENTUXIMAB VEDOTIN IN A HEAVILY PRE-TREATED HODGKIN
LYMPHOMA POPULATION
F. Pierdomenico1, A.L. Pinto2, J. Coutinho3, S. Chacim4, J. Raposo5,
A. Neves6, M. Fevereiro7, F. Principe8, M.H. Vitória9, J.P. Fernandes10,
S. Carvalho11
1Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal;
2Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 3Centro
Hospitalar do Porto, Porto, Portugal; 4Instituto Portugues de Oncologia do Porto
Francisco Gentil, Porto, Portugal; 5Centro Hospitalar de Lisboa Norte, Lisboa,
Portugal; 6Hospital São Bernardo, São Bernardo do Campo, Brasil; 7Centro
Hospitalar Lisboa Centro, Lisboa, Portugal; 8Centro Hospitalar São João, Porto,
Portugal; 9Centro Hospitalar Tondela Viseu, Tondela, Portugal; 10Hospital da
CUF, Porto, Portugal
Although HL is highly curable, 10-30% patients (pts) are refractory
or relapse after treatment. Salvage second line chemotherapy with
autologous stem cell transplant (ASCT) usually achieves 50% responses.
Refractory pts and those who relapse after ASCT have a poor prognosis.
BV is an anti_CD30 antibody-drug-conjugate with significant activity
against refractory/relapsed HL. We report a multicentric retrospective
analysis of 34 Portuguese pts receiving BV monotherapy for
refractory/relapsed HL between 9/2011 and 2/2016 at 10 centers. BV
(1.2 or 1.8 mg/Kg) was administered every 3w. Response was evaluated
by PET-CT. Overall (OS) and progression-free-survival (PFS) were esti-
mated using the Kaplan-Meier method; chi-square text was used to
evaluate relation between clinical variables and response. Pts (53%
female) were diagnosed between 1997 and 2015; 62% had advanced
disease. First-line treatment was ABVD in 91% with a 74% overall
response rate (ORR). Twenty-eight pts (82%) received salvage
chemotherapy with intent to perform ASCT, and 64% underwent trans-
plant. Median age at BV was 34.5 yo (23-69), 76% had advanced disease
and 1/3 B symptoms. Median time from initial diagnosis was 44 mo;
median number of prior treatments was 4 (2-6), with 79% pts refractory
to last one. Median number of BV cycles was 7.5. In 18 pts with early
evaluation of response (at cycles 2 to 4), ORR was 67% and CR 33%.
At the end of treatment, ORR was 21% (5 CR, 15%), while 76% had
either stable or progressive disease. Pts with ≤3 prior lines had ORR
47% as compared to none in pts with >3 (p<0,001). No difference in
ORR was noted according to gender, refractory/relapsed state and num-
ber of involved nodal areas. Ten pts (29%) were transplanted after BV,
only 4 in response; 18 started subsequent treatment after BV. After a
median follow-up of 12 mo 11 pts died, mostly of progressive disease.
OS and PFS at 12 months were 73.5% and 19% respectively. BV was
well tolerated with 18% peripheral neurotoxicity, 33% at least one
hematological toxicity and 9% grade 3-4 infections in all pts. In a real-
life setting, with a heavily pre-treated and mainly refractory population,
responses to BV were lower than previously described. In agreement
to others we observed loss of responses with prolonged treatment, sug-
gesting a benefit for early evaluation and treatment consolidation to
maximize the benefit of BV. Better ORR was observed after ≤3 prior
treatments, suggesting that BV should be offered early.
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THE ROLE OF STEM CELL TRANSPLANTATION IN HODGKIN’S DISEASE; PERSPECTIVES
FROM RETROSPECTIVE ANALYSIS
P. Mazza1, N. Cascavilla2, P. Galieni3, G. Palazzo1, A.M. Carella2,
S. Falcioni3, G. Pisapia1, E. Merla2, B. Amurri1, S. Angelini3
1Hematology and Bone Marrow Transplantation Unit “SS Annunziata” Hospital,
Taranto, Italy; 2Hematology and Bone Marrow Transplantation Unit “Opera
Padre Pio”, S. Giovanni Rotondo (FG), Italy; 3Hematology and Bone Marrow
Transplantation Unit “Mazzoni” Hospital, Ascoli Piceno, Italy
Purpose. To disclose the prognostic value of status of disease and lines
of therapy at transplantation (SCT) either autologous or allogeneic in
Hodgkin lymphoma we did a retrospective evaluation. Patients and
Methods. We accrued all patients who did a stem cell transplant (SCT)
procedure following resistance, residual disease, or relapse after previ-
ous conventional therapy. The accrual started in October 1998 when
we did the first autologous SCT with the use of peripheral stem cells
(PSC) and included patients up to December 2015. One hundred eighty
one patients with Hodgkin lymphoma did autologous and 40 patients
did allogeneic SCT and analyzed for prognosis according to status and
number of lines of therapy at transplant. Five categories of patients
were identified according the status at transplant: primary resistant,
with residual disease, in first relapse, in second relapse and more than
second relapse. Autologous SCT was done as II, III, IV line and more
than IV line of therapy. High dose therapy followed by autologous
PSCT represented a line of therapy for almost all patients who did allo-
geneic SCT. The analysis included the evaluation of survival according
to groups identified and see if there are significant differences. Results.
Worse chances of survival were for patients primary resistant, 6% at
138 months, and for those with more than two relapses,10% at 120
months; better chance were for patients with residual disease, 88% and
those who did transplantation following I relapse, 96% at 194 months
(p<0.0001) (Figure 1). In addition better survival was for patients who
received autologous SCT as II line of therapy, 93% survival at 194
months, and worse those with more than IV line of therapy, 12% at
146 months (p<0.0001). Allogeneic SCT was done in 38 (95%) patients
following autologous SCT; survival was 16% at 175 months and
relapse-free survival (RFS) was 18% at 174 months. The stratification
of survival in the setting of allogeneic SCT was worse for patients resist-
ant and with previous more lines of therapy. Conclusions. Our study
demonstrates that Hodgkin lymphoma may be cured by high-dose ther-
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apy and a procedure of SCT following failure to conventional therapies.
However, different outcomes were recorded according the status of
disease and the line of therapy at transplant; differentiated therapeutic
approaches to various patients categories will be discussed.
Figure 1.
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AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA: EXPERIENCE OF
TWO CENTERS IN BRAZIL
J. Sobreira de Almeida1, M. Seo Gomes Pinto2, S. Costa Fortier1,
T.M. Bueno da Silveira Rocha1, R.M. Augusto Passos3,
L. de Lourdes Martins Perobelli3, R. Rabelo Chiattone1,2, C.S. Chiattone2,4
1Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brasil;
2Hospital Samaritano, São Paulo, Brasil; 3Hospital de Transplantes Doutor
Euryclides de Jesus Zerbini, São Paul,  Brasil; 4Faculdade de Ciências Médicas
da Santa Casa de São Paulo, São Paulo, Brasil
Introduction. Hodgkin Lymphoma (HL) is considered a potentially cur-
able neoplasm in which most patients respond well to initial treatment.
However, 10-15% of patients with localized disease and 25-30% with
advanced disease experience treatment failure or relapse. In this patient
group, high-dose chemotherapy followed by salvage with hematopoietic
stem cells (HSCT) is considered the standard treatment. Objectives:
Analysis of Overall Survival (OS) and Progression-Free Survival (PFS) in
patients with HL submitted to HSCT, and identification of possible pre-
dictors of poor prognosis. Materials and Methods. A retrospective study
of HL patients submitted to HSCT at two Brazilian centers was conduct-
ed. Results. A total of 106 patients were analyzed with mean follow-up
time of 28.6 months (0.37 – 154.23). Regarding pre-HSCT disease status,
38 (40.9%), 45 (48.4%) and 10 (10.7%) patients had Complete Remission
(CR), Partial Remission (PR) and were refractory, respectively. Response
after HSCT was CR, PR and refractory in 51 (68.9%), 13 (17.6%) and 10
(13.5%) individuals, respectively. Of the 44 patients in PR before HSCT,
17 (38.6%) evolved to CR after HSCT. Three-year GS and PFS were
84.7% and 74%, respectively. Pre-HSCT influenced OS (p=0.012) and
PFS (p=0.007). Conclusions.We confirmed in a Brazilian population that
HSCT should be considered as a therapeutic option for patients with
refractory or recurrent HL since it can promote long-term responses. Fac-
tors associated with poor prognosis were determined, allowing an indi-
vidualized approach to improve response rates and minimize toxicity.
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PD1-INHIBITION WITH NIVOLUMAB AFTER ALLOGENEIC HAEMATOPOIETIC CELL
TRANSPLANTATION FOR HODGKIN’S LYMPHOMA
S. Schulze1, N. Jaekel1, A. Monecke2, S. Leiblein1, P. Schirmacher3,
D. Niederwieser1, H.K. Al-Ali1
1University Hospital of Leipzig, Division of Hematology and Oncology, Leipzig,
Germany; 2University Hospital of Leipzig, Department of Pathology, Leipzig,
Germany; 3University Hospital, Institute of Pathology, Heidelberg, Germany
Allogeneic hematopoietic cell transplantation (allo-HCT) is an
option for patients with Hodgkin’s lymphoma (HL) who relapse after
autologous HCT. Recently, response rates of 87% after treatment
with nivolumab (a monoclonal IgG4 anti-PD-1 antibody) in
relapsed/refractory HL even after autologous HCT were published
(Ansell et al., NEJM 2015). Yet, the impact of nivolumab with its
immune-related mechanism of action after allo-HCT is unknown. We
report the use of nivolumab after allo-HCT for relapsed HL. Patient
and Methods. The patient is a 52-year-old female with HL, stage IVLA
in 5th relapse. Earlier treatments were standard chemotherapies prior
to and after autologous HCT. In 2010, the patient received an allo-
HCT from an HLA-identical unrelated donor. She developed extensive
graft versus host disease (GvHD) of the skin and liver. The patient suf-
fered further relapses and was treated with brentuximab, and gemc-
itabine. Immunosuppression could be discontinued in 2014. Periph-
erally, NK- and T-cells were 100% of donor origin. A PET-CT prior to
nivolumab displayed a generalized lymph node, pulmonary and bone
involvement by HL. Immunohistochemical staining of a tissue biopsy
revealed that the Hodgkin- and Reed-Sternberg cells expressed the
PD-L1 protein. Results. Nivolumab was started (3mg/kg at week 1 and
4, and then every 2 weeks) in July, 2015. A PET-CT at week 5 revealed
a complete remission which is now maintained for 8 months. Two
weeks after the first infusion, an upsurge in eosinophils, NK- and T-
cell populations occurred (Table 1). CD279 (PD-1) was expressed on
21% of the T-cells. A grade 3 hepatotoxicity at week 6 necessitated
an interruption of nivolumab for 5 weeks and treatment with pred-
nisolone 25 mg QD. Nivolumab was resumed and prednisolone
tapered without evidence of further immune-mediated adverse events
or GvHD. Conclusions. A fast and complete remission with immuno-
logic checkpoint blockade is possible even after allo-HCT. However,
a therapeutic blockade of the PD-1 pathway may influence the func-
tion of lymphocytes and NK-cells. Thus, further data are needed to
establish the impact of PD-1/PD-L1 blockade after allo-HCT.
Table 1. Peripheral WBC counts under nivolumab.
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EFFICACY OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF RELAPSED HODGKIN
LYMPHOMA AND CONCOMITANT MYCOSIS FUNGOIDES
E. Meli1 C. Rusconi1, V.R. Zilioli1, P. Minga1, M. Zancanella1,
M. Anghilieri2, R. Cairoli1
1ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center,
Milan, Italy; 2ASST Lecco, Ospedale Alessandro Manzoni, Lecco, Italy
Background. Brentuximab Vedotin (BV) is currently used for the
treatment of relapsed/refractory Hodgkin Lymphoma (HL). Accord-
ingly to preliminary data, BV might be useful also against Mycosis
Fungoides (MF), even in patients with weak CD30 expression. Here
we describe a case of relapsed HL and concomitant MF treated with
BV. Case Report. A 73-year-old man was referred to our Center in Sep-
tember 2015 for relapsed HL and simultaneous MF. Medical history
included hypertension, moderate chronic renal impairment and acute
heart failure secondary to atrioventricular block. MF was diagnosed
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in 1987 and UVA, UVB and PUVA were delivered, with short term
partial remissions. Classical HL, clinical stage IIIB, was diagnosed in
2004 and patient obtained complete remission (CR) after 6 ABVD
cycles. After 7 years (68 years-old), HL relapse was histologically doc-
umented and clinical stage was IIIA. Three cycles of IGEV chemother-
apy obtained a second CR and 30 Gy involved-field radiotherapy was
given as consolidation. A third HL relapse, biopsy proven with strong
CD30 expression, occurred 3 years later and clinical stage was IIIA.
At time of HL relapse MF was in stage III and patient presented scaly
erythematous plaques distributed over most of his body. Patient start-
ed BV therapy at the reduced dose of 1.2 mg/kg/3ws due to creati-
nine-clearance of 53 ml/min. A significant regression of the skin
lesions was observed after the first BV dose, and after 4 BV cycles
both MF and HL achieved a CR, documented by clinical examination
and PET scan, respectively. Twelve of the 16 BV planned doses have
been administered, with no significant toxicity and no recurrence of
both HL and MF. Conclusions. This case confirms that BV is a well tol-
erated and effective treatment for HL; the quick response of the con-
comitant MF that we observed encourages further investigations on
the role of BV also in this setting.
Figure 1.
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PROGRAMMED DEATH 1 BLOCKADE WITH NIVOLUMAB AS SALVAGE THERAPY FOR HEAVILY
PRE-TREATED CLASSICAL HODGKIN’S LYMPHOMA RELAPSING AFTER ALLOGENEIC STEM
CELL TRANSPLANTATION: A CASE REPORT
A. Comai, E. Domingo-Domenech, A. Sureda
Clinical Hematology Department, Institut Català d’Oncologia, Hospitalet,
Barcelona, Spain
Introduction. Monoclonal antibody nivolumab (NIVO) blocks Pro-
grammed Death-1 ligands avoiding overstimulation of T-cell activity
therefore preventing autoimmunity. On May 2016, US Food and Drug
Administration granted its accelerated approval in patients with
Hodgkin’s lymphoma (HL) relapsed after both autologous stem cell
transplantation (ASCT) and brentuximab vedotin (BV), based on the
overall response rate (ORR) of 65% from the combined analysis of
phase I CheckMate-039 and phase II CheckMate-205 trials. In the set-
ting of allo-SCT, NIVO seems to be associated with increased trans-
plant related toxicity and mortality, e.g. higher incidence of veno-
occlusive disease and graft versus host disease (GVHD). Case Report. A
43 years-old male was diagnosed of classical HL stage IIA with bulky
mediastinal disease in June 2008. After achieving a PET negative com-
plete remission (CR) with ABVD x6 cycles and involved field radio-
therapy, the patient presented an early relapse with stage IIIA disease.
He was then treated with salvage second-line therapy with DHAP x3
cycles and consolidated with ASCT with BEAM as conditioning reg-
imen. He achieved a second PET negative CR but experienced a sec-
ond early relapse (<1 year) after the ASCT that was treated with
NOVPx6 cycles and consolidated with an allo-SCT from his HLA-
identical brother in November 2009. In spite of developing clinical
significant acute and chronic GVHD, the patient experienced two
more relapses treated with BV (1.8 mg/kg iv every 21 days up to 10
cycles – disease progression) and bendamustine single drug (120 mg
/m2 iv x2 days, 3 cycles) with disease progression. In September 2015,
NIVO was requested through the name patient program in our coun-
try. At that time, the patient had progressive disease, stage IVA (bone
marrow), no clinically relevant GVHD and no need for active
immunosuppression. NIVO was started in October 2015 at a dose of
3 mg/kg iv every 2 weeks with very good tolerance and no reactiva-
tion of the prior history of GVHD. The patient achieved a PET nega-
tive CR after 6 cycles and nowadays has an excellent performance
status under NIVO treatment, in continuous CR by PET CT 8 months
after starting this latter therapy. Conclusions. Our patient, treated in
the absence of immunosuppression and almost 6 years after allo-SCT,
has significantly benefited from NIVO with no relevant toxicity. Fur-
ther studies on the role of NIVO before and after allo-SCT should be
pursued.
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MAJOR RESPONSE OF HEAVILY PRETREATED HODGKIN LYMPHOMA TO NIVOLUMAB:
THE IMMUNE SYSTEM RELOADED
R. Dada1,2, J. Zekri1,2
1King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi
Arabia; 2College of Medicine, Al-Faisal University, Riyadh, Kingdom of Saudi
Arabia
Background.Cancer can escape the immune system through different
mechanisms. One of which is the expression of program death ligand-
1 (PD-L1). This ligand binds to PD-1 receptor on activated T cells, sub-
sequently leading to inhibition of the immune response. Nivolumab is
novel antibody that binds to PD-1 and prevents such immune tolerance.
Several recently published clinical trials confirmed the clinical efficacy
of single agent Nivolumab in pretreated patients with different cancer
types. Publications on Nivolumab in Hodgkin lymphoma (HL) are very
scares. The available literature is limited to only one phase 1 clinical
study with 23 pretreated patients (Ansell eta l., N Engl J Med
2015;372:311-9). Case description: We report on a 30 year-old man with
stage IVB HL. He failed 9 lines of prior therapy including: ABVD, ICE,
radiation, ESHAP and high dose BEAM chemotherapy and autologous
stem cell transplantation, IGEV, Brentuximab vedotin,. Brentuximab
and Ifosfamide, GVD and Bendamustine. The patient has multiple vis-
ceral involvement including lung and liver proven by histopathology.
He was wheelchair bound (ECOG 3) and oxygen dependent. He
received Nivolumab achieving a major radiological response after 4
cycles (Figure 1 and 2). The lung involvement by the HL has nearly
completely disappeared. The involved liver has markedly decreased in
size, in addition to improvement of splenomegaly. This radiological
response was associated with significant clinical improvement. The
performance status improved to ECOG 1and became oxygen independ-
ent. No treatment related significant side effects were observed. Con-
clusions. Pre-treated HL is amenable to novel immunotherapy. Nivolum-
ab induces clinically meaningful responses with excellent tolerance. The
drug enriches our treatments options by reloading the immune system
response against cancer. Further clinical studies are needed to determine
the effectiveness on large patients’ cohort.
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TREATMENT OF A PATIENT WITH PRIMARY REFRACTORY HODGKIN LYMPHOMA AND
CONCURRENT CENTRAL NERVOUS SYSTEM INVOLVEMENT
H. Móciková, Ľ. Gahérová, T. Kozák
Department of Internal Medicine and Haematology, University Hospital
Kralovske Vinohrady and Third Faculty of Medicine, Charles University in
Prague, Czech Republic
Background.The incidence of CNS involvement in Hodgkin lymphoma
(HL) is 0.05% and it can occur at the time of initial diagnosis or in a
relapsed/refractory disease. Case Report. 32-year-old female immunocom-
petent patient with classical HL (mixed cellularity) in initial clinical stage
IIB was treated in Lybia between 2011-2014 (6xABVD, 3x ICE, 4x
ASHAP, involved field irradiation of 36Gy on cervical lymph nodes, 2
cycles of Gemcitabine and Navelbine, steroid treatment) without achiev-
ing a sustained remission and HL was considered primary refractory. The
patient was admitted to our hospital with headache, blurred vision and
with disseminated disease in clinical stage IVA (2015): PET/CT confirmed
involvement of lymph nodes on both sides of diaphragm, liver, diffuse
skeletal and muscle infiltration. MRI of the brain revealed involvement
of paranasal sinuses, focal lesions in the right temporal lobe with perifocal
oedema and dislocation of the right lateral ventricle. A new biopsy of
the cervical lymph node confirmed HL- nodular sclerosis. Cerebrospinal
fluid and bone marrow examinations were negative for HL involvement.
She was treated with two cycles of brentuximab vedotine and bendamus-
tine (BVB) in combination with dexamethasone. Two cycles of BVB alter-
nated with two cycles of high-dose methotrexate 3,5g/m2 with procar-
bazine and dexamethasone. She achieved a partial remission according
to PET/CT and MRI of the brain after above mentioned treatment. The
patient received conditioning regimen BCNU/etoposide/thiothepa fol-
lowed by autologous stem cell transplantation (ASCT) in February 2016.
Neutrophil and platelet engraftment was reported on day+10 after ASCT.
Currently, consolidation treatment with brentuximab vedotine is ongoing
since day +30 after ASCT. Conclusions. BVB combination is a highly effec-
tive salvage chemotherapy for relapsed/refractory systemic Hodgkin lym-
phoma, and additional effect of bendamustine on CNS involvement in
combination with high-dose methotrexate, procarbazine and dexam-
ethasone can be anticipated. Conditioning regimen directed against CNS
and systemic HL involvement CNS may further potentiate the effect of
salvage chemotherapy.
Support. This work was supported by grant awarded by AZV 16-
29857A, Ministry of Health in Czech Republic and Research project P
27/2012 awarded by Charles University in Prague, 3rd Faculty of Med-
icine, Prague, Czech Republic.
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PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY
CLASSICAL HODGKIN LYMPHOMA: RANDOMIZED, PHASE 3 KEYNOTE-204 STUDY
M.A. Fanale1, J. Kline2, R. Chen3, V. Ribrag4, G. Salles5, I. Matsumura6,
Y. Zhu7, A.D. Ricart7, A. Balakumaran7, P.L. Zinzani8
1The University of Texas MD Anderson Cancer Center, Houston, USA;
2University of Chicago, Chicago, USA; 3City of Hope National Medical Center,
Duarte, USA; 4Gustave Roussy, Villejuif, France; 5Centre Hospitalier
Lyon-Sud, Lyon, France; 6Kinki University, Osaka, Japan; 7Merck & Co., Inc.,
Kenilworth, USA; 8Institute of Hematology “Seràgnoli“, University of Bologna,
Bologna, Italy
Background. The PD-1 ligands, PD-L1 and PD-L2, are frequently over-
expressed in relapsed or refractory classical Hodgkin lymphoma (R/R
cHL), and this is typically associated with chromosome 9p24.1 ampli-
fication. In the phase 1b KEYNOTE-013 study, PD-1 blockade with
pembrolizumab demonstrated high antitumor activity (65% ORR) in
heavily pretreated patients with cHL. KEYNOTE-204 (NCT02684292)
is a randomized, international, open-label phase 3 study designed to
compare the efficacy and safety of pembrolizumab versus brentuximab
vedotin (BV) in patients with R/R cHL. Methods. This study will enroll
patients aged ≥18 years with R/R cHL who (1) have failed to achieve a
response or progressed after autologous stem-cell transplantation (auto-
SCT) and have not had previous treatment with BV; or (2) are not auto-
SCT candidates because of chemotherapy-resistant disease (unable to
achieve complete remission or partial remission to salvage chemother-
apy), advanced age, or comorbidities, and have received at least 2 prior
multi-agent chemotherapy regimens that did not include BV. ~300
patients will be randomized 1:1 to receive either pembrolizumab 200
mg Q3W or BV 1.8 mg/kg Q3W. Treatments will continue for up to 35
cycles or until documented disease progression, unacceptable adverse
events (AEs), or investigator decision. Response will be assessed Q12W
by PET/CT scans per International Working Group (IWG) Revised
Response Criteria for Malignant Lymphoma by central imaging vendor
review. After the end of treatment, patients will be followed for 30
days for AE monitoring (90 days for serious AEs and events of clinical
interest). All patients will be followed for overall survival until death,
withdrawal of consent, or the end of the study, whichever comes first.
Primary end points are PFS and OS; secondary end points are ORR and
complete remission rate (CRR). Exploratory end points include PK pro-
file, duration of response, and comparison of ORR in patients with PD-
L1–positive versus PD-L1–negative lymphoid tumors. Assessment of
primary efficacy end points are based on blinded independent central
review according to IWG criteria; secondary/exploratory efficacy analy-
ses are based on investigator assessment. Enrollment to KEYNOTE-
204 is ongoing.
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Survivorship
T025
PATIENT PREFERENCES - SURVEY OF HL SURVIVORS ON TREATMENT-ASSOCIATED
BURDENS AND SIDE EFFECTS
C. Buerkle, H. Goergen, H. Müller, P.J. Bröckelmann, S. Kreissl,
M. Fuchs, A. Engert, P. Borchmann, K. Behringer
German Hodgkin Study Group (GHSG), University Hospital of Cologne,
Germany
Hodgkin lymphoma (HL) survivors often report impaired quality of
life due to side effects. For evaluation of the relevance of efficacy out-
comes and side effects from the patient’s point of view, we created a
questionnaire for HL long-term survivors. The questionnaire was sent
to randomly selected patients (male and female 150 each) of every trial
of our 5th trial generation (HD13, HD14, HD15) with no documented
refractory disease or relapse (N=900) and to all patients with document-
ed refractory disease or relapse (R/R) (N=249). 52% of contacted
patients participated and median follow up time was 106 month. R/R
was reported by 16% of the participants. Chemotherapy was a great
or very great burden for 77% of the participants, independent of stage
of disease, treatment and study. In early favorable (HD13) and early
unfavorable stages (HD14) treatment standard included radiotherapy
(RT) of 30 Gy. For 64% of participants this was a great or very great
burden. In advanced stages (HD15) RT was only performed in patients
with PET-positive residual tissue after chemotherapy. 26% of them rat-
ed RT as great or very great burden. Most frequent side effect was
fatigue reported by 87% during and 41% after treatment. About of
patients who experienced fatigue consider it as a great or very great
burden. Most long-term side effects were significantly more frequent
for participants with R/R. At time of first diagnosis >50% had concerns
about acute and long-term side effects, relapse and death due to HL.
Most frequently the concern about relapse is mentioned. At time of
survey, ≈25% without R/R worried much or very much about side
effects or death because of HL and ≈40% about long-term effects or
possibility of relapse. Of those participants with R/R, concern of side
effects or death because of HL was present in ≈35% and about long-
term effects or another relapse in ≈60%. Cure of HL was rated as the
most important treatment goal by 72% of patients. Only 9 participants
(2%) would have chosen a slightly less effective therapy to avoid side
effects. Chemotherapy is a great burden independent of duration and
intensity of administered regimen. HL Survivors are more concerned
about relapsing than dying from HL, which could be interpreted as fear
of another treatment. Results suggest that avoidance of relapse should
be the primary therapy goal and cure is above possible side effects.
Thus, progression-free survival is an important patient-relevant end-
point in clinical trials.
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CHANGE IN PERIPHERAL BLOOD LYMPHOCYTE TELOMERE LENGTH IN RELATION TO
MORTALITY AND MORBIDITY IN HODGKIN LYMPHOMA PATIENTS
R. M’kacher1,2, T. Girinsky3, B. Colicchio4, M. Ricoul1, A. Dieterlen4,
E. Jeandidier5, L. Heidingsfelder6, C. Cuceu1, J. Bourhis3,7, W. Hempel1,
S. Koscielny8, J.F. Paul9, L. Sabatier1, P. Carde10
1Radiobiology and Oncology laboratory, CEA, DSV/iRCM, Fontenay-aux-
Roses, France; 2Cell Environment Oncology Section, Paris, France; 3Department
of Radiation Oncology, Institut Gustave Roussy, Villejuif, France; 4Laboratoire
MIPS, Groupe TIIM3D Université de Haute-Alsace, Mulhouse, France;
5Department of genetics, CHU, Mulouse, France; 6MetaSystems GmbH,
Altlussheim, Germany; 7Laboratory of Radiation Sensitivity and Radio-carcino-
genesis, Villejuif, France; 8Biostatistics and Epidemiology Unit, Institut Gustave
Roussy, Villejuif, France; 9Department of Radiology, Marie Lannelongue,
Chatenay- Malabry, France; 10Department of Hematology, Institut Gustave
Roussy, Villejuif, France
Background. Short telomeres in peripheral blood lymphocytes are
associated to an increased cancer risk as well as age-related diseases.
Our previous studies demonstrated the significant correlation between
telomere dysfunction in peripheral blood lymphocytes of retrospective
cohorts of Hodgkin lymphoma (HL) patients and the high risk of late
complications, in particular secondary cancers and cardiovascular dis-
ease. In this study, we investigate telomere length in a prospective
cohort of HL patients followed more than 12 years after diagnosis.
Patients and Methods. Telomere length measurements were performed
at several time points in a prospective cohort of 220 HL survivors
patients (95.9% stage I and II). Patients were diagnosed between 1997
and 2005 with a median follow-up 11.2 years. All patients were treated
with a combination of chemotherapy and radiation therapy. We eval-
uated the association between telomere length measured at diagnosis,
after treatment and during follow-up. The dynamics of telomere change
between those time points in relation to HL cancer specific and all-
cause mortality and morbidity was assessed using Cox proportion haz-
ards models. Cardiovascular evaluation has been described previously
(Girinsky et al. 2014). Results. Fifty-seven patients developed cardiovas-
cular disease, 19 a secondary cancer and 10 died. Telomere length at
baseline and follow-up after treatment were associated with all-cause
mortality (p=0.02 and p=0.008, respectively). A stable telomere length
was associated with the absence of late complication. Changes in telom-
ere length were associated to the occurrence of a late complication,
either cardiovascular or secondary cancer (p<10-3). A high variation of
telomere length and the presence of a sub population of cells with dras-
tic telomere shortening was observed during follow-up preceding a sec-
ondary cancer (p<10-3). Telomere dysfunction was related to the pres-
ence of complex chromosomal exchanges. Conclusions. Telomere short-
ening was associated with an increased risk of the occurrence of sec-
ondary cancer and all-cause mortality. Changes in telomere length in
circulating lymphocytes over time may represent valid biomarkers for
the prognosis. Telomere dysfunction may play a significant role in the
initiation of genomic instability during carcinogenesis. Further investi-
gation to determine causes of telomere change is needed.
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THE IMPACT OF TREATMENT TYPE AND AGE ON OVARIAN TOXICITY IN THE RATHL STUDY
R.A. Anderson, R. Remedios, A.A. Kirkwood, P. Patrick, L. Stevens,
T. Roberts, A.M. Carella, M. Federico, A. Fossa, C. Hatton,
N. Kalakonda, D.W. Milligan, P. McKay, J. Radford, C. Rowntree,
F. Scott, P. Smith, P.W.M. Johnson
MRC Centre for Reproductive Health, The University of Edinburgh, Edinburgh,
UK; Cancer Research UK & UCL Cancer Trials Centre University College
London, London, UK; Cancer Research UK Centre, Southampton, UK
This analysis examined the differential effects upon ovarian function
of the treatment strategies within the international RATHL study
(NCT00678327). Women with newly diagnosed advanced HL (stages
IIb to IV, IIa with bulk or ≥3 involved sites) had two cycles of ABVD
followed by PET/CT scan. Those with negative scans were randomised
to ABVD or AVD for 4 more cycles, those with positive scans were
escalated to either BEACOPP-14 or escalated BEACOPP for 8-9 weeks.
Reproductive hormones were measured in women in the main cohort
of the trial (n=390) with additional samples taken in a sub-group for
measurement of anti-Müllerian hormone (AMH) as a marker of the
ovarian reserve (n=63). There were no differences between the ABVD
and AVD groups. AMH fell markedly from baseline to end of treatment,
but equally in all 3 groups. Thereafter, there was a return to concentra-
tions not different from pre-treatment in the ABVD/AVD groups within
1 year, but no recovery in the BEACOPP groups over 3 years. An FSH
threshold of >25IU/L was used to indicate premature ovarian insuffi-
ciency (POI). The prevalence of this threshold was substantially higher
for women treated with BEACOPP than those treated with ABVD/AVD
(see Table 1), with longer and less complete recoveries. Patients aged
over 35 were more likely to exhibit POI, especially after BEACOPP
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therapy. Pre-treatment AMH was associated with post-chemotherapy
ovarian damage in all groups. ABVD/AVD regimens are regarded as
low risk to fertility, and these results confirm the absence of detectable
ovarian damage in women aged <35, although there was some evi-
dence of ovarian toxicity in older women. Pre-treatment AMH may be
of value to predict early POI and loss of fertility following treatment
by identifying those women at particular risk who may wish to con-
sider fertility preservation strategies.
Table 1.
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OSTEONECROSIS AFTER TREATMENT FOR HODGKIN LYMPHOMA:
THE GERMAN HODGKIN STUDY GROUP EXPERIENCE
S. Borchmann1, H. Müller1, H. Haverkamp1, C. Baues2, J. Marková3,
A. Hüttmann4, A. Glunz4, M. Fuchs1, P. Borchmann1, A. Engert1
1First Department for Internal Medicine, University Hospital of Cologne, Köln,
Germany; 2Department of Radiooncology, University Hospital of Cologne, Köln,
Germany; 3Department for Internal Medicine and Haematology, University
Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University,
Prague, Czech Republic; 4Clinic for Hematology, Essen University Hospital,
Essen, Germany
Background. Osteonecrosis (ON) has been reported as an infrequent
but sometimes debilitating late effect of HL therapy. The goal of this
study is to provide a detailed analysis of ON as a late effect after treat-
ment for HL. Methods. 12,083 patients treated within first-line GHSG
trials between 05/98 and 07/14 were evaluated. ON cases were identi-
fied and information on patient characteristics, localizations, interven-
tions and outcomes was collected. Risk factors for ON were analyzed
by multivariate logistic regression. Results. 66 patients had a total of
140 ON. The cumulative incidence of ON was 0.16% [CI: 0.08-0.30]
in early (favorable or unfavorable) stage HL (esHL) (n=10) and 0.93%
[CI: 0.71-1.21] in advanced stage HL (asHL) (n=54). 75% of ON cases
were male. 71% of patients had more than one area affected and in
73% ON of the femoral head was present. 54% of patients needed sur-
gical intervention and 66% had lasting symptoms despite treatment.
Peak incidence (41%) was observed in the second year after diagnosis
and 83% of cases occurred within 3 years after HL diagnosis. In a mul-
tivariate logistic regression comprising all patients, male gender (OR
2.1; CI: 1.2-3.7) and asHL (OR 3.9; CI: 2.3-6.9) were identified as risk
factors for ON. Because ON was a rare complication in esHL, the fol-
lowing results focused on survivors of asHL. The median cumulative
prednisone dose in ON cases after asHL was 8,400mg (range: 3,920-
10,800) versus 7,350mg (range: 0-16,800) in not affected patients. In a
multivariate logistic regression model including only asHL patients,
young age (OR 0.7 for each additional 10 years; CI: 0.5-0.9) and a higher
cumulative dose of prednisone during therapy (OR 1.3 for each addi-
tional 1gr; CI: 1.1-1.5) were identified as additional risk factors. Nodal
pain after alcohol ingestion (p=0.78), radiotherapy (p=0.29), a large
mediastinal tumor (p=0.13), international prognostic score (IPS) (p=0.09)
and body-mass-index (BMI) (p=0.99) did not influence ON risk. Con-
clusions.We provide the most comprehensive analysis of ON after HL
therapy performed so far. ON after HL therapy is infrequent but often
leads to significant disease burden in affected patients. The described
risk factors and peak incidence timeframe could help to identify patients
at high risk for ON. Early evaluation of patients with suggestive symp-
toms is recommended. Decreasing the cumulative corticosteroid dose
in future regimens might reduce the incidence of ON after HL therapy.
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LONGITUDINAL EVALUATION OF HEALTH-RELATED QUALITY OF LIFE IN HODGKIN
LYMPHOMA PATIENTS AND SURVIVORS: RESULTS FROM THE GERMAN HODGKIN STUDY
GROUP
I. Hude1, H. Müller2, H. Görgen2, C. Bürkle2,3, K. Behringer2,3, V. Diehl2,
A. Engert2,3, P. Borchmann2,3, on behalf of the German Hodgkin Study
Group
1Department of Internal Medicine, Division of Hematology, University Hospital
Center Zagreb, Zagreb, Croatia; 2German Hodgkin Study Group (GHSG),
University Hospital of Cologne, Cologne, Germany; 3Department of Internal
Medicine I, University Hospital of Cologne, Cologne, Germany
Background.One of the most commonly used patient reported outcome
(PRO) measures in oncology is the European Organisation for Research
and Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).
In a recent publication by EORTC Quality of Life Group, global HRQoL
(gHRQoL), a single higher order measurement model for QLQ-C30, was
found to be robust and is recommended to supplement the traditional
15-outcome profile. Aim of this study is to evaluate longitudinal gHRQoL
from diagnosis to year 5 after end of treatment (y5EOT ) in GHSG clinical
trials for early-stage favorable (HD13), early-stage unfavorable (HD14)
and advanced-stage (HD15) HL. Methods. 5,306 qualified patients of the
HD13-HD15 trials (ISRCTN63474366, ISRCTN04761296,
ISRCTN32443041) ≤60 years at study entry were eligible for evaluation;
4,110 provided HRQoL data. Patients were treated with different risk-
adapted therapies . EORTC QLQ-C30 was used to evaluate gHRQoL
from diagnosis to y5EOT with means and 95% confidence intervals.
Treatment effects on gHRQoL in y2EOT and y5EOT were tested with
multiple linear regression analyses adjusting for age, gender and base-
line-gHRQoL. Results. Analysis showed significantly worse baseline-
gHRQoL with higher stage (means [95%-CI]: HD13 80.6 [79.5-81.8],
HD14 76.1 [75.2-77.0], HD15 71.0 [70.0-71.9]). During chemotherapy,
gHRQoL worsened in all stages (means [95%-CI]: HD13 63.5 [62.2-64.8],
HD14 62.8 [61.9-63.8], HD15 62.7 [61.9-63.6]), rapidly improving there-
after. Compared to baseline, gHRQoL in the early-stage group recovered
and remained stable from y1EOT, whereas in higher stages it improved
significantly above baseline value, also remaining stable during follow
up (y5EOT means [95%-CI]: HD13 82.6 [80.8-84.4], HD14 83.9
[82.6]85.1, HD15 82.5 [81.4-83.7]) (Figure 1). Age- and gender-adjusted
German reference values of gHRQoL (93.5-93.9 in HD13-HD15) were
not reached at any time point. Comparison of standard vs successful
experimental treatments showed that treatment intensity had no signif-
icant influence on long-term gHRQoL. Age and baseline gHROoL were
predictive of gHRQoL in y2EOT and y5EOT. Conclusions.Global HRQoL
is largely impaired among HL patients. Despite significant baseline dif-
ferences, gHRQoL after therapy seems independent of initial stage or
treatment regimen and does not recover to normal values, warranting
further investigation. QLQ C30 summary score seems like a promising
tool for PRO evaluation, encouraging further testing.
Figure 1.
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BREAST CANCER AFTER HODGKIN LYMPHOMA: INFLUENCE OF ENDOGENOUS AND
EXOGENOUS GONADAL HORMONES ON THE RADIATION DOSE-RESPONSE RELATIONSHIP
B.M.P. Aleman1, I.M. Krul2, A.W.J. Opstal van Winden2, C.P.M. Janus3,
A.M. van Eggermond2, M.L. De Bruin4, M. Hauptmann2, A.D.G. Krol5,
M. Schaapveld2, A. Broeks6, K.R. Kooijman2, S. Fase2, M. Lybeert7,
J.M. Zijlstra8, R.W.M. van der Maazen9, A. Kesminiene10, I. Diallo11,
F. De Vathaire11, N.S. Russell1,*, F.E. van Leeuwen2,*
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dam, The Netherlands; 2Department of Epidemiology, The Netherlands Cancer
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Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands;
5Department of Clinical Oncology, Leiden University Medical Center, Leiden,
The Netherlands; 6Division of Experimental Therapy and Molecular Pathology,
The Netherlands Cancer Institute, Amsterdam, The Netherlands; 7Department
of Radiotherapy, Catharina hospital, Eindhoven, The Netherlands; 8Department
of Hematology, VU University Medical Center Amsterdam, Amsterdam, The
Netherlands; 9Department of Radiation Oncology, Radboud University Medical
Center, Nijmegen, The Netherlands; 10Section of Environment and Radiation,
International Agency for Research on Cancer, Lyon, France; 11Department of
Clinical Research, Gustave Roussy, Villejuif, France
*Authors contributed equally to this work
Background. After chest radiotherapy (RT) for Hodgkin lymphoma (HL),
women experience a dose-dependent increase of breast cancer risk. It is
unknown whether endogenous and exogenous gonadal hormones affect
the radiation dose-response relationship. Methods. We conducted a case-
control study nested within a cohort of female 5-year HL survivors treated
before age 41 years between 1965 and 2000. Detailed data on HL treat-
ment, reproductive factors and hormone use were collected through med-
ical records and questionnaires for 174 breast cancer cases and 466
matched HL controls who did not develop breast cancer. RT charts, sim-
ulation films and mammography reports were used to estimate the radi-
ation dose to the location of the breast tumor (and similar location for
matched controls). Results. The median interval between HL diagnosis and
breast cancer diagnosis was 21.9 years. Ninety-eight percent of the cases
received supradiaphragmatic RT and 3% pelvic RT (without successful
oophoropexy) compared with 92% and 9% of the controls respectively.
We observed a linear radiation dose-response relationship for risk of breast
cancer with an adjusted excess odds ratio (EOR) of 5.4%/Gray
(95%CI:1.8%-13.3%). Women who reached menopause before age 30
years (caused by high dose of procarbazine or pelvic RT) had a lower risk
(OR 0.13; 95%CI:0.03-0.54) than women who reached menopause at age
≥50 years when adjusted for RT dose. Breast cancer risk increased by 7.4%
for each additional year of intact ovarian function after RT (P<0.001).
Among women with an early menopause (<45 years), the use of hormone
replacement therapy (HRT) for ≥2 years did not increase breast cancer risk
(OR 0.81, 95%CI:0.30-2.21), while this risk was non-significantly
increased among women who became menopausal at ages ≥45 years (OR
1.91, 95%CI:0.70-5.20). Moreover, endogenous and exogenous hormones
did not statistically significantly modify the slope of the linear radiation
dose-response relationship. Conclusions. Among female survivors of HL
treated with chest RT, a therapy-induced premature menopause reduces
their radiation-associated breast cancer risk. However, hormone replace-
ment therapy use did not appear to increase breast cancer risk in these
women. There was no evidence for interaction between RT dose and
number of years with intact ovarian function or HRT use.
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LAUNCH OF THE BREAST SCREENING AFTER RADIOTHERAPY DATASET - AN ENGLAND
WIDE INITIATIVE TO IMPROVE SCREENING FOR BREAST CANCER IN 9,000 WOMEN AT
HIGH RISK FOLLOWING RADIOTHERAPY TO BREAST TISSUE UNDER AGE 36
J. Radford1,2, S. Howell1,2, K. Vaughan1,2,4, V. Goode2, D. Worthington3,
N. Yates-Bolton3, E. Payne4, J. Jenkins4, M. Sibbering4, A. Swerdlow5,
R. Cowan1,2
1The University of Manchester, Manchester, UK; 2The Christie NHS Foundation
Trust, Manchester, UK; 3Consumer Representatives; 4Public Health England;
5Institute of Cancer Research, Sutton, UK
Introduction.Women who received radiotherapy (RT) involving breast
tissue when aged 36 yrs most usually for Hodgkin lymphoma are at
high risk of developing breast cancer. UK national guidelines published
in 2003 recommend that breast screening should start 8 years after RT
or at age 25 whichever is later. Screening depends upon individual
haemato-oncologists referring at-risk women to breast screening centres
and this is prone to delay/error leading to survivor anxiety/frustration
and time consuming troubleshooting to correct. A decision was there-
fore taken to develop a single national dataset of at-risk women (BARD)
from which annual screening appointments could be generated. Meth-
ods. 3 at-risk cohorts were identified: Cohort 1 women irradiated pre-
2003 identified from a national recall exercise in 2003 to inform about
risk and advise screening in accordance with national guidelines
(n~6,500); Cohort 2 women irradiated 2003-2016 identified from
National Cancer Registry and Radiotherapy Centre Records (n~2,500);
Cohort 3 women irradiated from now into the future identified prospec-
tively at the time of consent for RT. Prior to registration with BARD
family physicians were contacted to enquire whether a screening
appointment was still appropriate for each survivor. Results. Project sign-
off from NHS England and Public Health England occurred January
2016. A pilot phase across 4 RT centres in the northwest of England is
currently completing (May 2016) and once any learning from this has
been incorporated into the processes a national rollout will occur with
planned completion in Q4 2016. The NHS Breast Screening Programme
will use BARD to identify women irradiated under age 30 years who
require screening in any given year. Screening of women irradiated aged
30-35 years will be arranged by their family physician. Discussion. An
England wide dataset of ~9,000 women who have received RT involv-
ing breast tissue when aged 36 yrs has been launched to optimise breast
screening in this high risk group. It is hoped that as a result the service
to women will be enhanced and breast cancer outcomes improved. A
BARD research group has also been formed to undertake relevant
research; this will include qualitative assessments of the user experience,
evaluation of the effectiveness of current screening with a view to
improving the screening regime, studies of the biological characteristics
of RT induced vs sporadic breast cancers and risk reduction trials.
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MANAGED LOCAL FOLLOW-UP OF LONG TERM LYMPHOMA SURVIVORS – THE ADAPT
PROGRAMME
J. Radford1,2, V. Goode1, E. White1, R. Monkhouse1, R. Cowan1,2
1The Christie NHS Foundation Trust, Manchester, UK; 2The University of
Manchester, Manchester, UK
Introduction. A high proportion of patients treated for Hodgkin lym-
phoma and diffuse large B cell lymphoma are cured following
chemotherapy/radiotherapy but long term quality of life and survival
are undermined by the late toxicities of treatment including second can-
cers, cardiovascular disease and hormonal disorders. For best outcome
these need to be anticipated/well managed and survivors/health care
professionals made aware of how best to achieve this. The aim of
ADAPT is to improve the management of patients likely cured of lym-
phoma by increasing survivor/primary care physician awareness of late
treatment toxicities whilst reducing the burden on survivors of atten-
dance at hospital clinics and maintaining accurate outcomes data. Meth-
ods. After 5 yrs of hospital follow-up, likely cured patients are offered
a final “ADAPT consultation” focused on the future low risk of recur-
rence and potential for late treatment toxicity. An individualised treat-
ment summary and late toxicity management plan (LTMP) is given to
survivors and copied to their primary care physician. The LTMP is con-
structed by selecting from a menu of pre-written paragraphs describing
the possible late toxicities of each treatment, their symptoms, manage-
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ment and key points (cardiac key points; don’t smoke, take exercise,
check blood pressure). These paragraphs were all reviewed and
approved for relevance and readability by a panel of 25 lymphoma sur-
vivors. Following the ADAPT consultation, survivors receive no further
routine hospital appointments but can access the service immediately
if the need arises. An annual questionnaire is issued by e-mail or letter
according to survivor preference enquiring about quality of life, new
diagnoses, new medication or surgical interventions and this informa-
tion added to the survivor database. Results. 600 survivors have so far
been ADAPTed and anecdotal evidence suggests satisfaction with the
service. On the basis that the average time for a return journey from
home or work, waiting and consultation is 3 hours, 600x3=1800 sur-
vivor hours or 1800/40=45 working weeks have been saved per year.
Conclusions. The ADAPT programme provides long term lymphoma
survivors and their primary care physician with individualised infor-
mation about late treatment toxicity, shifts the focus of management
of this from the hospital to primary care and saves time whilst main-
taining accurate long term outcomes data. Formal evaluation of this
new service is planned.
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THE ROLE OF WATCH AND WAIT IN NODULAR LYMPHOCYTE PREDOMINANT HODGKIN
LYMPHOMA: SINGLE CENTRE DATA FROM THE MODERN ERA 
A. Navarro-Bailón1,2,*, J.G. Taylor1,3,*, J. Matthews3, S. Montoto1,3,
J.G. Gribben1,3
1Haemato-Oncology, St Bartholomew’s Hospital, London, UK; 2Hematology,
Hospital General Universitario Marañón, Madrid, Spain;3Barts Cancer Institute,
Queen Mary University of London, UK
*Contributed equally
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is
an indolent lymphoma with excellent overall survival (OS) and distinct
clinicopathological characteristics reclassified as separate to Classical
Hodgkin Lymphoma (CHL). Debate is ongoing as to optimum man-
agement. Guidelines differ in approach, particularly around watch and
wait (W+W); ranging from selected use in all stages (B J Haem 2015),
to advanced disease (NCCN 2015) to not at all (ESMO 2014). Few stud-
ies have assessed W+W, with discordant results. All were retrospective
and include cases diagnosed before reclassification. We conducted a
retrospective analysis to investigate outcomes of adults with NLPHL
diagnosed and managed at St Bartholomew’s hospital from 1994 (reclas-
sification) to 2014. This represents the largest single centre study report-
ing data obtained since reclassification. Clinical characteristics, treat-
ment, OS, progression free survival (PFS) and Disease Free Survival
(DFS) were collected. Forty-four patients were included. 82% had lim-
ited (stage IA or IIA) disease, 73% were male. Median age was 38.
Patients of Black (25%) and Asian (39%, mainly Bangladeshi) origins
were overrepresented compared to CHL cases (7% Black, 13% Asian)
or any haematological malignancy (8% Black, 10% Asian) managed
during this period. Initial management consisted of W+W +/- excision
(32%), Radiotherapy +/- excision (29%) and Chemotherapy (mostly
ABVD; in 2 cases R-ABVD) or Combined Modality (39%). W+W was
used in 36% of patients with limited and 25% with advanced disease.
Median follow-up was 63 months. 10-year OS and PFS estimates were
100% and 60% respectively. Two transformation events were
observed, none in the W+W group. One patient died from an unrelated
cause. 80% of W+W patients remained untreated at median follow up
of 29 (5-198) months. No significant differences were seen in PFS, DFS
or OS between W+W and immediate treatment. Our data is consistent
with an increased incidence seen in African-Americans. Raised inci-
dence in Asian groups has not previously been reported. The differing
racial demographic profile to CHL supports NLPHL’s separate classifi-
cation. The relatively good PFS and excellent OS support consideration
of W+W as a management option, given that most patients remained
treatment free after long follow up. Our data support the need for a
clinical trial to assess W+W versus immediate treatment. Given the rar-
ity of NLPHL this would require an international collaborative study.
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NEURO-BEHAVIORAL CHANGES IN HODGKIN LYMPHOMA SURVIVORS
E. Trachtenberg1, T. Mashiach2, J. Aharon-Peretz1,3, E.J. Dann1,4
1Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; 2Quality Assurance
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Background. Hodgkin lymphoma (HL), frequently diagnosed at the
young age, is currently treated with chemotherapy and/or radiotherapy
(RT). The combination of malignancy and chemotherapy is often asso-
ciated with neuro-behavioral impairment (NI), reported in up to 75%
of adult survivors in various malignancies. NI involves fatigue and cog-
nitive changes such as slowness and impairment of memory, concen-
tration and executive functioning. NI is particularly dramatic for young
adult HL survivors (YAHLS), given their age at diagnosis, long life
expectancy and high curability. The current research aimed to assess
the incidence and characteristics of NI in YAHLS. Methods. The study
evaluated YAHLS, who completed first-line therapy (chemo±RT) and
remained in complete remission (CR) for 6 months-5 years after the
end of treatment. All participants completed questionnaires evaluating
fatigue (MFI-20), depression (BDI-II), anxiety (HA), quality of life (QLQ-
C30) and cognitive function (FACT-cog), and underwent neuropsycho-
logical evaluation. The test battery included California verbal learning
test, Digit span (WAIS-III), Trail making test A+B, subtests from the
Computerized Battery (CANTAB), Stroop and Raven progressive matri-
ces tests. Processing speed, memory, and executive functions were
assessed and calculated for each subject. Test and subtest results were
presented in standard scores. Results. We report results of 21 YAHLS,
aged 19-47 years (median 28), with mean education duration of
14.4±2.2 years. No significant depression or anxiety was observed in
study participants. Severe fatigue was reported in 33% of patients.
Impairment in executive functions, with scores below 1.5SD in at least
2 parameters, was observed in 33% of patients (76% below 1SD).
Scores below 1.5SD in at least 2 parameters of memory were found in
19% of patients (53% below 1SD). Slow processing speed was depicted
in 38% of patients (TMT-B). No correlation was found between NI and
fatigue. Conclusions. NI and fatigue were observed in one third of
patients. An impairment score above 1SD and especially above 1.5SD
below that expected for age and education is usually regarded signifi-
cant. Our results were unexpected. Given the enormous impact of these
symptoms on all aspects of life, they need to be taken into consideration
while assessing the efficacy of therapeutic protocols applied in YAHLS. 
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HEALTHCARE USE AMONG YOUNG HODGKIN LYMPHOMA SURVIVORS IN THE ERA OF
INTENSIFIED CHEMOTHERAPY AND LIMITED RADIOTHERAPY
S. Eloranta1, K.E. Smedby1,2, S. Ekberg1, E. Chang3, M. Neovius1,
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Purpose. With today’s excellent cure rates for Hodgkin lymphoma
(HL), the number of long-term survivors is increasing. This study pro-
vides a global assessment of late effects for working-age HL survivors
treated with contemporary protocols (intensive chemotherapy and lim-
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ited radiotherapy). Patients and Methods. From Swedish nationwide reg-
isters we identified 1017 HL survivors diagnosed in 2000-2009, aged
18-60 years (median 32) and surviving at least one year post-diagnosis,
and 4031 age-, sex- and calendar-year-matched population comparators.
Incidence rate ratios (IRR) and 95% confidence intervals (95%CI) for
hospital outpatient visits and hospital bed-days after the first year and
up to 2013 (maximum 14 years post-diagnosis) were estimated across
treatment subgroups, considering relapse-free time and using negative
binomial regression. Scheduled outpatient visits for HL were excluded
but inpatient visits for HL were included in analysis of bed-days. Results.
The rate of outpatient visits among relapse-free survivors was nearly
double (IRR=1.8, 95%CI: 1.6-2.0) and the rate of bed-days was more
than triple that among comparators (IRR=3.6, 95%CI: 2.7-4.7). The
higher rates of outpatient visits persisted up to 10 years and bed-days
up to four years post-diagnosis. However, absolute numbers of extra
visits were low (mean=2 outpatient visits and 2 bed-days, respectively,
during follow-up). Patients requiring 6-8 chemotherapy courses had
higher rates of outpatient visits (IRR=1.4, 95%CI: 1.1-1.7) and bed-days
(IRR=4.7, 95%CI: 2.9-7.8) than patients treated with 2-4 courses+radio-
therapy. Established late effects including heart disease and second
malignancies accounted for a minority of outpatient visits. Previously
unstudied reasons for excess healthcare use included diabetes mellitus,
keratitis, chest pain, and asthma (Figure 1). Conclusions.Chemotherapy,
but not radiotherapy, appears to drive the slight excess healthcare use
among contemporarily treated HL survivors. The diagnoses of health-
care visits reflected a broad panorama of disorders, indicating the need
of comprehensive care in addition to specific screening programs. 
Figure 1.
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Background. Hodgkin lymphoma (HL) survivors are at increased risk
to develop late treatment-related complications, including second malig-
nant neoplasms (SMNs) and cardiovascular disease (CVD). Research to
date has focused on separate risk estimates for these outcomes. We
aimed to examine the combined risk of SMN and CVD, providing more
insight into the total burden of morbidity from these severe late effects.
Methods. Our multicenter cohort comprised 2,908 5-year HL survivors,
treated before age 51 between 1965 and 2000. CVD endpoints (coronary
heart disease, cardiomyopathy and congestive heart failure, and valvular
heart disease) were assessed through general practitioners. Data on
SMNs were obtained from linkage with the Netherlands Cancer Reg-
istry, including all invasive cancers except basal cell carcinomas. Cumu-
lative incidences of SMN and/or CVD were calculated with death from
other causes as competing risk. Treatment-specific risks of developing
SMN and/or CVD were quantified using Cox regression analysis. The
mean cumulative count (MCC) will be calculated as the average number
of events per individual in our cohort over a given follow-up period
(results will be available in October 2016). Results. After a median fol-
low-up of 22 years, we identified 874 SMNs and 1044 CVDs. 1249
patients developed ≥1 major event; of those 240 developed both an
SMN and CVD. After a follow-up of 40 years, at a median attained age
of 60 years, the cumulative incidence of SMN or CVD was 67.4%
(95%CI: 64.6-70.0), with 22.5% (95%CI: 19.8-25.3) of patients being
diagnosed with both events. Both supradiaphragmatic RT (Hazard Ratio
[HR]: 2.5, 95%CI: 2.1-3.1) and anthracycline-containing CT (HR: 1.2,
95%CI: 1.0-1.4) independently increased the risk of SMN or CVD.
Supradiaphragmatic RT was associated with a 4.1-fold increased
(95%CI: 2.3-7.3) risk of developing both SMN and CVD. Conclusions.
HL survivors experience a high disease burden from SMN and/or CVD
during follow-up. The cumulative incidence of SMN and/or CVD in
our HL population treated between 1965 and 2000 amounted to 67%
after 40 years from initial treatment. Supradiaphragmatic RT most
strongly increased the risk developing SMN and/or CVD.
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SURVIVAL IN WOMEN WITH LYMPHOMA: A SINGLE-CENTER EXPERIENCE
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Background. Lymphoma affects many women of childbearing age.
Fertility preservation (FP) prior to chemotherapy offers women an
opportunity for future pregnancy if fertility is compromised. Fear of
treatment delay is one factor contributing to low rates of referral for
fertility preservation. Methods.We performed a retrospective review of
female lymphoma patients who contacted a fertility preservation
patient navigator (FPPN) at Northwestern University from May 2006
until August 2015. Our primary objective was to assess the median
treatment delay associated with FP. Our secondary objective was to
assess progression free survival (PFS). Patients who underwent FP were
compared to women that contacted a FPPN but did not undergo preser-
vation. Results. Thirty-three subjects who underwent FP and 50 controls
were analyzed. Among FP patients, 21 had Hodgkin lymphoma, 12 had
non-Hodgkin lymphoma; 25 presented for upfront treatment and 8 with
relapsed/refractory disease. Controls had a higher median age (29 in
control versus 26 in FP, p=0.001); however, there was no difference
between groups in histology, treatment setting, or stage. Median fol-
low-up was 39.3 (1.5 – 103.4) months, and did not differ between con-
trols and those undergoing FP (p=0.16). Median time to treatment
among FP patients was 28 days (range: 18-76) versus 15.5 days (range:
0-74) for controls, resulting in a median delay of 12.5 days (p<0.001).
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The median time to first contact with a fertility specialist was 0 days
(range -15 to +11) from hematology consult, with several patients hav-
ing contact prior to their hematology visit. There was no difference in
5 year PFS between FP patients and controls (71.4% vs 83.7%, respec-
tively, p=0.11). Median time to complete the stimulation protocol was
11 days (range: 5-14). A median of 14 oocytes (range: 0-37) was
retrieved per patient. In 2 women, no oocytes could be successfully
retrieved. Five women achieved pregnancy following fertility preser-
vation. Of these, 3 were spontaneous, and 2 required reproductive assis-
tance, one from frozen embryos and one from frozen oocytes. Of three
women returning to use their frozen gametes, 2 were successful, and
one was unsuccessful. Conclusions.This study demonstrates that fertility
preservation is feasible and results in a small delay in therapy. This
approach does not significantly impact PFS in our series. 
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COMORBIDITY ASSESSMENT USING THE CIRS IN ELDERLY PATIENTS WITH HODGKIN
LYMPHOMA: PREDICTION OF SURVIVAL
A. Cuccaro, E. Galli, E. Maiolo, S. Bellesi, F. D’Alò, S. Hohaus
Institute of Hematology, Catholic University of the Sacred Heart, Rome, Italy
The ABVD regimen is the standard of care for patients with Hodgkin
lymphoma up to 70 years. This regimen has been considered to be too
toxic for elderly patients, and alternative regimens have been proposed,
that are often associated with a reduced efficacy. The evaluation of
comorbidity has not been extensively studied in HL. We reasoned that
evaluation of comorbidity according to a standardized approach, the
Cumulative Illness Scaling Rate (CIRS) might be a predictor for overall
survival (OS). We studied 62 consecutive elderly patients with HL
(median age 68 years, range 60-83 years), who had been treated in our
institution between 1999 and 2016. Chemotherapy was ABVD in 47
(76%) patients, COPP in 12 (19%) patients, and other in 3 (5%) patients.
OS at 2 years was 70% (95% C.I., 55-81%). Comorbidity was rated
on the 4-point CIRS scale for 13 main organ systems. 36 patients had
no severe comorbidity (score >3) and were considered fit (58%), while
26 patients had at least one severe comorbidity and were considered
frail (42%). Patients with at least one severe comorbidity were more
likely to be >70 years old (p=0.03), to have advanced stage disease
(p=0.02) and not to receive ABVD (p=0.01). Patients with at least one
severe comorbidity had a 2-year OS of 17% (95% C.I. 3-41%) versus
89% (95% C.I., 73-96%) in fit patients (p=0.001). We next restricted
the analysis to ABVD-treated patients. Frail patients still had a signifi-
cant worse 2-year OS (65%; 95% C.I., 25%-88%) with respect to fit
patients (97%; 95% C.I., 79-99%) (p=0.02), that was however better
than for patients treated with MOPP (2-year OS: 11%). We conclude
that a significant proportion of elderly HL patients has severe comor-
bidity on the CIRS scale, that impacts on prognosis. Prospective studies
including comprehensive geriatric assessment are warranted to better
tailor therapy in the often frail elderly patients with HL.
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RISK ADAPTED ABVD BASED PROTOCOL WITH RESTRICTED RADIOTHERAPY TO BULKY
DISEASE FOR HODGKIN LYMPHOMA: A 20 YEAR FOLLOW UP MULTICENTER ANALYSIS
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Introduction. The combination of radio and chemotherapy in HL has
led to the greatest advances in disease response. The benefit in terms of
overall survival (OS) has been jeopardized by long term toxicity related
to second malignancies and cardiovascular events. Aim.Analyze the risk
factors associated with survival and asses the frequency of secondary
malignancies with an ABVD based regimen that restricted radiotherapy
only to bulky disease. Materials and Methods.We retrospectively analyzed
HL patients diagnosed in 4 centers in Tarragona area (Catalonia, Spain),
between 1995 and 2015 treated uniformly according to a local protocol.
Patients were assigned into 4 groups: G1: favorable early stage: ABVDx6
cycles, G2: Bulky early stage without other risk factors: ABVDx6+IFRDT.
G3: unfavorable early stage (B symptoms) and advanced stage without
bulky disease: ABVDx8, G4: Bulky advanced stage: AVBDx8+IFRDT.
Results. A total of 183 patients were analyzed with a median follow up
of 82 months [range 1-244]. Male/female ratio was 1,29. Median age was
36 years [range 16-82]. Complete response was achieved in 160 patients
(87,4%). The estimated OS at 20 years for the whole group was 62.7%.
In univariate analysis, worse OS was found in patients with increased
LDH, non-NS subtype, albumin <3,5 g/d, B symptoms, HIV+, advance
stage and ESR >50 mm (log rank p=0,012; p=0,049; p=0,024; p=0,002;
p=0,005; p=0,004 and p=0,001 respectively). The multivariate Cox regres-
sion analysis identified B symptoms and ESR >50 mm as independent
prognostic factors for OS (p=0,002; p=0,006 respectively). Furthermore,
B symptoms was also found as an independent prognostic factor for OS
when patients were analyzed according to disease stage (localized and
advanced) (p=0,018; p=0,014) while ESR >50 mm was an independent
prognostic factor for the advanced disease group only (p=0,038). Second-
ary malignancies were observed in 18 patients (9,8%). The most frequent
were hematological in 6 patients (3 myelodysplastic syndrome, 3 non
Hodgkin lymphoma), gynecological 4 patients (2 breast cancer, 2 adnexal
carcinoma) and colorectal 2 patients. Two patients developed 2 malig-
nancies. Conclusions. Our risk adapted protocol showed a good rate of
response and overall survival with low rate of secondary malignancies.
B symptoms and elevated ESR were independently associated with OS
in the whole group.
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INFRADIAPHRAGMATIC HODGKIN LYMPHOMA: A LARGE SERIES OF PATIENTS STAGED
WITH PET-CT. A PARTICULAR SUBSET OF HL?
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Introduction. Infradiaphragmatic Hodgkin Lymphoma (IDHL) accounts
for 3-11% of adult cases of stage I-II Hodgkin Lymphoma. While the
treatment strategy of most clinical subsets of HL has been improved
and standardized along the last decades, it remains more heterogeneous
in IDHL. Moreover, previous studies considered IDHL, patients on the
basis of CT-scan staging which could underestimated advanced disease
compared to the more sensitive PET-CT staging currently widely avail-
able. Thus, this study aimed to evaluate the characteristics of PET-
staged IDHL patients compared to patients with an IDHL disease
defined on the basis of CT scan assessment, and to analyse the outcome
of patients with PET-defined disease. Methods. The baseline clinical,
biological data, and the outcome of patients with a first diagnosis of
stage I-II of IDHL treated with ABVD +/- radiotherapy were retrospec-
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tively collected in 8 french departments of hematology. Patients with a
positive HIV serology and those treated with radiotherapy alone were
excluded. Results. From 1986 to 2014, 99 patients were included whose
65 (66%) of them were staged with PET-CT. PET-CT staged patients
were older (53 years vs 47 years, p=0.043), had lower ESR (27 vs 58
mm, p= 0.022), higher haemoglobin level (13.6 vs 12.8g/dL, p=0.015),
less frequent Ann Arbor stage II (74% vs 91%) and less frequently cen-
tral adenopathy involvement (60% vs 80%, p=0.024). The median fol-
low-up of 99 patients was 3.8 years. For the PET-CT staged patients, at
five years, PFS was 78% (IC95% 0.64-0.87) and OS was 88% (IC95%
0.73-0.95). Thirteen relapses occurred (20%) whose eleven (16%) with-
in the five-years after diagnosis, and five patients died (8%), 3 from HL
progression and 2 from toxicity of chemotherapy. In univariate analysis,
patients with crural adenopathy involvement and treated with
chemotherapy alone (p=0.026) had a poorer PFS. The treatment modal-
ity retained significance (p=0.036) in the modelisation analysis and also
performans status (0.045) and crural involvement (0.005). Conclusions.
This multicenter study of IDHL shows that CT-scan defined IDHL
patients have more unfavorable characteristics than PET-CT staged
patients which might be related in some cases to more advanced dis-
eases specifically in younger patients. So, PET-CT is required for better
defining IDHL diseases. The present study suggests that chemo-radio-
therapy combined modality provides a better PFS than chemotherapy
alone in these patients.
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OF HODGKIN LYMPHOMA TREATED WITH BEACOPP ESCALATED CHEMOTHERAPY (20 YEAR
EXPERIENCE OF A SINGLE CENTRE)
J. Marková1, H. Móciková1, Ľ. Gahérová1, T. Jančárková1, Z. Vernerová2,
K. Dědečková3, T. Kozák1
1Department for Internal Medicine, Haematology, University Hospital Kralovske
Vinohrady and Third Faculty of Medicine, Charles University in Prague, Czech
Republic; 2Institute of Pathology, University Hospital Kralovske Vinohrady and
Third Faculty of Medicine, Charles University in Prague, Czech Republic; 3Proton
Therapy Center and Institute of Radiation Oncology, Na Bulovce Hospital and
1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background. BEACOPP escalated includes alkylating agents and its
gonadal toxicity has been reported in prospective and retrospective
studies. This retrospective study analyzed fertility of 98 female patients
(pts) with initial diagnosis of Hodgkin lymphoma (HL) in advanced
stages treated with BEACOPP escalated. Patients and Methods. Overall
98 women aged 18 – 34 years (median age at diagnosis was 27 years)
were treated with BEACOPP escalated between 1997 and 2015: 8 cycles
received 57 pts (58%), 6 cycles 39 pts (40%) and 4 cycles 2 pts (2%).
Additional radiotherapy was indicated in 33 pts (32%). Forty nine pts
(48%) received GnRH analogue (Diphereline) during chemotherapy to
preserve their ovarian function. Median follow-up after the end of treat-
ment was 144 months (range, 57 – 210). Results. Overall 26 women
delivered 33 babies including 7(27%) women with 2 deliveries. Median
age at diagnosis HL was 24 years (range, 19 – 32). Number of all deliv-
ered healthy babies was 32 and only one baby was born with small
cleft lip. All pregnancies were spontaneous except of 2 women that
undewent in vitro fertilization . Another 5 female pts are still pregnant.
Median time from the end of chemotherapy until the delivery of the
first baby was 78 months (range, 21 – 169). Two pregnancies were ter-
minated prematurely (week 20 and 22) due to congenital malforma-
tions: monosomy 45,X0 Turner syndrome and serious cleft lip. Despite
the low number of pts and a relatively short-term follow-up we assume,
that we can expect a higher rate of pregnancies and deliveries after the
reduction from 8 to 6 cycles of BEACOPP escalated. Conclusions. New
strategies for the protection of fertility should be offered to young
female HL patients treated with BEACOPP escalated therapy. Reduced
number of cycles of BEACOPP escalated may further contribute to
preservation of their fertility. 
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Background. Hodgkin Lymphoma treatment is associated with high
risk of treatment-related morbidity, including second cancers and car-
diovascular diseases. However, only few studies examined long-term
excess mortality. Methods. We studied cause-specific mortality in a mul-
ticenter cohort comprising 3,575 5-year HL-survivors, diagnosed before
age 51 and treated between 1965 and 1995. Follow-up was complete
until at least January 2010 for 96% of the patients. For 93% of deaths,
the cause was known. Mortality after HL was compared with mortality
in the general population by calculating standardized mortality ratios
(SMRs) and absolute excess mortality (AEM), expressed per 10,000 per-
son-years. Treatment-specific SMRs were compared by Poisson regres-
sion. Results. After a median follow-up of 21.6 years since HL treatment
1,328 patients had died (19.5% from HL, 32.5% from solid tumors,
15.5% from cardiac diseases, 7.0% from NHL/leukemia). The SMR for
causes other than Hodgkin Lymphoma was 8.2-fold that of the general
population. The cohort experienced 149.2 excess deaths per 10,000
patients per year. The SMR and AEM for causes of death other than
Hodgkin Lymphoma increased throughout follow-up: after ≥35 years
the SMR was 19.2, translating to 505.9 excess deaths per 10,000 patients
per year. Solid tumors accounted for the largest part of the excess mor-
tality (overall SMR 5.6, AEM 56.1). While the SMR for solid tumors
remained stable, the SMR for cardiac diseases (overall SMR 9.8, AEM
29.4) increased during follow-up (SMR at ≥35 years 28.8, p-
trend<0.001)). Adjusted for sex, age and follow-up time, risk of death
from cardiac diseases was increased for patients treated with supradi-
aphragmatic radiotherapy (Relative Risk (RR) 4.8, p<0.001) or anthra-
cyclines (RR 1.5, p=0.044). The SMR for infectious causes (2.9% of all
deaths, including deaths due to influenza/pneumonia) was 6.5-fold
increased. Both splenectomy (RR 2.1, p=0.041) and spleen radiotherapy
(RR 3.2, p=0.001) were associated with increased risk of death due to
infectious causes compared to patients not receiving such treatment.
Conclusions. Even 35 years after treatment, HL Hodgkin Lymphoma
patients experienced elevated SMRs and AEMs from solid tumors and
cardiac diseases. Both splenectomy and spleen radiotherapy increased
mortality due to infections.
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ELDERLY HODGKIN LYMPHOMA – MULTICENTER RETROSPECTIVE DATA ANALYSIS
FROM THE CZECH HODGKIN LYMPHOMA REGISTRY
A. Sýkorová1, H. Móciková2, V. Procházka3, M. Lukášová3,
P. Štěpánková1, D. Belada1, K. Klásková2, Ľ. Gahérová2, Z. Král4,
L. Martinková5, T. Nečasová6, E. Koriťáková6, J. Marková2
1Fourth Department of Internal Medicine - Haematology, Charles University
Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic; 2Department
of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady
and Third Faculty of Medicine, Charles University in Prague, Czech Republic;
3Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky
University and University Hospital Olomouc, Czech Republic; 4Department of
Internal Medicine and Haematooncology, University Hospital, Brno, Czech
Republic; 5Department of Haematooncology, University Hospital Ostrava and
Medical Faculty of the Ostrava University; 6Institute of Biostatistics and
Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic 
Background. The proportion of elderly Hodgkin lymphoma (HL)
patients (age ≥60 years) ranges between 15% and 35%. Outcome of
this group of patients (pts) is significantly inferior compared with
younger pts. Management of therapy is still unclear, standard treatment
is not yet defined. Purpose of this study was to analyze treatment and
outcome of elderly HL pts prospectively registered in Hodgkin Lym-
phoma Project in the Czech Republic. Patients and Methods. The pro-
portion of elderly patients in the Czech HL Registry was 11%. We ana-
lyzed 151 pts ≥60 years with classical HL (pts with nodular lymphocyte
predominant HL were excluded) diagnosed between 2000 and 2016.
Median age was 67 (60-83) years, 68.9% of them were 60-69 years old
and male gender represented 55% (83 pts). Histological subtype mixed
cellularity occured in 55%. Advanced clinical stage (CS) was confirmed
in 60.9%. Chemotherapy (CT) alone was used in 66.2% of pts
(initial/intermediate CS 23 pts, advanced CS 76 pts). Combined modal-
ity of treatment (CT and radiotherapy, RT) was used in 40 pts
(intial/intermediate CS 27 pts, advanced CS 13 pts). Anthracycline –
based CT received 79.4% of pts (86 pts). Five pts (4%) were treated
with RT alone, three pts received supportive care only and treatment
in three pts was not reported to the Registry. Results. Overall response
rate after the first-line treatment was observed in 70.9% (57.6% CR),
SD in 0.7% and primary disease progression in 7.3% of pts. Treatment
response was not evaluable in 21.2% of pts. Relapses occured in 12.6%
(19 pts) and 3 pts underwent high dose CT and autologous stem cell
transplantation (age 61, 63, 64 years). Median PFS and OS was 7.9 years
(y) and 10.2y, respectively. Two – year PFS and OS was 73.1% and
81.5%, respectively. Overall 53.6% pts are alive and 31.8% (48 pts) of
pts died: HL progression 11 pts, toxicity of treatment 14 pts, others
causes 13 pts. Conclusions.Outcome of our retrospectively analyzed pts
with classical HL compares favorably with other reported data in the
group of elderly pts. Long-term survival of our pts depended on te use
of anthracycline-containing CT. Prospective clinical studies are still
needed to determine an optimal effective regimen with low toxicity in
elderly pts. 
Support. This work was supported by grant awarded by AZV 16-
29857A, Ministry of Health in Czech Republic and Research project P
27/2012 awarded by Charles University in Prague, Third Faculty of
Medicine, Prague, Czech Republic
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INCIDENCE OF HYPERLIPOPROTEINEMIA IN LONG-TERM SURVIVORS OF HODGKIN
LYMPHOMA IN CHILDHOOD OR ADOLESCENCE AND IN HEALTHY CONTROLS
M. Cepelova1, V. Jerabkova1, J. Kruseova1, J. Stary1, P. Cepela2, P. Kraml2
1Department of Pediatric Hematology and Oncology, 2nd Medical Faculty
Charles University and University Hospital in Motol, Prague, Czech Republic;
22nd Department of Internal Medicine, 3rd Medical Faculty Charles University
and University Hospital Kralovske Vinohrady, Prague, Czech Republic
Background.The development of curative therapies has led to a grow-
ing population of chilhood Hodgkin lymphoma survivors. Approximate-
ly 75% of survivors experience some adverse event. Cardiac events are
among most important adverse events, causing long-term morbidity
and early mortality. Seriousness of these cardiovascular late adverse
events could be reduced only by their early recognition and also by rec-
ommendations of preventive measurements for modifiable cardiovas-
cular risk factors - hyperlipoproteinemia, hypertension, overwight or
obesity, smoking. Methods.The aim of our prospective observation study
is to compare the lipid profiles, markers of oxidative stress and endothe-
lial dysfunction together with evaluation of atherosclerotic changes at
main carotid artery between the long-term survivors of childhood
Hodgkin lymphoma more than 10 years after the treatment and the
matched group of healthy volunteers at the age of 25-40 years. Results.
Forty-seven long-term survivors of childhood Hodgkin lymphoma (29
males, 18 females) were recruited - all underwent clinical examination,
completed questionnaire collecting information on family history of car-
diovascular diseases, subject’s health habits and medical conditions,
underwent ultrasound examination of the carotid arteries and their
blood specimens were analyzed. Preliminary results are available in
forty-four long-term survivors - abnormal levels of blood lipids were
found in 52,3% of them. Elevated cholesterol levels (LDL and total cho-
lesterol) were detected in 12 pts. (in three of them also with elevated
levels of triglycerides), elevated level of triglycerides was found in four
pts., hyperglycemia was found in 12 patients (in 7 patients together with
elevated cholesterol or triglycerides levels). Plaques in main carotid artery
were found by ultrasonography in two patients, both of them have ele-
vated cholesterol levels. Recruitment of the long-term survivors will
continue and of matched group of healthy volunteers will start soon.
Conclusions. Our results will give us insight into atherosclerosis devel-
opment in this specific population and potential impact of hyperlipopro-
teinemia. It will help us to introduce appropriate guidelines for follow-
up and examinations of long-term survivors in the field of specialized
health care providers, but also in primary care together with the recom-
mendation of therapeutic interventions in this population.
Support. Supported by grant NV15-30494A.
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SURVIVORS OF ADULT HODGKIN LYMPHOMA: A FRAIL POPULATION. THE EXPERIENCE
OF THE SURVIVORSHIP CLINIC FOR ADULT HL SURVIVORS AT ISTITUTO NAZIONALE
TUMORI OF MILAN, ITALY
V. Simonetta1, M. Soldarini1, I. Arendar2, N. Cieri1, A. Guidetti1,3,
A. Busia2, P. Matteucci1, A. Gianni1, P. Corradini1,3
1Department of Hematology and Pediatric Onco-Hematology; 2Division of
Cardiology and Pneumology, Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy; 3Department of Oncology and Onco-Hematology, University of
Milan, Italy
Background. Nowadays more than 80% of adult patients (pts) diag-
nosed with HL have a long-life expectancy. Pts diagnosed from late
1960’ to 2000’s are at risk of developing long-term complications from
chemotherapy (CT) and radiation therapy (RT), The majority of data
on iatrogenic late effects are derived from registries or self-reported
interviews and only a few data on clinical outcome of suvivors followed
in survivorship clinics (SC) are available. Aim. To evaluate the incidence
of long-term complications among pts, in complete remission (CR) for
>5 years from the end of first-line treatment (EOT), followed in the SC
for adult HL survivors at INT. Methods. Medical records of 359 AHLS,
who underwent a routine visit, were analyzed to evaluate data on
demographic characteristics, treatment and incidence of late complica-
tions. Descriptive statistics were calculated. Results. From May 2014 to
April 2016, 359 AHLS (168 males, 191 female) diagnosed at a median
age of 31 (range, 17-71), underwent a routine visit at SC. Median time
from EOT and last follow-up visit was 17 years (range, 5-41 years).
Late complications were reported in 116 pts (32%), the majority of
whom had been treated with CT+RT. After a median of 19 years
(range,1-35) from EOT, 23 pts (6%) developed 29 second cancers (9
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breast, 2 bladder, 2 renal, 3 prostate, 1 lung, 4 melanoma, 1 pleural
mesothelioma, 1 non Hodgkin lymphoma, and 6 skin basal cell carci-
noma). Cardiovascular disease (CVD) was documented in 39 pts (11%),
after a median of 13.5 years (range, 3-32), and 10 pts had multiple CVDs.
Among CVD, myocardial infarction occurred in 8 pts, ischemic heart
disease in 4, heart failure in 4, moderate or severe valvular disease in 15
and cerebrovascular disease in 4 pts. Conventional CVD risk factors
were observed in 58 pts (16%). Hypothyroidism occurred in 9% of pts.
Conclusions. Results of our study confirm that a substantial proportion
of survivors of adult HL develop late complications. Specific health
resources should be addressed for prolonged follow-up programs,
lifestyle advices as well as prompt and aggressive management of risk
factors to improve health in this frail patient population.
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ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA HAVE HIGH RATES OF
SECONDARY B-CELL NON-HODGKIN LYMPHOMA
M. Gilbertson1, K. Maclaughlan1, G. Gregory1, S. Ratnasingham1,
I. Simpson1, B. Kumar1, G. Grigoriadis1,2, S.S. Opat1,2, J. Shortt1,2,
S. Patil1,3, E. Hawkes4,5, F. Ha-he5
1Monash Haematology, Monash1 Health, Australia; 2School of Clinical Sciences
at Monash Health, Monash University, Australia; 3Department of Haematology,
Alfred Health, Australia; 4Department of Clinical Haematology & Oncology,
Olivia Newton John Cancer Centre, Austin Health, Australia; 5Eastern Health,
Australia
Introduction. Elderly patients (>60 years old) with Hodgkin lymphoma
have inferior rates of survival compared to patients <60 years old due to
multiple factors including treatment toxicity and comorbidities influenc-
ing the intensity of chemotherapy that can be successfully delivered.
Hodgkin lymphoma is derived from germinal centre B-cells and con-
tributed to by latent Epstein Barr Virus (EBV) infection in a number of
patients. Aims. To examine the incidence and treatment outcomes of B-
cell NHL following completion of treatment for CHL in elderly patients
compared with younger patients. Methods.Adult patients diagnosed with
CHL at our institutions from 2000-2015 were followed prospectively fol-
lowing initial treatment for survival and toxicity outcomes. Any subse-
quent diagnosis of B-cell NHL was confirmed by two expert lymphoma
anatomical pathologists consistent with WHO 2008 diagnostic criteria.
Results. 165 adult patients were available for analysis, of which 56 (34%)
patients were >60 years old. There was no significant difference between
elderly and young cohorts in the number of patients with early stage
favourable, unfavourable or advanced stage CHL. Less elderly patients
received ABVD-like chemotherapy (71% vs 95%). There was a higher
number of relapses of CHL in elderly patients (31% vs 20%). At a median
follow-up of surviving patients at 2.7 years, there was a much higher
incidence of secondary malignancy in elderly patients n=11 vs n=2 (24%
vs 2%), of which there were far more haematological compared to solid
malignancies n=8 (17%) vs n=3 (6%). Specific histologies included Diffuse
Large B-cell Lymphoma (5), Follicular lymphoma (1), Lymphoplasmacytic
lymphoma (1) and Chronic lymphocytic leukaemia (1). Patients with
DLBCL were treated with R-CEOP and resulted in 2 patients achieving
long-term relapse free survival. Conclusions. There is a high incidence of
B-cell NHL in elderly patients with CHL, suggestive of a common germi-
nal centre derived progenitor cell of origin. Comparative genomic anno-
tation of such cases is required to better understand the lymphoma initi-
ating events in this cohort to enable selection of treatment which may
reduce this complication.
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ANALYSIS OF HODGKIN LYMPHOMA IN OLDER ADULTS IN A SINGLE CENTER
L. Cuevas1, A. Uranga1, I. López1, I. Zubicaray1, N. Robado1, A.N. Bizjak1,
A. Garcia2, M. Leturia2, I. Urreta3, H. Arrizabalaga1, N. Caminos1,
M. Sirvent1, E. Perez1, P. Romero1, T. Artola1, C. Lobo4, M. Araiz1,
I. Ceberio1
1Hematology; 2School of Medicine, EHU/UPV (University of the Basque Coun-
try); 3Epidemiology and Statistics; 4Department of Pathology, University Hospital
Donostia (H.U.D)
Introduction. Due to demographic changes, it is expected that the inci-
dence of the HL will increase in patients(pts) over 65 years(y), high-
lighting the need for therapeutic strategies designed specifically for the
geriatric population. The objective of this review is to evaluate our
everyday life practice and analyze the characteristics, prognostic factors
and survival of pts over 65y diagnosed of HL in our center. Methods.
This is an observational, retrospective review. A total of 44pts over 65y
and diagnosed of HL from May 2005 to December 2015 were included.
The Charlson Comorbidity Index (CCI) was used to evaluate the
comorbidities. Pts’s and disease’s characteristics are listed in Table 1.
Table 1.
Results. The treatment and the response rate are shown in Table 1.
58% of pts achieved CR and there were only 2 relapses recorded in
this group. 16% progressed during treatment (most of them had an
advanced stage at diagnosis). 18% did not receive any treatment owe
to comorbidities or denial by the pt. The estimated 5y overall survival
(OS) was 45%. Mortality rate was 54.5%: half due to the disease
itself, 27% as a result of the treatment’s toxicity (60% of this group
owe to pulmonary involvement), 14% by other neoplasia and 9% due
to comorbidities. In the univariate analysis factors associated with
lower survival were a CCI ≥3 and the age >80y, with a 5 y-OS of 28%
vs 51% (p=0.003) and 8% vs 60% (p=0.0002), respectively. Because
of the low sample size it is not rentable to assess a multivariate analy-
sis. Conclusions. Despite the limitations of a retrospective analysis, our
study confirms the data published in the literature: elderly patients
frequently present mixed cellularity subtype, achieve lower rates of
CR and OS, but relapse-free survival is less impaired and present high-
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er toxicity associated with treatment compared to young patients.
The fundamental cause of death remains being the disease. The age
over 80 years and CCI≥3 are associated with a worse prognosis. The
management of patients over 80 years represents a major therapeutic
challenge because of the high toxicity and low efficiency of current
treatments. It is important to include these patients in clinical trials
covering new drugs. The new drugs and new easy geriatric assess-
ment tools, which detect frailty, should assist in the better manage-
ment of these elderly patients. Our hospital intends to initiate a care
protocol that covers the assessment using the CIRS-C and GAH
scales.
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AN UPDATE ON BETER, THE DUTCH NATIONWIDE SURVIVORSHIP CARE PROGRAMME
FOR HODGKIN LYMPHOMA SURVIVORS
A. Nijdam1, B.M.P. Aleman1, M.B. van ’t Veer1,2, C.P.M. Janus3,
R. de Weijer4, L.A. Daniëls2, F.G. Stedema5, J.M. Zijlstra6,
R.W.M. van der Maazen7, J.H. Borger8, K. Verschueren9,
J. Manenschijn10, E.F.M. Posthuma11, J. Raemaekers7,12,
F.E. van Leeuwen1, on behalf of the BETER consortium
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Netherlands; 4University Medical Center Utrecht, Utrecht, the Netherlands;
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Zwolle, the Netherlands; 11Reinier de Graaf Group, Delft, the Netherlands;
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Background. Survivors of Hodgkin lymphoma (HL) are at increased
risk of various late adverse effects of treatment, leading to substantial
excess morbidity and mortality. The Dutch BETER consortium (Better
care after Hodgkin lymphoma: Evaluation of long-term Treatment
Effects and screening Recommendations) aims at improving life
expectancy and quality of life for HL survivors. Methods. The BETER
consortium has developed: (1) evidence-based follow-up guidelines
for HL survivors according to (inter)national standards; (2) a nation-
wide infrastructure for survivorship care clinics in which risk-based
care is provided to ≥5-year survivors of HL, who were treated after
1965 at ages 15-60 years. Moreover, the BETER consortium aims at
improving knowledge about late adverse effects of HL treatment in
patients as well as health care providers, e.g. through the website
www.beternahodgkin.nl. Results. BETER-guidelines for second malig-
nancies, cardiovascular disease, thyroid disease, osteoporosis and fer-
tility, functional asplenia, neck muscle weakness and other problems
(quality of life, weight, dental health, neurological problems, and pul-
monary disease) are expected to be approved soon by the respective
medical societies.  Currently, 11 out of 23 centres participating in the
BETER consortium have established a BETER Survivorship Care Clin-
ic. Other centres are planning to start shortly. The proportion of HL
survivors still under medical surveillance varied substantially across
BETER clinics. For these patients follow-up care is adapted to the new
screening guidelines. Among the HL survivors who were discharged
from follow-up care, there was a large variation in attendance rate
between BETER clinics, varying from 25% to 90%. Five to 35% of
patients did not respond to the invitation and 5 to 40% did not wish
to attend. Most common reasons to not attend were: undergoing
screening or treatment for late effects elsewhere, not wanting to be
reminded of HL, emotional burden and financial reasons. We will
evaluate reasons for non-attendance in more detail in the near future.
Conclusions. Clinical attendance rates of HL survivors who were pre-
viously discharged from follow-up, vary substantially between BETER
clinics. Evaluation of reasons for non-attendance will be used to
improve survivorship care.
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PROSPECTIVE EVALUATION OF PULMONARY TOXICITY IN FIRST LINE TREATMENT OF
HODGKIN LYMPHOMA PATIENTS
Á. Jóna, Z. Ujj, M. Szilasi, S. Póliska, B.L. Bálint, I. Garai, Z. Miltényi,
Á. Illés
Department of Hematology and Pulmonology, Genomic Medicine and Bioinfor-
matic Core Facility, University of Debrecen, Faculty of Medicine; Scanomed Ltd,
Debrecen , Hungary
Introduction. Bleomycin (bleo) containing first-line therapy ± irradia-
tion may cause pulmonary toxicity in Hodgkin lymphoma (HL)
patients.
Patients and Methods.Pulmonary function of newly diagnosed HL
patients were assessed, by using St. George Respiratory Questionnaire
(SGRQ), dynamic inhalation lung scintigraphy, diffusion capacity of
the lung for carbon monoxide (DLCO) and spirometry before, during
and after treatment, prospectively. Bleo hydrolase (BLMH) SNP A1450G
genotype polymorphism was determined by TaqMan genotyping
assay. Results. A total of 50 classical HL pts. data were available for
analysis, treated between February 2012 and March 2016 in our Insti-
tution. 38 pts. received ABVD (median cumulative bleo dose: 120
mg/m2) chemotherapy, 18 pts. received bleo intramuscularly (im.) and
20 intravenously (iv.). As control group, 12 pts. were treated with bren-
tuximab vedotin (BV)-AVD. Chest irradiation was involved in 11 pts.’
treatment. Pulmonary complains measured by SGRQ slightly improved
over treatment. Lung scintigraphy results of bleo-treated pts. signifi-
cantly worsened over treatment. More interestingly, results of BV-treat-
ed pts. not only significantly worsened over treatment, but was signif-
icantly inferior to bleo treated patients. By excluding smoker pts., dif-
ference became not significant, but still inferior to bleo treated pts.
DLCO much less explicitly confirmed these results. Spirometry param-
eters improved over treatment in both groups, with no significant dif-
ferences. Chest irradiation did not significantly worsen pulmonary
function. Pts. receiving iv. bleo had significantly worse results measured
with lung scintigraphy at the end of treatment and during treatment
with DLCO, than those receiving im.. BLMH SNP A1450G didn’t dis-
tinguished in this short run of bleo treated pts. Discussion. Pulmonary
function test results of bleo treated pts. worsened over treatment as
previously reported, however we found these results only with lung
scintigraphy. DLCO was much less supportive. Moreover, only one
patient was found with acute bleo induced lung injury in contrast with
the literature (20-46%). Surprisingly, BV-AVD, which is considered non-
pulmonary toxic, produced inferior results to bleo treated pts.. We have
to compliment, that these results were only seen with lung scintigraphy,
which has no literature, and data lacks of confirmation with gold-stan-
dard DLCO. Nevertheless, lung scintigraphy is supposed to measure
earlier epithelial damage.
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HODGKIN LYMPHOMA AND PREGNANCY - DILEMMAS OF HOW TO TREAT?
E. Lampka1, J. Tajer1, W. Osiadacz1, B. Brzeska1, M. Dębska2,
M. Rubach1, R. Dębski2
1The Maria Sklodowska-Curie Memorial Cancer Center and Institute, Warsaw,
Poland; 2The Medical Centre of Postgraduate Education, II Department of
Obstetrics and Gynecology, Warsaw, Poland
Introduction. The incidence of malignant neoplasms in women at
reproductive age has increased dramatically over the past decade and
is still rising. Hodgkin’s lymphoma (HL) is one of the most frequent
hematological malignancies in young women. When diagnosed HL dur-
ing pregnancy,it represents a major clinical dilemma and there is a lack
of established standards defining its optimal treatment during gestation.
The coincidence of HL and pregnancy poses an unusual challenge for
the mother and the medical team. Materials. 102 patients with Hodgkin
lymphoma(HL) were treated at the MSCMCC Warsaw between
01/1986 and 12/2015. Age: range (mean): 16-39 (29). Most patients
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Hodgkin’s lymphoma (HL) in the second stage of clinical Ann Arbor
(CS), histopathological type of NS (nodular sclerosis) and in the second
trimester of pregnancy. B symptoms- 51%, tumor mass -41%,
MMR>1/3 -38%. Methods of treatment: I trimester :therapeutic abor-
tion or radiotherapy (IF) upper cervical or axillary lymph nodes or mis-
carriage (7-8 Hbd), III trimester : method “watch and wait” and delivery
37-39 Hbd or chemotherapy scheme EVA (1-2 cycles before delivery )
(Etoposide 100mg/m2 days 1-3, Vinblastine 6 mg/m2 day 1, Doxorubicin
50mg/m2 day 1 repeated every 28 days) before delivery. II trimester
method “watch and wait” or radiotherapy (IF) total dose between 20-
44 Gy before delivery and chemotherapy LOPP, MOPP, MOPP/ABV
after delivery or radiotherapy (IF) total dose 30-35 Gy and chemother-
apy scheme EVA (2 cycles) before delivery or chemotherapy scheme
EVA (3-4 cycles) before delivery and radiotherapy (IF) total dose 30-40
Gy after delivery. In vivo dosimetry before delivery during radiotherapy
by irregular fields Thermoluminescent dosimetry HARSHAW 100 or
Thomson and Nielsen t.MOSFET TN –RD 51 and individually blocks
of the abdomen and fetus were used. The dose of the fetus was esti-
mated individually in all. Total dose 0 cGy -19.19 cGy.Results. Out of
102 treated women now live 94 (92%).Most of the living patients in
complete remission. In 2 patients after childbirth was made a full panel
of diagnostic tests. They remain in partial remission and continued
treatment regimen ABVD. Cause of death in 8 patients: relapse or pri-
mary refractory disease. Was born 90 children. Parturition and postpar-
tum correct. All bearings were subjected to histopathological examina-
tion. There was no cell lymphoma in the tested material. There were
no developmental or genetic defects in children. Children are under
constant medical care. Physical and mental development correct. One
infant developed acute respiratory distress syndrome and died 6 days
after delivery. Age surviving children 6 months - 29 years.
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SECOND CANCER RISKS IN PATIENTS WITH SUPRADIAPHRAGMATIC HODGKIN LYMPHOMA
S. Shahtarina, A. Danilenko, V. Pavlov
The Tsyb Medical Radiological Research Center, Obninsk, Russian Federation
Background. Second cancer s (SC) developing in Hodgkin Lymphoma
(HL) patients after treatment significantly affect survival. The studies
defining relative risc (RR) of SC in the cohort s of HL patients treated
with similar radiotherapy (RT) target volumes and total tumor doses
(TTD) are rare. Purpose. The aim was to evaluate RR of SC in HL
patients treated with RT alone or chemoradiotherapy (CRT) when irra-
diation was limited to the lymphatic areas above diaphragm and the
spleen. Methods. The study included 1789 initial HL pts, stages I, II, IV
(supradiaphragmatic, age 13-69 (87% under 40). Women 1177 (66%),
men 612 (34%). The treatment period was between 1968 and 1998.
Patients were given either RT alone limited to the lymphatic areas above
diaphragm and the spleen, TTD 40 Gy (363 pts, 20.3%) or 6 cycles of
chemotherapy COPP+similar RT (1426 pts, 79.7%). The incidence of
SC was compared with the data from Cancer Register of Russian Fed-
eration. Results. Follow-up was 6 mnths - 36 years (median 18 years).
The overall follow-up for the cohort was 18949 patients/years (men
5917, women 13032). SC developed in 80 (4.5%) patients: after RT in
27 (7.4%) of 363 pts, after CRT in 53 (3.7%) of 1426 patients. One
tumor occurred in 74 pts, two tumors, two tumors successively in 5
patients and three tumors in 1 patient. The total number of tumors was
87, including 85 (97.7%) solid tumors, 2(2.3%) hemoblastoses. The
time of SC occurrence was 1-31 years (median 18). SC RR: overall for
the cohort - 2.85 (95% confidence interval (95% CI) 1.85-2.98); in
women - 3.02 (95% CI 1.9-3.12); in men - 2.46 (95% CI 1.23-2.91).
After RT alone: in women - 3.22 (95% CI 2.11-4.75); in men - 2.51 (95%
CI 0.9-4.63). After CRT: in women - 2.9 (95% CI 1.48-3.02); in men -
2.4 (95% CI 1.04-2.96). The prevailing tumors were mammal, thyroid,
gastric. The RR of mammal cancer was 4.01 (95% CI 2.46-5.98); gastric
cancer: in women - 7.95 (95% CI 3.2-14.4), in men - 4.03 (95% CI 1.0-
9.0); thyroid cancer: in women - 7.8 (95% CI 3.47-13.9), in men -
beyond 95% CI. 19 (21.8%) of 87 tumors occurred within irradiation
fields. Conclusions. In our study the RR of SC in HL patients was 2.85,
which is lower than reported by other authors. This probably could be
explained by the fact that the study included HL patients in whom irra-
diation was limited to supradiaphragmatic areas and spleen.
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PROGNOSTIC VALUE OF CLINICAL, TREATMENT AND SOCIO-DEMOGRAPHIC RESULTS OF
PSYCHOLOGICAL DISTRESS AMONG HODGKIN LYMPHOMA SURVIVORS IN HUNGARY
F. Magyari1, Z. Miltényi1, S. Simon1, K. Kósa2, R. Berecz3, Á. Illés1
1Department of Hematology, Faculty of Medicine; 2Department of Behaviour
Sciences, Faculty of Public Health; 3Department of Psychiatry, Faculty of
Medicine, University of Debrecen, Debrecen, Hungary
Objectives. Due to risk and response adapted treatment strategies,
more than 80% of newly diagnosed classical Hodgkin lymphoma (HL)
patients can be cured, and are expected to be long-term survivors. A
remarkable number of HL survivors suffer from treatment related long-
term side effects, such as secondary malignancy, organ failure, persistent
fatigue and psychological distress. Purpose. The aim of this study was
to evaluate the frequency of psychological distress and it‘s risk factors
among HL survivorsin Hungary. Patients and Methods.163 (88 female
and 73 male) adult HL survivors were identified between 1st January
2012 and 31st March 2015 in our outpatient centre. The patients were
asked and agreed to completestandardized, self-administeredquestion-
naires: Hospital Anxiety and Depression scale (HADS14), General
Health Questionnaire (GHQ12), Perceived Stress Scale (PSS4) and socio-
demographic questions. Disease and treatment data were based on the
hospital records. Results.The mean age at thetime of diagnosis was
32.16±12.97 years, at the completion of the survey was44.84±14.51
years. A total of 25% had caseness scores with HADS14. Anxiety case-
ness scores were high infemale patients (p=0.003), and were strongly
associated with lack of employment (p=0.011) and treatment related
long-term side effects (p=0.001). Depression caseness scoreswere
increasedamong female patients (p=0.020), and were related to baseline
comorbidities (p<0.001), lack of employment (p<0.001), higher ECOG
scores at the time of diagnosis (p=0.036) and treatment related long-
term side effects (p<0.001). 14.11% of HL survivors had abnormal levels
of distress with GHQ12, which were significantly associated with base-
line comorbidities (p=0.041), lack of employment (p<0.001), higher
ECOG score at diagnosis (p=0.020) and treatment related long-term
side effects (p=0.001). The PSS4 scale results were found significantly
lower among employees (p<0.001), and in subjects without comorbidi-
ties (p=0,008) and with bulk tumor (p=0,026). There was a tight corre-
lation between the questionnaires and the time of survey completion.
Conclusions. Related to the literature and our own results, the majority
of cured HL patients survive without distress at caseness level. Based
on our experience HL survivors should be closely followed up by clini-
cians. If mental health disorder is suspected further psychologic or psy-
chiatric treatment is strongly recommended. 
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HODGKIN LYMPHOMA IN ELDERLY PATIENTS - A SINGLE CENTER EXPERIENCE
M. Santos, A. Pinto, D. Mota, R. Guilherme, M. Gomes, L. Ribeiro
Clinical Hematology Department, Coimbra University Hospital Center, Coimbra,
Portugal
Background. Classical Hodgkin lymphoma occurs in 20% of patients
aged over 60 years. Survival rates for elderly patients with Hodgkin
Lymphoma (eHL) are disproportionately inferior compared with
younger patients. In eHL poor outcome is related with biologically more
aggressive disease, treatment toxicity and comorbidities. Although
ABVD is regarded as standard of care for most eHL patients, adjusted
treatment strategies are lacking for this particular population and inno-
vative approaches are awaited. Aims.Characterize an elderly population
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with HL and analyze the impact of different treatment approaches
(response to treatment, long-term outcome and occurrence of second-
ary neoplasms). Methods.We performed a retrospective analysis of eld-
erly patients with HL (≥60 years) treated between 1991 and 2015, in a
tertiary center. Results. Forty-six eHL patients were considered, mainly
males (58.7%) with a median age of 70 years (60-80). The most preva-
lent histological subtype was nodular sclerosis (n=30; 65.2%). Ann
Arbor stage III/IV was observed in 31 patients (67.4%), B symptoms in
34 (73.9%) and bulky disease in 2 (4.3%). The risk stratification (GHSG)
was: limited n=4 (8.7%), intermediate n=10 (21.7%) and advanced
n=32 (69.6%). ABVD was performed in 19 patients (41.3%);
MOPP/MOPP like in 11(23.9%); other regimens in 8 (21.7%) and radi-
ation alone in 2. Six patients had an early death event before starting
chemotherapy. Overall response rate (ORR) was 72.5% (complete
response - CR 67.5%); with ABVD, ORR was 73.7% (all with CR).
With a median follow-up of 34.6 months (0.3-273.4), 5-year overall sur-
vival (OS) and progression free survival (PFS) were 46.1% and 35.9%,
respectively. Among 33 patients who died, 20 were due to HL. Median
OS and PFS were superior in patients treated with ABVD when com-
pared with other approaches (156.6 vs 22.5 months, p=0.047 and 156.6
vs 20.3 months, p=0.035). Using a univariate analysis most International
Prognostic Score factors didn’t show prognostic value, although multi-
variate analysis identified hemoglobin as a predictive factor of OS (HR
0.59; 95%CI 0.40-0.87, p=0.007) and PFS (HR 0.11; 95%CI 0.45-0.90,
p=0.011). Four patients presented late second malignant neoplasms
(n=2, ABVD; n= 2, other regimens). Conclusions. ABVD remains a stan-
dard of care in eHL. In our cohort we observed that this regimen was
effective and can improve survival. We concluded that hemoglobin
level is an independent predictor of survival in this population.
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ARE WE AWARE OF NUTRITIONAL STATUS AND VITAMIN D LEVEL IN HODGKIN LYMPHOMA
PATIENTS?
V. Djurasinovic1, B. Andjelic1,2, M. Saric3, S. Ignjatovic2,3,
M. Todorovic Balint1,2, D. Antic1,2, V. Vukovic1, J. Jelicic1, A. Sretenovic1,
B. Mihaljevic1,2
1Clinic for Hematology, Clinical Center of Serbiaal, Belgrade, Serbia; 2Medical
Faculty, University of Belgrade, Belgrade, Serbia; 3Clinic for Biochemistry, Clin-
ical Center of Serbia, Belgrade, Serbia
Background. Patients with Hodgkin lymphoma ussualy have weight
loss at the diagnosis of disease. None of the prognostic parameters so
far did not evaluate prognostic significance of weight loss. Also, vitamin
D is not ussualy assed in lymphomas. Aim. Evaluation of nutritional
status and level of vitamin D in de novo patients with Hodgkin lym-
phomas. Methods. 22 de novo pts diagnosed from january 2014. At Clinic
for hematology, Clinical center of Serbia, median age 34,5(19-60)years.
Initial clinica stage (CS) was: I in 1/22; II in11/22; III in 4/22 ans
IV5/22..ECOG PS: 0 in 5/22pts, 1 in 12/22, 2 in 5/22. All pts were treated
initialy with ABVD. Nutritional status was screened by NRS 2002 and
vitamin D was assesed with the chemiluminescent immunoassay for
the quantitative determination of total serum 25-hydroxyvitamin D
(25(OH) vitamin D). Pts were followed for median18,5 (12-26) months.
Results. Mean BMI was 24,08±3,39 while 3/22 pts had BMI less than
20,5kg/m2. 7/22 pts have lost ≥10%body weight (BW) during previous
6mts. 9/22pts had NRS 2002≥3. Median 25-OH vitamin D 26,7(10,2-
62,05)nmol/l and none of pts had normal level. 9/22 had severe defi-
tiency <25nmol/l, 9/22 defitiency 25-50nmol/l and 4/22 had unsufitient
level 50-75nmol/l. 7/22 pts progressed within one year. Median PFS
8(3-12) months. Pearson correlation between pts with weight loss over
10% BW and progression is 0,4, p=0,66, while for 25-OH vitamin D
lower than 25nmol/l and progression was 0,589, p=0,005. In binary
logistic model only severe defitency 25-OH vitamin D was significant
for progression while CS, NRS and ECOGPS over were not significant.
Conclusions. Around 40%pts are malnourished or in nutritional risk.
Any of pts had normal 25-OH vitamin D, there was a significant cor-
relation between severe defitiency and progression. Supportive care
along with chemotherapy may obtain better treatment results.
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MENTAL DISORDERS IN HODGKIN’S DISEASE PATIENTS
D. Vybornykh, L. Olexenko, S. Khrushchev, S. Kravchenko, I. Shitareva,
T. Moiseeva
National Research Center for Hematology, Moscow, Russia
Background. Data on mental disorders, manifesting in Hodgkin’s dis-
ease patients are rather limited. Such disorders are considered as within
somatogenic psychoses and adjustment disorders. Among described
psychoses identified isolated cases of delusional disorders, delirium,
oneiric. Among the adjustment disorders described is mainly anxiety,
depression, or combinations thereof. Systematic studies of psychiatric
disorders in patients with Hodgkin’s disease have not been conducted.
Aim. To identify the structure of mental disorders in patients with
Hodgkin’s disease. Materials and Methods. There were examined 95
patients with Hodgkin’s disease by clinical-psychopathological method.
Results of the study were subjected to statistical analysis using Stat for
Windows 5.5 licensing programs. Results and Discussion. It was revealed
that endogenomorphical psychoses (hallucinatory-paranoid and depres-
sive-delusional states) and somatogenically provoked schizophrenia
attacks in Hodgkin’s disease patients are much more likely (17 and 6,
respectively) than delirium, unlike other hematological malignancies, in
which be present (or was found observed) the opposite trends. In addi-
tion, Hodgkin’s disease is the only hematological malignancy in the
studied sample, in which the schizophrenia attacks are detected (were
detected). Among adjustment disorders in Hodgkin’s disease patients
were identified as follows: anxiety and dissociative (n=29) (anxiety and
dissociative reactions occur with symptoms of the phenomenon of alien-
ation of real hematological disease and signs of latent somatization of
anxiety, accompanied by abnormal behavior in the disease), hypomanic
(n=4), dissociative (n=25) (dominated by the phenomenon of alienation
of the hematological malignancy, reaching the degree of total denial of
the fact of the blood system diseases, revealed gross cognitive disorders
characterized by distinct partial peculiar syndrome pseudodementia)
and anxiety-koenestopathical (n=14) (somatogenically and / or psy-
chogenic provoked polymorphic functional symptoms, abnormal bodily
sensations). Conclusions. The study results show that in a sample of
Hodgkin’s disease patients schizoid spectrum disorders accumulate,
what could serve as a reason for further studies of this phenomenon,
involving both clinical and biological research methods.
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ANALYSIS OF ACCESS TIME TO CARE FOR PATIENTS WITH HODGKIN’S LYMPHOMA IN
PUBLIC HOSPITAL IN SÃO PAULO
N. Amaral, T. Fisher, S. Fortier, T. Silveira da Rocha, C.S. Chiattone
Santa Casa Medical School, Samaritano Hospital Center, Sao Paulo, Brazil
Introduction.Cancer is responsible for over 12% of all causes of death
in the world, where more than 7 million people die each year from this
evil. Early diagnosis coupled with existing therapeutic methods allow
higher survival rates for cases considered incurable before. Objectives.
To analyze the time spent on the access of patients with Hodgkin’s dis-
ease in philanthropic Hospital in São Paulo (SP) to the specialized serv-
ice. Methods. query the records with tabulation and analysis of data of
67 patients. Results.male Majority N=35 (52.2%) aged between 15 and
75 years and frequency of single N=33 (50.0%). As for the disease, 25
(37.3%) were in stage IVB and the waiting time interval until the first
examination (p=0.035). Gender variations, age and education were sig-
nificant in the elapsed time of the first signs and symptoms until the
first examination (p=0.008) and attendance at the Santa Casa to con-
sultation with a specialist (p=0.012). Younger patients (15 and 35)
sought the first faster service, and the time was 31 days; older (56 and
72 | haematologica | 2016; 101(s5)
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75) took more average time: 304 days. Conclusions. The most econom-
ically disadvantaged patients were in advanced stage. There is an
increased time interval to access health services, especially regarding
the type of service for the first visit. The variables showed significant
when analyzed “type of service” and “age” over time.
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THE USE OF COPING STRATEGIES AND SOCIAL SKILLS IN YOUNG ADULT PATIENTS WITH
HODGKIN’S LYMPHOMA: CORRELATION WITH ANXIETY AND/OR DEPRESSION SYMPTOMS
A. Silva, W. Bruscatto, T. Fisher, S. Fortier, T. Silveira da Rocha,
C.S. Chiattone
Santa Casa Medical, Samaritano Hospital Center, Sao Paulo, Brazil
Introduction. The oncologic disease exposes the patient into a dynamic
and complex treatment process along different steps of the disease,
requiring him/her adaptive coping answers; in other words, the patient
with cancer needs to mobilize psychosocial resources to deal with the
stress due to this illness. The Hodgkin’s lymphoma is a type of cancer
potentially curable, and the age range of this type of disease, presents a
bimodal distribution, having its first incidence peak between 15 and 35
years olds. Objectives. This study aimed to evaluate the coping strategies
and social skills in young adults against the oncologic treatment and the
correlation of these variables with anxiety and/or depression symptoms.
Materials and Methods. The sample was composed of 44 patients with
Hodgkin’s lymphoma diagnosis between the ages of 18-35 years old.
There have been used as research tools: Socio-demographic Record,
Ways of Coping Scale - EMEP, Social Skills Inventory – HIS, Hospital
Anxiety and Depression Scale – HAD. Results. By a quantitative analysis
of data, it has been possible to conclude that the coping strategy focused
on the problem presented higher scores in this population, while the
coping strategy focused on the emotion presented lower scores. The
correlation of coping strategy focused on the emotion showed symp-
toms (p=0,000) and depression (p=0,002). It has been verified that in
this population, the social skills factors related to the self-affirmation in
expression of positive affection, conversation and social resourcefulness,
and self-exposure to unknown or new situations, are above the average
if compared to the general population of the validation study. These fac-
tors might be associated to the oncologic treatment, environmental fac-
tors involved in this process, which favor the development of these skills.
There has not been significant statistically correlation among these social
skills and anxiety and depression symptoms.
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QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA
TREATED WITH NIVOLUMAB MONOTHERAPY IN CHECKMATE 205 (COHORT B), A PHASE
2 STUDY
A. Engert1, I. Hirji2, F. Taylor3, B. Bennett4, K. Cocks4, K. Kato2, D. Cella5
1University Hospital of Cologne, Cologne, Germany; 2Bristol-Myers Squibb,
Princeton, NJ, USA; 3Adelphi Values, Boston, MA, USA; 4Adelphi Values,
Bollington, Cheshire, UK; 5Northwestern University, Chicago, IL, USA
Background. Nivolumab (nivo), a fully human IgG4 immune check-
point inhibitor targeting PD-1, showed encouraging efficacy in
relapsed/refractory cHL in a ph1 study (Ansell et al.NEJM 2014). Cohort
B of CheckMate 205 ph2 study investigated nivo in cHL pts who had
failed autologous hematopoietic stem cell transplantation (auto-HSCT)
and brentuximab vedotin (BV): ORR per independent radiologic review
committee was 66% and 6-m PFS was 77% (Engert et al. EHA 2016;
abstr S793). Due to limited treatments there is a need to provide durable
efficacy while maintaining/improving QoL. Aim. Evaluate QoL in pts
receiving nivo in CheckMate 205 cohort B. Methods. This ongoing ph2
study (NCT02181738) assessed QoL in cHL pts receiving nivo 3 mg/kg
IV q2w. Pt-reported QoL was assessed using European Organization
for Research and Treatment of Cancer Quality of Life Questionnaire –
Core 30 (EORTC QLQ-C30) and EuroQol Five Dimensions Question-
naire (EQ-5D) q4 cycles on treatment. EQ-5D visual analog scale (VAS)
scores range 0–100 and EQ-5D utility index scores –0.6–1 (higher
scores=better health state). A 7- and 0.08-point change from baseline
(BL) in VAS and utility index score, respectively, represent a clinically
meaningful improvement (CMI). QLQ-C30 scores range 0–100 (high
scores=higher level of function/global health status [GHS]; for symptom
scales, higher level of symptom burden); 10-point change represents a
CMI. Changes from BL estimates are based on a mixed model with
time point as a fixed effect. Missing data was investigated to assess
possible bias. Results. BL and subsequent QoL assessment was complet-
ed by 72 treated pts (90%) from cohort B (n=80). Most pts with an on-
treatment study visit through wk33 (n=47/72) completed both ques-
tionnaires (n=42). CMI in mean EQ-5D VAS scores were maintained
over time on treatment (VAS mean change BL–wk33: 19.6, p≤0.001).
Changes of the utility index least squares were significant (p≤0.005) at
all treatment time points. For the QLQ-C30, significant improvements
from baseline were observed from wk9 for: fatigue, dysnpena, appetite
loss, physical function, role function and global health status. No QoL
scale indicated deterioration during treatment. Conclusions. In cHL pts
who had failed auto-HSCT and BV, nivo resulted in a trend towards
QoL improvement in this small cohort. An improvement in GHS (EQ-
5D VAS) was observed by wk9 and maintained over time on treatment.
Funding. BMS. Medical writing: S Addison, Caudex, funded by BMS.
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